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CHAPTER I 
PURPOSE 
Thrombin is known to play a key role in the development of various thrombotic 
conditions, such as stroke, myocardial infarction, pulmonary embolism and 
hypercoagulable states. Therefore it is the primary biochemical and pharmacologic target 
for developing newer antithrombotic drugs. One of the hypotheses underlying this 
approach is that sole inhibition of thrombin at blood and vascular sites is sufficient for 
the control of thrombogenesis and cellular activation processes. The purpose of this 
dissertation is to examine the hypothesis that inhibition of thrombin alone is sufficient for 
the control of thrombogenesis. This central question is addressed by determining the 
relative inhibitory effects of recombinant hirudin, a monospecific inhibitor of thrombin, 
along with the synthetic serine protease inhibitors (serpins) D-MePhe-Pro-Arg-H, Ac-
(D)Phe-Pro-boroArg-OH, argatroban and unfractionated heparin in the control of 
thrombogenesis. While the thrombin inhibitors included in this investigation represent 
varying degrees of specificities and potencies towards thrombin, heparin represents a 
poly-functional drug with mupltiple sites of action involving both the plasmatic proteases 
and cellular targets. Biochemical and pharmacologic models based on defined in vivo 
and in vitro experimental systems are used to investigate the comparative effects of each 
of these agents. This dissertation also provides supportive data on the relative role of 
non-specific serine protease inhibition in the mediation of the antithrombotic actions of 
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the newly developed thrombin specific peptide inhibitors. 
Several antithrombin agents with different mechanisms of action are studied in 
terms of their specificity for inhibiting thrombin and related serine proteases such as 
factor Xa, activated protein C, plasminogen activator, plasmin and kallikrein. It is 
widely accepted that hirudin exhibits its antithrombotic action by solely inactivating 
thrombin. On the other hand, heparin which also is an effective antithrombotic agent 
exhibits a more complex mechanism of action through endogenous serpins such as 
antithrombin or heparin cofactor II (HC-11), to inactivate serine proteases. The synthetic 
peptides and peptidomimetic inhibitors used in this study are reported to be potent 
inhibitors of thrombin but are not monospecific for thrombin. Tripeptide inhibitors site-
directed towards the catalytic region of thrombin vary in their specificity and potency for 
thrombin inhibition, which is largely dependent on their structure. The thrombin 
inhibitors chosen for this study provide structurally defined tools with different serpin 
profile which may be useful in identifying the activation processes which lead to a 
thrombogenic event. The relative efficacy of each one of these inhibitors in valid animal 
models of venous as well as arterial thrombosis provides a clear indication as to whether 
or not sole inhibition of thrombin is the most effective method to prevent 
thrombogenesis. 
Many of these agents are in various phases of clinical development. However, 
a comparative account of their biochemical and pharmacological actions has not been 
available until now. Several studies indicate that these agents are not only different from 
heparin but marked differences among these inhibitors in terms of their mechanisms of 
action and pharmacologic properties are predictable. 
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Since each of the thrombin 
inhibitors exhibit a specific structural and biochemical profile, this investigation 
represents valuable information on the structure activity relationship for these agents. 
Furthermore, a direct comparison with heparin also provides additional insight into the 
role of endogenous macromolecular ligands and receptors in the mediation of the 
pharmacologic actions of the newly developed synthetic and recombinant agents. 
Except for heparin, all of the agents included in this study are homogeneous, 
structurally characterized peptides or peptidomimetics, whose pharmacologic actions can 
be expressed in terms of molarity in relation to their interactions with endogenous 
enzymes, ligands and other sites. Thus, the anticoagulant and anti-protease actions of 
these agents can be quantified and compared in defined terms. A direct comparison of 
these data with heparin also provides new information on the mechanisms of mediation 
of the actions of these antithrombin agents. 
The comparative anticoagulant profile of these agents does not correlate with their 
in vivo antithrombotic actions. Furthermore, the global clotting tests do not provide 
information on the precise site of action of anticoagulants but rather provide an indication 
of a general area of the protease cascade where inhibitory activities may take place. 
One of the novel features of this investigation is the development and utilization 
of defined in vitro protease generation systems, which allow for the assessment of the 
relative importance of inhibition of specific factors in the coagulation cascade in defined 
and plasma based matrices. Furthermore, the studies on the inhibition of thrombin as 
well as its generation from specific precursors along with the studies on the broader 
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inhibitory spectrum of these agents on other purified proteases such as plasmin, activated 
protein C and kallikrein, adds to the understanding of the mechanisms of mediation of 
both the anticoagulant and anti thrombotic actions of these agents. 
Another important purpose of this research was to demonstrate the impact of the 
non-specific inhibition of regulatory serine proteases. While the amidolytic assays for 
the direct inhibition of many of the serine proteases and the generation of plasmin assays 
have been employed in isolated studies, a comparative investigation of these in a uniform 
manner has not been reported before. Furthermore, in this investigation all comparisons 
are made in a manner where the inhibitor levels as well as the enzymes (preformed or 
generated) can be directly compared at molar levels. Such a comparison can be used to 
project the relative impact of these thrombin inhibitors in the modulation of coagulation, 
fibrinolysis and kallikrein system. 
Protease generation assays using in vitro plasmatic systems also provide a useful 
approach to characterize the multiple sites at which these thrombin inhibitors act. In the 
fibrinogen deficient human plasmatic systems, where thrombin is generated by activation 
of either the intrinsic or the extrinsic pathway, the difference in the pharmacologic 
actions of these antithrombin agents can be determined. These methods provide insights 
to the overall mode of actions of the thrombin inhibitors in a diluted plasma matrix where 
feedback modulatory actions of thrombin can be simultaneously studied. 
Defined non-plasmatic protease generation systems have also been used to trigger 
the generation of thrombin is provided by extrinsic activation of prothrombin complexes 
(FEIBA® and KONYNE®), to determine the role of other plasmatic proteins in the 
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mediation of the anticoagulant effects of the thrombin inhibitors. Agents such as heparin, 
which require endogenous cofactors for the mediation of their inhibitory activities do not 
prevent the generation of thrombin or inhibit thrombin in these systems, whereas agents 
not specific for thrombin and possessing other serine protease inhibitory actions, are 
more effective in these assays. 
To measure the relative in vivo antithrombotic actions of heparin, hirudin, Ac-
(D) Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H, pharmacologic models of acute 
thrombosis are utilized. In the rabbit jugular vein stasis thrombosis model, the 
effectiveness of these agents in preventing clot formation is assessed in terms of potency, 
efficacy and duration of antithrombotic actions. However, the physiology of venous 
thrombosis differs from that of arterial thrombosis, thus, inhibition of thrombin and its 
generation and/or inhibition of other serine proteases may be of different importance in 
each model. Therefore, the antithrombotic actions of these agents are also studied in a 
rat laser-induced arterial thrombosis model. The results from these two models are 
useful in understanding not only the relative importance of direct thrombin inhibition as 
compared to the inhibition of thrombin generation and/or other serine proteases, but also 
the role of the proteases inhibited in the venous system as compared to the arterial 
system. 
Since trace amounts of thrombin are required for the hemostatic function of 
platelets, thrombin inhibitors may also compromise this hemostatic process. At relatively 
higher dosage, indiscriminate inhibition of all effects of thrombin may lead to bleeding. 
Thus, the studies on the rabbit ear blood loss model can provide useful data on the 
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relative bleeding effects of these agents. Based on these observations, some projections 
on the role of platelets in the mediation of the thrombotic events and their modulation by 
thrombin inhibitors can also be made. 
The animal model of venous thrombosis also allows for ex vivo analyses of blood 
samples so that a comparison of the pharmacodynamic actions (anticoagulant and 
antiprotease) with the antithrombotic effects of each antithrombin agent can be made. 
This is important in the understanding of the additional mechanisms of action for each 
agent. Additional correlations between the ex vivo antithrombin or related anticoagulant 
actions with the observed hemorrhagic actions in a rabbit model of ear blood loss 
provides data on the endogenous interactions of these agents resulting in bleeding effects. 
Thus, a safety/efficacy index can be developed for each of the agents studied. 
Another important feature of this investigation is the utilization of recombinant 
tissue factor (rTF) in the in vitro biochemical assays and the in vivo rabbit venous 
thrombosis studies. The thrombogenic environment developed by using this trigger is 
rather defined and the role of heparin and antithrombin agents can be readily assessed 
in the rTF mediated thrombogenesis. The use of rTF in the stasis thrombosis model is 
more defined than the existing models using mixtures of enzymes or human serum. The 
tissue factor used in this investigation is produced by recombinant technology and is 
molecularly characterized and packaged in phospholipids. In the in vivo thrombogenic 
studies, it acts as a strong extrinsic pathway activator that leads to thrombogenic events. 
Thus, the data generated on rTF in both the biochemical and pharmacologic studies 
represent more defined information on the control of thrombogenesis with the new 
7 
antithrombin agents. 
The experimental approaches included in this dissertation are designed to 
differentiate the pharmacological profile of antithrombin agents as a class from those of 
heparin. Furthermore, these studies also provide crucial data on the significant 
differences which exist amongst these agents. In addition, this dissertation also addresses 
the question of standardization, relative role of thrombin inhibitors in the mediation of 
antithrombotic actions and some of the non-thrombin mediated modulatory actions of 
these agents, such as their effects on the fibrinolytic network and activated protein C 
modulated regulatory processes. 
The experimental methods included in this dissertation represent optimal and 
pharmacologically defined systems to obtain valid data in a systematic fashion on the 
biologic actions of these antithrombin agents of different origins. It is expected that the 
reported data in this dissertation will serve as a systematic approach for the valid 
pharmacologic investigation of newer antithrombin agents. 
CHAPTER II 
REVIEW OF LITERATURE 
A. Overview of Hemostasis 
Unicellular organisms derive their nutrients by simple physiochemical process 
and/or by phagocytotic process. However, more complex multicellular organisms require 
more complex mechanisms of essential nutrient delivery to their cells. The vasculature 
in mammals serves as a conduit via which nutrients reach individual cells. Evolution has 
shaped the vascular physiology with mechanisms to take corrective measures to cope with 
the disruptive events. Blood is a non-Newtonian fluid which flows through the vessels 
to provide oxygen and nutrients and regulate the vascular integrity. While the process 
of hemostasis (arrest of bleeding) will prevent blood loss, the fibrinolytic process 
facilitates the dissolution of clot as the healing process progresses, allowing the 
restoration of blood flow. Despite all of the mechanisms which serve to regulate 
hemostasis, uncontrolled activation of this process leads to a range of disorders, including 
both the thrombotic and hemorrhagic disorders. 
It is now becoming clear that the role of the endothelial cell monolayer is rather 
important in the regulation of hemostasis and extends beyond providing a non-
thrombogenic surface for the continuous flow of blood. The products of the vascular 
cells are essential in regulating various physiologic processes. Receptors expressed on 
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the surface of these endothelial cells regulate many of their hemostatic functions. Cell 
surface interactions on the endothelium and on other blood-borne cells control a multitude 
of natural processes, among these is the localized production and control of thrombin, 
the key enzyme in clot formation. The importance of these components is evident when 
there is a defect in one of these which can lead to a wide range of clinical disorders 
ranging from thrombosis and atherosclerosis to neurological disease, inflammatory and 
immune disorders, microangiopathy and vasculitis. 
Focusing on the processes that regulate the flow of blood, while the recognition 
of the role of fibers has been noted since the time of Plato, the specifics of blood clotting 
started to become unravelled in the beginning of the 19th century (Bloom et al. 1994). 
By 1964, enough was known about specific coagulation proteins to develop the 
"waterfall" or "cascade" coagulation model (Macfarlane 1964), in which activation of one 
zymogen leads sequentially to the activation of another, until thrombin is generated to 
mediate the conversion of liquid fibrinogen to solid fibrin clots. Since then, an 
exponential increase in the knowledge of about these proteins has led to several 
modifications of the original simplified scheme to develop increasingly more complex 
networks. It has also become clear that these processes are not independent of other 
cellular components and that there is a constant interaction with many different cell types 
mediating equally diverse physiologic responses (Loscalzo and Schafer 1994). 
The pathophysiology of thrombotic events is multicomponent and involves blood, 
vascular system and target sites. Vascular injury results in the localized alterations of 
the vessels and subsequent platelet activation. Activated cells mediate several direct or 
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signal transduction mediated processes resulting in the activation of platelets. Cellular 
activation also results in the release of various mediators which amplify vascular spasm 
and the coagulation process. Thus, anaphylatoxins (C3a and C5a), superoxide, 
leukotrienes (LTC4), thromboxane B2 (TxB2), serotonin, platelet factor 3 (PF3), platelet 
factor 4 (PF4), platelet activating factor (P AF), endothelin-1 and numerous cytokines 
play a role in the overall pathophysiology of the thrombotic process. Drugs that target 
various sites of the activation process can be developed to control thrombotic events. 
Because of the coupled pathophysiology, a single drug may not be able to target these 
sites to produce therapeutic actions. Furthermore, many of these mediators produce 
localized actions at cellular and subcellular levels. The feedback amplification process 
also plays an important role in the pathology of these disorders. This understanding has 
led to the concept of polytherapy in the management of thrombotic disorders. 
Venous insufficiency, blood plasma related disorders, fibrinolytic deficit and an 
imbalance of regulatory proteins result in the activation of the hemostatic process. Post-
surgical trauma, inflammation and sepsis also lead to the activation of the hemostatic 
process leading to venous thrombosis. The primary process in venous thrombosis is the 
generation of thrombin. Thus, drugs targeting coagulation protease activation are useful 
in the treatment of venous disorders (Fareed 1992). However, platelet and cellular 
activation contribute significantly to arterial thrombotic events, and therefore, drugs 
targeting those sites are important in the management of arterial thrombosis and 
microangiopathic disorders. 
The newer developments in antithrombotic drugs are significant. Many advanced 
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techniques to develop anti thrombotic drugs are used at the present time. Advances in 
biotechnology and separation techniques have also contributed to the development of 
newer antithrombotic drugs (Fareed et al. 1988-1992). These drugs may prove to have 
a better efficacy in the control of thrombogenesis and its treatment. Drugs and devices 
which have been or are being developed based on newer concepts and range from heparin 
related drugs and antiplatelet agents to endothelial lining and viscosity modulators. 
Antithrombotic drugs represent a wide spectrum of natural, synthetic, semi-
synthetic and biotechnology produced agents with marked differences in chemical 
composition, physicochemical properties, biochemical actions and pharmacologic effects. 
The use of physical means to treat thrombotic disorders, and advanced means of drug 
delivery, add to the expanding nature of this area. 
The endogenous actions of the antithrombotic drugs are remarkably complex. It 
is no longer valid to assume that an antithrombotic drug must produce an anticoagulant 
action in blood as the conventional heparin and oral anticoagulants. Many of these 
drugs, such as platelet inhibitors, do not produce any alteration of blood clotting 
parameters, yet they are effective therapeutic agents because of their interactions with the 
various elements of the vasculature and other blood components. Another perspective 
is that several of these agents require endogenous transformation to become active 
products. Therefore, it becomes important to rely on the pharmacodynamic actions of 
these agents rather than on their in vitro characteristics to assess potency or efficacy of 
the product. Hematologic modulation plays a key role in the mediation of the 
antithrombotic actions of these drugs involving red cells, white cells, platelets and blood 
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proteins. This is particularly true for the case of trauma induced thrombotic disorders 
where multiple processes are involved in thrombogenesis. 
B. Role of Serine Proteases i.n the Regulation of Coagulation, 
Fibrinolytic, Kallikrein and Complement Pathways 
Blood is a complex liquid tissue that serves as an interface between its own cells 
and those of the organ systems which it perfuses to mediate many vital physiologic 
processes, one of which is prevention of excessive bleeding following trauma, a process 
which is usually referred to as hemostasis. A crucial component of hemostasis is the 
coagulation system. Upon activation, this system results in clotting of liquid blood. The 
processes involved in the activation of the coagulation system are enzymatic in nature and 
are mostly mediated through a series of coagulation factors (proteins) and cofactors 
whose activities are enhanced by ca++ and phospholipids. The activation of the 
coagulation system leads to formation of a key active coagulation factor, thrombin. 
Thrombin is essential in converting liquid fibrinogen to fibrin clots which are deposited 
in platelet plugs to arrest bleeding. In addition, thrombin plays a key role in many other 
physiologic and pathologic processes. 
Thrombin is generated in the blood through two separate enzymatic pathways 
(Ratnoff et al. 1964, Macfarlane et al. 1964). In the intrinsic pathway, components 
intrinsic to whole blood (circulating in blood) are involved through contact activation, 
in the reactions leading to thrombin generation. In the extrinsic pathway, components 
extrinsic to whole blood (not normally in contact with whole blood) are generated or 
activated to initiate a cascade of events leading to thrombin formation. These pathways 
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coalesce at the level of activation of a common enzyme, factor Xa, which activates 
prothrombin leading to thrombin formation. An integrated version of the coagulation, 
fibrinolytic and kallikrein systems is illustrated in Fig 1. 
All of the enzymes involved in blood coagulation normally circulate in inactive 
proenzyme forms as zymogens. When a zymogen is activated to an enzyme, this enzyme 
further activates another zymogen to its active enzymatic state, thus propagating the 
coagulation cascade. The activated form of the zymogen is denoted with a lower case 
"a" following the name of the zymogen. 
The extrinsic pathway is initiated physiologically when membrane surface bound 
tissue factor (TF), on tissues outside the circulatory system, comes in contact and forms 
a complex with blood born factor VIIa through trauma (Bloom et al. 1994). In the 
presence of Ca++ this complex is able to directly activate factor X to factor Xa, also 
shown in Fig.1. Beside the activation of coagulation, this complex is also involved in 
cellular activation at various sites. 
The kallikrein-kinin system is a system of protease interactions in the blood, 
whose major physiological function is to produce bradykinin and other low molecular 
weight kinins. The effects of these peptides on the circulatory system include increased 
vascular permeability, vasodilation of smaller blood vessels, pain, smooth muscle 
contraction and synthesis and enhancement of prostaglandins (Bloom et al. 1994). This 
system also interacts with both the coagulation system and the fibrinolytic system in a 
complex manner. The kallikrein-kinin system can be stimulated by a variety of factors 
such as tissue damage, allergic reactions, viral infections and inflammatory processes that 
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Fig. 1. The coagulation and fibrinolytic system. The interactions and feedback amplifications within the coagulation system 
are depicted, as are its interactions with the fibrinolytic system. - - - indicates inhibition by the major endogenous serpins. '.j;'. 
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lead to plasmatic generation of bradykinin (via proteolytic action of plasma kallikrein on 
high molecular weight kininogen or HMWK) and direct activation of the complement 
system (kallikrein can directly activate CS) (Bloom et al. 1994). Of relevant interest is 
the generation of plasma kallikrein, which is generated through the proteolytic action of 
factor XIIa on prekallikrein, as depicted in Fig. I. Factor XIIa is generated from factor 
XII upon interaction with negatively charged surfaces or collagen as with tissue damage 
and is accelerated by HMWK. The generated kallikrein, with HMWK as a catalyst, can 
then further catalyze the activation of factor XII to factor XIIa. Thus, the kallikrein-
kinin system is linked to the intrinsic activation pathway via kallikrein and factor XII 
(Loscalzo et al. 1994). 
The intrinsic pathway is initiated physiologically by disruption of the vessel wall 
inner lining and exposure of connective tissue elements which provide the negatively 
charged surface necessary for the activation of factor XII by kallikrein and HMWK 
(Loscalzo et al. 1994), as seen in Fig. I. Factor XIIa in turn activates factor XI to factor 
XIa in the presence of Ca++ and HMWK. Kallikrein, factors XII and XI and HMWK 
comprise the group of contact factors. Factor XIa converts factor IX to factor IXa in the 
presence of ca++. Factor IXa binds to a membrane surface bound cofactor, factor VIIIa, 
to form the tenase complex, which activates factor X to factor Xa. 
The extrinsic and intrinsic pathways are not completely independent up to the 
point of formation of factor Xa and interact at different levels during feedback processes. 
For example, factor XIIa from the intrinsic pathway is also capable of activating factor 
VII to VIIa in the extrinsic pathway and factor VIIa is capable of converting factor IX 
to IXa in the intrinsic pathway. Furthermore, factor IXa from the intrinsic pathway is 
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capable of activating factor V in the extrinsic pathway. Thus, enzymatic activations are 
complex and feedback controls are abundant. 
The activation of the two pathways leads to formation of factor Xa which is a 
component of the common pathway. Factor Xa binds to membrane bound factor Va in 
the presence of Ca++ to form the prothrombinase complex. This complex converts 
prothrombin to thrombin which converts fibrinogen to fibrin clot. In addition to 
prothrombin activation, factor Xa also mediates the activation of factor VII in the 
extrinsic pathway, cofactor VIII in the intrinsic pathway and cofactor V in common 
pathway. The function of thrombin in the coagulation cascade is not restricted to 
conversion of fibrinogen to fibrin, but also includes further activation of cofactors V and 
VIII (as does factor Xa), as well as activation of factors XI and XIII. The common 
pathway ends in stabilization of the formed fibrin by factor XIIIa mediated cross-linking 
of the fibrin strands. 
The coagulation system is controlled at various levels by four major physiological 
inhibitors, also shown in Fig. 1: antithrombin, heparin cofactor II (HC-II), tissue factor 
pathway inhibitor (TFPI) and activated protein C (APC). Antithrombin mediates its 
anticoagulant effects by inhibiting thrombin and factor Xa and to a lesser extent factors 
XIIa, Xla, IXa and kallikrein. HC-II directly inhibits only thrombin, while TFPI forms 
an inactive complex with TF and factor Xa. The inhibitory mechanism of APC is more 
complex in that while this enzyme is activated by thrombin and it degrades cofactors 
VIIIa and Va (which are necessary for factor X and prothrombin activation), it requires 
two cofactors for its anticoagulant activities: protein S and factor V (which it degrades 
in the activated form). Thus, activation of coagulation and formation of thrombin also 
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triggers its inactivation. 
The fibrinolytic system, balances the coagulation system by ultimately resulting 
in fibrin clot dissolution. The two systems regulate and balance each other intricately 
and offset towards one or the other system leads to thrombosis or bleeding respectively. 
The enzymes involved in fibrinolysis, similar to the ones involved in coagulation, 
also circulate in their inactive forms under normal physiological conditions. In an 
oversimplified scheme, shown in Fig.1, fibrinolysis is initiated with the formation of 
fibrin clots where plasminogen and thrombin become entrapped. Plasminogen binds to 
fibrin weakly but activators such as tissue plasminogen activator and urokinase, which 
also diffuse into the clot, accelerate the binding of plasminogen to fibrin and mediate its 
activation to plasmin (Bloom et al. 1994). Plasmin then can degrade fibrin to fibrin 
degradation products. The interaction of the kallikrein -kinin system with the fibrinolytic 
system is at the level of urokinase, where kallikrein can directly activate single chain pro-
urokinase to the two chain urokinase (Bloom et al. 1994), also depicted in Fig. 1. 
1. Biochemical Characteristics of Serine Proteases 
All of the blood coagulation factors and enzymes involved in fibrinolysis belong 
to the family of serine proteases with the following exceptions: tissue factor, factors V 
and VIII and HMWK which function as cofactors, factor XIII which is a transamidase 
and fibrinogen which is a non-enzymatic glycoprotein. The blood coagulation serine 
proteases share some common features in terms of their structure and mode of action. 
All are synthesized in the liver, except for Von Willebrand factor (vWF), initially with 
a signal peptide which allows for their translocation to the endoplasmic reticulum, where 
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this peptide is cleaved (Loscalzo et al. 1994). Some of the characteristics of serine 
proteases involved in coagulation are summarized in Table 1. 
The catalytic domain of all blood clotting enzymes is highly homologous to that 
of trypsin (Furie et al. 1982). This domain is composed of a specific site for recognition 
of macromolecular substrates referred to as the specificity pocket and an active site 
referred to as the catalytic triad, which serves for the conversion of inactive zymogens 
to active enzymes via cleavage of specific bonds. The blood clotting enzymes are trypsin-
like enzymes, meaning that they recognize and cleave peptide bonds involving arginine. 
They are also serine proteases. meaning that their active site in the catalytic domain is 
composed of a specific catalytic triad: serine, aspartate and histidine (Stroud et al. 1974). 
Other common features shared among blood coagulation enzymes are epidermal 
growth factor (EGF) domains which consist of 3 disulfide bonds in a characteristic 
covalent structure (Gregory 1977). Factors VII, IX, X, XII, protein C and protein S, 
as well as tPA and pro-urokinase (proUK) from the fibrinolytic system, all have at least 
1 EGF domain. These structures may mediate the binding of factor IX to endothelial 
cells (Ryan et al. 1989). Another structure shared among many blood proteins is the 
Kringle domain, also composed of 3 disulfide bonds in a characteristic covalent structure 
but involving double the amount of amino acids involved in EGF domains and with a 
different three dimensional structure. This type of domain is thought to be important in 
protein complex formation (Parket al. 1986). Among the blood proteins possessing such 
a structure are prothrombin (Magnusson et al. 1973), factor XII (Cool et al. 1987), 
plasminogen (Malinowski 1984), pro-urokinase (Holmes et al. 1985) and tissue- type 
plasminogen activator (Ny et al. 1984). 
Table 1 -- Characteristics of Procoagulant and Pro-fibrinolytic Proteins 
Enzyme Proenzyme 
Commission # MW Plasma Level Natural Substrates Enzyme Type 
Kallikrein 3.4.21.34 85,000 0.6µM Factor XII, sc-uPA, C5 Serine protease 
HMWK 120,000 0.7 µM Cofactor for prekallikrein, 
kallikrein and factor XI 
Factor XIIa 3.4.21.38 80,000 0.4 µM Prekallikrein, factors VII and XI, C 1 Serine protease 
Factor Xla 3.4.21.27 160,000 0.025 µM Factors XII XI and IX Serine protease 
Factor IXa 3.4.21.22 45,000 0.09 µM Factors X, VII and VIIIa Serine protease 
Factor VIIIa 166,000 0.3pM Cofactor for factor IXa 
Factor VIIa 3.4.21.21 50,000 0.01 µM Factors X, IX and VII Serine protease 
Tissue Factor 37,000 OµM Cofactor for TF 
Factor Xa 3.4.21.6 48,000 0.17 µM Prothrombin, factors XII, X, VIII, V Serine protease 
and VIIIa, protein C 
Factor Va 180,000 0.03 µM Cofactor for factor Xa 
Thrombin 3.4.21.5 36,000 2µM Fibrinogen, factors V, VII, VIII, XI Serine protease 
and XIII, protein C 
Fibrinogen 340,000 6-12 µM Non-enzymatic glycoprotein 
Factor XIIIa 2.3.2.13 150,000 0.03 µM Fibrin, a 2plasmin inhibitor, fibronectin, Transglutaminase 
von Willebrand factor, vitronectin, 
actin, myosin, lipoprotein(a) 
Plasmin 3.4.21.7 92,000 2µM Fibrin, plasminogen Serine protease 
tPA 3.4.21.68 68,000 70 pM Plasminogen Serine protease 
uPA 3.4.21.73 33,000 150 pM Plasminogen Serine protease 
The proenzyme forms of these proteases have the same MW as the active enzymes, with the following exceptions: factor XI (MW 
of 55,000), factor VIII and factor V (MW of 330,000), factor X (MW of 59,000), prothrombin (MW of 72,000), factor XIII (MW 
of 320,000) and sc-uPA (MW of 54,000). Loscalzo and Schafer 1994, Bloom et al. 1994, High and Roberts 1995. 
......... 
\0 
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Prothrombin, factors VII, IX, X, and the inhibitory proteins, namely protein C 
and protein S require vitamin K for their synthesis (Stenflo et al. 1974, Nelsestuen et al. 
1974). These are the vitamin K-dependent proteins and the requirement for vitamin K 
stems from a characteristic string of 10-12 glutamic acid residues of these proteins in the 
first 45 amino acids of their amino termini. Vitamin K is required for the carboxylation 
of these residues to form dicarboxylic acid side chains ( 'Y-carboxyglutamic acid residues 
or Gla domains) which are necessary for binding ca++ and assembly on membrane 
surfaces in the presence of these ions. The carboxylation of these residues is catalyzed 
by a membrane bound hepatic microsomal '}'-Carboxylase in the presence of reduced 
vitamin K, as a post-translational step in the synthesis of these proteins. 
2. Role of Serine Proteases and Cofactors in the 
Hemostatic and Hemorrhagic Processes 
Certain defects in the coagulation and fibrinolytic systems as well as other causes 
can lead to development of thrombosis. The pathophysiology of thrombosis in the 
arterial system is quite different from that in the venous system and it is important that 
they are recognized and understood for effective differential clinical management. 
Arterial thrombosis is frequently associated with atherosclerosis (Davies et al. 
1985). Thrombosis is initiated by disruption of atherosclerotic plaques which exposes 
the subendothelium to the blood (Falk et al. 1983, Fuster et al. 1988, Davies et al. 1984, 
1985). This leads to activation of platelets and their aggregation, followed by 
stabilization of this platelet aggregate by fibrin generated from the activation of the 
coagulation cascade (Davies et al. 1986). Therefore, the plug formed at the site of 
atherosclerotic lesioning is a platelet-rich clot. This clot may remain attached to the site 
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of injury and may grow to completely obstruct the blood vessel. Thrombogenic factors 
involved in this kind of thrombosis are damage to the vessel wall exposure of TF and 
connective tissue elements with subsequent activation of coagulation. Treatment of 
arterial thrombotic disorders include antiplatelet agents (to prevent further activation of 
platelets which are the building block of arterial thrombi), anticoagulants (to inhibit the 
coagulation cascade, highly controversial but with positive results -Resnekov et al. 1989, 
Theroux et al. 1988) and thrombolytic therapy (to accelerate fibrinolysis, Cairns et al. 
1989). When these non-invasive treatments fail to re-open an occluded vessel, invasive 
procedures are employed such as endarterectomy, embolectomy, arterial bypass surgery 
and angioplasty. More recently, to stabilize the vessels non-thrombogenic supporting 
devices such as stents are also used. 
There is always a low basal level (subclinical) of coagulation activation produced 
even in normal subjects (Conway et al. 1987) but the activated coagulation factors are 
normally cleared by flowing blood, or controlled by plasma inhibitors and inhibitors on 
the surface of endothelial cells (Esmon et al. 1987). When blood coagulation exceeds 
the anticoagulant system and the fibrinolytic system, thrombosis occurs, most frequently 
in the large venous sinuses of the calf and in the deep vein valve cusps of the calf. The 
thrombi formed in such locations are composed primarily of fibrin and red cells (no 
platelets) (Frieman 1987). The thrombogenic factors involved are activation of blood 
coagulation, venous stasis and vessel wall damage.~.~~~!!y:ation ofbleed·-eoagulation may ··- ·· · 
occur as a result of disseminated malignant disease (Gordon et al. 1975) or even infusion 
. " ' 
of activated factor concentrates (Kingdon et al. 1979). Venous stasis (impediment in 
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venous return) can be the result of immobility, increased venous pressure, venous 
dilation, venous obstruction or increased blood viscosity (Leonard 1987). Vessel wall 
damage may occur after surgical procedures or after trauma and results in the expression 
of tissue factor activity which leads to activation of coagulation and thrombus formation. 
Pharmacological treatment of venous thrombosis consists of thrombolytic and 
anticoagulant therapy. The most common preventable cause of death in a hospital setting 
is venous thromboembolism (Salzman et al, 1987), where a venous thrombus breaks off 
to produce satellites which lodge in pulmonary vessels causing a variety of pathologic 
effects which may lead to death if untreated. Prophylaxis of venous thromboembolism 
consists of anticoagulants in conjunction with intermittent leg compression. 
A hypercoagulable state can arise not only from the above clinical disorders, but 
may also be a result of an inherited thrombotic disorder. These inherited disorders may 
be deficiencies in protein C or protein S, antithrombin, plasminogen and fibrinogen. 
Taking a closer look at the coagulation enzymes, it is evident that activation of certain 
enzymes has a stronger impact than that of others. This point is illustrated best when 
comparing the coagulation disorders arising from deficiencies or disorders in various 
blood coagulation factors. 
a. High Molecular Weight Kininogen (HMWK) 
In the coagulation cascade, HMWK functions as a cofactor for prekallikrein, 
kallikrein and factor XI. Prekallikrein and factor XI circulate in the blood as complexes 
with HMWK (which mediates surface binding) while the presence of HMWK catalyzes 
the activation of factor XII by kallikrein. Apart from its role in the coagulation cascade, 
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HMWK is also the precursor to the vasoactive peptide bradykinin, which results from 
the proteolytic action of kallikrein on HMWK. Deficiency in HMWK is a rare 
autosomal recessive deficiency and the individuals characterized with this disorder do not 
suffer from bleeding complications, despite markedly prolonged coagulation tests 
(Cheung et al, 1993, Hayashi et al, 1990). No association between HMWK deficiency 
and hypertension has been made. 
b. Prekallikrein 
Prekallikrein circulates in the blood as a complex with HMWK and is activated 
to kallikrein by the action of factor XIIa (Bloom et al. 1994). Kallikrein then, in the 
presence of HMWK further activates factor XII. In addition, kallikrein also 
proteolytically releases bradykinin from HMWK, directly activates C5 in the complement 
system and activates pro-urokinase to urokinase in the fibrinolytic system. Thus, 
deficiency in this factor may be expected to be precipitate disorders associated with all 
of these systems. However, individuals diagnosed with this deficiency appear to have 
no bleeding diatheses, even though the APTT is prolonged, and although intrinsic 
fibrinolytic activity is reduced, the association with thromboembolic complications is 
questionable (Wuillemin et al. 1993, Hess et al. 1991, Castaman et al. 1990, Bouma et 
al. 1986, Sollo and Sallem, 1985). This deficiency is transmitted in an autosomal 
recessive manner. 
c. Factor XII 
Factor XII is activated by kallikrein (Meier et al. 1977, Griffin et al. 1978, 
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Fujikawa et al. 1980) and this conversion of factor XII to factor XIIa is accelerated by 
HMWK and negatively charged surfaces or collagen (Ratnoff et al. 1966, Wilner et al. 
1968). Factor XIIa functions to convert factor XI to factor Xla and prekallikrein to 
kallikrein. In addition, factor XIIa can directly stimulate the complement system, by 
activating C 1. As with deficiencies in HMWK or prekallikrein, deficiency in this factor 
(Ratnoff et al. 1955) may be discovered in preoperative evaluations and is not associated 
with a bleeding history nor with excess bleeding during surgical procedures. Factor XI's 
coagulant function is not impaired even if its physiological activator (factor XIIa) is 
absent. Patients lacking factor XII also have low plasminogen activity which, however, 
is not associated with defective fibrinolysis. 
d. Factor XI 
Factor XI circulates in blood as a complex with HMWK, as does prekallikrein. 
Factor Xla (resulting from the action of factor XIIa on factor XI, described above) 
functions to catalyze the activation of factor IX to factor IXa (Bloom et al. 1994). 
Deficiency in factor XI (Rosenthal et al. 1953) is inherited and is due to abnormalities 
in the gene of this factor which may lead to heterozygote, compound heterozygote or 
homozygote patients. Bleeding complications arise only after trauma and the severity of 
these episodes varies proportionally with the deficiency in the factor. However, low 
levels of factor XI are not always associated with bleeding and this may be due to platelet 
membrane factor XI-like activity or the interaction with factor VIia in the extrinsic 
pathway which can also activate factor IX. 
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e. Factor IX 
Factor IX is activated by either factor Xia (Fujikawa et al. 1974, DiScipio et al. 
1978, Davie et al. 1987) or factor VIia/tissue factor complex (Osterud et al. 1977), 
always in the presence of Ca++ while it is in solution (in contrast to the other vitamin 
K dependent clotting factors which have to be bound to be activated). Both factors IX 
and IXa bind on platelet surfaces or the surface of endothelial cells. This binding to cell 
surfaces is enhanced by factors V, VIII and X and renders factor IXa about 3 times more 
active than in solution. The activation of factor IX is slow compared to the rest of the 
coagulation steps, which signifies its importance in the control of the coagulation 
cascade. At the site of injury, factor IX is slowly activated which leads to inefficient 
activation of factor X on cell surfaces. This activated factor Xa then leads to activation 
of factor VII/tissue factor complex which then can further activate both factors IX and 
X leading to "burst" of coagulant activity (Warn-Cramer et al. 1986). 
Deficiency in factor IX is sex-linked recessive and may arise from defects in its 
gene on chromosome X, such as point mutations, gene deletions, missense mutations and 
gene insertions, and are the cause of the bleeding disorder termed Hemophilia B and 
Christmas disease. Hemophilia B (Mandel et al. 1988) can also result from production 
of normal levels of factor IX but defective post-translational factor IX protein processing 
that may affect the ')'-carboxylation, EGF domain and function, zymogen activation, 
substrate recognition and enzyme activity (Green et al. 1989). Hemophilia B patients 
suffer from excessive bleeding in the form of easy bruising and frequent hematomas that 
often spread after a few days and may become life-threatening. Current treatment 
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approaches include factor IX concentrates, fresh-frozen plasma or supernatant from 
cryoprecipitates. 
f. Factor VIII/von Willebrand Factor Complex 
Although factor VIII is a cofactor and not a serine protease, it deserves attention 
since deficiencies in this protein lead to Hemophilia A. The circulating form of this 
cofactor is inactive and it is activated to factor Villa by thrombin or factor Xa (Pittman 
et al. 1988). Factor VIII is an unstable protein when free in solution and it circulates as 
a stable complex with von Willebrand factor (vWF), a completely different protein under 
separate genetic control (Kaufman et al. 1988, Weiss et al. 1977, Brinkhaus et al. 1985, 
Koedam et al. 1989). The two proteins have different physiologic functions as well: 
vWF is essential for platelet adhesion to subendothelium, whereas factor VIila serves as 
a cofactor for factor IXa to activate factor X. Whereas phospholipid surfaces serve to 
anchor and concentrate factors IXa and X (enzyme and substrate respectively) factor 
Villa binds to both previous factors, increasing the forward rate of catalysis of factor X 
to Xa by factor IXa. Factor Villa is thus able to accelerate the activation of factor X by 
factor IXa by 10,000 in the presence of Ca++ and phospholipids. 
Hemophilia A is sex linked and is due to defects of the factor VIII gene located 
on the X chromosome, such as deletions, insertions, base mutations, transitions and point 
mutations (White et al. 1989, Antonarakis et al. 1988, Vehar et al. 1989, Gitschier et al. 
1989). The bleeding abnormalities associated with factor VIII deficiency include joint 
and muscle hemorrhages that lead to disabling long-term events, easy bruising and 
prolonged post-operational bleeding. The platelet function is normal and therefore there 
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is no excessive bleeding from minor cuts. Current clinical treatment strategies include 
immobilization, compression, E-aminocaproic acid (EACA) which is an anti-fibrinolytic 
agent and in more severe cases factor VIII or factor IX concentrates. 
g. Tissue Factor 
Tissue factor (TF) is a 30,000 integral membrane glycoprotein that serves as a 
cofactor and is required for the activation of factor VII (Broze et al. 1985, Guha et al. 
1986, Bach et al. 1986, Nemerson 1988). In addition to catalyzing the activation of 
factor VII, TF also enhances the catalytic activity of factor VIia (Andree and Nemerson, 
1995), since factor VIia alone has negligible coagulant activity. The crystal structure of 
the TF /factor VIia has been recently reported (Banner et al. 1996). While TF is 
expressed on the surface of a variety of cell types, non of these cells are normally in 
contact with blood. Basal coagulation levels are due to circulating factor VIia, which 
corresponds to about 1 % of the total factor VII antigen. However, since blood is not 
physiologically exposed to TF and free factor VIia has minimal activity, only low level 
of coagulation is normally in effect and is readily counteracted by endogenous inhibitors 
and the basal fibrinolytic system. 
Other functions of TF are currently unknown, however various cells are believed 
to have TF receptors. Many of the post-surgical and post-interventional thrombotic 
events are due to the release of TF. Increased levels of TF are associated with several 
pathologic conditions such as cancer, sepsis and inflammation (Bloom et al. 1994). 
Cellular necrosis also results in an increase of TF as the cells in the traumatized area lyse 
and release endogenous cell surface-bound TF. TF has been mapped by using 
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immunohistochemical methods in various tissues, such as the brain, kidney, spleen, liver, 
skin, gut, vessels, adrenal glands and peripheral nerves (Feleck et al. 1990). TF is 
produced constitutively by cells that are normally separated from blood by the vascular 
endothelium. It is present in the subendothelial sites and is only exposed after endothelial 
damage. TF is also produced in response to a host of stimuli, including endotoxin, 
complement C5a, immune complexes, interleukin-I and tumor necrosis factor (Fleck et 
al. 1990) in a variety of cells. In addition, TF is also generated under some pathological 
conditions by monocytes, some tumor cells, foam cells of atherosclerotic lesions, smooth 
muscle cells and their mesenchymal derivatives (Koyama et al. 1994, Takahashi et al. 
1994, Adamson et al. 1994, Carty et al. 1990, Marmur et al. 1993, Muller et al. 1993, 
Callander et al. 1992, Lockwood et al. 1991). No deficiencies in this factor have been 
reported. 
h. Factor VII 
After factor VII has complexed with TF, it is most rapidly activated by factor Xa, 
although factors Vila (auto-activation), IXa, Xlla and thrombin also activate this factor. 
Factor Vlla/TF complex then activates factor X directly or via activation of factor IX to 
IXa (Radcliffe et al. 1973, Jesty et al. 1974). A small amount of generated factor Xa 
serves as feedback loop to activate factor VII to Vila, resulting in amplification of 
extrinsically generated thrombin. Deficiency in factor VII is a rare autosomal recessive 
disorder and results from point mutations or partial gene deletions and can lead to worse 
bleeding than deficiency in factor IX (Ragni et al. 1981, Briet et al. 1987, Bernardi et 
al. 1994, Chaing et al. 1994). The clinical symptoms are variable and poorly 
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understood, ranging from none (Ohiwa et al. 1994) to cerebral hemorrhage (Papa et al. 
1994) to thromboembolism Martini et 1992, Mitropoulos et al. 1992). Factor VII 
deficiency is the only deficiency that results in prolongation of the PT with a normal 
APTT. Therapy of factor VII deficient patients consists of factor IX concentrate or 
plasma supplementation. 
I. Factor X 
Factor X is a Ca++ dependent protein that interacts with acidic phospholipids. 
Factor X and factor Xa bind to endothelial cells and are endocytosed. While factor Xa 
is degraded by lysosomes, factor X reappears on the cell surface. The activation of 
factor X to factor Xa is the point where the intrinsic and extrinsic pathways of 
coagulation join, since it is activated by either factor VIIa/TF complex or by factor 
IXa/factor VIIIa complex. Factor V is a cofactor necessary for the catalytic activity of 
factor Xa and is activated to factor Va by thrombin. Factor Xa can then form a complex 
with factor Va to form the prothrombinase complex, and this complex catalyzes the 
conversion of prothrombin to active thrombin, which then in turn converts fibrinogen to 
fibrin. 
The concentration of factor V in plasma is lower than that of factor X (Nesheim 
et al. 1981, Miletich et al. 1981) and without TF available (as under normal conditions) 
only the VIIIa/IXa complex can catalyze the activation of factor X (Drake et al. 1989). 
Thus, as in the PT assay, the supplementation of large exogenous TF, after complexation 
with the basal factor VIIa, causes a direct activation of factor X that is then able to 
saturate all of the available factor V. The generated factor Xa can then further catalyze 
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the activation of factor VII, thus resulting in an amplified loop of the extrinsic pathway 
of coagulation, leading to generation of massive amounts of thrombin with the end result 
of formation of thrombi. 
Factor X deficiency (Hougie et al. 1956) is an autosomal recessive trait resulting 
from 4 point mutations to its gene (Watzke et al. 1990, Reddy et al. 1989). Treatment 
regimens include fresh-frozen plasma or factor IX concentrate supplementation. 
j. Factor XIII 
Factor XIII is a transglutaminase that, once activated by thrombin to factor XIIIa, 
it cross links fibrin ~trands, thus making them more stable and less susceptible to 
proteolytic digestion by plasmin. Factor XIII deficiency is a rare autosomal recessive 
disorder that results in bleeding diathesis and delayed hemorrhages in soft tissues after 
a primary plug is successfully formed. About fourteen different mutations have been 
reported and most of them are due to point mutations (Mikkola et al. 1996). 
k. Plasmin 
Just as thrombin is the key enzyme in the coagulation cascade, plasmin is the key 
enzyme in the fibrinolytic system. Plasmin results from the two-step activation of 
plasminogen, upon the action of plasmin and plasminogen activators (tissue type 
plasminogen activator and urokinase type plasminogen activator). The activators cleave 
the Arg561-Val562 bond which on the plasminogen molecule converts it Glu-plasmin (a less 
active form of plasmin) and on the Lys-plasminogen molecule converts it to fully active 
plasmin. Plasmin cleaves the Lys77-Lys78 bond, which on the plasminogen molecule 
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converts it to Lys-plasminogen and on Glu-plasmin converts it to fully active plasmin. 
Plasmin then acts on both fibrin and fibrinogen to produce degradation products, which 
is the mechanism by which plasmin mediates clot dissolution (Bloom et al. 1994). 
Genetic variations in the plasminogen molecule are present in the normal population and 
they are not associated with pathologic states. However, mutation resulting in 
dysfunctional plasminogen, associated with thromboembolic complications, have been 
isolated in Japanese populations and in one European Jewish patient (Robbins 1992). 
I. Tissue Type Plasminogen Activator (tPA) 
tPA is a serine, protease of the fibrinolytic system (Pennica et al. 1983). tPA is 
a relatively insignificant enzyme when not bound to fibrin, but after binding to fibrin it 
is able to activate plasminogen to plasmin (Hoylaerts et al. 1982). Plasmin (also a serine 
protease) then can degrade fibrin, thus exposing new tPA binding sites on the underlying 
fibrin (Higgins et al. 1987). In addition to binding to fibrin, tP A also binds to receptors 
on endothelial cells as does plasminogen which may provide focal points for plasmin 
generation. An association between the contact system and the stimulation of the 
fibrinolytic system is made at this point: bradykinin, resulting from the action of 
kallikrein on HMWK, directly stimulates the release of tP A from endothelial cells 
(Tranquille et al. 1989), so that when intrinsic activation of the coagulation cascade 
occurs, the fibrinolytic system is also activated. Furthermore, thrombin is the most 
potent inducer of secretion of tissue-type plasminogen activator (tPA) from endothelial 
cells (Mosher 1990). 
Although no reports on mutant tPA production have been made, reduced tPA 
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production or decreased release of tPA may contribute to thrombosis in about 10-20 % 
of patients with deep vein thrombosis who have an inadequate fibrinolytic response 
(Juhan-Vague et al. 1987). However, there is little evidence to support this hypothesis 
and the current thinking is that reduction of available tP A is mostly due to increased 
complexation with plasminogen activator inhibitors, secondary to increase in plasminogen 
activator inhibitors. 
m. Urokinase Type Plasminogen Activator (uPA) 
Single-chain urokinase type plasminogen activator (sc-uPA) acts on plasminogen 
to convert it to plasmin-Lijnen et al, 1987). Plasmin then converts sc-uPA to a two chain 
derivative (tc-uPA, Lijnen et al. 1987). This tc-uPA further cleaves plasminogen to 
plasmin. The difference between tc-uP A and sc-uP A is that the former accelerates the 
conversion of plasminogen to plasmin without being specific towards fibrin while sc-uPA 
is specific towards fibrin (Lijnen et al. 1986). An additional association between the 
contact system and the fibrinolytic system is made at this level: kallikrein can directly 
mediate the conversion of sc-uP A to tc-UP A, so that intrinsic activation of coagulation 
also precipitates fibrinolytic activation (Bloom et al. 1994). 
3. Regulation of Serine Proteases by Serpins 
Blood coagulation is controlled by many physiologic inhibitors, called serpins 
(serine Q.rotease inhibitors). Among these are protein C and protein S, antithrombin 
(antithrombin-III), Heparin Cofactor II, C1inactivator (C1esterase inhibitor), a 2plasmin 
inhibitor (a2antiplasmin), a 1proteinase inhibitor (a1antitrypsin) and a 2macroglobulin. 
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Some of the characteristics of these inhibitors are listed in Table 2. Acquired and 
congenital deficiency of these factors predisposes to thrombotic or bleeding diseases. 
a. Antithrombin 
Thrombin is inactivated by a class of serpins called antithrombins. The most 
significant of these inhibitors is antithrombin (also referred to as antithrombin III) which 
inactivates heparin bound thrombin faster than free thrombin (Pomerantz and Owen 1978, 
Griffith 1982, Nesheim 1983). The activity of antithrombin is catalyzed by the presence 
of heparin which acts as a cofactor by binding to antithrombin to form a non-covalent 
ternary complex. Ad~itional actions of antithrombin include inhibition of factors IXa, 
Xa, Xla, XIIa, kallikrein and plasmin. 
I 
Deficiency in antithrombin, congenital heterozygous or acquired, leads to 
thrombotic episodes when the hemostatic system is stressed. Hereditary deficiencies of 
antithrombin include quantitative and qualitative abnormalities and their classification is 
controversial at present, although many of them have been molecularly analyzed and over 
50 point mutations have been reported (Lane et al. 1993). Treatment of patients with 
thromboembolic disorders due to deficiency in antithrombin consists of replacing the 
levels with antithrombin concentrates and heparin. 
b. Heparin Cofactor II 
Thrombin is also inactivated by heparin cofactor II (HC-II). HC-II is present in 
plasma at concentrations approximately half of antithrombin. HC-II has a similar 
mechanism of action to that of antithrombin in that its action is catalyzed in the presence 
Table 2 -- Characteristics of Inhibitors of Procoagulant and Pro-fibrinolytic Proteins 
MW Plasma Level Natural Targets 
Antithrombin 58,000 2.6µM Thrombin, factors IXa, Xa, Xia and Xlla, kallikrein, plasmin 
HC-11 66,000 0.09 µM Thrombin 
TFPI 33,000 3.5 nM Factor Vlla/TF and factor Xa 
APC 62,000 0.08 µM Factor Va and VIiia, PAI-1 (enzyme commission# 3.4.21.69) 
Factor V 330,000 0.03 µM cofactor for APC 
Protein S 75,000 0.33 µM cofactor for APC, factor Va, factor Xa 
a 2plasmin inhibitor 65,000 0.6-1.2 µM Plasmin, thrombin, kallikrein, tP A, uP A, trypsin, chymotrypsin 
PAI-1 52,000 0.4 µM APC, tPA, uPA 
PAl-2 47,000 <0.001 µM uPA, tPA, plasmin 
PCI 57,000 0.06-0.12 µM Thrombin, factors Xa and Xia, kallikrein, trypsin, tPA, uPA, APC 
PN-1 50,000 0 Thrombin, factor Xa, trypsin, kallikrein, tP A, uP A, plasmin 
a 2macroglobulin 845,000 22-50 µM Thrombin, factor Xa, kallikrein, plasmin, tPA, trypsin, elastase, 
collagenase, cathepsin C, APC 
a 1proteinase 104,000 13-31 µM Thrombin, kallikrein, factors Xa, Xia, trypsin, plasmin, elastase, 
inhibitor cathepsin G, APC 
cl inactivator 725,000 0.25 µM Factor Xia, complement system 
Loscalzo and Schafer 1994, Bloom et al. 1994, High and Roberts 1995.2 
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of heparin (Blinder et al. 1988). The physiologic role of antithrombin and HC-II differ 
in that HC-II is a specific inhibitor of thrombin without reacting with other serine 
proteases, while in contrast to antithrombin, it can slowly inactivate chymotrypsin-like 
proteases (Parker et al. 1985, Church et al. 1985). Only two deficiencies of this cofactor 
have been molecularly analyzed, HCII Oslo (Blinder et al. 1989) which is asymptomatic 
and HCII Awaji (Kondo et al. 1996) which is associated with coronary artery disease 
(Matsuo et al. 1992). 
c. Tissue Factor Pathway Inhibitor 
Tissue factor pathway inhibitor (TFPI) , also known as extrinsic pathway inhibitor 
(EPI) or lipoprotein associated coagulation inhibitor (LACI), is present in plasma in 
different molecular forms which are primarily determined by its association with 
circulating lipoproteins. TFPI is a Kunitz-type protease inhibitor (Wun et al. 1988, 
Girard et al. 1989). One domain of this protease binds to the factor VIIa/TF complex 
while another binds to factor Xa, thus blocking both the extrinsic pathway leading to 
thrombin formation and the amplification of the same pathway by factor Xa (Broze et al. 
1988, Hjort et al. 1957). Therefore, while antithrombin controls the final stage of 
coagulation, TFPI regulates the activation of coagulation (Abildgaard 1995). TFPI is 
present in the plasma at ng/ml concentrations (Warr et al, 1989). The vascular 
endothelium secretes TFPI in culture (Broze et al. 1987, Warr et al. 1989) but the stimuli 
that lead to release or increase in plasma TFPI are not well defined and neither is their 
mechanism of action. It is known that intravenous and subcutaneous heparin as well as 
low molecular weight heparins, acidic glycosaminoglycans and their synthetic analogues, 
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cause the release of TFPI bound to the luminal surface of the vascular endothelium 
(Sandset et al. 1988, Fareed et al. 1994, Hoppensteadt et al. 1995, Samama et al. 1994, 
Jeske et al. 1995). Recently, there has been a proposal of a heparin-recognition site on 
the TFPI molecule, but further studies are needed to support this model (Harenberg et 
al. 1995). 
d. Protein C 
Protein C and protein S are vitamin K dependent proteins produced in the liver. 
Protein C is slowly activated by free thrombin to activated protein C (APC), but when 
thrombin is bound to its endothelial receptor, thrombomodulin, the activation of protein 
<2 is catalyzed (Esmon et al. 1989). The function of APC is to inactivate factors Va and 
VIiia (the two cofactors of the coagulation system) via proteolysis. Factor Va bound to 
factor Xa is protected from protein Ca inactivation, as is factor VIiia bound to factor IXa 
(Walker et al. 1987, Bertina et al. 1984, Rick et al. 1988). However, when factor Va 
is bound to the endothelial surface it catalyzes the activation of protein C (Maruyama et 
al. 1984). 
Another function of APC is to complex with plasminogen activator inhibitor 3 
(PAl-3), also referred to as protein C inhibitor (PCI), which renders both proteins 
inactive (De Fouw et al. 1987). While PAl-3 is the major APC inhibitor, plasminogen 
activator inhibitor 1 (P Al-1) also inhibits APC. Other inactivators of APC include 
a 2macroglobulin and a 1proteinase inhibitor (a1antitrypsin). 
Acquired and congenital deficiencies of APC have been reported to cause 
thrombotic syndromes such as DVT, microangiopathy and necrosis due to a deficit of 
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protein C or its production (Griffin et al. 1981, Broekmans et al. 1983). At least 55 
different mutations of protein C have been discovered and they are transmitted as 
autosomal dominant traits (Gandrille et al. 1995). These mutations result in variable 
degrees of plasma protein C levels and the individuals with these mutations may be 
asymptomatic or they may develop thrombotic episodes such as purpura fulminans, skin 
necrosis and disseminated intravascular coagulation (Gandrille et al. 1995). 
e. Protein S 
APC is potentiated by protein S, which is a cofactor synthesized and secreted in 
the liver and endothelial cells. In addition, protein S is capable of independently 
inactivating factor Va (Heeb et al. 1993) and factor VIIIa (Heeb et al. 1994). Its activity 
is regulated by the C4b-binding protein, which forms an inactive complex with proteins 
S. Familial protein S deficiency is associated with recurrent venous thrombosis (Comp 
and Esmon, 1984, Schwartz et al. 1984) and with arterial thrombosis (Girolami et al. 
1989, Allaart et al. 1990). 
f. Factor V 
Another essential cofactor for the activity of APC is factor V in its native 
proenzyme form. Thus, while the active form of factor V serves as a cofactor for factor 
Xa to mediate procoagulant activities, factor V is a cofactor for APC that mediates the 
inactivation of factor Va (and VIIIa). More recently, a new syndrome known as APC 
resistance has been identified and is claimed to be the most common cause of inherited 
venous thrombosis (Svensson and Dahlback 1994). Most of the individuals exhibiting 
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APC resistance possess a point mutation of factor V represented by a substitution of 
Arg506 with Gln (Factor V Leiden). In contrast to the normal factor V molecule, the 
mutant form does not retain its regulatory function as a cofactor in the mediation of 
APC's effects in the inactivation of factor Va and factor VIIIa. In addition, the mutant 
form of factor V is activatable by thrombin to factor Va and it retains its procoagulant 
activity as a cofactor for factor Xa. Furthermore, the mutant form of factor Va is non-
susceptible to the digestive action of APC. Another recently characterized factor V 
mutation resulting in factor V deficiency has been characterized, in which a missense 
mutation of Ala221-to-Val occurs (Factor VNew Brunswick, Murray et al. 1995). 
g,___g_2Plasmin Inhibitor 
Free plasmin is rapidly inactivated by a 2plasmin inhibitor (or a 2antiplasmin), 
another serpin (Collen et al. 1986, Wiman et al. 1978). When plasmin is bound to 
fibrin, the binding sites for a 2plasmin inhibitor on plasmin are occupied so that 
inactivation is slow (Wiman et al. 1978). a 2plasmin inhibitor also inhibits tPA. 
Aprotinin is a synthetic inactivator of plasmin, approved in 1995 by the U.S. FDA for 
clinical usage during cardiac bypass surgery. 
Additional plasmin inhibitors include plasminogen activator inhibitor 1, protease 
nexin 1, a 2macroglobulin, a 1proteinase inhibitor and C1inactivator. 
h. Plasminogen Activator Inhibitors 
Plasminogen activator inhibitor 1 (PAI-1) is the primary inhibitor of tPA and uPA 
in plasma (Lawrence et al. 1989, Pannekoek et al. 1986, Kruithof et al. 1984). In 
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addition, PAI-1 inhibits plasmin, thrombin and APC. The major source of PAI-1 is 
vascular smooth muscle cells and it is also released from activated platelet ex granules. 
In endotoxemia and other pathological disorders endothelial cells are the major site of 
P AI-1 synthesis. 
Plasminogen activator inhibitor 2 (PAI-2), or placental PAI, is produced by the 
placenta and is significantly increased during pregnancy. PAI-2 inhibits tc-uPA and tPA, 
but the physiological function of this inhibitor is unknown. 
Plasminogen activator inhibitor 3 (PAI-3) or protein C inhibitor (PCI), is 
synthesized in the liver and inactivates several serine proteases including APC, kallikrein, 
thrombin, factors Xa and Xla, uPA and tPA. PCI is the major inhibitor of APC. 
C. Thrombin: Structure, Function, Physiologic, 
Pathologic and Pharmacologic Mechanisms 
1. Biology of Thrombin Formation and Structure of the Thrombin Molecule 
Negatively charged phospholipids such as on the surface of activated platelets promote 
factor activation leading to thrombin formation. More specifically, thrombin is formed 
by the proteolytic cleavage of prothrombin by the prothrombinase complex, which is the 
complex of factor Xa, Va, ca++ and phospholipids, that cleaves prothrombin twice 
(Suttie et al. 1977). It is the amino terminal prothrombin fragment that results in active 
ex thrombin (Magnusson et al. 1975) and in contrast to most activated serine proteases, 
thrombin loses most of its activation peptide which forms the small A chain of the 
molecule (Dodt et al. 1990). A diagrammatic representation of the tertiary conformation 
of the thrombin molecule (Fenton et al. 1988) is depicted in Fig. 2. 
FIBRINOPEPTIDE 
GROOVE 
CHO 
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'-----APOLAR BINDING SITE 
Fig. 2. Three dimensional model of human a-thrombin (Fenton 1988). Among other 
important structural features, the proteolytic cleavage sites fi and "Y (autoproteolytic 
digestion or trypsin), E (elastase), ~ (chymotrypsin or cathepsin G) are depicted near the 
anion-binding site. 
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a thrombin is different from the other serine proteases in its mode of proteolytic 
action: this protein possesses three important exosites adjacent to its catalytic site which 
serve to align protein substrates and inhibitors optimally. The human thrombin molecule 
is composed of two chains, A (36 residues) and B (259 residues), linked together by a 
single disulfide bridge. The function of the A chain remains unknown although it may 
be implicated in conformational stability of the protein. From crystallographic (Bode et 
al. 1989) and computer-generated models (Fenton et al. 1986, Bing et al. 1981, Furie 
et al. 1982) of the thrombin molecule, the structure and nature of the molecule has been 
characterized. The B chain of thrombin assumes a round conformation with a substrate 
groove resembling a deep narrow canyon. The catalytic site of thrombin, composed of 
the catalytic triad His-57, Asp-102, Ser-195, lies in the center of the global mass, in the 
groove. When fibrinogen fits into this groove and it is cleaved at the catalytic site of 
thrombin, the right half of the groove is occupied by fibrin (fibrin groove, carboxy 
terminus of fibrinogen) while the left half is occupied by the fibrinopeptide 
(fibrinopeptide groove, amino terminus of fibrinogen). The interior of the groove is 
composed of apolar residues and lined on the exterior with charged groups (Fenton 
1986). The region above the catalytic site is also very hydrophobic. The site of 
fibrinopeptide groove next to the catalytic site is notably hydrophobic and forms the 
apolar binding site of thrombin (Berliner et al. 1977, Sonder et al. 1984). On the 
opposite site of the catalytic site across from the apolar binding site is the anion binding 
exosite I, which is composed of a long peptide segment rich in arginines and lysines 
(Fenton et al. 1986). This cluster of positively charged residues is involved in fibrinogen 
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recognition and hirudin complexation (Fenton et al. 1988). ex thrombin possesses another 
anion binding exosite II which seems to play a synergistic role with the anion binding 
exosite I in the binding of heparin (Church et al. 1989). This second anion binding 
exosite is located above the catalytic groove. Thrombin also has a single carbohydrate 
attachment for carboxylation but no known function has been yet attributed to this moiety 
(Horne et al. 1984). Another domain of ambiguous importance is the Arg-Gly-Asp 
sequence which may be involved in thrombin receptor recognition under certain 
circumstances. 
Differences between the bovine and the human thrombin molecule are distinct in 
structure and lead to functional differences. The structural differences were delineated 
with electron spin resonance and fluorescence studies (Nienaber and Berliner, 1991). 
These studies revealed that the active site region of the bovine molecule is more apolar 
but more accessible. Furthermore, a hydrophobic insertion loop penetrates and thus 
obstructs the human thrombin active site. This is not observed with the bovine molecule 
and this difference accounts for the inability of aprotinin to inhibit the human form but 
not the bovine variant. Deletion of this insertion loop in the human thrombin resulted 
in the mutant des-PPW thrombin, which remains a specific serine protease but is 
sensitive to aprotinin, indicating that other structural factors are also involved in the 
narrow specificity of thrombin (Le Bonniec et al. 1993). The apolar binding site on the 
human and bovine ex thrombin molecules also differs, as does the 'Y cleavage site that 
converts human ex thrombin to 'Y thrombin (Nienaber and Berliner, 1991). In the bovine 
ex thrombin, the 'Y cleavage site does not exist and therefore 'Y bovine thrombin cannot 
be formed (Fenton and Bing, 1986). 
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2. Molecular Variants of Thrombin 
Human a thrombin degrades either auto-proteolytically (slowly) or via the action 
of trypsin (rapidly) to 6 and then to 'Y thrombin with loss of its clotting activity (Fenton 
et al. 1977, a and b). The cleavage sites for formation of both thrombins lie in the anion 
binding exosite I (fibrinogen recognition site, Fenton 1986, Fenton 1988). Since trypsin 
does not normally circulate in the bloodstream and since autoproteolytic cleavage is slow, 
these forms of thrombin (6 and 'Y) are not found in vivo (Fenton and Bing, 1986). Since 
bovine thrombin lacks the 'Y cleavage site, only 6 bovine thrombin can be formed (Fenton 
and Bing, 1986). Leukocyte elastase and cathepsin G cleave human a thrombin at sites 
before the 'Y site to yield E and r thrombin respectively (Brower et al. 1987' Brezniak et 
I 
al. 1990). The elastase-mediated conversion is enhanced by heparin and occurs at 
physiologically relevant concentrations, so that E form may occur in vivo to mediate non-
clotting thrombin activities (Fenton and Bing, 1986). !: thrombin retains about 85 % of 
the a thrombin clotting activity (Brezniak et al. 1990). Except for !: thrombin, the 
previous forms that result from the a form after proteolytic cleavage, have no clotting 
activity but retain high amidolytic and esterolytic activities (Fenton and Bing, 1986). 
3. Thrombin Standardization 
Highly purified preparations of human a thrombin are prepared by the same 
procedure (Fenton et al. 1977) and supplied from the same source around the world for 
standardization purposes. However, the first standardization of human thrombin was 
attempted in 1942 (Seegers and Smith, 1942), with the definition of the Iowa Unit as the 
amount of thrombin that clots 1 ml of standardized fibrinogen solution (bovine plasma 
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based) in 15 sec at 28°C. The Division of Biologics Control, National Institutes of 
Health, U.S. Public Health Service issued specifications for commercial thrombin 
preparations in 1946, attempting to define the NIH unit equal to the Iowa unit. The two 
units are not equal and 1 NIH unit equals about 1.25 Iowa units. Both of these units are 
based on the clotting activity of thrombin. The NIH standard thrombin is also referred 
to as the US standard. In 1975, the Expert Committee on Biological Standardization of 
the World Health Organisation established an International Standard for thrombin, which 
is used to define the thrombin International Unit (IU, Gaffney and Edgell, 1995). 
Another International Standard for thrombin was established in 1991. Although the IU 
was originally defined to approximate the NIH unit, 1 NIH unit equals 1.15 IU (Gaffney 
and Edgell, 1995). Currently, both units are used in the literature and the reagent and 
pharmaceutical grade products are standardized in terms of NIH units. 
4. Physiologic Regulation of Thrombin Formation 
Thrombin has a unique mechanism of regulation of its generation from 
prothrombin. As mentioned above, thrombin is generated from prothrombin by the 
double proteolytic activity of factor Xa in the prothrombinase complex. The activated 
thrombin can then activate factors V and VIII to amplify its generation to a burst of 
coagulant activity (Mosesson et al. 1990 a, b). These steps are the targets of the natural 
antithrombins (antithrombin and HC-II). Thrombin down-regulates its own activity by 
binding to thrombomodulin, which results in loss of thrombin's ability to convert 
fibrinogen to fibrin. Furthermore, thrombomodulin bound thrombin activates protein C, 
which then can degrade factors V and VIII with protein S as a cofactor, thus blocking 
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the generation of thrombin (Esmon et al. 1987). 
5. Cellular Interactions of Thrombin 
In addition to proteolytic activities, thrombin exhibits several non-enzymatic or 
hormonal activities. Thrombin activates platelets and other factors to promote 
hemostasis. In vitro, thrombin addition to platelets causes phosphatidyl inositol (Pl) 
hydrolysis, eicosanoid formation, protein phosphorylation, increase in cytosolic free 
ca++, change in their shape, granule secretion and fibrinogen receptor expression. 
Thrombin also suppresses cAMP synthesis and has other effects as well, such as on 
endothelial cells (stimulation of PGl2 formation, proliferation, angiogenesis, 
neovascularization), fibroblasts (production of cAMP, proliferation, chemotaxis), and 
vascular smooth muscle cells, all of which may be implicated in platelet activation, for 
example PGI2 inhibits platelet activation by stimulating cAMP synthesis. Other hormonal 
activities of thrombin include monocyte (Bar-Shavit et al. 1983) and neutrophil 
chemotaxis and aggregation (Bizios et al. 1984), mitogenesis in certain macrophage-like 
cells (Bar-Shavit et al. 1983), albumin transport across endothelial cell monolayers 
(Malik et al. 1986) and inhibition of neurite outgrowth (Gurwitz et al. 1988, Hawkins 
et al. 1986). 
6. Thrombin Receptors 
Thrombin activates a variety of receptors. It interacts with a specific high affinity 
receptor on platelets to cleave the amino terminus thus exposing a tethered ligand which 
activates the receptor (Vu et al. 1991). This receptor is linked to an inhibitory G protein 
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and activation of it results to inhibition of adenylate cyclase and decrease in cAMP 
(Seiler et al. 1992). The same receptor also regulates the Na+/H+ exchange in platelets 
during stimulation with thrombin. This receptor is thought to be linked through another 
G protein to phospholipase A2 which may be the main source of arachidonate production 
(Siess et al 1984, Silk et al. 1989, Kajiyama et al. 1989). Thrombin also interacts with 
a lower affinity receptor on the platelets, but this one is thought to be linked through a 
G protein to phospholipase C and protein kinase C (McGowan et al. 1986). Activation 
of this receptor could be the source of the thrombin-induced elevations in cytoplasmic 
Ca++ levels. 
Cultured fibroblasts also have a high affinity thrombin receptor, activation of 
I 
which leads to increase in cAMP (Carney et al. 1978, 1984, 1992), which is identical 
to the high affinity receptor found on platelets. The same thrombin receptor is also 
expressed by endothelial cells, smooth muscle cells and lymphocytes (Brass 1995). 
Thrombomodulin is the thrombin specific receptor found on endothelial cells (Awbrey 
et al. 1979). This receptor recognizes the fibrinogen recognition site on thrombin which 
is independent of its catalytic site (Hofsteenge et al. 1986). There appear to be over 1 
million low affinity receptors with a kd of about 30 nM, on the endothelial cells (Isaacs 
et al. 1981, Bauer et al. 1983). 
D. Pharmacologic Control of Thrombin's Action. 
Understanding the mechanisms through which thrombin mediates its various 
activities, as well as knowing the structural requirements for these actions, provides the 
basis of the strategies for the modulation of thrombin's action. Thrombin mediated 
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effects can thus be controlled at four different levels: (1) blockade of the thrombin 
receptors, (2) physiological antagonism of the effects mediated by thrombin, (3) 
inhibition of the generation of thrombin and (4) direct inhibition of formed thrombin. 
1. Inhibition of Thrombin Receptors 
Thrombin has multiple receptors in a variety of tissues. Some of these receptors 
have been characterized and studied extensively, but most remain insufficiently 
characterized. The obvious thrombin receptor targets is the newly cloned thrombin 
receptor found on platelets and endothelial cells (Vu et al, 1991). Effective antagonists 
of the cloned thrombin receptor are currently under investigation. Aplysillin A (1,4-D-
Phe-1,3-butadiene disulfate ester) is a compound isolated from a deep water sponge, with 
a reported IC50 for binding to the thrombin receptor of 20 µM (Gulavita et al. 1995). 
Another thrombin receptor inhibitor, Cl86-65 (3-mercapto-propionyl-Phe-Cha-Cha-Arg-
Lys-Pro-Asn-Asp-Lys-amide), has been recently reported to be effective in inhibiting 
vascular smooth muscle relaxation and platelet aggregation, phospolipase A2 and the 
Na+/H+ exchange, all mediated through the thrombinreceptor (Tesfamariam 1994, Seilet 
et al. 1995). A phage selection technique has also resulted in the isolation of a thrombin 
receptor inhibitor that was effective in antagonizing platelet aggregation, serotonin release 
and tyrosine phosphorylation (Doorbar and Winter 1994). The clinical potential of these 
thrombin receptor inhibitors is unknown. 
2. Inhibition of Cellular Processes Mediated by Thrombin 
Targeting of the cellular processes mediated by thrombin provide an alternative 
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mode of pharmacological control of the actions of thrombin. This approach is 
complicated by the fact that thrombin mediates a spectrum of cellular processes ranging 
from platelet activation to stimulation of proliferation of various cell types. An agent 
that has such effects and is being used clinically is defibrotide. The exact modes of 
action and the full pharmacologic potential of this agent is currently being explored 
(Ulutin et al. 1988). This agent is different from the usual antithrombotic and 
anticoagulants in that it is a functional antagonist of thrombogenesis and not necessarily 
a direct antithrombin. This approach of pharmacological management of thrombin 
becomes even more complicated when considering the effects of thrombin on platelets 
and whether thrombin is the main activator of platelets or other activators play an equally 
I 
important role. If thrombin is indeed the most important activator of platelets as 
suggested by Badimon et al. (1990), then single thrombin targeting would be an efficient 
method for controlling arterial thrombosis (in which platelet activation is the key event). 
However, this has not been proven and management of platelet activation with antiplatelet 
agents such as cyclooxygenase inhibitors are still widely used with success. On the other 
hand, Cadroy et al. (1989) have indicated with their work that thrombus formation is a 
complex situation where inhibition of platelets and coagulation pathways may be required 
for optimal management of thrombosis. 
3. Inhibition of Thrombin Generation 
Inhibition of the formation of thrombin may prove to be more effective in 
prevention and management of thrombotic disorders than direct inhibition of thrombin 
after it has formed. The issue of whether monospecific targeting of thrombin is the most 
49 
effective method for controlling thrombogenesis is a controversial one, and inhibition of 
other proteases contributing to the generation of thrombin is under study. By inhibiting 
the formation of thrombin, the hormone-like effects that it mediates may also be 
prevented and complications may be avoided. In inhibiting the formation of thrombin, 
the target sites should be the serine proteases that lead to this event. The candidates for 
this type of targeting would be factor VIIa and/or TF and factors IXa, VIIIa, Xa and Va. 
Considerable interest has been shown in the role of TFPI and in animal models 
of DIC it has been found to be effective (Rapaport et al. 1985, 1989), but the clinical 
usefulness of this recombinantly produced agent is not established. Recently, a report 
of selective factor VIIa/TF inhibitors, derived from mutagenesis of the inhibitor of the 
Alzheimer's amyloid fl-protein precursor, demonstrated that one of these proteins is 
specific for factor VIIa/TF or factor VIIa, with no activity against thrombin, factors Xa 
and Xla and kallikrein, but with some activity against plasmin (Lazarus et al. 1995). 
These inhibitors exhibit promising anticoagulant effects, but their in vivo effects have not 
been published (Refino et al. 1995, Kirchhofer et al. 1995). The same group has used 
alanine-scan mutagenesis to develop a specific factor VIIa inhibitor that resembles TF. 
This inhibitor inhibits selectively the extrinsic pathway (Kelley et al. 1995) but in vivo 
studies are not complete. An anti-rabbit TF antibody has been recently developed 
(Himber et al. 1996) and was found to produce stringer in vivo antithrombotic effects 
than heparin in a rabbit model of arterial thrombosis. 
The same group that isolated the factor VIIa/TF inhibitors based on the inhibitor 
of the Alzheimer's amyloid fl-protein precursor, also isolated during these studies an 
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inhibitor of kallikrein, which also has weaker activities against factor Xia (Lazarus et al. 
1995). This compound is also comparable to the factor VIIa/TF inhibitors in terms of 
anticoagulant effects (Refino et al. 1995, Kirchhofer et al. 1995). 
Although APC has been synthesized by recombinant technology, only the purified 
product from human plasma has been used clinically in individual case studies of patients 
with inherited protein C deficiency (Alhenc-Gelas et al. 1995, De Stefano et al. 1993) 
or patients with purpura fulminans in meningococcemia (Rivad et al. 1995). An 
alternative approach resulting in activation of endogenous protein C has been reported 
(Gibbs et al. 1995): a thrombin mutant (E229K) has been developed which has lost its 
fibrinogen-cleaving ability but has retained its thrombomodulin-dependent activating 
I 
capability for protein C. This compound produces dose-dependent and reversible 
anticoagulant effects in Cynomolgus monkeys. Based on the same principle of 
developing a thrombin mutant which lacks its procoagulant activity while retaining its 
protein C activating capabilities, a series of thrombin mutant molecules have been 
constructed where the insertion loop that obstructs the catalytic site and the Na+ binding 
site on thrombin have been mutated (Guinto et al. 1995). The in vivo effects of these 
mutants remain to be examined. 
Focusing on the role of APC in the coagulation system, another approach reported 
recently was the design of a protein C mutant which can be activated by factor Xa, 
instead of thrombin (Friedrich et al. 1996). This factor Xa activatable protein C mutant 
was found to produce in vitro anticoagulant effects but the potential of this agent is 
unclear at this time. 
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Beside the direct inhibition of thrombin, an additional approach to develop new 
antithrombotic agents is the inhibition of factor Xa. It is known for some time that low 
molecular weight high antithrombin affinity heparin fractions, upon complexing with 
antithrombin, produce selective inhibition of factor Xa (Barrowcliffe et al. 1986). Based 
on this, a synthetic heparin pentasaccharide has been developed. This pentasaccharide 
represents an indirect factor Xa inhibitor requiring the presence of plasmatic antithrombin 
for its biological effects. Many different structural analogues of this pentasaccharide with 
varying anti-Xa potency have been developed. This pentasaccharide is currently in phase 
II clinical trials for the post hip replacement prophylaxis (personal communication). It 
is also interesting to note that pentasaccharide also inhibits thrombi generation and almost 
I 
has no effects on formed thrombin (Lormeau and Herault 1993). 
The direct factor Xa inhibitors include both the recombinant and synthetic agents. 
Recombinant tick anticoagulant peptide (TAP) represents an anticoagulant principle which 
was first isolated from the soft tick Ornithodoros moubata. This 60 amino acid 
containing peptide exhibits reversible tight binding to factor Xa (Vlasuk et al. 1991). It 
has also been shown to exhibit varying degrees of antithrombotic actions in different 
animal models. Despite its safety and low immunogenicity, this agent is not developed 
clinically until now. 
Another recombinant anti-Xa agent is antistatin, which represents a 15 ,000 peptide 
isolated from the mexican leech Hirudo officinalis (Dunwiddie et al. 1989). This peptide 
is found to be active in various animal models of thrombosis (Schaffer et al 1991). 
However, in contrast to TAP, it is strongly immunogenic and thus, its development is 
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carried out only in preclinical stages. 
Novel factor Xa inhibitors from the saliva of the medicinal leech Hirudo 
medicinalis have also been reported (Righi et al. 1995). These inhibitors share 503 
homology and have similar patterns of inhibition, which include in addition to factor Xa, 
chymotrypsin and trypsin. However, apart from these enzymes, these inhibitors are 
selective for factor Xa. 
The synthetic anti-Xa agents include both the peptidic and peptidomimetic agents. 
A series of orally active highly specific factor Xa inhibitors have been reported (Ostrem 
et al. 1995). These include the series of compounds referred to as SEL followed by a 
number which inhibit the free and prothrombinase factor Xa. These compounds are of 
I 
a low molecular weight (550-750). One of these agents has been found to be a selective 
factor Xa inhibitor with lesser activities towards thrombin, plasmin and APC. While the 
antithrombotic effects and the pharmacokinetics of this agent are species-dependent, this 
agent exhibits oral and S.C. bioavailability. 
Another peptidomimetic factor Xa inhibitor, DX 9065A, is a bis-amidino 
derivative with relatively specific anti-Xa activities (Hara et al. 1994, Yamazaki et al. 
1994). After I.V. and oral administration, this compound prolonged the global clotting 
assays and did not exhibit any antithrombin activity. In animal models of thrombosis and 
DIC, this agent produced dose-dependent antithrombotic effects. 
In contrast to thrombin inhibitors, the factor Xa inhibitors are claimed to exhibit 
much lesser bleeding effects. Furthermore, these agents are also reported to be superior 
inhibitors of thrombin generation (Prasa et al. 1996). 
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A novel broad-spectrum serine protease inhibitor has been isolated from 
Eschericia coli, ecotin (Lauwereys et al. 1993). Notably, the inhibitory constant of this 
agent for factor Xa is in the pM range. While ecotin inhibits chymotrypsin, elastase, 
kallikrein, factor XIIa and Xia, it has no activities against APC, tPA and uPA. This 
compound has been shown to be an effective dose-dependent antithrombotic agent in a 
rat model of chemically induced arterial thrombosis. 
Aprotinin is a broad-spectrum protease inhibitor that has been approved by the 
U.S. FDA for clinical use as an anti-fibrinolytic drug during cardiac surgery. The 
primary structure of aprotinin is depicted in Fig. 3, lower panel. Based on the structure 
of aprotinin, a series of mutants have been synthesized that have inhibitory activities 
I 
against coagulation enzymes in the nM range (Stassen et al. 1995). One of these mutants 
was coupled to PEG to optimize biological half life, without affecting its inhibitory 
activities. These aprotinin mutants were shown to inhibit factors Xia, Xa and TF/VIIa, 
as well as plasmin, trypsin and kallikrein. However, they possessed no detectable 
activity against thrombin, uPA and APC. 
4. Inhibition of Formed Thrombin 
The most direct method of controlling the actions mediated by thrombin is by 
inhibiting this enzyme directly. The thrombin inhibitors described earlier above are all 
designed or selected for this direct approach in controlling thrombin. Understanding the 
structure-activity relationship of thrombin is very important in this approach since 
inhibitors of different epitopes of the thrombin molecule result in differential management 
of thrombin's spectrum of activity (eg. although the anion-binding exosite of thrombin 
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1 10 
HV-1 Val-Val-Tyr-Thr-Asp-Cys-Thr-Glu-Ser-Gly-Gln-Asn-Leu-Cys-Leu-Cys-Glu-Gly-
HV -2 Ile-Thr 
HV-3 Ile-Thr 
20 30 
HV-1 Ser-Asn-Val-Cys-Gly-Gln-Gly-Asn-Lys-Cys-Ile-Leu-Gly-Ser-Asp-Gly-Glu-Lys-
HV-2 Lys Asn Lys-Gly 
HV-3 Lys Gln Lys-Asp 
40 50 
HV-1 Asn-Gln-Cys-Val-Thr-Gly-Glu-Gly-Thr-Pro-Lys-Pro-Gln-Ser-His-Asn-Asp-Gly-
HV-2 Asn Glu Asn 
HV-3 Gln 
60 * 
HV-1 Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu- -Tyr-Leu-Gln 
HV-2 
HV-3 Pro Asp-Ala Asp-Glu 
I 
Aprotinin: 
1 10 
Arg-Pro-Asp-Phe-Cys-Leu-Glu-Pro-Pro-Tyr-Thr-Gly-Pro-Cys-Lys-Ala 
20 30 
Arg-Ile-Ile-Arg-Tyr-Asn-Ala-Lys-Ala-Gly-Leu-Cys-Gln-Thr-Phe-Val-Tyr 
40 
Gly-Gly-Cys-Arg-Ala-Lys-Arg-Asn-Asn-Phe-Lys-Ser-Ala-Glu-Asp-Cys 
50 
Met-Arg-Thr-Cys-Gly-Gly-Ala 
Fig. 3. Primary structures of natural hirudin variants 1, 2 and 3 (HV-1, Dodt et al. 
1984, HV-2, Harvey et al. 1986 and HV-3, Dodt et al. 1986) and bovine aprotinin 
(Stassen et al. 1995). 
* denotes sulfation, which is absent in the recombinant forms of these molecules. 
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may be blocked, its catalytic activity towards smaller substrates may not be prevented). 
E. Thrombin Inhibitors 
The development of substrate-related synthetic inhibitors of thrombin started with 
the discovery of the specificity of thrombin for hydrolysis of arginyl bonds. There is a 
broad spectrum of interests from which the thrombin inhibitors related work stems, 
including the identification of reactive groups in active site, demonstration of similarities 
and differences between binding areas of related enzymes, selective inhibition of one 
protease in the presence of another and in vivo anticoagulation. Physical methods such 
as NMR and x-ray crystallography for topography of the thrombin active site have also 
contributes substantially to these developments. Direct inhibitors of thrombin can be 
classified according to source and structure into endogenous, analogues of natural 
substrates, recombinant and synthetic inhibitors. Some of these are directed against the 
catalytic site of thrombin while others bind to the exosites of thrombin. In addition, 
some are reversible inhibitors while others are irreversible. 
1. Inhibitors of Plasma Origin 
The natural inhibitors of thrombin belong to a class of serpms called 
antithrombins. The most important ones are antithrombin and HC-II (which recognizes 
the anion binding site as well as the catalytic site of thrombin, Hortin et al. 1989). The 
mechanisms of actions of these is discussed previously. In addition to the above 
thrombin inhibitors, thrombin forms complexes and is inhibited by two other proteins 
secreted form platelets upon activation: platelet protease nexin and thrombospondin 
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(Detwiler et al. 1992). Platelet protease nexin is secreted from activated platelets and 
forms a 77,000 MW complex with thrombin through thrombin's anion binding exosite 
to inactivate it (Detwiler et al. 1992). Thrombospondin is a 420,000 MW glycoprotein 
secreted by activated platelets and binds to many cells and proteins (Lawler 1986) and 
is incorporated into polymerizing fibrin (Bale et al. 1985) and extracellular matrix (Jaffe 
et al. 1983). The nexin-thrombin complex is further complexed with thrombospondin 
via a disulfide bond (Detwiler et al. 1992). 
2. Synthetic Inhibitors 
Prior to the development of peptide-based inhibitors of thrombin, several non-
peptidic inhibitors have been described (Geratz and Tidwell, 1977). These non-peptidic 
inhibitors of thrombin can be classified according to the extent of the domain they occupy 
(Geratz and Tidwell, 1977). There are three important binding sites in the catalytic 
domains of the arginine specific proteases (Schechter and Berger, 1967): 
1) The specificity pocket to which the protonated arginine side chain of a substrate is 
attracted, located at the entrance of the enzyme's catalytic mechanism (the pocket 
consisting of His-57, Asp-102, Ser-195). 
2) The area to left of the specificity pocket which accommodates the amino terminal 
leaving group of substrate (towards the apolar binding exosite or fibrinopeptide groove). 
This is the S 1 site of the enzyme and corresponds to the Pl site of the substrate. The 
sites following the SI and Pl sites, away from the catalytic site, are designated S2, S3 ... 
and P2, P3 on the enzyme and the substrate respectively. 
3) The area to the right of the specificity pocket which accepts the carboxy terminus of 
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the substrate (towards the anion binding exosite or fibrin groove). This is the S 1' site 
of the enzyme and corresponds to the Pl' site of the substrate. The sites following the 
S 1' and P 1' sites, away from the catalytic site, are designated S2 ', S3 '. .. and P2 ', P3' 
on the enzyme and substrate respectively. 
The classification of the synthetic inhibitors can then fall into three categories 
(Geratz and Tidwell, 1977), according to the extent of the catalytic domain of thrombin 
that they occupy. 
a. Compounds Restricted to the Specificity Pocket of the Catalytic Domain of Thrombin 
Synthetic cationic compounds were used to decipher the spatial relationship of the 
S'pecificity site of thrombin and establish an optimal structure for hydrophobic binding 
and ionic interactions with the negatively charged aspartate moiety at the bottom of the 
pocket (Geratz and Tidwell, 1977). Of the benzene analogues, the ones with an amidino 
side chain rather than an aminomethyl or a guanidino side chain, exhibited a stronger Ki 
(Geratz and Tidwell, 1977). This led to benzamidine incorporation as a building block 
in more complex thrombin inhibitors. Ring systems other than benzene, had an even 
tighter fit due to the improved hydrophobic interaction with the pocket (Geratz and 
Tidwell, 1977). Introduction of a pyruvic acid group in the para position to the amidino 
side chain of benzamidine led to an increase in inhibitory potency. The augmented 
inhibition extended to plasmin, trypsin and enterokinase (Geratz and Tidwell, 1977). 
An alternative building block for these molecules was arginine and its modified 
forms. The D-configuration of arginine had little activity while chemical modifications 
on the guanidino part or the a-amino part of L-arginine decreased the antithrombin 
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activity (Tonomura et al. 1980). 
b. Compounds Extending Unidirectionally Beyond the Specificity Pocket of the Catalytic 
Site of Thrombin 
These compounds were molecularly designed by attaching a side chain to a starter 
compound (benzamidine mostly). The side chains were aliphatic, aromatic or aryl 
aliphatic and extended usually to the right od the specificity pocket. Only the agents 
resulting from the link-up of two benzamidine groupings were active (Geratz and 
Tidwell, 1977), more so than benzamidine alone, and they led to the study of factors 
affecting potency (length, nature and bulkiness of central chain, presence of various 
substituents, position of amidino groups). Diamidines proved effective and it was shown 
that the second amidino group is essential for full potency, especially for inhibition of 
kallikrein (Geratz and Tidwell, 1977). 
Based on the work done with arginine as a building block, C-terminal 
modifications of L-arginine were synthesized and studied. Ester compounds were easily 
hydrolyzed by thrombin and other trypsin-like enzymes, so non-hydrolyzable tertiary 
amides that were found to combine only with thrombin were focused on (Okamoto et al. 
1980, Kikumoto et al. 1980, Tonomura et al. 1980). 
Modification on the N-terminal of L-arginine were also studied (Okamoto et al. 
1980, Kikumoto et al. 1980). Dansyl group incorporation as well as other bulky 
aromatic substituents to the arginine increased the antithrombin activity of the arginine. 
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c. Compounds Extending Bidirectionally Beyond the Specificity Pocket of the Catalytic 
Domain of Thrombin 
Since the most efficient natural substrates of thrombin bind to thrombin in the 
binding groove on both sides of specificity pocket, the idea of furnishing diamidines with 
a side chain that provides additional interaction with the thrombin groove led to the 
alteration of the location of the amidino groups, substitution of the halogen and 
replacement of one amidino moiety by a nitro group. In general, amidines exhibited 
inhibitory effects against any arginyl or lysyl specific protease, but had a preference for 
one protease over others. The degree of differential inhibition reflected the topographical 
variations in active sites of related enzymes. 
An alternative building block used to develop small inhibitors for the catalytic site 
of thrombin is amidinopiperidine. Modifications of this molecule yielded competitive 
inhibitors of thrombin with Ki's of 20-50 nM (Hilpert et al. 1994). Further 
modifications of the central building block has led to the development of napsagatran (Ro 
46-6240) as a reversible thrombin inhibitor with a Ki of 0.27nM. This compound has 
been found to be an effective antithrombotic agent in a variety of animal models (Gast 
et al. 1994, Carteaux et al. 1995). 
The compounds synthesized based on the L-arginine as the building block and 
incorporating both C and N-terminal optimal modifications, were found to be highly toxic 
due to inhibition of butyl cholinesterase (Hijikata-Okunomiya and Okamoto, 1992). The 
introduction of a COOH group on the carboxy terminal resulted in decreased affinity for 
butyl cholinesterase (and therefore less toxicity) and after further modifications an isomer 
named argatroban (MD805 or MCI9038 or argipidine), depicted in Fig. 4, was generated 
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Fig. 4. Chemical structures of thrombin inhibitors: D-Phe-Pro-Arg-H, D-MePhe-Pro-
Arg-H, Boc-D-Phe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH and argatroban. 
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as a selective inhibitor of thrombin (Ki=0.039 µM, Hijikata-Okunomiya and Okamoto, 
1992). This compound also has a sizeable affinity for trypsin (Ki=5.0 µM, Hijikata-
Okunomiya and Okamoto, 1992). It has been characterized pharmacologically and has 
a plasma half life of 40 minutes (in humans, Tamao et al. 1986 a, b). Argatroban is also 
effective in preventing thrombus formation in various animal models at low 
concentrations ( > 1 µM, Maruyama 1990, Hijikata-Okunomiya and Okamoto 1992, Hara 
et al. 1994, Kawai et al. 1995). This compound is being tested clinically for several 
indications (Yonekawa et al. 1986, Kumon et al. 1984, Oshiro et al. 1983, Matsui et al. 
1992). 
A new low molecular weight compound, that competitively inhibits thrombin with 
I 
a Ki of 15 nM is inogatran (pINN, Teger-Nilsson et al. 1995). Preclinical and phase I 
studies have been completed with this compound in numerous investigations (Gustafsson 
et al. 1995, Eriksson et al. 1995). This agents was found to be selective for thrombin 
when compared to other serine proteases. Inogatran was also found to have more 
effective antithrombotic effects than hirudin and hirulog in an in vivo rat model of arterial 
thrombosis. No interaction with fibrinolytic processes were noted when inogatran was 
studied in rat and dog models of thrombolysis. The half life of inogatran is about one 
hour (Teger-Nilsson et al. 1995). This compound also has a substantial oral 
bioavailability that is species and gender specific (Gustafsson et al. 1995, Eriksson et al. 
1995). 
3. Peptide Inhibitors 
With the elucidation of the primary structure of procoagulant proteins and the 
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identification of the proteolytic activation cleavage sites, specific chromogenic substrates 
for thrombin and factor Xa were developed by synthesis of peptides mimicking the amino 
acid sequence adjacent to the substrate's cleavage site and attaching a para nitro-aniline 
(pNA) group on the carboxy terminus of these peptides (Bang and Mattler, 1977). A 
comprehensive study reported on the effects of many peptide inhibitors belonging to 
various classes on a spectrum of serine proteases using clotting and novel amidolytic 
systems (Fareed et al. 1981). 
a. Aldehyde Derivatives 
In 1975 a series of tripeptide aldehydes containing arginine were developed as the 
first reversible peptide thrombin inhibitors. The prototype compound to be synthesized 
was D-Phe-Pro-Arg-H (GYKI 14166, Bajusz et al. 1975), depicted in Fig. 3, which 
although was a selective and potent inhibitor of thrombin, was very unstable in neutral 
aqueous solution where it cyclized and was inactivated (Bajusz et al. 1989). To prevent 
cyclization, a derivative was synthesized with a protective amino terminal t-
butyloxycarbonyl (Boe) group: Boc-D-Phe-Pro-Arg-H (GYKI 14451, Bajusz et al. 1978), 
also depicted in Fig. 3. This compound was more stable than its parent compound but 
was not as specific for thrombin since it inhibited plasmin as well. In order to achieve 
compounds that are both stable and specific for thrombin, a series of N-alkyl derivatives 
were synthesized (a basic amino terminus promotes thrombin specificity) and from this 
series the methyl derivative D-MePhe-Pro-Arg-H (GYKI 14766, Bajusz et al. 1987), 
depicted in Fig. 3, was found to be as potent and selective reversible inhibitor of 
thrombin as the prototype aldehyde. The Ki for the aldehyde derivatives is around 0.1 
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µM. The aldehydes D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H have been studied 
pharmacologically. From toxicity studies in mice and rabbits, the LD50 for these 
compounds was about 40-45 mg/kg. Both agents were devoid of hemorrhagic effects as 
determined by a rabbit ear bleeding model. The unprotected aldehyde however did 
produced a blood pressure lowering effect (40% decrease) when injected I.V. which may 
have been due to contaminants. When these aldehydes were administered to rabbits and 
dogs orally, they produced persistent anticoagulant effects, although the bioavailability 
may have been low. Similar results indicated a high bioavailability when these 
compounds were administered subcutaneously. The biologic half life of both aldehydes 
after I.V. administration to primates was estimated to be around 90-180 minutes. The 
anticoagulant activities of the compounds were evident in the global clotting tests and 
were independent of antithrombin (Bajusz et al. 1990, Bagdy et al. 1992). Both agents 
inhibited thrombin-induced platelet aggregation in a concentration dependent manner, but 
the platelet count was not reduced after systemic administration. All three of the 
tripeptide aldehydes had antithrombotic activities as tested in various models of 
thrombosis (rats, rabbits, baboons). The free aldehyde as well as the methylated 
derivative were effective antithrombotics after I. V., S.C. and P.O. administration while 
the Boe derivative was active only after I. V. administration. 
An analogue of the D-MePhe-Pro-Arg-H aldehyde, D-1-Piq-Pro-Arg-H 
(LY303496), is being developed as an orally effective thrombin inhibitor. This 
compound has been shown to be an effective antithrombotic agent in rat models of deep 
venous thrombosis (Wilson et al. 1995) and arterial thrombosis (Kurz et al. 1995). 
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b. Chloromethyl Ketone Derivatives 
Peptides of arginine chloromethyl ketones correspond to the primary structure of 
physiological substrates of target proteases (Kettner and Shaw 1977). Chloromethyl 
ketones inactivate serine proteases by the formation of an intermediate reversible 
substrate-like complex with the protease followed by irreversible alkylation of the active 
site histidine. Peptides of arginine chloromethyl ketone are more effective than lysine 
analogues since thrombin hydrolyzes only specific arginine bonds in its substrates. Thus, 
arginine in the Pl position of the substrates is more effective. Factor XIII and 
prothrombin cleavage sites as well as other thrombin substrates have praline at the P2 
site while the A and B chains of fibrinogen do not have this proline in the P2 site. After 
I 
testing a series of these cleavage site analogues it has been found that the tripeptide 
chloromethyl ketone analogues of factor XIII cleavage site (Val-Pro-Arg-CH2Cl) and the 
prothrombin cleavage site (Ile-Pro-Arg-CH2Cl and Val-Ile-Pro-Arg-CH2Cl) are the most 
potent thrombin inhibitors with the tetrapeptide being the optimal as well as the most 
specific thrombin inhibitor, probably due to occupation of a fourth binding site. These 
inhibitors also inactivate plasmin, kallikrein and urokinase but slowly and to a limited 
extent. Binding at secondary sites contributes to the compounds' s selectivity for trypsin-
like proteases. The most effective irreversible inhibitor of thrombin synthesized from 
this class of substrates is D-Phe-Pro-ArgCH2Cl (PPACK or FPRCH2Cl, Kettner et al. 
1979). This compound's two first amino residues occupy the specificity pocket in a tight 
manner, while the arginine drops into the catalytic pocket. This allows for high 
specificity for thrombin as opposed to other serine proteases. Thus, D-Phe-Pro-
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ArgCH2Cl has been utilized in biochemical studies of thrombin and hemostasis as well 
as in pharmacological studies. The toxicity of this tripeptide chloromethyl ketone is 
species dependent. Thus, although in mice are no toxic effects after I. V. infusions of 
up to 50 mg/kg, in rabbits nearly all platelets agglutinate even though clotting is 
prevented. The biological half life of this agent, as measured after I. V. administration 
to rabbits, is about 3 minutes. The agent is also absorbed in an active form 
subcutaneously. The anticoagulant effects of the ketone are detectable in a concentration 
dependent manner with the TT and APTT clotting tests as well as with the TEG whole 
blood clotting test. However, these effects are lost after incubation with plasma 
suggesting inactivation of the compound by plasma components. The antithrombotic 
effects of this tripeptide derivative have been examined extensively in various animal 
models (rats, dogs and rabbits) and in all the compound is an effective antithrombotic 
after both I.V. and S.C. administration. 
c. Nitrile Derivatives 
Tripeptide derivatives with cx-nitrile groups have been synthesized as competitive 
inhibitors of thrombin. The peptide derivative D-Phe-Pro-Arg-CN 112 is a strong 
competitive inhibitor of thrombin with a Ki =0. 7 µM. This agent has been studied 
pharmacologically in mice, rats and rabbits. The LD50 is 30-40 mg/kg I.V. in mice. 
Intravenous infusion of the agent to rats has serious blood pressure lowering effects (70-
80 % reduction). The bleeding effects are minimal (Stuber et al. 1988), an indication that 
primary hemostasis is not affected by this compound. The biological half life of the 
agent after I.V. injection to rabbits is around 12 minutes and it is effective after S.C. 
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administration as well. Biliary excretion accounts for about 30 % of route of excretion 
of the total agent administered. This tripeptide nitrile exhibits anticoagulant effects in 
a concentration dependent manner as detected by the global clotting tests and the TEG 
whole blood clotting assay. It is also an effective antithrombotic in various rat models 
of thrombosis. 
d. Boronic Acid Derivatives 
The search for selective and potent inhibitors of thrombin has led to the 
development of three more classes of reversible tripeptide inhibitors: a) Trifluoromethyl 
ketones: the representative compound D-Phe-Pro-Arg-CF3 (Neises et al. 1991) with a Ki 
in the nM range b) a-aminophosphonic acid tripeptide derivatives with Kis in the nM 
range. c) a-aminoboronic acid derivatives. The boronic acid derivatives were initially 
developed as inhibitors of elastase and chymotrypsin. In order to develop a compound 
that would be specific for thrombin, the arginine in the sequence D-Phe-Pro-Arg has 
been substituted with its boronic acid derivative. This has led to the synthesis of Ac-(D)-
Phe-Pro-boroArg (Ki=41 pM), depicted in Fig. 3, Boc-(D)-Phe-Pro-boroArg (Ki=3.6 
pM) and H-(D)-Phe-Pro-boroArg (Ki< 1 pM) (Kettner et al. 1990). The boroarginine 
derivatives have been a recent development and their pharmacologies are not complete. 
The Ac-(D)-Phe-Pro-boroArg appears to have a biological half life of around 15 minutes 
after intravenous administration to rabbits and it is an effective anticoagulant after S.C. 
administration. The anticoagulant effects of this compound are dose dependent and 
detectable with the global clotting tests after administration to rats, rabbits and baboons. 
This agent also exhibits antithrombotic effects as demonstrated by two thrombosis 
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models. The H-(D)-Phe-Pro-boroArg also exhibits antithrombotic effects in a baboon 
model of thrombosis and when compared to the aldehyde analog (D)-Phe-Pro-Arg-H, the 
boronic acid derivative achieves the same effect at a dose 20 times lower than that of the 
aldehyde derivative. 
In attempting to develop a more specific, orally bioavailable thrombin inhibitor, 
the above boronic acid derivatives have been modified to yield the compound Ac-D-Phe-
N-cyclopentylGly-boroArg (S18326, Verbeuren et al. 1995). Although this compound 
is more specific than Ac-D-Phe-Pro-boroArg and it is shown not to interfere in vitro with 
fibrinolysis, it possesses sizeable inhibitory activities against other fibrinolytic enzymes 
(Verbeuren et al. 1995). However, this compound has potent antithrombotic activities 
I 
in rat models of arterial and venous thrombosis and is orally bioavailable (Verbeuren et 
al. 1995). 
The above described boronic acid derivatives lack specificity for thrombin. In an 
attempt to overcome this, the C terminal of the tripeptides has been extended (Ketnner 
et al. 1990). However, the resulting compounds still lack in specificity for thrombin. 
Tapparelli et al. (1993) has further modified these compounds by replacing the boroArg 
in the third position (corresponding to the S 1 pocket site of thrombin) with a neutral 
boron containing moiety. The compound Z-D-Phe-Pro-boromethoxypropylGly-pinendiol 
has a lower Ki for thrombin (8.9 nM) than its predecessors, but the specificity for 
thrombin is improved (Tapparelli et al. 1993). However, this compound is a weak 
anticoagulant in the global clotting tests and does not inhibit thrombin induced platelet 
aggregation in vitro and in vivo. 
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Another series of boronic acid derivatives has been developed as specific 
inhibitors of thrombin. These are Z-D-Phe-Pro-boroMpgOPin, Z-D-Phe-Pro-
boroMpgOPinacol and Z-D-Phe-Pro-boroPgIOPin (TRI50, TRI50b and TRil 1 
respectively, Esmail et al. 1995). The most promising antithrombin agent appears to be 
the pinacol ester derivative, TRI50b, with a Ki of 7nM. This compound is also an 
effective antithrombotic in various animal model of arterial and venous thrombosis, after 
intravenous and intraduodenal administration (Goddard et al. 1995, Gerrard et al. 1995). 
e. Other Peptide Analogues 
Substituting Arg with amidinoPhe in the D-Phe-Pro-Arg prototype sequence, led 
t0 the development of a series of compounds with inhibitory activities for various 
enzymes. The compound N-a-(2-napthylsulfonylGly)-4-amidinoPhepiperidine (NAP AP) 
was found to be the most optimal thrombin inhibitor with a Ki of 6 nM (Stiirzebecher et 
al. 1983). NAPAP is an effective antithrombotic in a series of animal models (Kaiser 
et al. 1985). However, in addition to adverse side effects (hypotension and respiratory 
depression, the half life of this compound is even shorter than most thrombin inhibitors 
(less than 10 min versus greater than 20 min for other thrombin inhibitors, Kaiser et al. 
1985) and thus clinical development has been abandoned. 
Another direct thrombin inhibitor under current development is CVS-1123 
[(CH3CH2CH2) 2-CH-CO-Asp(OCH3)-Pro-Arg-CHO, Vlasuk et al. 1995]. This compound 
has an oral bioavailability of > 30 % when administered to cynomolgous monkeys and 
is an effective antithrombotic in a dog model of coronary artery thrombosis (Cousins et 
al. 1995). 
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4. Recombinant Inhibitors 
a. Aptamers 
Aptamers are oligonucleotides (double or single stranded DNA, or single stranded 
RNA) which act directly on proteins to inhibit disease processes. Thirty two such 
aptamers have been recently isolated as inhibitors of thrombin with binding affinities in 
the range of 20-200 nM (Boch et al. 1992). One of the most potent thrombin aptamers 
has been found to interact with thrombin's anion binding exosite, so that it competes with 
substrates that interact with that specific site, such as fibrinogen and thrombin platelet 
receptors (Macaya et al. 1993, Paborsky et al. 1993). This aptamer has been shown 
recently to reduce arterial platelet thrombus formation in an animal model, as well as to 
inhibit clot bound thrombin in an in vitro system (Li et al. 1994). Recently, a second 
pool of aptamers, with a different sequence composition than the first class, incorporating 
modified bases, has been isolated, which has shown promising anticoagulant activities 
(Latham et al. 1994). Another recent development in the area of oligonucleotide 
inhibitors of thrombin has been the isolation of two RNAs that bind thrombin with high 
affinity (Kd in the nM range). These oligonucleotides have been shown to inhibit 
fibrinogen clotting in an in vitro test (Kubik et al. 1994). 
b. Hirudin and its Variants 
Hirudin is the most potent family of natural thrombin inhibitors, found in the 
saliva of the leech Hirudo medicinalis. It is a single polypeptide chain of 64-66 amino 
acid residues, stabilized in a characteristic conformation by three disulfide bridges in the 
N-terminal (Petersen et al. 1976). The Tyr moiety in position 63 is sulfated and 
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important in imparting inhibitory potency against thrombin (Verstraete 1995). The mode 
of interaction of hirudin with thrombin has been elucidated from X-ray studies on the 
crystallized thrombin-hirudin complex (Griitter et al. 1990, Rydel et al. 1990). The 
amino terminus of this polypeptide interacts with the apolar binding site of thrombin 
(Wallace et al. 1989) while the carboxy terminus, which is highly acidic, interacts with 
the anion binding exosite for fibrinogen recognition (Chang et al. 1990). Thus, by 
binding to these two sites on thrombin, hirudin masks the catalytic site thus rendering 
thrombin inactive. Because hirudin recognizes two different exosites on thrombin, rather 
than its catalytic site, it is a highly specific inhibitor of thrombin. 
Several isotypes of hirudin exist and they all have similar thrombin inhibitory 
I 
potencies. These hirudin variants are named HV-1 (Dodt et al. 1993), HV-2 (Harvey 
et al. 1985) and HV-3 (Dodt et al. 1986) and their primary structures are shown in Fig. 
4. All of these isoforms have been produced by recombinant technology (Harvey et al. 
1986, Dodt et al. 1989, Scharf et al. 1989) and the expression systems include Eschericia 
coli, Bacillus subtilis and Saccharomyces cerevisiae. The recombinant forms differ from 
the natural ones in that the Tyr residue in position 63 is not sulphated in the recombinant 
forms. Although this lack of sulfation reduces the antithrombin activity of hirudin, the 
reduction is negligible since the formation of the thrombin-hirudin complex is almost 
irreversible (Verstraete 1995). The recombinantly produced hirudins are also named 
desulfatohirudins or desirudin, due to the lack of sulfation at position 63. The hybrid 
recombinant hirudin CX-397 has been synthesized composed of the N-terminal fragment 
of HV-1 and the C-terminal fragment of HV-3 (Komatsu et al. 1993). This hybridization 
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results in a molecule that has an improved inhibitory potency for thrombin over the 
natural occurring hirudins. Point mutations to develop variant forms of hirudin have 
been used (Scharf et al. 1989). 
Binding of recombinant hirudin to dextran has been reported (Markwardt et al. 
1990) in an attempt to prolong its biologic t1h. More recently, polyethylene glycol 
coupling of recombinant hirudin, to develop longer lasting agents, has been accomplished 
(Kurfurst et al. 1992, Zawilska et al. 1993). This modification results in a molecular 
weight increase of hirudin from 7,000 to 17,000, which prevents extravasation of this 
agent and retards renal elimination, substantially increasing its biological half life 
(Riibsamen et al. 1991, Bucha et al. 1996). Furthermore, the PEG-hirudin metabolites 
differ from those of hirudin, suggesting different renal metabolism of the two agents 
(Lange et al. 1996). PEG-hirudin as well as hirudin are capable of inhibiting clot-bound 
thrombin when compared to heparin (Iorio et al. 1993). PEG-hirudin has also been 
shown to be effective in a rabbit model of DIC (Zawilska et al. 1993). Another 
application of PEG-hirudin is stent coating (Sternberger et al. 1996) and expansion to 
usage of this agent in reducing the thrombogenicity of other biomaterials, such as 
catheters, vascular prostheses and oxygenators is being considered. 
In addition to PEG, albumin has also been linked to the carboxy terminus of 
hirudin to prolong its half life, without impairing its antithrombin activity (Syed and 
Sheffield, 1995). The albumin-hirudin product has not been tested in vivo. 
Extensive pharmacological studies have been competed with recombinant hirudin. 
This compound has been repeatedly shown to be effective in various venous and arterial 
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thrombosis model of the rat, rabbit and the pig (Verstraete 1995). The effects are always 
dose-dependent at µmol/kg doses even after subcutaneous injection. Interestingly, the 
pharmacokinetics of desirudin reveal that it is distributed in extracellular compartments 
and that renal metabolism and excretion is an important component of the overall 
excretion profile (Verstraete 1995). 
5. Inhibitors of Thrombin not Directed Against its Catalytic Site 
Based on the structure of the carboxy terminus of hirudin, which interacts with 
the anion binding exosite of thrombin, a series of synthetic peptides cyclized via disulfide 
linkages were synthesized as inhibitors of thrombin (Krstenansky et al. 1988). These 
iRhibitors block the anion binding exosite of thrombin thus preventing fibrinogen cleavage 
and subsequent fibrin clot formation and optimal N terminal substitution of these peptides 
can lead to inhibition of fibrin formation (Owen et al. 1988). 
A 22 and a 27 amino acid peptide has been synthesized, modelled after the 
sequence of HC-II that interacts with thrombin's anion binding exosite, which prevents 
proteolytic cleavage of fibrinogen. The IC50 values for these two peptides in inhibiting 
thrombin are 38 and 28 µM respectively. These peptides however do not interfere with 
thrombin's catalytic site (Glen et al. 1989, 1990). 
The same group that studied the HC-II analogues, compared these to a fibrinogen 
(18 residues) and a thrombomodulin (19 residues) cleavage site analog and to a peptide 
corresponding to the 12 terminal amino acids of hirudin. The IC50 values for these 
compounds are 130, 140 and 1.3 µM respectively. 
A fibrinogen analog has also been synthesized as a thrombin inhibitor (Binnie et 
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al. 1991). This 24 amino acid peptide is modelled after the sequence of fibrinogen 
downstream of the thrombin cleavage site (different from the one studies by Glen et al. 
above). It is able to prevent fibrinogen clotting with a Ki of around 190 µM (Binnie et 
al. 1991). This peptide also does not block the thrombin catalytic site. 
A new thrombin inhibitor, triabin, is a 17,000 protein isolated and cloned from 
the saliva of the assassin bug Triatoma pallidipanis (Noeske-Jungblut et al. 1995). This 
agent inhibits thrombin by binding to its anion-binding exosite but does not interfere with 
its catalytic site. A recent report (Glusa et al. 1996) shows that this agent is potent in 
inhibiting thrombin mediated platelet aggregation and smooth muscle contraction. 
6. Chimeric Thrombin Inhibitors 
Coupling of peptides that mimic the carboxy terminal of hirudin to peptides that 
are specific for inhibition of the catalytic site of thrombin (D-Phe-Pro-Arg) has led to the 
development of a series of chimeric molecules termed hirulogs, in which the amino 
terminus consists of the catalytic site-directed peptides, while the carboxy terminus 
consists of the 12 terminal residues of hirudin. The two moieties are linked together by 
a bridge of glycine residues of variable length (DiMaio et al. 1990, Maraganore et al. 
1990). Thus, hirulogs inhibit thrombin by binding to both its catalytic site and its anion 
binding exosite, thus conferring specificity to these molecules for thrombin. Hirulog-1 
has been developed aggressively for several cardiovascular indications (Topol et al. 1993, 
Cannon et al. 1993, Theroux and Lidon 1994). However, its superiority over heparin 
has not been established. 
Recently, there has been a report of a novel synthetic thrombin inhibitor, 
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CVS#995 (Vlasuk et al. 1994), comprised of 19 amino acids, in which recognition 
sequences for the catalytic and primary exosite binding domains of thrombin have been 
linked by a transition state analog (Vlasuk et al. 1994). The Ki value for thrombin is in 
the pM range for this slow and tight binding thrombin inhibitor. When compared to 
hirulog-1, this agent is claimed to be superior at inhibiting platelet aggregation and 
venous thrombosis in a rat model (Vlasuk et al. 1994, Biemond et al. 1995). 
An interesting chimeric molecule has been developed, in which the 12 terminal 
residues of hirudin are coupled to the tripeptide Arg-Gly-Asp (Church et al. 1991). This 
tripeptide is a sequence found in thrombin and the adhesive proteins fibrinogen, 
fibronectin, vitronectin and von Willebrand factor and is recognized by the platelet 
surface receptor GPIIb/IIIa which mediates platelet cell adhesion and aggregation 
(Ruoslahti et al. 1987, Phillips et al. 1988, Plow et al. 1989). The chimeric molecule 
is able to inhibit platelet adhesion to surfaces as well as inactivate thrombin. The 
implications of this type of structuring are that thrombin inactivation can be targeted to 
specific cells trapped in thrombi. Based on this hybrid molecule and the crystal structure 
of the hirudin-thrombin complex, a new class of recombinant hirudin variants has been 
developed, called hirudisins (Knapp et al. 1992) These recombinant hirudins have 
residues 32-35 replaced by the sequence Arg-Gly-Asp-Ser or Lys-Gly-Asp-Ser to yield 
molecules with characteristics similar to those of the Arg-Gly-Asp-C-terminal of hirudin 
chimera. 
In a novel approach to target a thrombin inhibitor to the surface of a clot, hirudin 
was covalently linked to a fibrin specific monoclonal antibody (Bode et al. 1996). This 
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chimeric agent was shown to be more effective than hirudin alone in preventing platelet 
deposition and clot formation in vitro and in an in vivo baboon arteriovenous shunt 
model. 
7. Thrombin Directed Antibodies 
Acquired antithrombin autoantibodies are rare and have been poorly characterized. 
In one reported case (Sie et al. 1991) the patient had mild bleeding symptoms and 
markedly prolonged clotting times and eventually died of cerebral hemorrhage. The 
antibody was found to be an immunoglobulin that recognized at least in part the apolar 
binding site of thrombin, adjacent to the catalytic site. In another case, the patient 
developed antibodies against thrombin and factor Xa after exposure to topical treatment 
with bovine thrombin (Zehnder and Leung, 1990). Polyclonal antibodies against 
thrombin have been raised by using the human a thrombin B chain (Noe et al. 1988). 
These antibodies were found to inhibit the functions of thrombin that require involvement 
of its anion binding site, such as activation of protein C when bound the 
thrombomodulin, cleavage of fibrinogen and binding to hirudin. On the other hand, the 
catalytic site of thrombin was not hindered and thus the enzyme retained its activity to 
activate protein C and interact with small chromophores (directed against thrombin' s 
catalytic site). These antibodies are useful tools in capturing complexes of thrombin 
(Lackman and Geczy, 1991, Lackman et al. 1991) as well as in studying requirements 
of thrombin sites in other interactions (Chang and Detwiler, 1991, Noe et al. 1988). 
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F. Clinical Applications of Thrombin Inhibitors 
Ever since their introduction, most of the clinical indications for these new 
anticoagulants have been in the interventional cardiovascular areas (Herrman and 
Serruys, 1994). Initial focus has been on the prevention of abrupt closure during 
coronary angioplasty (Topol et al. 1993, Topol 1995). These agents have also been tried 
for the post-PTCA prevention of both the early and late reocclusion (Suzuki et al. 1995). 
In addition, some of the thrombin inhibitors have been used for the treatment of unstable 
angina (Topol 1995). More recently, some of these agents have been tested for their 
efficacy in stenting (van Beusekom et al. 1994, Buchwald et al. 1993, Sternberger et al. 
1996). Although several reports on the experimental use of these agents have been made 
available on their use in cardiovascular surgery in animal models, only isolated reports 
in human studies are available (Riess et al. 1995, Edmunds 1995). Concerns over the 
use of these agents have been expressed (Edmunds 1995). 
Thrombin inhibitors are attractive to both clinicians and surgeons as substitute 
anticoagulants in heparin compromised patients in particular. For patients requiring 
anticoagulation, exhibiting heparin induced thrombocytopenia, several trials are currently 
in progress to test the efficacy of new antithrombin agents (Edmunds 1995, Chamberlin 
et al. 1995). 
There is a growing interest in the use of these agents in the prevention and 
treatment of DVT (Bridey et al. 1995). Eriksson (1995) reported on the successful use 
of recombinant hirudin in the prophylaxis of post-orthopaedic surgery. In this study he 
compared unfractionated heparin (5000 IU s.c. t.i.d.) with hirudin (15 mg s.c. b.i.d.) 
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and found hirudin to be superior. Several additional trials are currently being conducted 
on different antithrombin agents. 
1. Antithrombin 
The major application of antithrombin is in disorders associated with antithrombin 
deficiency, acquired or hereditary. Antithrombin replacement therapy in patients with 
hereditary antithrombin deficiency is in phase I and Phase II clinical studies. 
Supplementation of antithrombin to these patients before and after undergoing various 
surgical procedures with or without other treatments has proven effective (Menache 
1991). The combination of antithrombin/heparin is effective in prophylaxis of venous 
tllrombosis following total hip and total knee replacement surgery (Franscis et al. 1991). 
The role of antithrombin replacement therapy in prophylaxis of thrombotic episodes 
during pregnancy remains controversial (Owen 1991). From a study by Demers et al. 
(1992), it appears that replacement therapy of antithrombin in people who are deficient 
should be a mode of prophylaxis only during periods of high risk for thrombotic 
phenomena. In addition to these uses, antithrombin has been evaluated in clinical trials 
in patients with septic shock and DIC (Maki et al. 1987, Blauhut et al, 1985, Fourrier 
et al. 1993). The outcomes of these trials proved that antithrombin is effective in 
attenuating and correcting DIC early, but the mortality rate is not affected. 
2. Argatroban 
Although argatroban has been studied in wide range of animal models and has been used 
clinically in Japan for some years (it is approved for treatment of peripheral arterial 
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occlusive disease), only recently has the European and American community started to 
evaluate its clinical usefulness. 
In an initial study in the U.S., argatroban was evaluated in patients with unstable 
angina (Gold et al. 1993). Even though myocardial ischaemia did not occur during the 
argatroban infusion, some patients had recurrent angina within 6 hours after discontinuing 
the infusion. However, the outcomes may be improved by changing the infusion 
protocol. This recurrent angina was correlated with an increase in the thrombin-
antithrombin complex and was described as a rebound phenomenon. This observation 
was explained by either the premature cessation of argatroban infusion which resulted in 
inhibition of thrombin but was not enough to inhibit the generation of thrombin Gold et 
al. 1993), or by the heparin withdrawal prior to argatroban infusion, which itself results 
in recurrent angina (Willerson and Casscells, 1993). Furthermore, heparin alone 
promotes antithrombin clearance, so that antithrombin levels may have been artificially 
low prior to argatroban infusion (Willerson and Casscells, 1993). 
There are currently two phase II trials in North and South America, in which 
Argatroban is being evaluated as an adjunct to thrombolytic agents and aspirin. The 
Argatroban in Myocardial Infarction (AMI) study is evaluating two doses of argatroban 
in conjunction with streptokinase and aspirin in patients with acute myocardial infarction 
(P. Theroux, M.D., Montreal Heart Institute, Principal Investigator). The Myocardial 
Infarction with Novastan and tPA (MINT) study is comparing two doses of argatroban 
to heparin in patients diagnosed with acute myocardial infarction and receiving tP A and 
aspirin (1.K. Jang, M.D., Harvard Medical School, Massachusetts General Hospital, 
79 
Principal Investigator). Argatroban is also evaluated in two phase II trials (ARG-911, 
B. Lewis, M.D., Loyola University Medical Center, Principal Investigator and ARG-
912, G. Pineo, M. D. and R. Hull, M. D. , University of Calgary, Principal Investigators) 
in patients with heparin induced thrombocytopenia. In the ARG-912 study, argatroban 
is being compared to ancrod (a defibrinating enzyme). The results of these trial are 
expected to be available in early 1997. Argatroban is also proposed as an anticoagulant 
for cardiovascular bypass surgery. (ARG-240, R. Pifarre, Loyola University Medical 
Center, Principal Investigator). 
3. Ef egatran 
The tripeptide aldehyde D-MePhe-Pro-Arg-H is currently marketed under the 
generic name efegtran sulfate by Eli Lily, U.S.A. Although efegatran has been examined 
in various animal models and has been in studied experimentally for several years with 
promising results, only in the last two years has it been considered for clinical usage. 
Five clinical studies have been performed with efegatran in normal male volunteers, to 
assess safety and pharmacokinetics/ pharmacodynamics. Interestingly, some of the 
subjects experienced short-lived headaches, postural dizziness and vasovagal episodes 
when moving from a lying to a sitting position following I. V. infusion of efegatran. It 
is currently being studied in a phase II trial, the Prevention of Reocclusion by Inhibition 
of thrombin during Myocardial Events (PRIME) study, in patients with acute myocardial 
infarction. This trial is comparing adjunct usage of tPA and aspirin with efegatran at 
different doses versus adjunct usage of tPA and aspirin with heparin. The results of this 
study are expected in the beginning of 1996. 
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4. lnogatran 
While inogatran is a new competitive thrombin inhibitor and limited information 
on its pharmacology is available, phase I studies on this thrombin inhibitor are already 
completed (Teger-Nilsson, 1995). It is shown that inogatran is an effective anticoagulant 
with a biological half life of about 1 hour, which is longer than the other thrombin 
inhibitors currently under clinical evaluation. There appear to be not metabolites of this 
agent and it is excreted evenly between kidneys and faeces. However, this thrombin 
inhibitor prolongs the capillary bleeding time in some healthy human subjects. 
Currently, inogatran is evaluated in a phase II trial in patients with unstable angina. 
5. N apsagatran 
As with inogatran, napsagatran is a newly developed reversible thrombin 
inhibitor. It is currently evaluated in phase II clinical trials for the prevention of post-
operative thrombosis and in treating established venous thrombosis. 
6. Hirudin 
The antithrombotic and anticoagulant effects of recombinant hirudin have been 
well established in experimental animal models. In the clinical setting, hirudin has been 
studied in various clinical trials for a range of indications. Hirudin was compared with 
heparin in the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial, in acute myocardial 
infarction patients treated with tPA and aspirin (Cannon et al. 1995). Although there was 
an improvement in clinical endpoints with hirudin as compared with heparin, there was 
no hirudin dose-dependence on the outcomes. The TIMI 6 Trial compared hirudin with 
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heparin in acute myocardial infarction patients receiving streptokinase and aspirin (Lee 
et al. 1995) and there was a trend for an improved outcome with the higher dose of 
hirudin compared to the lower hirudin dose and to heparin. However, the subsequent 
larger phase 3 Hirudin for Improvement of Thrombolysis (HIT Ill) trial, that compared 
hirudin to heparin in acute myocardial infarction patients treated with tP A and aspirin 
(Neuhaus et al. 1994), was stopped prematurely due to excessive intracranial bleeding 
in the hirudin group. Another large phase 3 trial stopped prematurely due to excessive 
intracerebral bleeding was the Global Use of Strategies to Open Occluded Arteries 
(GUSTO) II trial (GUSTO Ila Investigators, 1994). In this trial, hirudin was again 
compared to heparin, in patients with acute coronary syndromes (with unstable angina 
or myocardial infraction). It was observed that the incidence of hemorrhagic strokes 
increased in patients receiving concomitant thrombolytic therapy. Another interesting 
finding of this study is that hirudin, irrespective of dose, is less effective in inhibiting 
thrombin generation when compared to heparin (Zoldelhyi et al. 1995). The 
Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial, 
designed to compare heparin and hirudin as adjuncts to thrombolytic therapy, was also 
prematurely stopped because of increased incidence of hemorrhagic strokes in patients 
receiving either heparin or hirudin (Antman and TIMI 9A Investigators, 1994). Both the 
GUSTO II and TIMI 9A trials were re-initiated with lower doses of both hirudin and 
heparin under the acronyms GUSTO Ilb and TIMI 9B (Verstraete and Zoldheyi, 1995). 
In the GUSTO-Ilb, over 12,000 patients from 373 hospital sites in 13 countries were 
included to compare intravenous recombinant hirudin and heparin. Dr. Topol (45th 
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Annual Scientific Session of the American College of Cardiology Meeting in Orlanso FL, 
oral presentation) described this study as validating the direct thrombin inhibition 
hypothesis where hirudin at adjusted dosage exhibited comparable anticoagulant actions 
to heparin. However, even at this dose, the hirudin treated group showed slightly 
increased bleeding events. The HIT-SK trial, designed to compare hirudin and heparin 
as adjunct treatments to streptokinase in patients with acute myocardial infarction 
(Molhoek et al. 1996) was recently completed. The results of this study also showed that 
no clear dose-response relationship was evident and furthermore major bleeding events 
were also increased. 
Hirudin has also been evaluated in the indication of coronary angioplasty, in the 
phase III, Hirudin in a European Restenosis Prevention Trial Versus Heparin in 
Treatment of PTCA Patients (HELVETICA, Serruys et al. 1994). When compared to 
heparin, the hirudin group exhibited an improvement of clinical outcomes (fewer 
myocardial infarctions, bypass surgeries and ischemic events) in the early stages of 
treatment, but in the 7 month follow-up there was no difference in the rate of restenosis 
between the two groups. 
In the indication of unstable angina, hirudin has been compared with heparin and 
found to decrease the rate for subsequent myocardial infarction (OASIS, Organization to 
Assess Strategies for Ischemic Syndromes 1995). However, there was no dose-response 
relationship in the hirudin group. Another problem emerging from treatment of unstable 
angina with hirudin or heparin is that there is an increase of ischemic events after hirudin 
or heparin is stopped. A recent study on coagulation markers in unstable angina patients 
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treated with heparin or hirudin in conjunction with aspirin showed that although 
coagulation was suppressed during treatment with these agents, coagulation was 
reactivated when the treatment was stopped (Flather et al. 1995). Therefore, treatment 
should be continued for longer time periods ( > 72 hours). 
Hirudin has been compared to heparin in patients undergoing elective total hip 
replacement in small phase 2 trials (Eriksson et al. 1994a,b, Ekman et al. 1996). In a 
recent report (Eriksson et al. 1996) a fixed dose of 15 or 20 mg hirudin pre-operatively 
and administered S.C. twice daily for at least 9 days, was shown to be superior to 
heparin and safe prophylactic regimen for thromboembolic complications in patients 
undergoing total hip replacement surgery. However, such a study should have compared 
hirudin to the standard treatment, which is currently low molecular weight heparin S.C. 
b.i.d. Thus, there is a need for additional clinical trials for hirudin in this indication. 
A recent report describes the usage of hirudin in ten patients with severe venous 
thromboembolism (Parent et al. 1993, Schiele et al. 1994). It was concluded that 
thrombin generation was only partial and the dose of hirudin should be increased in 
subsequent studies and should be compared to heparin or low molecular weight heparin. 
Novel and successful applications of hirudin have been reported recently in two 
case studies, where the patients involved developed heparin induced thrombocytopenia. 
In one case, the patient successfully underwent cardiopulmonary bypass surgery by using 
hirudin instead of heparin for anticoagulation during this procedure (Potzsch et al. 1994). 
In the second case, the another patient with heparin induced thrombocytopenia 
successfully underwent cardiopulmonary bypass surgery with an aortic valve replacement, 
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after being anticoagulated with hirudin in place of heparin (Riess et al. 1995). Since these 
two isolated cases, an additional 11 patients with heparin-induced thrombocytopenia have 
been successfully treated with hirudin during cardiopulmonary bypass for cardiac surgery 
(Potzsch et al. 1996). However, concerns regarding replacement of heparin with hirudin 
during cardiopulmonary bypass surgery include the absence of an antidote to hirudin and 
the questionable ability of hirudin to suppress thrombin generation (Edmunds 1995). 
Another novel application of hirudin was in a patient with diabetic nephropathy 
and heparin induced thrombocytopenia (Nowak et al. 1996). The continual usage of 
hirudin in this patient in conjunction with hirudin-impermeable dialyzers proved to be 
safe and efficacious. 
While hirudin has been regarded as a weakly immunogenic agent, a recent study 
reports on the detection of IgG anti-hirudin antibodies in 38 out of 82 patients with 
heparin induced thrombocytopenia that were treated successfully for more than 6 days 
with hirudin (Eichler and Greinacher 1996, Greinacher et al. 1996). Even though no 
allergic reactions were induced in any of the patients, the effects of these antibodies on 
the pharmacologic responses of hirudin are not clear at this time. 
The recombinant hirudin CX-397, a chimeric molecule between HV-1 and HV-3, 
has been compared with heparin in two groups of 5 patients receiving aspirin, prior to 
coronary angiography (Ffrench et al. 1995). This agent is shown to be a strong anti-
coagulant that warrants further investigations in patients undergoing coronary angioplasty. 
The interactions of PEG-hirudin with aspirin were studied recently in 9 healthy 
human volunteers (Breddin et al. 1996). It was shown that PEG-hirudin in combination 
85 
with aspirin may be associated with a higher risk of bleeding. These bleeding additive 
effects were not correlated with any of the platelet function tests nor any of the 
coagulation parameters. To avoid bleeding complications, it was suggested that the PEG-
hirudin dose should be decreased or that aspirin should be given after PEG-hirudin 
treatment was completed. 
Phase I clinical studies on PEG-hirudin have shown that this agent is a safe 
thrombin inhibitor in healthy human volunteers after I.V. or S.C. injection (Esslinger et 
al. 1995). Due to its prolonged t1h when compared to hirudin, PEG-hirudin appeared 
to be from these studies a promising agent for prophylactic development as a once daily 
S.C. injection. The rapid clearance of PEG-hirudin from the central compartment, 
following I. V. injection also indicates that this agent may be suitable for low-dose 
continuous infusions. 
7. Hirulog 
Hirulog peptides have been characterized biochemically extensively. They are 
specific thrombin inhibitors and in the in vitro clotting studies they appear to be potent 
anticoagulants (Ofosu et al. 1992, Witting et al. 1992, Maraganore et al. 1990). Hirulog 
has been compared to heparin as an adjunct to streptokinase and aspirin in patients with 
acute myocardial infarction (Lidon et al. 1994). Based on the favorable findings for 
hirulog, a larger trial is now underway for the same indication (Weitz et al. 1995). 
A large phase 3 trial, Hirulog Angioplasty Study, compared hirulog to heparin in 
patients undergoing coronary angioplasty for unstable angina or for ongoing ischaemia 
after myocardial infarction (Strony et al. 1995). Hirulog was found to be superior in 
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high-risk patients undergoing angioplasty after myocardial infarction, although there was 
no difference in the rate of primary outcome events (mortality, myocardial infarction, 
emergency bypass) overall. The same study also revealed that hirulog does not prevent 
restenosis after coronary angioplasty (Burchenal et al. 1995), even though the thrombin 
rebound effect is more suppressed with hirulog than with heparin (Strony et al. 1995). 
In the TIMI 7 trial, the effects of hirulog were examined in patients with unstable 
angina receiving aspirin. Although death and myocardial infarction were reduced at the 
higher doses of hirulog, there were no heparin controls included in this study. 
Hirulog also has been evaluated in prophylaxis of venous thrombosis in high-risk 
patients undergoing major orthopaedic surgery. The highest hirulog dose used proved 
to be as effective as other forms of prophylaxis, including low molecular weight heparin 
(Ginsberg et al. 1994). 
G. Drug Interactions 
Polypharmacology is necessary for an effective approach in the management of 
thrombotic disorders, ranging from disseminated intravascular coagulation (DIC) to deep 
venous thrombosis (DVT) to acute myocardial infarction (AMI). While different classes 
of drugs currently used adjunctly have different targets, all of which contribute to the 
ultimate safety and efficacy outcome, little has been done to study the direct interactions 
of the antithrombotic agents with other drugs. Because of the complex nature of 
thrombotic disorders, the impact of drug interactions in various disorders has to be 
carefully assessed. 
The primary agents used in management of thrombotic disorders include either 
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antiplatelet agents or inhibitors of thrombin and/or factor Xa. Fibrinolytics (thrombolytic 
drugs) are also used in many of these disorders, often in conjunction with anticoagulants. 
Since thrombolytic drugs are believed to target clots, relatively little attention has been 
given to interactions of these agents with anticoagulant drugs such as heparin and newly 
developed antithrombin agents. Antithrombin drug-induced impairment of physiologic 
fibrinolysis may result in a hypercoagulable state, whereas impairment of pharmacologic 
thrombolysis could lead to a compromised outcome, despite a strong systemic 
anticoagulant state. 
Although the above described thrombin inhibitors have been studied in terms of 
their antithrombotic activity, little work has been completed in the area of fibrinolysis. 
I 
So far, only D-Phe-Pro-Arg-H, D-Me-Phe-Pro-Arg-H, Boc-D-Phe-Pro-Arg-H, argatroban 
and D-Phe-Pro-ArgCH2Cl have been studied in vitro, for effects in fibrinolytic 
mechanisms. A fibrin plate assay and thrombelastography were used to compare the 
three arginals (Barabas et al. 1993) and it was concluded that the first two arginals were 
more selective than third one for thrombin in comparison to fibrinolytic enzymes such 
as plasmin, urokinase and streptokinase. In addition, the first two arginals were found 
to promote fibrinolysis (Barabas et al. 1993). The effects of argatroban on the clot lysis 
of human and rabbit plasma demonstrated that argatroban shortens the time to clot lysis 
in these systems when fibrin is cross-linked (Tamao et al. 1986). In contrast, argatroban 
has no effect in clot lysis when fibrin is not cross-linked (Tamao et al. 1986), indicating 
that argatroban prevents thrombin from activating factor XIII which is the fibrin cross-
linking enzyme. Furthermore, the same group demonstrated that argatroban had weak 
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inhibitory activities against tissue and urokinase type plasminogen activators. D-Phe-Pro-
ArgCH2Cl was found to inhibit tPA and plasmin (Gilboa et al. 1988), suggesting this 
agent to be an anti-fibrinolytic agent. 
Only a few animal models of thrombolysis have been studied for in vivo effects 
of antithrombin agents on fibrinolytic processes. The thrombin inhibitors examined in 
these model have been argatroban, D-Me-Phe-Pro-Arg-H, Boc-D-Phe-Pro-Arg-H, D-Phe-
Pro-ArgCH2Cl, hirulog-1 and hirudin. Argatroban has been shown to either decrease 
time to reperfusion and/or increase time to reocclusion when administered in conjunction 
with a fibrinolytic agent in dog and rabbit models of thrombolysis. In a dog model of 
coronary arterial thrombosis, occlusive thrombi are produced by mechanical injury to 
the vessel's endothelium (Martin et al. 1993). Thus the clots formed are platelet-rich and 
the amount of fibrin is minimal. Argatroban was shown to improve reperfusion in this 
model. In another model of dog femoral arterial thrombosis, the occlusive thrombus was 
formed with thrombin (Yasuda et al. 1990). Thus, this clot structure was more fibrin-
rich. In this model, it was found that although time to reperfusion was not affected, time 
to reocclusion was prolonged by argatroban. In a dog model of femoral arterial 
thrombosis, occlusive thrombi were again produced by mechanical injury to the vessel's 
endothelium and thus platelet-rich clots are formed (Mellot et al. 1990). In these 
studies, argatroban enhanced time to thrombolysis. In the rabbit model of carotid artery 
occlusion, the damage to the endothelium was chemically induced and the thrombi thus 
generated were platelet aggregates (Tamao et al. 1986). Here, argatroban enhanced 
thrombolysis. In a model of femoral artery thrombosis model, the occlusive clot was 
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generated by thrombin and thus was a fibrin structure (Schneider 1991, Jang et al. 1990). 
In this model, argatroban was also found to increase time to reocclusion and decrease 
time to reperfusion in conjunction with a fibrinolytic agent. 
The D-Me-Phe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H were studied for their 
effects on time to reperfusion in a dog model of coronary artery thrombosis, where the 
occlusive thrombus was induced electrochemically, thus producing a platelet-rich clot 
(Jackson et al. 1993). It was found that while the D-Me-Phe-Pro-Arg-H increased the 
time to reocclusion when used with tP A, the time to reperfusion was not influenced. 
Furthermore, Boc-D-Phe-Pro-Arg-H increased the time to reperfusion when used 
adjunctly with tP A. This finding indicates a fibrinolytic compromise induced by this 
thrombin inhibitor, which in contrast to the first arginal is less specific for thrombin. 
D-Phe-Pro-ArgCH2Cl, hirulog-I and hirudin were compared in a rat model of 
abdominal aortic thrombolysis (Klement et al. 1992). The occluding thrombus was 
produced by a combination of endothelial injury and blood flow stasis. In these studies 
it was found that all three agents prolonged the time to reocclusion and the number of 
reocclusions. Interestingly enough, while D-Phe-Pro-ArgCH2Cl and hirulog-I decreased 
the time to thrombolysis, hirudin did not, suggesting that hirudin does not access clot-
bound thrombin as effectively as the other two agents. However, the doses of these 
agents were based on their prolongation of activated partial thromboplastin time (APTT) 
to similar extents. The usage of this global clotting test to decipher equivalent doses of 
thrombin inhibitors with distinct mechanisms of thrombin inhibition is arguable. Hirudin 
was also studied in a dog model of coronary artery occlusion (Sitko et al. 1992, Martin 
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et al. 1992, Lunch et al. 1994). Here, the occluding thrombus was induced by electrical 
damage to the vessel and hirudin was found to decrease the time to reperfusion and 
increase the time to reocclusion. 
The above observations, both in vitro and in vivo, indicate that the effects of 
thrombin inhibitors on fibrinolytic processes are complex and depend not only on the 
specificity of the inhibitors for thrombin in comparison to other enzymes, but also on the 
structure and type of the clot used to study the effects, the fibrinolytic agent used to lyse 
the clot and the endpoints measured. 
Drug interactions play an important role in the overall safety and efficacy of 
anticoagulant agents such as thrombin inhibitors. In many indications, antithrombin 
agents are administered in conjunctions with other drugs. Many of the patients are often 
on other medications. A systematic study on the interactions of antithrombin agents with 
other drugs is not available. However, it wold be feasible to develop a testing system 
for thrombin inhibitors before this interaction with other drugs can be studied. 
Hirudin, unlike other peptide or peptidomimetic antithrombin agents, because of 
its high specificity for thrombin does not exhibit any complex interactions (Callas et al. 
1995, Fareed et al. 1995). Its actions are readily predictable because of the known 
pharmacologic profile. However, dosage optimization in the presence of other 
anticoagulant/ antithrombotic drugs is important. Hirudin and the other thrombin 
inhibitors are expected to exhibit augmentation of the anticoagulant actions of oral 
anticoagulant actions of oral anticoagulant drugs since these agents suppress the formation 
of functional forms of factors II, VII, IX and X. In addition, these agents also augment 
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the functional forms of protein C and S. In this situation, hirudin and the low molecular 
weight thrombin inhibitors are capable of inhibiting thrombomodulin-bound thrombin, 
which is needed for the activation of protein C. The consequences of this process are 
not known. While there is no preclinical or clinical data available, the in vitro studies 
suggest that thrombin inhibitors may produce other additive or synergistic actions of the 
anticoagulant effects of these agents. Dosage adjustments may be required depending on 
the dose of heparins, to optimize the therapeutic index of the direct antithrombin agents. 
Most of the cardiovascular patients are on aspirin for prophylactic or therapeutic 
reasons. Since thrombin plays a key role in the activation of platelets, thrombin 
inhibitors are expected to produce augmentation or synergism of the antiplatelet actions 
of aspirin. This may be a complex situation, however, it would result in compromised 
hemostasis. The bleeding complications observed in the TIMI 9A and GUSTO II trials 
may be attributable to the use of aspirin by the patients included in this study (Antman 
and TIMI 9A Investigators 1994, GUSTO II Investigators 1994). This is supported by 
a recent report (Breddin et al. 1996), the interaction of hirudin and aspirin on normal 
healthy human volunteers resulted in prolongation of the bleeding time which was not 
correlated with any of the platelet function tests nor any of the coagulation parameters. 
On the other hand, the interaction may also be of clinical benefit to the patients if the 
dose of those agents are optimized. Other platelet interactions such as the IIb/IIIa 
inhibitors and ADP antagonists are expected to have similar interactions with hirudin. 
Unlike many direct thrombin inhibitors, hirudin does not produce any direct 
inhibition of such fibrinolytic enzymes as plasmin and plasminogen activators. However, 
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hirudin is capable of inhibiting thrombomodulin-bound thrombin which would result in 
inhibition of the anticoagulant action of thrombin (activation of protein C) and thus 
precipitate a prothrombotic situation at higher doses. Furthermore, hirudin does augment 
the anticoagulant actions of the fibrinogen/fibrin degradation products in various 
experimental settings. Thus, hirudin is expected to produce an augmentation of the 
thrombolytic efficacy and may prevent rethrombosis (reocclusion). The net effect of 
hirudin can be validated only in clinical trials. 
H. Synopsis 
There is a continual influx of both the basic and clinical data in the area of 
thrombin inhibitors. Ever since the introduction of commercially feasible antithrombin 
agents such as hirudin and other synthetic inhibitors of thrombin, a strong interest in the 
development of these drugs is eminent. It should also be noted that thrombin plays an 
important role in several biological process such as mitogenesis, cellular proliferation, 
vascular modulation and the modulation of ion channeling processes. The focus of this 
review is primarily on the thrombogenic effects of this enzyme (thrombin), in context 
with the pharmacology of various thrombin inhibitors included in this dissertation. It is 
conceivable that many of the thrombin inhibitors discussed in this review also modulate 
non-clotting/thrombogenic functions of thrombin. Additional information on some of 
these actions of thrombin have been extensively reviewed. At the present time, 
additional information on the basic mechanism of thrombin as a procoagulant and the 
behavior of thrombin inhibitors as anticoagulant/ antithrombotic drugs is far from 
complete. A periodic update on the subject is therefore essential. 
CHAPTER ill 
MATERIALS AND METHODS 
A. Synthesis and Characterization of Serine Protease Inhibitors 
The tripeptide aldehydes D-Phe-Pro-Arg-H · H2S04 (GYKI 14166), D-MePhe-Pro-
Arg-H · H2S04 (GYKI 14766) and Boc-D-Phe-Pro-Arg-H · 1hH2S04 (GYKI 14451) were 
synthesized and were obtained from the Institute for Drug Research, Budapest, Hungary. 
All of these agents were provided in dried powder forms and were kept in refrigerated 
desiccators. The procedures for the synthesis and the chemical characterization of these 
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compounds has been described (Bajusz et al. 1975, 1978, 1983, 1984, 1987, 1990). 
Because the free tripeptide aldehyde D-Phe-Pro-Arg-H was found to be an unstable 
compound and its functional inactivation was associated with the formation of a less polar 
heterocyclic derivative, N substitution was employed to synthesize more stable analogues. 
While the N-Boc derivative (Boc-D-Phe-Pro-Arg-H) was more stable than the free 
tripeptide aldehyde, it was not as specific as the other agents. On the other hand, N-
alkyl substitution resulted in synthesis of stable D-Phe-Pro-Arg-H analogues, such as D-
MePhe-Pro-Arg-OH, that retained the basic amino terminus characteristic which confers 
specificity for thrombin. The structures of these peptide aldehydes are depicted in Fig. 
3. The formula molecular weights of each of these peptides is D-Phe-Pro-Arg-H · H2S04 
[500.6], D-MePhe-Pro-Arg-H · H2S04 [514.6] and Boc-D-Phe-Pro-Arg-H · 1hH2S04 
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[551.6] respectively. Stock solutions of these agents were made in appropriate buffers 
and saline prior to use. The saline stock solutions were frozen at -70°C and thawed only 
once prior to use. The same buffer and saline were used to make serial dilutions of these 
agents. 
The compound Ac-(D)Phe-Pro-boroArg-OH · HCl (DuP 714) was obtained from 
DuPont Merck Pharmaceutical Company, Wilmington, DE, in a powder form. The 
procedure for the synthesis and chemical characterization of this compound has been 
published (Kettner et al. 1990). The structure of this compound is depicted in Fig. 3. 
The formula molecular weight for this compound is 496.8. Stock and working solutions 
of this agent were also made prior to use in the appropriate buffers or saline. As with 
the peptide aldehydes, the saline stock solutions of this agent were frozen at -70°C and 
thawed once prior to usage. 
Argatroban, (2R,4R)-4-methyl-l-(N2-( (3-methyl-1, 2, 3 ,4-tetrahydro-8-
quinolinyl)sulfonyl]-L-arginyl)]-2-piperidine carboxylic acid, consists of a mixture of the 
diastereoisomers 21-(R)- and 21-(S)- around the 2- and 4- positions of the piperidine 
ring, in a ratio of approximately 65:35. The method for the synthesis of this compound 
was described by Okamoto and Hijikata (1981). Argatroban was obtained from Texas 
Biotechnology Corp., Houston, TX. This compound was provided in a 0.5 mg/ml 
solution. Light resistant vials containing 10 mg of argatroban in 20 ml sterile isotonic 
solution were provided and kept at room temperature. The structure of this compound 
is depicted in Fig. 3. The formula molecular weight of this compound was 532. Further 
dilutions of argatroban were made also in saline and appropriate buffers prior to use. 
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Recombinant hirudin variant 1 (rHV-1) was obtained from Knoll AG, 
Ludwigshafen, Germany in lyophilized form in vial containing 20 mg, 17,000 ATU/mg, 
(Batch No: 00300AL). This recombinant material was produced in Escherichia coli and 
was a single 65 amino acid polypeptide chain. The primary structure of this hirudin is 
given in Fig. 4. The purity was > 95 % with 0.5 % moisture. The additives were 
succinate and sodium chloride. The molecular weight for this compound is 6,963. The 
specification data provided with this material are found in Appendix 1. Stock and 
working solutions of his agent were also made in saline and appropriate buffers. The 
saline stock solutions were frozen at -70°C and thawed once prior to use. 
Unfractionated porcine mucosal heparin (PMH, lot no. RB 21055) was obtained 
from Sanofi, Choay Institut, Paris, France. It was provided in a white powder form as 
a sodium salt. The molecular weight for this compound is 10, 700. The specific activity 
of this agent was found to be 160 U/mg. 
Aprotinin is broad spectrum Kunitz-type serine protease inhibitor. Aprotinin was 
obtained in powder form from Pentapharm AG, Basel, Switzerland (6,120 KIU1/mg). 
This compound is a Kunitz type of inhibitor, consisting of a single 58 amino acid 
polypeptide chain, with a molecular weight of 6,512, extracted from bovine lungs (Fritz 
and Wunderer, 1983). The primary structure of aprotinin is depicted in Fig. 4. This 
polypeptide chain is cross-linked by 3 disulfide bridges (Fritz and Wunderer, 1983). 
11 Kallikrein Inactivator Unit (KIU) = amount of aprotinin that reduces the 
biologic activity of 2U of kallikrein by 503 
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B. Analytical Profile of Peptide Thrombin Inhibitors 
Due to the instability of the D-Phe-Pro-Arg-H compound, methods for 
determining the purity and stability of all tripeptide thrombin inhibitors studied in these 
experiments were utilized. The HPLC system utilized for these studies was a Waters A-
45 system (2 Waters 510 HPLC pumps, Waters 712 Waters Intelligent Sample Processor, 
Waters 484 Tunable Absorbance Detector). The column used was a reversed phase 
analytical column (RAININ Microsorb-MV HPLC Column, C18, 5 µm, 100 A, 
reversed-phase column, 4.6 mm ID x 25 cm). The detection was at 214 nm. The 
injection volume was 25 µl of 1 mg/ml of each peptide. 
The eluent systems and gradients for determining the purity of the tripeptide 
aldehydes (D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H) were 
suggested and described in detail by Dr. Sandor Bajusz (Institute for Drug Research, 
Budapest, Hungary) and also published by Bajusz et al. (1975, 1978). All peptides 
eluted in 3 peaks corresponding to equilibrium structures, as was described by Bajusz et 
al. 1990. All other additional peaks were due to impurities (side products, epimers, 
racemized derivatives etc.). The amount of each peptide was determined by summing 
the area under the three equilibrium peaks and subtracting it from the area under all 
background-adjusted peaks. 
The peptide Ac-(D)Phe-Pro-boroArg-OH was also profiled by an HPLC method, 
utilizing the same equipment and parameters as with the peptide aldehydes. The eluent 
system and gradients for determining the purity of Ac-(D)Phe-Pro-boroArg-OH, were 
suggested by Dr. Charles Kettner (DuPont-Merck Pharmaceuticals, Wilmington, DE). 
1. D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H 
Purity Determination 
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The purity and concentration of the tripeptide aldehyde thrombin inhibitors was 
determined by standard HPLC methods, using the above described system. The 
specification data provided with these materials are provided in Appendix 2. The two 
eluent systems, for pump A and pump B respectively, were distilled water with 0.1 3 
trifluoroacetic acid (in which the peptides are dissolved at concentrations of 1 mg/ml) and 
acetonitrile with 0.1 3 trifluoroacetic acid (as the gradient). For D-Phe-Pro-Arg-
H · H2S04 and D-MePhe-Pro-Arg-H · H2S04 , the flow rate was 1.2 ml/min and the 
gradient was 0-5 min: 0 - 8 3 pump B 
5-30 min: 8 3 pump B (isocratic) 
30-45 min: 8 - 60 3 pump B 
45-50 min: 603 pump B (isocratic) 
50-55 min: 60 - 0 3 pump B 
55-60 min: 03 pump B 
For the Boc-D-Phe-Pro-Arg-H · 1/2H2S04 the flow rate was 1 ml/min and the 
gradient was 0-10 min: 0 - 30 3 pump B 
10-25 min: 303 pump B (isocratic) 
25-40 min: 30 - 603 pump B 
40-45 min: 603 pump B (isocratic) 
45-50 min: 60 - 0 3 pump B 
50-55 min: 0 3 pump B. 
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2. Ac-(D)Phe-Pro-boroArg-OH Purity Determination 
The purity and concentration of the tripeptide boronic acid thrombin inhibitor was 
determined by using the above described system, as described by Dr. Kettner. The 
specification data provide with this material are in Appendix 3. The two eluent systems, 
for pump A and pump B respectively, were distilled water with 10 3 methanol and 0. 005 
M octane sulfonate sodium salt (in which the boronic acid derivative was dissolved at a 
concentration of 1 mg/ml), and distilled water with 903 methanol and 0.005 M octane 
sulfonate sodium salt. The flow rate was 1.5 ml/min and the gradient was 54 3 pump 
A and 46 3 pump B. The total run time was 20 min. 
C. Analytical Profile of the Unfractionated Heparin 
Unfractionated heparins are poly-component agents and depending on the source 
and method of purification they vary in composition. The unfractionated porcine 
mucosal heparin used in these studies was characterized by using a published GPC 
method (Ahsan et al. 1994). The GPC-HPLC hardware used in this study was a Waters 
A-45 system (2 Waters 510 HPLC pumps, Waters 712 Waters Intelligent Sample 
Processor, Waters 484 Tunable Absorbance Detector and a differential refractometer 
joined in series with the outlet end of the columns attached to the tunable absorbance 
detector), equipped with Expert Ease software designed for polymer analysis. The 
columns used were a tandem column system (TSK 2000/TSK 3000, Beckman, San 
Ramon, CA). The mobile phase was 0.5 M NaiS04 , the flow rate was 0.5 ml/min and 
the injection volume was 20 µl. The run time was 65 min and the UV detection was at 
234 nm. A simultaneous recording of the heparin profile was also made using the 
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refractive index detector. The calibration used in this system was described in detail in 
the publication by Ahsan et al. 1994 and comprised of 19 narrow range calibrators. The 
heparin used in this study was provided as a white-powder sodium salt and was dissolved 
in 0.5 M Na2S04 to a concentration of 10 mg/ml for the GPC profiling. 
D. Biochemical Assays 
1. Thrombin Titration Assay 
An amidolytic method was used to determine the direct antithrombin actions of 
various thrombin inhibitors. This method was developed by Iyer and Fareed (1995), as 
an assay for the determination of the specific activity of recombinant hirudin and as a 
tool for quality assurance and for the determination of batch to batch variation. The 
objective of these studies was to determine and compare the antithrombin potencies of 
direct thrombin inhibitors in terms of antithrombin units (ATU), utilizing a thrombin 
titration method. Since the definition of ATU is the amount of thrombin inhibitor that 
inhibits 1 NIH unit of thrombin, this assay was developed so that the final concentration 
of thrombin in the system was 1 NIH unit/ml. Therefore, the amount of thrombin 
inhibitor that produced 1003 inhibition of thrombin's activity was designated as the 
potency of a thrombin inhibitor in ATU/mg. a-thrombin (E.C. # 3.4.21.5, lot a375, 
specific activity 3,369 U/mg, protein concentration 0.68 mg/ml) was obtained from Dr. 
John Fenton II, New York State Dept. of Health, Albany, NY. This thrombin was 
diluted in buffer to a working concentration of 23.5 U/ml. Each of the thrombin 
inhibitors were diluted to various working concentrations in sterile saline solution (Baxter 
Healthcare Corp., Deerfield, IL). The amidolytic activity of thrombin was detected with 
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the chromogenic substrate Spectrozyme®TH (H-D-HHTyr-Ala-Arg-pNA · 2AcOH, 
American Diagnostica, Greenwich, CT), at a working concentration of 1.5 mM (diluted 
in deionized water). Cleavage of this substrate by thrombin results in release of the 
yellow chromophore pNA (para-nitroaniline). 
The buffer used to dilute the a thrombin to 23.5 U/ml was composed of Tris 
(0.05 M), NaCl (0.2 M) and polyethylene glycol 6000 (0.1 %), adjusted to pH 7.9. The 
buffer used for the assay described below was composed of triethanolamine HCl (0.1 M) 
and NaCl (0.2 M), adjusted to pH 8.4. 
The method used was carried out as follows utilizing quartz cuvettes (path length 
= 1 cm, Beckman Instruments, Inc., Irvine, CA) and a spectrophotometer (DU-7®, 
Beckman Instruments, Inc., Fullerton, CA): 1975 µl of buffer were mixed and incubated 
for 2 min at 37°C with 25 µl of the thrombin inhibitor at a particular concentration. 100 
µl of thrombin were added to this mixture and allowed to incubate for 1 min at 37°C. 
250 µl of Spectrozyme®TH were added and the rate of change in absorbance was 
measured for the next min at 405 nm. Sterile saline solution was used in place of the 
thrombin inhibitor as a control. 
Residual thrombin activity, remaining after incubation with a thrombin inhibitor 
was expressed as a percentage of the saline control by dividing the two respective rates 
of change in absorbance. The final concentration of the thrombin inhibitor was plotted 
against the residual thrombin activity. 
The order of the regression analysis utilized was the lowest that yielded regression 
coefficients >0.99. The thrombin inhibitor concentration that produced 503 residual 
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thrombin activity was the concentration that inhibited 0.5 NIH U/ml thrombin and 
therefore the thrombin inhibitor's ATU was double of that concentration. From these 
values, the relative antithrombin activity of each agent is calculated in terms of ATU/mg 
or ATU/nmole. Each concentration-response curve was repeated in triplicate on separate 
runs. 
2. Thrombin Time (TT) in a Fibrinogen Based System 
The fibrinogen based TT is a biochemically defined functional method for 
measuring the antithrombin effects of thrombin inhibitors, using human fibrinogen as the 
substrate for thrombin. While the thrombin titration method, described in the previous 
section, provides a measurement of the antithrombin activity of thrombin inhibitors 
utilizing thrombin's amidolytic activity, the fibrinogen based TT provides a measurement 
of the antithrombin activity of thrombin inhibitors utilizing thrombin's biologic activity 
, where soluble fibrinogen is transformed into fibrin. To perform the TT assay, a known 
amount of preformed human thrombin is added to the fibrinogen sample (containing 
varying amounts of a thrombin inhibitor) and the time required for clot formation 
measures the rate at which fibrin is formed. TT measurements were carried out using 
a solution of human fibrinogen (IMCO, Stockholm, Sweden, > 97% clottable fibrinogen, 
each vial containing 0.25g fibrinogen, O. lg sodium chloride and 0.25g sodium citrate, 
3 µg plasminogen/mg fibrinogen and < 5 µg plasmin/g fibrinogen) at 100 mg/dL, made 
in Owren's Verona! Buffer (Baxter Dade, Miami, FL). Each of the thrombin inhibitors 
was diluted at various concentrations in the buffered fibrinogen solution. Fibrindex™ 
brand of human thrombin (lyophilized, 50 U/ampule, Ortho Diagnostic Systems, Raritan, 
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NJ) at a concentration of 10 NIH U/ml in 0.025 M CaC12 , or in sterile saline solution 
(Baxter Healthcare Corp., Deerfield, IL) was used to initiate fibrinogen conversion to 
fibrin. In this procedure 100 µl of 10 U/ml human thrombin prewarmed at 37°C were 
added to 200 µl of fibrinogen prewarmed at 37°C for 3 min, and the clotting time was 
measured. Each concentration-response curve was repeated in triplicate on separate days. 
3. Antithrombin Assays 
The antithrombin assays provided a measurement of thrombin inhibitor 
concentration, utilizing the inhibitory effect against the amidolytic activity of thrombin 
(Fibrindex™), quantitated by a chromogenic substrate for thrombin (Spectrozyme®TH). 
This method was initially described by Walenga et al. 1983. Calibration curves (in vitro 
supplementation of thrombin inhibitors at various concentrations) were constructed with 
both normal human plasma and normal rabbit pool plasma. Due to the differences in 
blood clotting factor levels between human and rabbit plasma, the antithrombin 
amidolytic assay method varied, depending on the source of the plasma. 
Regardless of the species the plasma was obtained from and the procedure 
followed, the thrombin inhibition by each agent at each concentration or dose was 
calculated by the following formula: % thrombin inhibition by agent = [l - agent ~A405 
I saline ~A405] x 100 
The agent concentration versus % inhibition graphs provided the basis for the 
calculation of the IC50 for each agent. Since the molecular weights of these agents are 
known, all data were converted to molar concentrations or doses. Each concentration-
response curve was repeated in triplicate on separate days. 
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a. Preparation of Normal Human Plasma (NHP) 
Normal human plasma was obtained from the Loyola Blood Bank and was 
certified to be free of viral contamination (tested for Hepatitis B surface antigen, 
Hepatitis B antibodies, Hepatitis C antibodies, Hepatitis core antibodies, HIV 1 and 2 
antibodies, HTLV 1 antibodies, STS antibodies). The blood was collected from normal 
healthy human volunteers in bags containing CPDA-1 mixture (26.3 g/L trisodium 
citrate, 3.27 g/L citric acid, 31.9 g/L dextrose, 2.22 g/L monobasic sodium phosphate, 
and 0.275 g/L adenine), so that 450 ml of blood were mixed with 63 ml of CPDA-1 
anticoagulant-preservative. Within 8 hours of collection, this blood was centrifuged at 
1,200xg for 30 min at 4 °C. The separated plasma was then frozen at -70°C. Routinely, 
four or five frozen plasma bags were obtained from the blood bank and these were 
thawed and the plasmas were mixed to obtain a pool. This pool was then aliquoted and 
re-frozen at -70°C. The aliquots were thawed only once and used as needed. The 
unused pool plasma was appropriately disposed. 
b. Antithrombin Amidolytic Assay with NHP 
Each of the thrombin inhibitors was diluted in NHP to obtain vanous 
concentrations. When human plasma samples were evaluated, the assay was carried out 
in a fast kinetic centrifugal analyzer (ACL 300 plus, Instrumentation Laboratory, 
Lexington, MA). The procedure for the antithrombin amidolytic assay was as follows: 
10 µl of a sample containing thrombin inhibitor were incubated with 100 µl of 5 U 
104 
thrombin (diluted in Tris/EDTA buffer2) for 60 sec and then 40 µl of the thrombin 
substrate (1 mM in deionized H20) were added and the optical density was measured 
over a period of 30 sec. 
c. Preparation of Normal Rabbit Plasma (NRP) 
To study the concentration-dependent effects of thrombin inhibitors in the various 
plasma based assays and to prepare calibration curves, pools of rabbit plasma were 
prepared. To obtain these pools, 10 to 15 white male New Zealand rabbits weighing 2.5 
to 3.5 kg were obtained from LSR Industries, Union Grove, WI and housed individually. 
The animals were kept on standard rabbit chow diet and had access to water ad libitum. 
Each rabbit was lightly anesthetized with ketamine hydrochloride (Ketaset®, 100 mg/ml, 
Aveco Co. Inc., Fort Dodge, IA) at a dose of 50 mg/kg I.M. in combination with 
xylazine (Rompun®, 100 mg/ml, Mobay Corporation, Shawnee, KS) at a dose of 25 
mg/kg I.M. Blood was collected through the major ear artery of each rabbit. The first 
3 ml were discarded, while the subsequent 9 ml were collected in 3. 8 % sodium citrate 
(Vacutainer®, Becton Dickinson, Franklin Lakes, NJ). The rabbits were then monitored 
for 20 min to ensure hemostasis and then returned to their cages. Subsequently, the 
blood was centrifuged (Beckman GPR Centrifuge, Beckman Instruments Inc., Irvine CA) 
at 1200xg at 4 °C for 20 min to achieve platelet poor plasma which was pooled, mixed 
and frozen in aliquots at -70 °C. Aliquots were thawed and used immediately as needed 
(never re-frozen). 
2Tris/EDTA buffer:50mM Trizma Base, 175mM NaCl, 7.5mM 
Na2EDTA · 2H20,pH 8.4. 
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d. Antithrombin Amidolytic Assay with NRP 
Each of the thrombin inhibitors was supplemented at various concentration to 
NRP. When rabbit plasma samples were tested, the antithrombin assay was carried out 
in a spectrophotometer (DU-7®), utilizing quartz cuvettes. The procedure for the 
antithrombin amidolytic assay was as follows: 25 µI of a sample containing thrombin 
inhibitor were incubated with 400 µI of Tris/EDTA buffer at 37°C for 1 min. Then, 
25 µI of 10 U thrombin (diluted in sterile saline solution) were added and incubated for 
1 min at 37°C. At the end of the incubation period, 50 µI of the thrombin substrate (1 
mM in deionized H20) were added and the rate of change of optical density was 
measured over a period of 1 min at 405 nm. 
4. Anti-Xa Assays 
The anti-Xa assay provided a measurement of the relative inactivating actions of 
various agents, by measuring their inhibitory effects against the amidolytic activity of 
factor Xa. Human factor Xa (E.C. # 3.4.21.6, 0.65 ng/ml, Enzyme Research, South 
Bend, IN), was analyzed using a chromogenic substrate for factor Xa (Spectrozyme®FXa, 
MeO-CO-D-CHG-Gly-Gly-Arg-pNA · AcOH, American Diagnostica, Greenwich, CT). 
This method was described by Walenga et al. (1983). Calibration curves (in vitro 
supplementation of thrombin inhibitors at various concentrations) were constructed with 
both normal human plasma and normal rabbit plasma. Due to the differences in factor 
concentrations between human and rabbit plasma, the anti-Xa amidolytic assay method 
differed, depending on the source of the plasma. 
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Regardless of the species the plasma was obtained from and the procedure 
followed, the factor Xa inhibition by each agent at each concentration or dose was 
calculated by the following formula: % factor Xa inhibition by agent = [l - agent AA405 
I saline AA405] x 100 
The agent concentration versus % inhibition graphs provided the basis for the 
calculation of the IC50 for each agent. Since the molecular weights of these agents are 
known, all data were converted to molar concentrations or doses. Each concentration-
response curve was repeated in triplicate on separate days. 
a. Anti-Xa Amidolytic Assay with NHP 
Each of the thrombin inhibitors was diluted to various concentrations in NHP. 
When human plasma samples were evaluated, the assay was carried out in a fast kinetic 
centrifugal analyzer (ACL 300 plus). The procedure for the anti-Xa amidolytic assay 
was as follows: 10 µl of a sample containing thrombin inhibitor were incubated with 100 
µl of factor Xa (6.6 pg/ml, diluted in Tris/EDTA buffer2) for 300 sec and then 75 µl of 
the factor Xa substrate (2.5 mM in deionized H20) were added and the optical density 
was measured over a period of 30 sec. 
b. Anti-Xa Amidolytic Assay with NRP 
Each of the thrombin inhibitors was supplemented at various concentration to 
NRP. When rabbit plasma samples were tested, whether in vitro supplemented with a 
thrombin inhibitor or obtained during the rabbit stasis thrombosis model for ex vivo 
analyses, the anti-Xa assay was carried out in a spectrophotometer (DU-7®) utilizing 
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quartz cuvettes. The procedure for the anti-Xa amidolytic assay was as follows: 25 µl 
of a sample containing thrombin inhibitor were incubated with 375 µl of Tris/EDTA 
buffer2 at 37°C for 2 min. Then, 50 µl of factor Xa (5 nkat/ml, diluted in Tris/EDT A 
buffer2) were added and incubated for 2 min at 37°C. At the end of the incubation 
period, 50 µl of the factor Xa substrate (2.5 mM in deionized H20) were added and the 
rate of change of optical density was measured over a period of 1 min at 405 nm. 
5. Inhibitory Actions of Various Thrombin Inhibitors on 
Specific Serine Proteases 
Although some thrombin inhibitors are designed to inhibit the catalytic site of 
thrombin, because of the similarity between the catalytic sites of all serine proteases, it 
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is possible that the agents that inhibit the catalytic site of thrombin, also inhibit the 
catalytic site of other serine proteases. The following assays were designed to examine 
the inhibitory effects that thrombin inhibitors may have against other serine proteases, 
utilizing the amidolytic activity of these enzymes, in purified systems. The general 
procedure followed in the following assays was conducted on a fast kinetic centrifugal 
analyzer (ACL 300 plus). Generally, each thrombin inhibitor was diluted in sterile saline 
solution at various concentrations. Ten µl of the thrombin inhibitor were incubated with 
100 µI a known amount of the specific enzyme for 1 min. At the end of the incubation 
period, 40 µl a chromogenic substrate specific for the enzyme was added and the optical 
density was measured over a period of 999 sec. The serine protease inhibition by each 
thrombin inhibitor at each concentration was calculated by the following formula: 
% protease inhibition = [l - inhibitor .AA405 I saline .AA405] x 100 
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The thrombin inhibitor concentration versus 3 inhibition graphs provided the 
basis for the calculation of the IC50 for each agent. Since heparin is devois of any direct 
serpin activities and its actions are mediated primarily through potentiation of 
antithrombin, the stock solution of heparin was made as 10 mg/ml in 1 U/ml 
antithrombin (Kabi Vitrum, Stockholm, Sweden). Further dilutions of this mixture were 
made in saline, as were for the other thrombin inhibitors. In addition to the thrombin 
inhibitors, aprotinin was also tested in these system as a positive control for the 
evaluation of the thrombolytic enzymes. Since the molecular weights of these agents are 
known, all data were converted to molar concentrations. Each concentration-response 
curve was repeated in triplicate on separate days. 
a. Inhibition of Chymotrypsin 
Chymotrypsin (E.C. # 3.4.21.1, Zolyse®, from ox pancreas, 750 U.S.P. 
units/vial) was obtained from Ben Venue Laboratories, Inc., Bedford, OH. 
Chymotrypsin was used at a final assay concentration of 6.67 U/ml. The chromogenic 
substrate used to detect the activity of chymotrypsin was S-2586 (MeO-Suc-Arg-Pro-Tyr-
pNA · HCl, Kabi Diagnostica, KabiVitrum, Stockholm, Sweden), at a final assay 
concentration of 0.27 mM. 
b. Inhibition of Trypsin 
Porcine pancreatic trypsin (E.C. # 3.4.21.4, type II, crude, trypsin activity: 1740 
BAEE units3/mg, chymotrypsin activity: 1150 ATEE units4/mg) was obtained from 
3 1 BAEE unit = AA253 of 0.001/min in 3.2 ml at pH 7.6 at 25°C 
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Sigma Chemical Company, St, Louis, MO. Trypsin was utilized at a final assay 
concentration of 66.67 µg/ml . The chromogenic substrate used to detect the activity of 
trypsin was S-2423 (CH3-CO-Ile-Glu-Gly-Arg-pNA · HCl, Kabi Diagnostica, KabiVitrum, 
Stockholm, Sweden), at a final assay concentration of 0.27 mM. 
c. Inhibition of Activated Protein C (APC) 
APC (E.C. # 3.4.21.69) was obtained from American Red Cross, Holland 
Laboratories, Rockville, MD, lyophilized, 5 mg/vial. The final assay concentration of 
APC was 62.5 µglml. S-2288 (H-D-Ile-Pro-Arg-pNA · 2HC1, Kabi Diagnostica, 
KabiVitrum, Stockholm, Sweden) was the chromogenic substrate used to detect the 
activity of APC, at a final assay concentration of 0.27 mM. 
d. Inhibition of Glandular Kallikrein 
Pancreatic kallikrein (E.C.# 3.4.21.35, 4.7 units5/mg solid, 4.8 units/mg protein) 
was obtained from Sigma Chemical Company, St, Louis, MO. kallikrein was used at 
a final assay concentration of 0.67 mg/ml. The chromogenic substrate used to detect the 
activity of kallikrein was S-2302 (H-D-Pro-Phe-Arg-pNA · 2HC1, Kabi Diagnostica, 
KabiVitrum, Stockholm, Sweden), at a final assay concentration of 0.27 mM. 
e. Inhibition of Tissue Plasminogen Activator (tP A) 
tPA (E.C. # 3.4.21.68) was obtained from Genentech, South San Francisco, CA 
4 1 ATEE unit = t:.A237 of 0.001/min in 3 ml at pH 7.0 at 25°C 
5 1 unit hydrolyzes 1.0 µM of a-N-Benzoyl-Arg-Ethyl-Ester (BABE) to a-N-
Benzoyl-L-Arg and EtOH/min at pH 8.7 at 25°C 
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(Activase®, Alteplase, recombinant, 50 mg or 29 million IU /vial). The final assay 
concentration oft-PA was 0.67 mg/ml. Spectrozyme®TH was the chromogenic substrate 
used to detect the t-PA activity, at a final assay concentration of 0.27 mM. 
f. Inhibition of Urokinase 
Urokinase (E.C. # 3.4.21.73, Abbokinase®, 250,000 I.U./vial, from human 
kidney cells by tissue culture, low molecular weight form) was obtained from Abbott 
Laboratories, North Chicago, IL. The final assay concentration of urokinase was 6,667 
U/ml. The chromogenic substrate used to detect the urokinase activity was S-2444 
( < Glu-Gly-Arg-pNA · HCl, Kabi Diagnostica, KabiVitrum, Stockholm, Sweden) at a 
final assay concentration of 0.27 mM. 
g. Inhibition of Plasmin 
Plasmin (E.C. # 3.4.21.7, 6 nKat/vial) was obtained from Diagnostica Stago, 
Asnieres-Sur-Seine, France. Plasmin was utilized at a final assay concentration of 1.2 
nKat/ml. The chromogenic substrate used to detect the activity of plasmin was S-2251 
(H-D-Val-Leu-Lys-pNA · 2HC1, Kabi Diagnostica, KabiVitrum, Stockholm, Sweden), at 
a final assay concentration of 0.27 mM. 
6. Inhibition of Piasminogenolysis 
While the direct effects of thrombin inhibitors on serine proteases were studied 
utilizing the above described assay systems, the relevance of these effects to the process 
of activation of plasminogen to plasmin, or plasminogenolysis, was not addressed. 
Plasminogenolysis after activation by streptokinase or t-PA was measured in the systems 
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described below. The source of the plasminogen was either purified plasminogen (25 
CU6, 15 CU/mg, AB KABI, Stockholm, Sweden), or pooled human blood bank plasma 
(Loyola Blood Bank). 
In all plasminogenolysis assays, the inhibition of plasminogenolysis by each 
thrombin inhibitor and aprotinin at each concentration was calculated by the following 
formula: % inhibition = [1 - inhibitor Ll.A405 I saline Ll.A405] x 100 
The inhibitor concentration versus % inhibition response curves provided the basis 
for the calculation of the IC50 and IC25 for each agent. Since the molecular weights of 
these agents are known, all data were converted to molar concentrations. Each 
concentration-response curve was repeated in triplicate. 
a. Pure Plasminogen System 
In these assays, each thrombin inhibitor and aprotinin was diluted at various 
concentration in a TRIS/EDT A buffer2 • Pure plasminogen at a final assay concentration 
of 0.97U/ml was lysed by either streptokinase (E.C. # 3.4.22.10, purified streptokinase 
from Group C streptococci, 600,000 I.U./vial, AB KABI, Stockholm, Sweden) at a final 
assay concentration of 2,500 U/ml, or t-PA (Activase®) at a final assay concentration of 
5,000 U/ml. The generated plasmin was detected with a substrate specific for plasmin 
(Spectrozyme®PL, H-D-Nle-HHTyr-Lys-pNA · 2AcOH, American Diagnostica, 
Greenwich, CT), at a final assay concentration of 0.75 mM. The effects of thrombin 
inhibitors and of aprotinin on the process of plasminogenolysis were studied on a 
6CU = casein unit (Sgouris et.al, 1960) 
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spectrophotometer (model 35, Beckman Instruments, Inc., Fullerton, CA) and quartz 
cuvettes. 750 µl of a thrombin inhibitor were incubated for 1 min at 37°C. At the end 
of this incubation period, 100 µl of streptokinase or t-PA and 25 µl of plasminogen were 
added and the mixture was incubated for 3 min at 37°C. At the end of this incubation 
period, 100 µl of Spectrozyme®PL were added and the rate of change of optical density 
was measured over a period of 1 min. 
b. NHP System 
In these assays, each thrombin inhibitor and aprotinin was diluted at various 
concentration in a TRIS/EDT A buffer2 • NHP at a final assay dilution of 1: 10, was used 
as the source of human plasminogen. The plasminogen contained within the NHP was 
lysed by either streptokinase (AB KABI) at a final assay concentration of 2,500 U/ml, 
or t-PA (Activase®) at a final assay concentration of 5,000 U/ml. The generated plasmin 
was detected with a substrate specific for plasmin (Spectrozyme®PL) at a final assay 
concentration of 0. 75 mM. The effects of thrombin inhibitors and of aprotinin on the 
process of plasminogenolysis were studied on a spectrophotometer (model 35) and quartz 
cuvettes. 750 µl of a thrombin inhibitor were incubated for 1 min at 37°C. At the end 
of this incubation period, 100 µl of streptokinase or t-PA and 50 µl of NHP were added 
and the mixture was incubated for 3 min at 37°C. At the end of this incubation period, 
100 µl of Spectrozyme®PL were added and the optical density was measured over a 
period of 1 min. 
7. Inhibition of Extrinsic Activation Systems in Fibrinogen Deficient 
Human Plasma by Thrombin Inhibitors 
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While the antithrombin and anti-Xa assays are useful in determining the direct 
antithrombin or anti-Xa effects of thrombin inhibitors, they do not provide information 
on the effects of these inhibitors on the overall process of coagulation, or on the 
generation of thrombin and factor Xa. These plasmatic methods were developed by 
Kaiser et al. 1992, and were used to determine the thrombin and factor Xa generation 
inhibitory actions of various thrombin inhibitors, following extrinsic activation of the 
coagulation cascade. In these assays the materials used were: chromogenic substrate 
specific for thrombin (Spectrozyme®TH), chromogenic substrate specific for factor Xa 
(Spectrozyme®FXa), fibrinogen deficient plasma (fibrinogen < 15mg/dL, George King 
Biomedical, Overland Park, KS) and extrinsic activator (lyophilized acetone-dehydrated, 
rabbit brain Thromboplastin C, Dade, Miami, FL). The instrument used was a fast 
kinetic centrifugal analyzer (ACL 300 plus). 
The extrinsic thrombin and factor Xa generation inhibition by each thrombin 
inhibitor at each concentration was calculated by the following formula: 
% thrombin or factor Xa generation inhibition by agent = [l - agent .lA405 I saline 
.lA405] x 100 
The thrombin inhibitor concentration versus % inhibition graphs provided the 
basis for the calculation of the IC50 for each thrombin inhibitor. Since the molecular 
weights of these agents are known, all data were converted to molar concentrations. 
Each concentration-response curve was repeated in triplicate on separate days. 
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a. Inhibition of Extrinsic Thrombin Generation 
The chromogenic substrate for thrombin was reconstituted to 1 mM with 0.025 
M CaC12 and subsequently mixed with thromboplastin C (1:6). The fibrinogen deficient 
plasma was diluted with Tris/EDTA buffer2 (1:8). The procedure for this amidolytic 
assay was as follows: 60 µl of a known gravimetric amount of thrombin inhibitor diluted 
in sterile saline solution were incubated with 60 µl of fibrinogen depleted plasma for 300 
sec. Then 60 µl of the thrombin substrate mixed with thromboplastin C were added and 
the optical density was measured over a period of 999 sec. 
b. Inhibition of Extrinsic Factor Xa Generation 
The chromogenic substrate for factor Xa was reconstituted to 1 mM with 0.025 
M CaC12 and subsequently mixed with thromboplastin C (1:6). The fibrinogen deficient 
plasma was diluted with Tris/EDTA buffer2 (1:8). The procedure for this amidolytic 
assay was as follows: 60 µl of a known gravimetric concentration of thrombin inhibitor 
diluted in sterile saline solution were incubated with 60 µl of fibrinogen depleted plasma 
for 300 sec. Then 60 µl of the factor Xa substrate mixed with thromboplastin C were 
added and the optical density was measured over a period of 999 sec. 
8. Inhibition of Intrinsic Activation Systems in Fibrinogen Deficient 
Human Plasma by Thrombin Inhibitors 
While the previous two methods were used to investigate effects of inhibitory 
agents on the extrinsic activation of coagulation, the following plasmatic methods were 
used to determine the thrombin and factor Xa generation inhibitory actions of various 
thrombin inhibitors, following intrinsic activation of the coagulation cascade.. These 
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assays were also developed by Kaiser et al. 1992. In these assays the materials used 
were: chromogenic substrate specific for thrombin (Spectrozyme®TH), chromogenic 
substrate specific for factor Xa (Spectrozyme®FXa), fibrinogen deficient plasma (George 
King Biomedical) and intrinsic activator (Actin, Dade, Miami, FL). The instrument used 
was a fast kinetic centrifugal analyzer (ACL 300 plus). 
The intrinsic thrombin and factor Xa generation inhibition by each thrombin 
inhibitor at each concentration was calculated by the following formula: % thrombin or 
factor Xa generation inhibition by agent = [1 - agent AA405 I saline AA405] x 100 
The thrombin inhibitor concentration versus % inhibition graphs provided the 
basis for the calculation of the IC50 for each thrombin inhibitor. Since the molecular 
weights of these agents are known, all data were converted to molar concentrations. 
Each concentration-response curve was repeated in triplicate on separate days. 
a. Inhibition of Intrinsic Thrombin Generation 
The chromogenic substrate for thrombin was reconstituted to 1 mM with 0.025 
M CaC12 and subsequently mixed with actin (1 :2). The fibrinogen deficient plasma was 
diluted with Tris/EDTA buffer2 (1:8). The procedure for this amidolytic assay was as 
follows: 60 µl of a known gravimetric concentration of thrombin inhibitor diluted in 
sterile saline solution were incubated with 60 µl of fibrinogen depleted plasma for 300 
sec. Then 60 µl of the thrombin substrate mixed with actin were added and the optical 
density was measured over a period of 999 sec. 
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b. Inhibition of intrinsic Factor Xa Generation 
The chromogenic substrate for factor Xa was reconstituted to 1 mM with 0.025 
M CaC12 and subsequently mixed with actin (1:2). The fibrinogen deficient plasma was 
diluted with Tris/EDTA buffer2 (1:8). The procedure for this amidolytic assay was as 
follows: 60 µl of a known gravimetric concentration of thrombin inhibitor diluted in 
sterile saline solution were incubated with 60 µl of fibrinogen depleted plasma for 300 
sec. Then 60 µl of the factor Xa substrate mixed with actin were added and the optical 
density was measured over a period of 999 sec. 
9. Inhibition of KONYNE® Based Systems by Thrombin Inhibitors 
The extrinsic activation systems in human fibrinogen deficient plasma described 
above are not devoid of intrinsic activation, since the two pathways of coagulation 
interact at various levels, feedback loops amplify certain steps and all plasma factors with 
the exception of fibrinogen are present. To develop systems in which only extrinsic 
activation is possible without interference from the intrinsic factors, prothrombin complex 
concentrates extrinsically activated were used in the following described methods. These 
methods were initially developed by Kaiser et al. 1994. These defined methods were 
used to determine the factor Xa and thrombin generation inhibitory actions of various 
thrombin inhibitors. 
In these assays the materials used were: chromogenic substrate specific for 
thrombin (Spectrozyme®TH), chromogenic substrate specific for factor Xa 
(Spectrozyme®FXa), extrinsic activator (Thromboplastin C) and the prothrombin complex 
KONYNE® (of human origin, lyophilized, 580 U/vial, Cutter Laboratories, Berkeley, 
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CA), which represents a mixture of factors II, VII, IX and X. The instrument used was 
a fluorescence light scattering micro centrifugal analyzer (Multistat III, Instrumentation 
Laboratory, Lexington, MA). 
The inhibition of thrombin and factor Xa generation by each thrombin inhibitor 
at each concentration was calculated by the following formula: 3 inhibition of thrombin 
or factor Xa generation = [ 1 - agent ~A405 at 660 sec I saline ~A405 at 660 sec] x 100 
The thrombin inhibitor concentration versus 3 inhibition curves provided the 
basis for the calculation of the IC50 for each agent. Since the molecular weights of these 
agents were known, all data were converted to molar concentrations. 
a. Inhibition of thrombin Generation from KONYNE® 
The buffer used in this procedure was composed of 1 mM Tris/HCl and 6 mM 
CaC12, adjusted to pH 8.1. The procedure for this amidolytic assay was as follows: 165 
µl of the antithrombin agent diluted in buffer were incubated with 25 µl of the thrombin 
substrate (2.5 mM in deionized water) and 25 µl of Thromboplastin C (diluted 1: 10 in 
0.025 M CaC12) for 30 sec. Then 25 µl of KONYNE® at 10 U/ml working concentration 
(diluted with sterile saline solution), and 10 µl of buffer were added and the optical 
density was measured every 60 sec for 12 min. 
b. Inhibition of Factor Xa Generation from KONYNE® 
The buffer used in this procedure was composed of 1 mM Tris/HCI and 6 mM 
CaC12 , adjusted to pH 8.1. The procedure for this amidolytic assay was as follows: 165 
µl of the antithrombin agent diluted in buffer were incubated with 25 µl of the factor Xa 
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substrate (2.5 mM in deionized water) and 25 µl of Thromboplastin C (dilute 1: 10 in 
0.025 M CaClz) for 30 sec. Then 25 µl of KONYNE® at 10 U/ml working concentration 
(diluted with sterile saline solution) and 10 µl of buffer were added and the optical 
density was measured every 60 sec for 12 min. 
10. Inhibition of FEIBA ® Based Systems by Thrombin Inhibitors 
These systems, like the KONYNE® based systems, also determine the inhibitory 
activities of various agents on the extrinsic activation of the coagulation system. The 
prothrombin complex KONYNE® used in the above described assays contains factors in 
their pro-enzyme form only. The prothrombin complex FEIBA ® IMMUNO (anti-
inhibitor coagulant complex, of human origin, lyophilized, 490 U/vial, Osterreichisches 
Institut fiir Haemoderivate GES.M.B.H., subsidiary of Immuno Ag, Vienna, Austria) 
differs from KONYNE® in that in addition to factors II, VII, IX and X, it also contains 
trace amounts of factor VIIa. In these assays the materials used were: chromogenic 
substrate specific for thrombin (Spectrozyme®TH), chromogenic substrate specific for 
factor Xa (Spectrozyme®FXa), extrinsic activator (Thromboplastin C) and the 
prothrombin complex FEIBA ® IMMUNO. The instrument used was a fluorescence light 
scattering micro centrifugal analyzer (Multistat III). 
The inhibition of thrombin and factor Xa generation by each thrombin inhibitor 
at each concentration was calculated by the following formula: % inhibition of thrombin 
or factor Xa generation = [ 1 - agent .LlA405 at 660 sec I saline .LlA405 at 660 sec] x 100 
The thrombin inhibitor concentration versus % inhibition graphs provided the 
basis for the calculation of the IC50 for each agent. Since the molecular weights of these 
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agents were known, all data were also converted into molar concentrations. 
a. Inhibition of Thrombin Generation from FEIBA ® 
The buffer used in this procedure was composed of 1 mM Tris/HCl and 6 mM 
CaC12 , adjusted to pH 8.1. The procedure for this amidolytic assay was as follows: 165 
µl of the antithrombin agent diluted in buffer were incubated with 25 µl of the thrombin 
substrate (2.5 mM in deionized water) and 25 µl of Thromboplastin C (diluted 1: 10 in 
0.025 mM CaC12) for 30 sec. Then 25 µl of FEIBA® at 10 U/ml working concentration 
(diluted with sterile saline solution) and 10 µl of buffer were added and the optical 
density was measured every 60 sec for 12 min. 
b. Inhibition of Factor Xa Generation from FEIBA ® 
The buffer used in this procedure was composed of 1 mM Tris/HCl and 6 mM 
CaC12 , adjusted to pH 8.1. The procedure for this amidolytic assay was as follows: 165 
µl of the antithrombin agent diluted in buffer were incubated with 25 µl of the factor Xa 
substrate (2.5 mM in deionized water) and 25 µl of Thromboplastin C (diluted 1: 10 in 
0.025 mM CaCl2) for 30 sec. Then 25 µl of FEIBA® at 10 U/ml working concentration 
(diluted with sterile saline solution) and 10 µl of buffer were added and the optical 
density was measured every 60 sec for 12 min. 
E. Anticoagulant Effects of Thrombin Inhibitors in NHP 
Previously described amidolytic methods based on the intrinsic and extrinsic 
activation of plasma, provide information on the effects of agents on the generation of 
thrombin and factor Xa, utilizing the amidolytic activities of these factors. To study the 
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functional inhibitory effects on clot formation, or the anticoagulant effects of thrombin 
inhibitors and which pathways are inhibited most effectively, each of these agents was 
in vitro supplemented to NHP and tested in the global clotting tests described below. 
The following clotting time tests were performed on a fibrometer (Becton, Dickinson and 
Company, Cockeysville, MD) according to the specifications set by each of the 
manufacturers. NHP was obtained from the Loyola Blood Bank. Each concentration-
response curve was repeated in triplicate on separate days. 
1. Prothrombin Time (PT) 
This method is based on the method originally described by Quick et al. ( 1935). 
The PT reveals defects in the extrinsic system (factor VII) and in the factors common to 
the extrinsic and intrinsic systems (factors V and X, prothrombin and fibrinogen). 
Thromboplastin is added to a known amount of plasma and it activates factor VII to 
factor VIIa, thus activating the extrinsic pathway of coagulation. PT was measured using 
Thromboplastin C. In this procedure 100 µl of plasma were incubated for 3 min at 
37°C. At the end of this incubation time 200 µ1 of Thromboplastin C prewarmed at 
37°C were added and the clotting time was measured. 
2. Activated Partial Thromboplastin Time (APTT) 
The APTT is based on the originally described method be Proctor and Rapaport 
(1961). This method measures the intrinsic coagulation factors (factors VIII, IX, XI and 
XII), the factors common to both extrinsic and intrinsic systems (factors V, X and 
prothrombin) and the conversion of fibrinogen to fibrin. Prolonged clotting times reflect 
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deficiency or inhibition of one or more of the above factors. The time to clot formation 
after citrated plasma has been activated by a platelet substitute (a rabbit brain 
phospholipid with micronized silica as activator) and ca++ is measured. APTT was 
measured using the APTT reagent from Organon Teknika Corporation, Durham, SC. 
In this procedure 100 µl of plasma were incubated for 5 min with 100 µl of APTT 
reagent (platelet substitute). At the end of this incubation time 100 µl of 0.025 M CaC12 
prewarmed at 37°C were added and the clotting time was measured. 
3. Thrombin Time (TT) 
The TT method is based on the method described by Bonsnes and Sweeney 
(1955). In the determination of citrated plasma TT, a known amount of preformed 
human thrombin is added to plasma and the time required for clot formation measures 
the rate at which fibrin is formed. TT was carried out using Fibrindex™ human thrombin 
at a concentration of 10 NIH U/ml in 0.025 M CaC12• In this procedure 100 µl of 10 
U/ml human thrombin prewarmed at 37°C were added to 200 µl of plasma prewarmed 
at 37°C for 3 min, and the clotting time was measured. 
4. Ecarin Clotting Time (ECT) 
ECT is a new plasma-based clotting method, based on the original description by 
Nowak and Bucha (1993). This method is similar to the TT described above with the 
exception that an enzyme (ecarin) is used to activate the pre-existing prothrombin in the 
citrated plasma to a procoagulant form, whereas in the TT, exogenous preformed 
thrombin is added. Ecarin is an enzyme purified from the Echis carinatus snake venom. 
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Ecarin activates prothrombin to meizothrombin and other intermediates, rather than fully 
functional thrombin. However, meizothrombin has also procoagulant activities, although 
weaker than thrombin. This clotting time assay was carried out on a fast kinetic 
centrifugal analyzer (ACL 300 plus). In this assay, 100 µl of citrated plasma were 
incubated for 2 min at 37°C. At the end of the incubation period, 100 µl of ecarin 
(Knoll AG, Ludwigshafen, Germany) were added and the time to clotting was measured. 
5. Heptest 
The Heptest assay, originally developed by Yin et al. (1973), measures the ability 
of an agent to inhibit exogenous factor Xa. Heptest clotting time is measured using the 
Heptest reagents (Haemachem, St. Louis, MO): bovine factor Xa and Recalmix™ (CaC12 
and brain cephalin in a bovine plasma fraction). In this procedure 100 µl of plasma were 
incubated with 100 µl of bovine factor Xa reagent for 2 min at 37°C. At the end of this 
incubation time 100 µl of Recalmix™ were added and the clotting time was measured.At 
the final stage of this assay, thrombin is generated and results in the formation of a 
detectable clot. 
F. Anticoagulant Effects of Thrombin Inhibitors in Native Human Whole Blood 
While thrombin inhibitors can be effective anticoagulants when studied in the 
plasma based clotting assays described above, the same agents may behave differently 
when supplemented to whole blood, since plasma is only one component of whole blood. 
The following thrombin inhibitors were studied in these assays: D-MePhe-Pro-Arg-H, 
Ac-(D)Phe-Pro-boroArg-OH, argatroban, hirudin and heparin. To determine whether 
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these thrombin inhibitors were effective anticoagulants after in vitro supplementation at 
various concentrations to native whole blood and to compare these whole blood 
anticoagulant effects to the plasmatic anticoagulant effects, each thrombin inhibitor was 
studied in the two following assays. 
Whole blood was collected from normal healthy human volunteers, after written 
consent (blood donation consent form in Appendix 4), via venipuncture. The first 3 ml 
of blood drawn were discarded. Each thrombin inhibitor concentration was repeated in 
triplicate in normal human whole blood collected from three separate donors. 
1. Activated Clotting Time (ACT) 
ACT is an assay that also measures whole blood clotting time and was originally 
described by Hattersley in 1966 (Hattersley 1984). Because native whole blood is used, 
the clotting time depends on both coagulation and platelet functionality. In determining 
the ACT of freshly drawn blood samples, special pre-filled glass tubes containing celite 
(an intrinsic system activator) were used. The activated clotting time was measured 
utilizing a Hemochron coagulation timing instrument (International Techidyne 
Corporation, Edison, NJ). The procedure for determining the ACT was carried out as 
specified by the manufacturer. Briefly, 2 ml of freshly drawn whole blood were added 
to celite pre-filled glass tube (International Techidyne Corporation, Edison, NJ) and the 
tube was immediately inserted into the Hemochron coagulation timing instrument and the 
timer was started. 
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2. Thrombelastographic analysis 
The Thrombelastograph® Coagulation Analyzer (Haemoscope Corp., Skokie, IL) 
automatically records the viscoelastic changes in a sample of whole blood as the sample 
clots, retracts and/or lyses. The resulting profile is a measure of the kinetics of clot 
formation and dissolution and of clot quality. Thrombelastographic measurements were 
made on freshly drawn whole blood samples, pre-incubated at 37°C in a glass tube for 
3 min using an Hellige thrombelastograph (Haemoscope Corp., Skokie, IL.). The 
thrombelastograms (TEG) generated in this manner were analyzed using the standard 
procedure as described by Fiedel and Ku (1986): the length from the beginning of the 
recording until the point where the graph reaches a 2 mm divergence was recorded as 
the r value; the length from the beginning of the thrombelastogram until the point where 
the graph reaches a 2 cm divergence was recorded as the rk value; the difference 
between the r and rk values was the k value; the angle defined by the center line 
transversing the length of the graph and the tangent from the initial point of divergence 
and the first inflection point of the tracing, was the cx angle. 
G. Anticoagulant Effects of Thrombin Inhibitors in 
Normal Rabbit Plasma (NRP) 
To study the anticoagulant effects of thrombin inhibitors and which pathways are 
inhibited effectively, and to construct calibration curves, each of the following agents was 
supplemented to NRP in vitro and tested in the PT, APTT, TT and Heptest, as described 
earlier for NHP: D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin and 
heparin. The clotting time tests were performed on a fibrometer according to the 
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specifications set by each of the manufacturers and described earlier. NRP was obtained 
from rabbits as described previously. Each concentration-response curve was repeated 
in triplicate on separate days. 
H. Anticoagulant Effects of Thrombin Inhibitors in Normal Rabbit Whole Blood 
To determine the anticoagulant effects of thrombin inhibitors on normal rabbit 
whole blood, the following thrombin inhibitors were supplemented in vitro in freshly 
drawn rabbit whole blood: D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin 
and heparin. The rabbit whole blood was obtained from White male New Zealand 
rabbits weighing 2.5 to 3.5 kg. Each rabbit was lightly anesthetized with ketamine 
hydrochloride at a dose of 50 mg/kg I.M. in combination with xylazine at a dose of 25 
mg/kg J.M. Blood was drawn through the major ear artery. After the first 3 ml were 
discarded, the subsequently drawn blood was immediately supplemented with each of the 
thrombin inhibitors and tested in the ACT and TEG assays, as described above with the 
normal human whole blood. The only modification was in the glass tubes used in the 
ACT: when rabbit whole blood was tested, saline pre-filled glass tubes (International 
Techidyne Corporation, Edison, NJ) were used instead of the celite pre-filled glass tubes. 
Each thrombin inhibitor concentration was repeated in triplicate in normal rabbit whole 
blood collected from three separate rabbits. 
I. Antithrombotic Effects of Thrombin Inhibitors as Studied in the 
Rabbit Stasis Thrombosis Model 
Although thrombin inhibitors are effective anticoagulants in various in vitro 
systems, their anticoagulant effects do not always correlate with in vivo antithrombotic 
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effects. Furthermore, the degree of anticoagulation as measured by clotting tests does 
not always correspond to the degree of antithrombotic effects. To study the comparative 
antithrombotic effects of various thrombin inhibitors, four representative anticoagulants 
from the series studied in vitro were selected: D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-
boroArg-OH, hirudin and heparin. A modified Wessler stasis thrombosis model (Fareed 
et al. 1985) was used for the determination of the in vivo antithrombotic effects of these 
four agents. The principle of this model is that clot formation in the jugular segments 
of the rabbit, in response to a thrombogenic trigger, can be prevented by administration 
of anti thrombotic agents prior to administration of the thrombogenic trigger. The 
thrombogenic trigger used varies from serum to factor concentrates to snake venoms such 
as the Russel's viper venom, and the resulting clots differ morphometrically accordingly 
(Callas et al. 1995). In this series of experiments, recombinant tissue factor (1.38 µM 
r-TF in 2.57 mM phospholipid, biosynthesized and reconstituted as described in Bach et 
al. 1986, provided by Dr. Yale Nemerson, Mount Sinai School of Medicine, New York, 
NY) was used as the trigger for clot formation in the jugular segments. This 
thrombogenic trigger represented a defined approach in which the r-TF activated the 
clotting process through the extrinsic pathway. 
1. Standardization of the Rabbit Stasis Thrombosis Model 
The dose of r-TF to be used for comparing the antithrombotic effects of the 
antithrombin agents was selected based on a series of experiments where the dose-
thrombogenic response relationship was established in this model. The r-TF was thawed 
and reconstituted in sterile saline to a final concentration of 5.5 nM and re-frozen in 
127 
aliquots. Immediately prior to the experiment, an aliquot was thawed and diluted in 
sterile saline. In order to keep the volume of r-TF injected consistent independent of 
dose, a dilution was made such that the injection volume was always 0.25 ml/kg in every 
rabbit. Therefore, the r-TF was diluted to concentrations corresponding to quadruple the 
doses that were used, eg. 5.41 pmol/ml for dosing at 1.35 pmol/kg. The r-TF doses that 
were tested were 1.35, 0.68, 0.34, 0.17 and 0.04 pmol/kg. Groups of six rabbits were 
tested at each r-TF dose. 
The stasis thrombosis procedure was carried out as follows: White male New 
Zealand rabbits weighing 2.5 to 3.5 kg were obtained from LSR Industries and housed 
individually. The animals were kept on standard rabbit chow diet and had access to 
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water ad libitum. Ketamine hydrochloride at a dose of 50 mg/kg I.M. in combination 
with xylazine at a dose of 25 mg/kg I.M. was used to anesthetize each rabbit. Both 
jugular veins and the right carotid were carefully isolated. The right carotid was 
cannulated for blood collection utilized in ex vivo analyses. The left marginal ear vein 
was also cannulated for I. V. administration of the thrombogenic and antithrombotic 
agents or saline. After a baseline blood draw was performed, the sterile saline solution 
was injected at 1 ml/kg, through the cannulated marginal ear vein. After 5 min of the 
saline injection, a second blood draw was performed. Immediately following the second 
blood draw, r-TF was injected through the cannulated marginal ear vein as the 
thrombogenic challenge. Twenty sec after the I.V. administration of r-TF, the jugular 
segments were tied. 
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a. Clot Score Analyses 
Ten min after the injection of r-TF the right segment was dissected in a petri dish 
and the contained thrombi were graded. Twenty min after the administration of r-TF the 
same procedure was repeated on the left segment. The grading system for the thrombi 
was on a scale of 0 to +4, as previously established (Fareed et al. 1985). The animal 
was euthanized with an I.V. injection of 0.5 ml sodium pentobarbital and phenytoin 
sodium solution (Beuthanasia®-D, Steris Laboratories, Phoenix, AZ). 
The r-TF dose that consistently gave a clot score of at least + 3 was determined 
to be 0.68 pmol/kg and therefore was selected as the dose used in determining the 
antithrombotic effects of the thrombin inhibitors, as described in the following sections. 
In the following sections, each thrombin inhibitor was diluted in sterile saline to 
various concentrations, so that the agent concentration matched the dose (eg. 1 mg/ml 
thrombin inhibitor for dosing at lmg/kg). Thus, the volume injected in each rabbit 
(either I. V. or S. C.) remained at a 1 ml/kg animal weight. 
b. Ex Vivo Analyses of Plasma and Whole Blood Samples 
Each time a blood draw was performed (at baseline and 5 min post saline 
injection as described in the previous section), the first 3 ml were discarded, the next 3 
ml were tested in the ACT and saline TEG assays, as described in section H. 
Anticoagulant Effects of Thrombin Inhibitors in Normal Rabbit Whole Blood, and the 
next 9 ml were collected in 3. 8 3 sodium citrate and processed as described in section 
D.3.c. Preparation of Normal Rabbit Plasma and frozen in aliquots at -70°C. At the 
conclusion of the rabbit stasis thrombosis model experiments, these aliquots were thawed 
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in batches and the following amidolytic and clotting tests were performed as described 
earlier: antithrombin assay (section D.3.d. Antithrombin Amidolytic Assay with NRP), 
anti-Xa assay (section D.4.b. Anti-Xa Amidolytic Assay with NRP), PT, APTT, TT and 
Heptest (section G. Anticoagulant Effects of Thrombin Inhibitors in NRP). 
2. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors 
After I. V. Administration at Fixed Time Points 
To determine the dose-dependent antithrombotic effects of the thrombin inhibitors 
after I. V. administration in the above described rabbit stasis thrombosis model, each 
thrombin inhibitor was injected through the marginal ear vein of the left ear, 5 min prior 
to injecting r-TF, in place of saline, as described above. Each thrombin inhibitor was 
injected at various doses, to obtain a dose-response curve. The doses of each thrombin 
inhibitor studied were for D-MePhe-Pro-Arg-H, 0.097, 0.194, 0.485, 0.971 and 1.942 
µmol/kg; for Ac-(D)Phe-Pro-boroArg-OH, 0.010, 0.025, 0.050 and 0.101 µmol/kg; for 
hirudin, 0.001, 0.004, 0.007, 0.014 and 0.036 µmol/kg and for heparin 0.002, 0.005, 
0.009 and 0.023 µmol/kg. Groups of six rabbits were tested at each dose. Blood 
samples were collected at baseline and 5 min post antithrombin agent injection. 
a. Clot Score Analyses 
The jugular vein segments were isolated in sequence and the clots contained 
within were graded, as described earlier in section I.1.a Clot Score Analyses. 
b. Ex Vivo Analyses of Plasma and Whole Blood Samples 
Blood samples drawn at baseline and 5 min post thrombin inhibitor injection were 
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processed and analyzed in exactly the same manner as described earlier in section I.1.b. 
Ex Vivo Analyses of Plasma and Whole Blood Samples. 
3. Duration of Antithrombotic Effects of Thrombin Inhibitors 
After I. V. Administration at a Fixed Dose 
To determine the time-dependance of the antithrombotic effects of the thrombin 
inhibitors studied in this rabbit stasis thrombosis model after I. V. administration, the dose 
of each agent that produced sub-maximal antithrombotic effects in the dose-dependent 
I.V. studies was selected and studied at different circulation times, prior to injecting r-TF 
as described above. The dose of each thrombin inhibitor studied was: D-MePhe-Pro-
Arg-H at 1.942 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 0.101 µmol/kg, hirudin at 
0.036 µmol/kg and heparin at 0.023 µmol/kg. The circulation time points selected for 
studying the antithrombotic effects of these thrombin inhibitors at these doses were 5, 30, 
60 and 90 min (prior to r-TF injection). Groups of six rabbits were tested at each time 
point for each thrombin inhibitor. Blood draws were performed at baseline and prior to 
r-TF injection (5 or 30 or 60 or 90 min post thrombin inhibitor injection). 
a. Clot Score Analyses 
The jugular vein segments were isolated in sequence and the clots contained 
within were graded, as described earlier in section I.1.a Clot Score Analyses. 
b. Ex Vivo Analyses of Plasma and Whole Blood Samples 
Blood draws were performed at baseline and prior to r-TF injection (5 or 30 or 
60 or 90 min post thrombin inhibitor injection). These samples were processed analyzed 
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in exactly the same manner as described earlier in section 1.1.b. Ex Vivo Analyses of 
Plasma and Whole Blood Samples. 
4. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors 
After S.C. Administration at Fixed Time Points 
To determine the dose-dependent antithrombotic effects of the thrombin inhibitors 
after S.C. administration in the above described rabbit stasis thrombosis model, each 
thrombin inhibitor was injected subcutaneously 45 min prior to injecting r-TF, in place 
of saline, as described above. Each thrombin inhibitor was injected at various doses, to 
obtain a dose-response curve. The doses of each thrombin inhibitor studied were for D-
MePhe-Pro-Arg-H, 0.194, 0.485, 0.971, 1.942 and 4.854 µmol/kg; for Ac-(D)Phe-Pro-
boroArg-OH, 0.050, 0.097, 0.201and0.503 µmol/kg; for hirudin, 0.004, 0.007, 0.014, 
0.036, 0.072 and 0.144 µmol/kg and for heparin 0.046, 0.091, 0.250 and 0.455 
µmol/kg. Groups of six rabbits were tested at each dose. Blood samples were collected 
at baseline and 45 min post thrombin inhibitor injection (prior to r-TF injection). 
a. Clot Score Analyses 
The jugular vein segments were isolated in sequence and the clots contained 
within were graded, as described earlier in section 1.1.a Clot Score Analyses. 
b. Ex Vivo Analyses of Plasma and Whole Blood Samples 
Blood draws were performed at baseline and 45 min post thrombin inhibitor 
injection. These samples were processed analyzed in exactly the same manner as 
described earlier in section 1.1. b. Ex Vivo Analyses of Plasma and Whole Blood Samples. 
5. Duration of Antithrombotic Effects of Thrombin Inhibitors 
After S.C. Administration at a Fixed Dose 
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To determine the time-dependance of the antithrombotic effects of the thrombin 
inhibitors studied in this rabbit stasis thrombosis model after S.C. administration, the 
dose of each agent that produced sub-maximal antithrombotic effects in the dose-
dependent S.C. studies was selected and studied at different circulation times, prior to 
injecting r-TF as described above. The dose of each thrombin inhibitor studied was: D-
MePhe-Pro-Arg-H at 4.854 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 0.503 µmol/kg, 
hirudin at 0.144 µmol/kg and heparin at 0.455 µmol/kg. The circulation time points 
selected for studying the antithrombotic effects of these thrombin inhibitors at these doses 
were 15, 45, and 90 min (prior to r-TF injection). Groups of six rabbits were tested at 
each time point for each thrombin inhibitor. Blood samples were collected at baseline 
and prior to r-TF injection (15, 30, 45, 60 or 90 min post antithrombin agent injection). 
a. Clot Score Analyses 
The jugular vein segments were isolated in sequence and the clots contained 
within were graded, as described earlier in section 1.1.a Clot Score Analyses. 
b. Ex Vivo Analyses of Plasma and Whole Blood Samples 
Each time a blood draw was performed, at baseline and prior to r-TF injection 
(15, 30, 45, 60 or 90 min post thrombin inhibitor injection). These samples were 
processed analyzed in exactly the same manner as described earlier in section I.1.b. Ex 
Vivo Analyses of Plasma and Whole Blood Samples. 
J. Antithrombotic Effects of Thrombin Inhibitors as Studied in the 
Rat Model of Laser-Induced Thrombosis 
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The physiologic responses in the arterial and venous systems involve different 
mechanisms which include differences in blood flow conditions and clot compositions. 
Therefore, thrombin inhibitors may have different effects on arteries when compared to 
veins. Since the rabbit stasis thrombosis model simulated venous thrombosis, a rat model 
of laser-induced thrombosis was selected to study the antithrombotic effects of the 
thrombin inhibitors in the arterial system, as described in detail by Weichert et al. 1988. 
In this procedure the rat (Wistar, male, 300-350 g, LSR Industries, Inc., Union Grove, 
WI) was anesthetized with sodium pentobarbital, 100 mg/kg I.P. (Butler Co., Colombus, 
OH). An intestinal loop was exposed through a hypogastric incision and continuously 
irrigated with sterile saline solution, spread on a stage mounted on a microscope table 
(Nikon, inverted microscope, Diaphot-TMD, Nippon Kogaku K.K., Tokyo, Japan). 
Vascular lesions were induced with an argon laser system (INNOV A® 70-2 Argon Laser, 
Coherent, Inc., Santa Clara, CA). The laser beam was directed through the optical path 
of the microscope on small mesenteric arterioles (10-15 µm I.D.) of the fat-free portion 
of the mesentery. The laser beam pathway was controlled by means of a camera shutter 
(Uniblitz® VS1452ZO, Vincent Associates, Rochester, NY) and driver (Uniblitz® Tl32, 
Vincent Associates, Rochester, NY). The effective constant energy was 50 mW as 
measured with a power meter on the microscope stage (model 200/lOW, Coherent, Inc., 
Santa Clara, CA). The exposure time of the laser lesions was 150 msec. The time 
interval between laser shots was 1 min. Results were evaluated by direct microscopic 
observation of the occlusive changes in the blood vessel. The number of laser injuries 
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required to induce a thrombus which was of a length equal to 1.5 x I.D. of the vessel, 
or that produced complete occlusion was the endpoint. The rat was sacrificed at the end 
of the experiment by I.V. injection of sodium pentobarbital (Beuthanasia®, 0.5 ml/kg). 
Each thrombin inhibitor was diluted in sterile saline to various concentrations, so 
that the agent concentration corresponded to the dose (eg. 1 mg/ml thrombin inhibitor 
for dosing at lmg/kg). Thus, the volume injected in the rat (either I.V. or S.C.) was 
always lml/kg animal weight. After the rat was prepared and placed on the microscope 
stage and a suitable vessel was located, each thrombin inhibitor was injected I. V. through 
one of the rat tail veins, at various concentrations. Each thrombin inhibitor was allowed 
to circulate for 5 min prior to the initiation of the laser-induced vascular lesion. The 
doses of each thrombin inhibitor used in this model were as follows: D-MePhe-Pro-Arg-
Hat 0.97, 1.94, 3.40 and 4.86 µmol/kg; Ac-(D)Phe-Pro-boroArg-OH at 0.10, 0.15 and 
0.20 µmollkg; hirudin at 0.07, 0.14 and 0.72 µmol/kg; heparin at 0.05, 0.09 and 0.46 
µglkg. Groups of six rats were tested at each dose for each thrombin inhibitor. 
K. Hemorrhagic Effects of Thrombin Inhibitors as Studied in the 
Rabbit Ear Bleeding Model 
While thrombin inhibitors can be potent antithrombotic agents in vivo due to their 
inhibitory actions on the coagulation cascade, they can also produce hemorrhagic effects 
since coagulation is involved in hemostasis and platelet activation. To study the 
hemorrhagic effects of thrombin inhibitors, a rabbit model of ear blood loss as described 
by Cade et al. 1975 was used. In this procedure, white male New Zealand rabbits 
weighing 2.5 to 3.5 kg were obtained from LSR Industries. The animals were kept on 
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standard rabbit chow diet and had access to water ad libitum. Ketamine at a dose of 50 
mg/kg I.M. was injected in combination with xylazine at a dose of 25 mg/kg I.M. to 
induce anesthesia. The marginal ear vein was cannulated for I. V. administration of 
antithrombin agents at various doses. After a constant circulation time, the right ear was 
immersed in a 950 ml, 37°C saline bath for a few seconds and then 5 uniform, full 
thickness incisions were made in the ear in areas free of major vascularization, and 
returned to the saline bath for 10 min. The saline was collected and the red blood cells 
were counted using a hemacytometer (Brightline, Improved Neubauer, Hausser Scientific 
0. 100 mm deep). The same procedure was repeated on the other ear 15 min after the 
procedure was initiated on the first ear. At the end of the experiment, hemostasis was 
ensured and the animal was returned to its cage. 
In the following sections, each thrombin inhibitor was diluted in sterile saline 
(Baxter Healthcare Corp., Deerfield, IL) to concentrations corresponding to 10-fold the 
dose to be used, so that the volume of the injected agent remained constant at 0.1 ml/kg 
(1.V. or S.C.) animal weight for every rabbit. 
1. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors 
After I. V. Administration at Fixed Time Points 
To determine the dose-dependent hemorrhagic effects of the thrombin inhibitors 
after I. V. administration, each thrombin inhibitor was injected through the marginal ear 
vein of the left ear, 5 min prior to making the incisions in the right ear, as described 
above. The incisions in the left ear were made 20 min after the I. V. injection of the 
antithrombotic agent. Each thrombin inhibitor was injected at various doses, to obtain 
136 
a dose-response curve. The doses of each thrombin inhibitor studied were for D-MePhe-
Pro-Arg-H, 0.97, 1.94 and 4.85 µmollkg; for Ac-(D)Phe-Pro-boroArg-OH, 0.10, 0.25, 
0.50 and 1.00 µmollkg; for hirudin, 0.07, 0.14 and 0.36 µmol/kg and for heparin 0.05, 
0.09, 0.23 and 0.46 µmollkg. Groups of six rabbits were tested at each dose. Groups 
of six rabbits were used for each treatment. 
2. Duration of Hemorrhagic Effects of Thrombin Inhibitors 
After I. V. Administration at a Fixed Dose 
To determine the time-dependance of the hemorrhagic effects of the thrombin 
inhibitors studied in this hemorrhagic model after I.V. administration, the dose of each 
agent that produced sub-maximal hemorrhagic effects in the dose-dependent I.V. studies 
was selected and studied at different circulation times, prior to making the incisions in 
the ears as described above. The dose of each thrombin inhibitor studied was D-MePhe-
Pro-Arg-H at 4.85 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 0.50 µmollkg, hirudin at 
0.36 µmollkg and heparin at 0.46 µmol/kg. The circulation time points selected for 
studying the hemorrhagic effects of these thrombin inhibitor at these doses were 5, 20, 
30, 45, 60 and 90 min after I.V. administration. Groups of six rabbits were tested at 
each time point for each thrombin inhibitor. 
3. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors 
After S.C. Administration at Fixed Time Points 
To determine the dose-dependent hemorrhagic effects of the thrombin inhibitors 
after S.C. administration, each thrombin inhibitor was injected subcutaneously 45 min 
prior to making the incisions in the right ear, as described above. The incisions in the 
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left ear were made 60 min after the S.C. injection of the antithrombotic agent. Each 
thrombin inhibitor was injected at various doses, to obtain a dose-response curve. The 
doses of each thrombin inhibitor studied were for D-MePhe-Pro-Arg-H, 1.94, 4.84 and 
9. 71 µmol/kg; for Ac-(D)Phe-Pro-boroArg-OH, 0.20, 0.50, 1.00 and 2.01 µmol/kg; for 
hirudin, 0.07, 0.14, 0.36 and 0.77 µmol/kg and for heparin 0.46 and 0.91 µmol/kg. 
Groups of six rabbits were tested at each dose. 
4. Duration of Hemorrhagic Effects of Thrombin Inhibitors 
After S.C. Administration at a Fixed Dose 
To determine the time-dependance of the hemorrhagic effects of the thrombin 
inhibitors studied in this hemorrhagic model after S.C. administration, the dose of each 
agent that produced sub-maximal hemorrhagic effects in the dose-dependent S. C. studies 
was selected and studied at different circulation times, prior to making the incisions in 
the ears as described above. The dose of each thrombin inhibitor studied was D-MePhe-
Pro-Arg-H at 9.71 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 2.01 µmol/kg, hirudin at 
0.77 µmol/kg and heparin at 0.91 µmol!kg. The circulation time points selected for 
studying the hemorrhagic effects of these thrombin inhibitor at these doses were 15, 30, 
45, 60 and 90 min after I.V. administration. Groups of six rabbits were tested at each 
time point for each thrombin inhibitor. 
L. Effects of Thrombin Inhibitors on Blood Pressure After 
I. V. Administration to Rabbits 
Since the building block for many of the synthetic thrombin inhibitors is arginine, 
concerns have been expressed over the potential effects of these thrombin inhibitors or 
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their metabolites on the vascular endothelium, independent of their actions on serine 
proteases. Specifically, the potential blood-pressure lowering effects of these agents may 
be compromising. 
The effects of thrombin inhibitors on blood pressure after I. V. injection to rabbits 
were monitored during the procedures of the stasis thrombosis model, for the highest 
dose of each thrombin inhibitor used (D-MePhe-Pro-Arg-H at 1.942 µmol/kg, Ac-
(D)Phe-Pro-boroArg-OH at 0.101 µmol/kg, hirudin at 0.036 µmol/kg and heparin at 
0. 023 µmol/kg). After isolating and cannulating the femoral artery, the mean arterial 
pressure was monitored via a pressure transducer (Type 4-327-C, range 0-400 mmHg, 
Beckman Instruments Inc., Irvine, CA) connected to a physiograph (model R511A, 
Beckman Instruments Inc., Irvine CA). The blood pressure was continuously monitored 
from before any agents were injected into the rabbit (after induction of anesthesia and 
cannulation of the femoral artery), until the rabbit was sacrificed at the end of the stasis 
thrombosis model procedure. 
M. Statistical analysis 
The experimental data derived from the in vitro assays were compiled as mean 
± SD (standard deviation of the sample). The data derived from the in vivo and ex vivo 
studies were compiled as mean ± SEM (standard error of the mean). The sample mean 
was the average of the measurements within each group. The SEM was reported along 
with the mean to provide an indication of the precision of estimation of the population 
mean and to facilitate comparison between means of different groups. 
The data in the figures were presented as mean ± SD or mean ± SEM, 
139 
depending on whether they were derived from in vitro or in vivo/ex vivo procedures. All 
figures were drawn using SigmaPlot® software. The error bars were not shown if the 
they were smaller than the size of the symbols in the figure. 
The statistical tests performed on the data included one-way ANOV A followed 
by Neuman Keuls multiple comparison test when the one-way ANOV A revealed a 
significant difference. These statistical tests were used to evaluate the results from the 
all studies except for the clot scores from the stasis thrombosis model. The Kruskal-
Wallis test was used to examine the differences between clot scores obtained in the rabbit 
stasis thrombosis model. 
CHAPTER IV 
RESULTS 
This dissertation represents an integrated account of both the biochemical and 
phannacolgic properties of heparin and several thrombin inhibitors. The results on 
various experimental protocols are divided into various sections. In the first section, the 
basic physicochemical and analytical properties of each of these agents are discussed. 
The available information on the individual chemical and molecular properties along with 
the data generated using gas permeation chromatography (GPC) is discussed. The 
comparative biochemical profiling included the studies on the potency evaluation, 
inhibitory profiling utilizing purified serine proteases and the effects of these agents on 
the generation of protease in both the coagulation and fibrinolytic based systems. The 
global anticoagulant effects of each of these inhibitors are reported in terms of their 
ability to prolong the clotting profile of either the normal human plasma or normal rabbit 
plasma. A newly developed highly specific test, namely the ecarin clotting time (ECT), 
is employed to determine the relative anticoagulant potency of these agents. Whole blood 
studies using both the normal human whole blood and normal rabbit whole blood based 
assays in the TEG and ACT analyses are also included. All of these results are reported 
in statistically defined gravimetric and molar values. 
The comparative pharmacological data on various agents included in this 
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dissertation are presented in various sections representing the antithrombotic effects in 
the venous stasis thrombosis model in the I.V. and S.C. studies, where the dose-response 
relationship is reported. These data are also compared in terms of the ED50 for each 
individual agent in different experimental conditions. The duration of the fixed I. V. and 
S.C. dosage of each of the antithrombin agents studied is also reported and the t1h of 
each agent is provided. The ex vivo analysis using different assays is also compiled to 
compare the antithrombotic action with measurable ex vivo effects. The results of the 
comparative antithrombotic actions for each of these agents in a rat model of laser-
induced thrombosis are also presented. No ex vivo analyses from these studies are 
included. The comparative hemorrhagic effects of various thrombin inhibitors and 
heparin are reported for both the I.V. and S.C. studies, which were carried out in a 
rabbit model for ear blood loss. Time-dependance of the hemorrhagic effects in this 
model is also reported for the fixed dosage studies in both the I. V. and S. C. experiments. 
The results on the effect of various thrombin inhibitors and heparin on blood pressure 
measurements in rabbits are also compiled for the I. V. studies. 
The comparative data for both the biochemical and pharmacological studies are 
compiled in individual figures where the tabulated data are plotted to represent a 
cumulative data analysis. Similarly, individual tables on the data compiled from various 
experiments are tabulated in terms of means and standard deviations or standard error 
of the means, to represent each of the data points in either gravimetric or molar values 
or both. Appendix 4 represents supportive data tables for each of the tables included in 
the text for both biochemical and pharmacologic study results. The tables in Appendix 
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IV are numbered by arabic numerals corresponding to the main text tables, followed by 
sequential lower-case letters. 
A. Analytical Profile of Peptide Thrombin Inhibitors 
All of the tripeptide thrombin inhibitors employed in these studies were obtained 
in dry powdered form and were stored at 4 °C in desiccators. The purity of these agents 
was evaluated by utilizing the HPLC methodology described in Chapter III. B. The 
elution profiles described below were compared against reference elution profiles of the 
medium in which each compound was dissolved in distilled H20. The background peaks 
appearing in the elution buffer elution were then subtracted from the elution profile of 
individual peptides. The background-adjusted peaks were then integrated by the system 
software and assigned to particular structures, in accordance according to reported 
analyzed values (Bajusz et. 1990). 
1. Stability and Homogeneity Profile of D-Phe-Pro-Arg-H, 
D-MePhe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H. 
The tripeptide aldehyde D-Phe-Pro-Arg-H has been reported to be unstable in 
solution and is transformed into an inactive 5,6,8,9,10,10a-hexahydro-2-(3'-
guanidinopropyl)-5-benzyl-6-oxoimidazo[l ,2-a]pyrrolo[2, 1-c ]pyrazine (Bajusz et al. 
1989). To determine the extent of possible racemization, a validated HPLC method was 
employed. The result of this profile for the compound D-Phe-Pro-Arg-H · H2S04 is 
depicted in the panel A of Fig. 5. This peptide eluted between the 36 and 42 min after 
injection of the compound into the column. Peaks B', A and B represented the three 
equilibrium structures of the D-Phe-Pro-Arg-H aldehyde, the aldehyde hydrate (peak A) 
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Fig. 5. Analytical profile of D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and Boc-D-Phe-
Pro-Arg-H, as detected at 214 nm. The X axis represents the time (min) at which the 
various components of the agent injected eluted, while the Y axis represents the intensity 
of the signal (m V) emitted by the substance detected. Panel A depicts the HPLC profile 
of D-Phe-Pro-Arg-H, represented by peaks B' (retention time 37.5 min), A (retention 
time 38.5 min) and B (retention time 39.0 min). Panel B depicts the HPLC profile of 
D-MePhe-Pro-Arg-H, represented by peaks B' (retention time 37.1 min), A (retention 
time 38.3 min) and B (retention time 39.4 min). Panel C depicts the HPLC profile of 
Boc-D-Phe-Pro-Arg-H represented by peaks B' (retention time 25.2 min), A (retention 
time 29.2 min) and B (retention time 33.8 min). 
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and the two amino cyclols (peaks B and B'). The poorly resolved peak between peaks 
A and B was due to the additional equilibrium structure of either the aldehyde or to the 
impurity arising from one of the three forms of the DLD epimer (the D-Arg-H containing 
epimer). The three peaks following peak B were due to the other two forms of the DLD 
epimer and the inactive decomposition product respectively. All peaks appearing during 
its elution were integrated and their % area, based on the sum of all background-adjusted 
peaks, was calculated by the system software. The % peptide content was calculated by 
summing the % area under peaks B', A and B and was found to be 89. 64 % . 
Table 3 -- Integration of various peaks eluted during the analysis of D-Phe-Pro-Arg-
H · H2S04 
Retention 
Structure Time (min) % Area 
Peak B' equilibrium structure, amino cyclol 37.5 40.73 
Peak A equilibrium structure, aldehyde hydrate 38.5 3.89 
Unknown equilibrium aldehyde or DLD epimer 38.7 0.59 
Peak B equilibrium structure, amino cyclol 39.0 45.02 
Unknown DLD epimer 39.7 2.51 
Unknown DLD epimer 40.5 4.12 
Unknown inactive decomposition product 41.6 3.14 
The peptide D-MePhe-Pro-Arg-H · H2S04 was also eluted in a similar manner as 
the D-Phe-Pro-Arg-H · H2S04, as depicted in the panel B of Fig. 5. The equilibrium 
peaks that appeared during its elution profile were also due to the three equilibrium 
structures of the D-MePhe-Pro-Arg-H aldehyde, the aldehyde hydrate (peak A) and the 
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two amino cyclols (peaks B and B'). As in the case of D-Phe-Pro-Arg-H, the peak 
between peaks A and B was due to an impurity arising from one of the three forms of 
the DLD epimer (the D-Arg-H containing epimer). The peak following peak B was due 
to one of the other two forms of the DLD epimer. Unlike the D-Phe-Pro-Arg-H elution 
profile, D-MePhe-Pro-Arg-H did not exhibit any unstable products. All peaks appearing 
during this elution were integrated and their % area, based on the sum of all background-
adjusted peaks appearing, was calculated by the system software. The % peptide content 
was calculated by summing the % area under peaks B', A and B and was found to be 
94.99 %. 
Table 4 -- Integration of various peaks eluted during the analysis of D-MePhe-Pro-Arg-
H ·H2S04 
Retention 
Structure Time (min) % Area 
Peak B' equilibrium structure, amino cyclol 37.1 17.60 
Peak A equilibrium structure, aldehyde hydrate 38.3 31.32 
Unknown DLD epimer 39.0 2.89 
Peak B equilibrium structure, amino cyclol 39.4 46.07 
Unknown DLD epimer 40.8 2.11 
The compound Boc-D-Phe-Pro-Arg-H · 1/2H2S04 also eluted in a similar manner 
as D-MePhe-Pro-Arg-H · H2S04 , as depicted in panel C of Fig. 5. The equilibrium peaks 
appearing in the elution of this peptide were due to the three equilibrium structures of 
the Boc-D-Phe-Pro-Arg-H aldehyde, the aldehyde hydrate (peak A) and the two amino 
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cyclols (peaks B and B'). No additional peaks due to impurities or epimers appeared 
during the elution of Boc-D-Phe-Pro-Arg-H. All peaks appearing in this analysis were 
integrated and their respective 3 area, based on the sum of all background-adjusted 
peaks appearing, was calculated by the system software. The 3 peptide content was 
calculated by summing the 3 area under peaks B' , A and B and was found to be 100 3 . 
Table 5 -- Integration of various peaks during the analysis of Boc-D-Phe-Pro-Arg-
H · 1hH2S04 
Retention 
Structure Time (min) 3 Area 
Peak B' equilibrium structure, amino cyclol 25.2 34.18 
,Peak A equilibrium structure, aldehyde hydrate 29.2 9.12 
Peak B equilibrium structure, amino cyclol 33.8 56.70 
/ 
2. Ac-(D)Phe-Pro-boroArg-OH Purity Determination 
The elution profile of Ac-(D)Phe-Pro-boroArg-OH · HCl is depicted in Fig. 6. 
After subtracting the background peaks this agent eluted in 4 distinct peaks. These peaks 
were integrated and the respective 3 area was calculated and reported in Table 6. The 
elution of this peptide exhibited a rather heterogeneous polycomponent behavior. As 
stated, 4 distinct peaks were eluted. The first peak represented the major compound with 
a retention time of 8 min and a relative abundance of about 60 3. Close to the first 
peak, the second peak eluted at 8.4 min and showed a rather sharp distribution profile 
with a relative abundance of 293. Two minor peaks eluted at 9.2 and 9.7 min with 
baseline separation with a 1.4 and 9.43 abundance respectively. 
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Fig. 6. Analytical profile of Ac-(D)Phe-Pro-boroArg-OH, as detected at 214 nm. The 
X axis represents the time (min) at which the various components of the agent injected 
eluted, while the Y axis represents the intensity of the signal (m V) emitted by the 
substance detected. The elution profile of this compound was composed of four peaks, 
starting at retention times of 8.0, 8.4, 9.2 and 9.7 min respectively. 
Table 6 -- Integration of various peaks during the analysis 
of Ac-(D)Phe-Pro-boroArg-OH · HCI 
Retention 
Time (min) Area% 
1st Peak 8.0 60.27 
2nd Peak 8.4 28.91 
3rd Peak 9.2 1.44 
4th Peak 9.7 9.37 
B. Analytical Profile of the Unfractionated Heparin 
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The molecular profile of unfractionated heparin mainly depends on the source. 
P,0rcine mucosa! heparin usually has a lower molecular mass distribution. The 
unfractionated heparin used in these studies was of porcine origin and was provided in 
a white powdered sodium salt form (Sanofi, Paris, France). To determine the molecular 
profile of this glycosaminoglycan mixture and the relative purity, this agent was analyzed 
using a GPC method. The elution profile of heparin is depicted in Fig. 7, with panel A 
being the profile detected in the UV detector at 234 nm and panel B being the profile 
detected in the differential refractometer (RI). In both panels, the first peak from the left 
is due to heparin, eluted between 23 and 45 min. The subsequent peaks represent the 
salt peaks. In both panels, the heparin peak was integrated by the system software and 
the % distribution was calculated. As described by Ahsan et al. 1994, based on narrow 
range calibrators, the software system also assigned molecular weights corresponding to 
retention time. Thus, for each heparin peak, the % heparin falling in a particular range 
of molecular weight was calculated. Table 7 summarizes the molecular weight 
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Fig. 7. Analytical profile of unfractionated porcine mucosa! heparin. The X axis 
represents the time (min) at which the various components of the agent injected eluted, 
while the Y axis represents the intensity of the signal (m V) emitted by the substance 
detected. Panel A represents the GPC profile of heparin as detected by the UV detector 
at 234 nm. Panel B represents the GPC profile of heparin as detected by the RI detector. 
As detected by both methods, heparin eluted in a profile represented by a single peak, 
between retention times of 23 and 45 min. The peaks eluted at 47 min represent NazS04 • 
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distribution in this unfractionated heparin. The results from both the UV and RI 
detectors were in close agreement. Nearly half of the material was found to be between 
8,000-12,000. About 203 of heparin was in the 5,000-8,000 range and just as much 
was in the 16,000-20,000 range. Less than 103 of the total heparin was found to be 
greater than 16,000 or lower than 5,000. The weight average was approximately 10,700, 
with a peak MW of 11, 100 and 11,400 for the UV and RI analyses respectively. 
Table 7 -- Molecular Weight Distribution of Unfractionated Heparin 
UV (234 nm) RI 
Weight 10,717 10,680 
Average 
Peak MW 11, 121 11,445 
>20,000 4.13 3.63 
16,000-20,000 5.13 5.33 
12,000-16,000 21.23 20.73 
8,000-12,000 45.43 48.33 
5,000-8,000 20.03 16.83 
2,500-5,000 4.03 4.33 
<2,500 0.23 1.03 
C. Biochemical Assays 
The inhibition of the activity of thrombin can be explored in vitro utilizing the amidolytic 
and the clotting activities of thrombin, by using chromogenic substrates that yield color 
when cleaved by thrombin, and by using fibrinogen which is converted to fibrin when 
digested by thrombin. The following studies were designed to explore the relative in 
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vitro inhibition of the formed thrombin by various agents, amidolytically with the 
thrombin titration assay and the plasma-based antithrombin assay, and functionally with 
thrombin time in the fibrinogen-based assay. In addition, the inhibition of the generation 
of thrombin in various assay systems was also explored in the fibrinogen-deficient plasma 
assay systems, as well as in the KONYNE® and FEIBA® assays. The effect of these 
thrombin inhibitors on other serine proteases, such as factor Xa, chymotrypsin, trypsin, 
activated protein C, tissue-type plasminogen activator, urokinase and plasmin was studied 
in assays based on the amidolytic activity of these enzymes. The effects of these 
antithrombin agents on the generation of some of these enzymes was also examined in 
the thrombin and factor Xa generation assay systems. Each of these inhibitors was also 
tested for its effects on the plasminogenolysis assays where the generation of plasmin was 
measured. 
1. Thrombin Titration Assay 
An amidolytic method was used to compare the direct antithrombin activity of 
thrombin inhibitors. The results of the studies of inhibition of the amidolytic activity of 
thrombin by specific thrombin inhibitors are depicted in Fig. 8. Panel A represents the 
inhibitory activity of D-Phe-Pro-Arg-H, panel B shows the effects of D-MePhe-Pro-Arg-
H, panel C represents the inhibition produced by Boc-D-Phe-Pro-Arg-H. The inhibitory 
profile exhibited by Ac-(D)Phe-Pro-boroArg-OH is shown in Panel D, while Panel E 
represents the effects of argatroban and Panel F depicts the effects of hirudin. The 
concentration of each antithrombin agent that resulted in 50 % inhibition of thrombin was 
the agent concentration that inhibited 0.5 thrombin units, since a total of 1 thrombin 
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unit/L was present in the assay. Therefore, based on this value, the amount of thrombin 
units inhibited by a mg or a nmol of each thrombin inhibitor was calculated. The 
specific activities in terms of ATU potencies for each thrombin inhibitor, based on the 
results depicted in Fig. 8, are reported in Table 8. On a gravimetric basis, the most 
potent thrombin inhibitor appeared to be Ac-D-Phe-Pro-boroArg-OH with about 200, 700 
ATU/mg. The aldehydes D-Phe-Pro-Arg-H and D-Me-Phe-Pro-Arg-H followed with 
about half of the activity of Ac-D-Phe-Pro-boroArg-OH (about 118,500 and 102,400 
ATU/mg respectively), while Boc-D-Phe-Pro-Arg-H and hirudin exhibited much weaker 
( < 10%) activities when compared to Ac-D-Phe-Pro-boroArg-OH (around 29,600 and 
22,400 ATU/mg respectively). Argatroban appeared to be the weakest thrombin 
inhibitor with about 1 % of the activity of Ac-D-Phe-Pro-boroArg-OH (2,800 ATU/mg). 
Table 8 -- Specific Activities of Various Thrombin Inhibitors as Assessed 
by Utilizing an Amidolytic Assay. 
D-Phe-Pro-Arg-H 
D-MePhe-Pro-Arg-H 
Boc-D-Phe-Pro-Arg-H 
ATU/mg 
118,493 ± 6,868 
102,422 ± 6,342 
29,605 ± 2,326 
Ac-D-Phe-Pro-boroArg-OH 200,669 ± 11,825 
Argatroban 2,774 ± 138 
Hirudin 22,382 ± 1,929 
ATU/nmol 
59,365 ± 3,441 
52,747 ± 3,266 
16,342 ± 1,284 
99,732 ± 5,877 
1,476 ± 73 
155,849 ± 13,432 
Each value represents the mean ± 1 SD of three separate determinations. 
On the ATU/mg basis, all values were significantly different from each 
other, except for those produced by Boc-D-Phe-Pro-Arg-H and hirudin. 
On the ATU/nmol basis, all values were significantly different from each 
other except for those produced by D-Phe-Pro-Arg-H and D-MePhe-Pro-
Arg-H. (p < 0.05, ANOV A followed by Student-Newman-Keuls test). 
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Fig. 8. Fig. 9. Concentration dependent inhibition of the amidolytic activity of 
thrombin by antithrombin agents. Panel A depicts the results produced by D-Phe-Pro-
Arg-H. Panel B represents results produced by D-MePhe-Pro-Arg-H. Panel C 
represents results produced by Boc-D-Phe-Pro-Arg-H. Panel D represents results 
produced by Ac-(D)Phe-Pro-boroArg-OH. Panel E represents results produced by 
argatroban. Panel F represents results produced hirudin. Each agent was tested in 
triplicate. The mean % residual thrombin activity ± SD for each concentration and the 
gravimetric equivalent is given in Tables 8a-8f. 
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The order of potency for each of these thrombin inhibitors on a molar basis was 
found to be different from the order of potency on a gravimetric basis. On a molar 
basis, hirudin was found to be the strongest thrombin inhibitor with 155,800 ATU/nmol, 
followed by Ac-(D )Phe-Pro-boroArg-OH with about 99, 700 ATU /nmol. D-Phe-Pro-Arg-
H and D-MePhe-Pro-Arg-H exhibited about 59,400and 52,700 ATU/nmol, while Boc-D-
Phe-Pro-Arg-H exhibited about 16,300 ATU/nmol. Argatroban was again the weakest 
thrombin inhibitor in this assay with 1,500 ATU /nmol. Individual 3 inhibitory values 
for each thrombin inhibitor concentration are given in Tables 8a through 8f. 
2. Thrombin Time (TT) in a Fibrinogen Based System 
A buffered fibrinogen based clotting assay was developed to evaluate the 
comparative antithrombin effects of individual inhibitors on the clotting function of 
thrombin in an isolated test system. Human thrombin was added to a human fibrinogen 
solution to mediate clotting, with no feedback and amplification processes involved (as 
there would be in a plasmatic medium where other factors are present). The results of 
these studies are depicted in Fig. 9. Panel A depicts the results from the assay where 
thrombin reconstituted in sterile saline was used, while panel B depicts the results from 
the test where thrombin was reconstituted in 0.025 M CaC12• To evaluate the 
comparative effects of thrombin inhibitors in these assays, an index was devised whereby 
the concentration of a thrombin inhibitor required to prolong the fibrinogen clotting time 
to 100 sec (CT100) was calculated. These values are reported in Table 9. The clotting 
time at each concentration point for the individual inhibitors can be found in Tables 9a -
9d and Tables 9e - 9h, for the saline/thrombin and the CaCl2/thrombin tests, 
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respectively. The order of potencies for each of the individual inhibitors was similar in 
both assays: hirudin was consistently found to be the strongest anticoagulant with CT100s 
of 47 and 56 nM in the saline and CaC12 tests respectively, followed closely by Ac-
(D)Phe-Pro-boroArg-OH with CT100 of 49 and 100 nM in the same assay systems. 
Table 9 -- Antithrombin potencies of thrombin inhibitors as determined in fibrinogen 
clotting systems. 
Prolongation of clotting time to 100 sec [ nM] 
10 UTT 10 Ca++TT 
D-Phe-Pro-Arg-H 181 ± 5 512 ± 5 
D-MePhe-Pro-Arg-H 134 ± 10 592 ± 12 
Boc-D-Phe-Pro-Arg-H 586 ± 190 1542 ± 150 
'Ac-D-Phe-Pro-boroArg-OH 49 ± 1 100 ± 6 
Argatroban 140 ± 24 422 ± 128 
Hirudin 47 ± 3 56 ± 3 
Heparin >9,090 >9,090 
Each value represents the mean ± 1 SD of three separate determinations. In the 10 U 
TT fibrinogen-based assay, only the value produced by Boc-D-Phe-Pro-Arg-H was 
significantly different from all others. In the 10 U ca++TT fibrinogen-based assay, all 
values were significantly different from each other except for the following pairs: D-Phe-
Pro-Arg-H vs D-MePhe-Pro-Arg-H, D-Phe-Pro-Arg-H vs argatroban, D-MePhe-Pro-Arg-
H vs argatroban and Ac-(D)Phe-Pro-boroArg-OH vs hirudin. (p <0.05, ANOVA 
followed by Student-Newman-Keuls test). 
Heparin had no effects in these assays at concentrations as high as 9 µM. In the 
saline/thrombin system, D-MePhe-Pro-Arg-H with a CT100 of 134 nM was more potent 
than argatroban, D-Phe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H (CT100s of 140, 181 and 
586 nM respectively), while in the CaClzfthrombin assay system argatroban with a CT100 
of 422 nM was more potent than D-Phe-Pro-Arg-OH, D-MePhe-Pro-Arg-H and Boc-D-
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Fig. 9. Concentration dependent prolongation of the fibrinogen-based TI by various 
agents. Panel A depicts the effects produced by thrombin inhibitors in the fibrinogen-
based TI system where thrombin was reconstituted in saline. The individual values at 
each concentration point and their gravimetric equivalents are given in Tables 9a-9d. 
Panel B represents effects produced by antithrombin agents in the fibrinogen-based TT 
system where thrombin was reconstituted in CaC12 • The individual values at each 
concentration point and their gravimetric equivalents are given in Tables 9e-9h. ( •) D-
Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H, (~) Ac-(D)Phe-
Pro-boroArg-OH, (•) argatroban, (0) hirudin, ( +) heparin. Each point represents a 
mean ± 1 SD of three individual determinations. 
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Phe-Pro-Arg-H with CT100s of 512, 592 and 1542 nM respectively. With the exception 
of heparin, all thrombin inhibitors were capable of prolonging the clotting time to > 300 
sec at nM concentrations. Hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-Phe-Pro-Arg-H 
appeared to have all-or-none anticoagulant effects, while the other thrombin inhibitors 
exhibited a more graded concentration-anticoagulant response relationship. 
3. Antithrombin Effects of Thrombin Inhibitors 
As in the thrombin titration assay, these assays are based on the ability of 
antithrombin agents to inhibit the amidolytic activity of thrombin, as detected by the 
release of pNA from a specific chromogenic substrate. In these assays the thrombin 
inhibitors are diluted in plasma rather than buffer, to mimic circulating plasma matrix. 
Thus, these assays represent a more physiologic condition in which the effects of 
plasmatic factors on the antithrombin agents can be readily observed. Both the NHP and 
NRP preparations were used to carry out these studies. 
a. Antithrombin Amidolytic Assay with NHP 
The results of the antithrombin activities of various agents after in vitro 
supplementation to NHP are depicted in panel A of Fig. 10. With the exception of 
heparin, all other thrombin inhibitors exhibited a sigmoidal concentration-response curve, 
that eventually reached 1003 thrombin inhibition. After calculating the IC50 for each 
thrombin inhibitor, as seen in Table 10, it was apparent that even though heparin did not 
completely inhibit the amidolytic activity of thrombin, it appeared to be the strongest 
inhibitor with an IC50 of 9.6 nM. Hirudin, D-Phe-Pro-Arg-H and Ac-(D)Phe-Pro-
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Fig. 10. Concentration dependent inhibition of the amidolytic activity of thrombin by 
various agents. Panel A depicts the effects produced by thrombin inhibitors in the NHP-
based system. The individual values at each concentration point and their gravimetric 
equivalents are given in Tables 10a-10d. Panel B represents effects produced by 
antithrombin agents in the NRP-based system. The individual values at each 
concentration point and their gravimetric equivalents are given in Table lOe. (•) D-Phe-
Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H, (L>) Ac-(D)Phe-Pro-
boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin. Each point represents a mean 
± 1 SD of three individual determinations. 
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boroArg-OH followed closely, with IC50s of 21, 28 and 32 nM respectively, while Boe-
D-Phe-Pro-Arg-H was weaker with an IC50 of 110 nM. The weakest inhibitor in this test 
was found to be argatroban with an IC50 of 1,250 nM. While most thrombin inhibitors 
reached maximal thrombin inhibition in the nM range, Boc-D-Phe-Pro-Arg-H and 
argatroban produced its effects only in the µM range. The individual % thrombin 
inhibitory values for each thrombin inhibitor concentration are given in Tables lOa - lOd. 
Table 10 -- Antithrombin potencies of thrombin inhibitors as determined in amidolytic 
systems in NHP and NRP. 
D-Phe-Pro-Arg-H 
D-MePhe-Pro-Arg-H 
Boc-D-Phe-Pro-Arg-H 
Ac-D-Phe-Pro-boroArg-OH 
Argatroban 
Hirudin 
Heparin 
NHP 
28 ± 5 
32.2 ± 7 
110 ± 30 
26.8 ± 5 
1,250 ± 140 
21 ± 2 
9.6 ± 0.5 
IC50 [nM] 
NRP 
19.4 ± 4.2 
21.8 ± 1.2 
25 ± 4 
6.1 ± 1.1 
Each value represents the mean ± 1 SD of three separate determinations. In the NHP-
based antithrombin amidolytic assay, only the value produced by argatroban was 
significantly different from all others. In the NRP-based antithrombin amidolytic assay, 
the value produced by heparin was significantly different from those produced by D-
MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH and hirudin. (p<0.05, ANOVA 
followed by Student-Newman-Keuls test). 
b. Antithrombin Amidolytic Assay with NRP 
Fig. 10, panel B depicts the results of the antithrombin activities of D-MePhe-Pro-
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Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin, after in vitro supplementation 
into NRP. All four agents produced a sigmoidal concentration-response. In this test, 
heparin appeared to be the most potent inhibitor of the amidolytic activity of thrombin 
with an IC50 of 6.1 nM. The activity of heparin was followed by that of D-MePhe-Pro-
Arg-H, Ac-(D)Phe-Pro-boroArg-OH and hirudin with IC50 values of 19.4, 21.8 and 25 
nM respectively. The concentration-response curves of the three other agents 
overlapped. Although heparin was the most potent inhibitor in this assay, its inhibitory 
activity plateaued around 803 inhibition, in contrast to the other antithrombin agents, 
which achieved maximal inhibition of thrombin at the higher concentrations used. The 
individual inhibitory values for every agent concentration can be found in Table lOe. 
4. Anti-Xa Effects of Thrombin Inhibitors 
These assays are based on the ability of thrombin inhibitors to suppress the 
amidolytic activity of factor Xa, as detected by a specific chromogenic substrate. As in 
the antithrombin assays, the thrombin inhibitors were diluted in plasma, to demonstrate 
any matrix effects. 
a. Anti-Xa Amidolytic Assay with NHP 
The results of the anti-Xa activities of thrombin inhibitors after in vitro 
supplementation to NHP are depicted in the panel A of Fig. 11. With the exception of 
heparin and Ac-(D)Phe-Pro-boroArg-OH, none of the thrombin inhibitors exhibited any 
anti-factor Xa activity. After calculating the IC50 for heparin and Ac-(D)Phe-Pro-
boroArg-OH, as described in Table 11, it was apparent that even though heparin failed 
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to achieve a complete inhibition of the amidolytic activity of factor Xa, it was the most 
potent inhibitor with an IC50 value in the nM range (5.4 nM). While Ac-(D)Phe-Pro-
boroArg-OH also exhibited concentration-dependent anti-Xa effects with an IC50 also in 
the nM range (390 nM), it was about 72 fold weaker than heparin. Interestingly, a 
gradual decrease in the inhibitory activity of heparin against factor Xa was noted at 
concentrations greater than 100 nM with a concomitant increase in the scatter of the data. 
The individual % factor Xa inhibitory values for each thrombin inhibitor concentration 
point are found in Tables lla and llb. 
Table 11 -- Anti-factor Xa potencies of thrombin inhibitors as determined in amidolytic 
systems in NHP or NRP. 
D-Phe-Pro-Arg-H 
D-MePhe-Pro-Arg-H 
Boc-D-Phe-Pro-Arg-H 
Ac-D-Phe-Pro-boroArg-OH 
Argatroban 
Hirudin 
Heparin 
NHP 
> 11,000 
> 10,500 
> 10,000 
390 ± 60 
> 10,000 
>800 
5.4 ± 0.2 
IC50 [nM] 
NRP 
>5,000 
-1,000 
>300 
56 
Each value represents the mean ± 1 SD of three separate determinations. In the NHP-
based factor Xa amidolytic assay, the values produced by Ac-(D)Phe-Pro-boroArg-OH 
and heparin were significantly different. (p < 0.05, AN OVA followed by Student-
Newman-Keuls test). 
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Fig. 11. Concentration dependent inhibition of the amidolytic activity of factor Xa by 
various agents. Panel A depicts the effects produced by thrombin inhibitors in the NHP-
based system. The individual values at each concentration point and their gravimetric 
equivalents are given in Tables lla-llb. Panel B represents effects produced by 
antithrombin agents in the NRP-based system. The individual values at each 
concentration point and their gravimetric equivalents are given in Table 1 lc. ( •) D-Phe-
Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H, (c.) Ac-(D)Phe-Pro-
boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin. The broken line denotes that 
results may be due to a precipitation effect mediated by heparin. Each point represents 
a mean ± 1 SD of three individual determinations. 
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b. Anti-Xa Amidolytic Assay with NRP 
Fig. 11, panel B depicts the anti-Xa activities of various thrombi inhibitors after 
in vitro supplementation to NRP. While D-MePhe-Pro-Arg-H and hirudin exhibited no 
anti-Xa activities, heparin and Ac-(D)Phe-Pro-boroArg-OH produced concentration-
dependent inhibition of the amidolytic activity of factor Xa. The IC50 values for these 
compounds were found to be 52 and -1,000 nM, respectively. The individual values 
for the factor Xa inhibition produced by each agent concentration are given in Table 1 lc. 
5. Inhibitory Actions of Various Thrombin Inhibitors on 
Specific Serine Proteases 
To evaluate the anti-protease spectrum of thrombin inhibitors, amidolytic assays 
utilizing enzyme specific synthetic substrates were used. In these biochemically defined 
assays, only one enzyme was present in purified form, thus ensuring that inhibition of 
amidolytic activity was due to inhibition of the particular enzyme. Since heparin is 
devoid of any direct antiprotease activities and its mechanism of action is mediated 
primarily through antithrombin, stock solutions of heparin were made with antithrombin, 
and then further diluted in saline, prior to studying the effects of heparin on each one of 
the following serine proteases. In addition to the thrombin inhibitors, aprotinin was also 
included as a broad spectrum serine protease inhibitor and a positive control. 
a. Inhibition of Chymotrypsin 
Fig.12 depicts the inhibitory activities of various agent against the amidolytic 
activity of chymotrypsin. In this study, none of the thrombin inhibitors studied were 
capable of producing any inhibition of this amidolytic activity at high concentrations: 
Table 12 -- Inhibition of serine proteases by thrombin inhibitors as determined in biochemically defined amidolytic systems. 
IC5o [µM] 
Chymo- Trypsin APC Glandular tPA Urokinase Plasmin 
trypsin Kallikrein 
D-Phe-Pro-Arg-H >27 0.47±0.13 4.2±0.4 >67 33.6±2.2 >67 3.2±0.2 
D-MePhe-Pro-Arg-H >26 0.18±0.02 8.4±0.8 >65 52.7±2.9 >65 1.58±0.10 
Boc-D-Phe-Pro-Arg-H >24 0.24±0.02 14.6± 1.4 >60 7.3±0.06 15.3±0.7 0.33±0.05 
Ac-D-Phe-Pro- >27 0.095 ±0.025 0.75±0.05 14.7±0.6 6.8±0.05 1.3±0.3 0.095±0.02 
boroArg-OH 
Argatroban >25 > 125 > 115 > 115 > 115 > 115 > 115 
Hirudin > 1.9 > 1.9 >9.6 >9.6 >9.6 >9.6 >9.6 
Heparin > 1.2 > 1.2 >62 >62 >62 >62 >62 
Aprotinin 0.8 0.39±0.09 16.6±0.2 0.322±0.015 >5 >5 0.057 ±0.005 
Each value represents the mean ± 1 SD of three separate determinations. In the trypsin assay, D-Phe-Pro-Arg-H and aprotinin were 
significantly different from D-MePhe-Pro-Arg-H, Boc-D-Phe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH. In the APC assay, all 
values (except for argatroban, hirudin and heparin) were significantly different from each other. In the kallikrein assay, the values 
produced by Ac-(D)Phe-Pro-boroArg-OH and aprotinin were significantly different from each. In the tPA assay, all values (except 
for argatroban, hirudin, heparin and aprotinin) were significantly different from each other except for the pair Boc-D-Phe-Pro-Arg-H 
vs Ac-(D)Phe-Pro-boroArg-OH. In the urokinase assay, the values produced by Boc-D-Phe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-
OH were significantly different from each other. In the plasmin assay, the values produced by all thrombin inhibitors (except for 
argatroban, hirudin and heparin) were significantly different from each other, with the exception of the Boc-D-Phe-Pro-Arg-H vs 
Ac-(D)Phe-Pro-boroArg-OH comparison. (p < 0.05, ANOV A followed by Student-Newman-Keuls test). 
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Fig. 12. Concentration dependent inhibition of the amidolytic activity of chymotrypsin 
by various agents. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-
Pro-Arg-H, (Ll) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin, 
( <>) aprotinin. The individual values at each aprotinin concentration point and the 
gravimetric equivalents are given in Table 12a. 
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Fig. 13. Concentration dependent inhibition of the amidolytic activity of trypsin by 
thrombin inhibitors. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-
Pro-Arg-H, (Ll) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin, 
( <>) aprotinin. Each point represents a mean± 1 SD of three individual determinations. 
The individual values at each concentration point and their gravimetric equivalents are 
given in Table 12b. 
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D-Phe-Pro-Arg-H > 27 µM, D-MePhe-Pro-Arg-H > 26 µM, Boc-D-Phe-Pro-Arg-H > 24 
µM, Ac-(D)Phe-Pro-boroArg-OH > 27 µM, argatroban > 25 µM, hirudin > 1.9 µM, 
heparin > 1.2 µM. However, aprotinin, produced a concentration-dependent inhibition 
of chymotrypsin with an apparent IC50 of 0.8 µM, as reported on Table 12. The 
individual inhibitory values produced by aprotinin are given in Table 12a. 
b. Inhibition of Trypsin 
Fig. 13 depicts the results from the trypsin inhibitory studies by various agents. 
In this assay, argatroban, hirudin and heparin had relatively weaker inhibitory activities 
against the amidolytic activity of trypsin at concentrations higher than 125, 1.9 and 1.2 
µM respectively. The other thrombin inhibitors demonstrated a concentration dependent 
inhibition of trypsin. According to the IC50 values for each thrombin inhibitor, as 
reported in Table 12, the most potent thrombin inhibitor in this assay was Ac-(D)Phe-
Pro-boroArg-OH (IC50 0.095 µM), followed by D-MePhe-Pro-Arg-H (IC50 0.18 µM), 
Boc-D-Phe-Pro-Arg-H (IC50 0.24 µM) and then by D-Phe-Pro-Arg-H (IC50 0.47 µM). 
The anti-fibrinolytic agent aprotinin, used in these studies as the positive control, also 
exhibited a concentration-dependent ant-trypsin effect with an IC50 of 0.39 µM. The 
inhibition produced by each antithrombin agent is found in Table 12b. 
c. Inhibition of Activated Protein C (APC) 
The inhibitory effects of thrombin inhibitors against the amidolytic activity of 
APC are depicted in Fig. 14. With the exception of heparin, hirudin and argatroban, all 
of the other thrombin inhibitors exhibited a concentration-dependent inhibitory effect 
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Fig. 14. Concentration dependent inhibition of the amidolytic activity of APC by various 
agents. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H, 
(.c.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, ( +) heparin, ( O) 
aprotinin. Each point represents a mean ± 1 SD of three individual determinations. The 
individual values at each concentration point and their gravimetric equivalents are given 
in Table 12c. 
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Fig. 15. Concentration dependent inhibition of the amidolytic activity of kallikrein by 
thrombin inhibitors. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-
Pro-Arg-H, (.c.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin, 
( O) aprotinin. Each point represents a mean ± 1 SD of three individual determinations. 
The individual values at each concentration point and their gravimetric equivalents are 
given in Table 12d. 
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against APC. While heparin, hirudin and argatroban did not exhibit any inhibitory 
actions at high concentrations ( > 9, > 10 and > 100 µM, respectively), the other 
thrombin inhibitors had IC50 values < 10 µM, as shown in Table 12. The most potent 
inhibitor was Ac-(D)Phe-Pro-boroArg-OH with an IC50 of 0. 75 µM, followed by D-Phe-
Pro-Arg-H, D-MePhe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H with IC50s of 4.2, 8.4 and 
14.6 µM respectively. Aprotinin was slightly weaker than the thrombin inhibitors. 
However, this agent also inhibited APC in a concentration-dependent manner with an IC50 
of 16.6 µM. All four agents were capable of completely inhibiting the APC amidolytic 
activity at concentrations around 100 µM. The individual % APC inhibitory values for 
each inhibitor concentration point are found in Table 12c. 
d. Inhibition of Glandular Kallikrein 
The representative data of the inhibition of glandular kallikrein by various 
thrombin inhibitors are depicted in Fig. 15. In this assay, only heparin and Ac-(D)Phe-
Pro-boroArg-OH exhibited concentration-dependent inhibitory effects against the 
amidolytic action of glandular kallikrein. When compared to aprotinin (IC50 0.32 µM), 
these thrombin inhibitors were found to be relatively weaker inhibitors, with Ac-(D)Phe-
Pro-boroArg-OH exhibiting an IC50 of 14. 7 µM, whereas for heparin it was > 62 µM. 
Furthermore, neither of the thrombin inhibitors was capable of completely inhibiting 
kallikrein at concentrations higher than 60 µM. The IC50 values of these agents are 
found in Table 12, while the individual % kallikrein inhibitory values for each inhibitor 
concentration point are found in Table 12d. 
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e. Inhibition of Tissue Plasminogen Activator (tPA) 
The amidolytic activity of tPA was inhibited by all of the tripeptide thrombin 
inhibitors, as seen in Fig. 16. As can be seen in this figure, argatroban, hirudin, heparin 
and aprotinin did not affect the amidolytic activity of tP A at extremely higher 
concentrations of up to 60, 10, 62 and 5 µM respectively. The tripeptide thrombin 
inhibitors exhibited a concentration-dependent tPA inhibition. The estimated IC50 values 
for these inhibitions are shown in Table 12. The most potent inhibitor was found to be 
Ac-(D)Phe-Pro-boroArg-OH (IC50 6.8 µM) followed closely by Boc-D-Phe-Pro-Arg-H 
(IC50 7.3 µM). The peptides D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H also inhibited 
the amidolytic activity of tPA, but at higher concentrations wit IC50s of 33. 6 and 52. 7 
µM respectively. Furthermore, while Ac-(D)Phe-Pro-boroArg-OH and Boc-D-Phe-Pro-
Arg-H reached 1003 inhibition of tPA at concentrations under 60 µM, the other two 
tripeptides were not as potent at similar concentrations. The individual 3 tPA inhibitory 
values for each inhibitor concentration point are found in Table 12e. 
f. Inhibition of Urokinase 
Fig. 17 depicts the inhibitory activities of various agents on the amidolytic action 
of urokinase. Argatroban, hirudin, heparin and aprotinin did not inhibit the amidolytic 
activity of urokinase at high concentrations ( > 60, > 10, > 62 and > 5 µM respectively). 
While all tripeptide thrombin inhibitors reduced the amidolytic activity of tPA in a 
concentration-dependent manner, only two of these were capable of inhibiting the 
amidolytic action of urokinase. Table 12 depicts the IC50 values for Ac-(D)Phe-Pro-
boroArg-OH and Boc-D-Phe-Pro-Arg-H, which were 1.3 and 15.3 µM respectively. On 
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Fig. 16. Concentration dependent inhibition of the amidolytic activity of t-PA by 
antithrombin agents. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-
Pro-Arg-H, (.A) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin, 
( <>) aprotinin. Each point represents a mean ± 1 SD of three individual determinations. 
The individual values at each concentration point and their gravimetric equivalents are 
given in Table 12e. 
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Fig. 17. Concentration dependent inhibition of the amidolytic activity of urokinase by 
various agents. ( •) D-Phe-Pro-Arg-H, ( o) D-MePhe-Pro-Arg-H, ( •) Boc-D-Phe-Pro-
Arg-H, (.A) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin, ( <>) 
aprotinin. Each point represents a mean ± 1 SD of three individual determinations. The 
individual values at each concentration point and their gravimetric equivalents are given 
in Table 12f. 
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the other hand, D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H did not exhibit inhibitory 
activities in this assay at concentrations > 60 µM. The individual % urokinase inhibitory 
values for each inhibitor concentration point are found in Table 12f. 
g. Inhibition of Plasmin 
As depicted on Fig. 18, with the exception of hirudin, the amidolytic activity of 
plasmin was inhibited by all thrombin inhibitors and aprotinin. Argatroban exhibited the 
weakest inhibitory activity and even the highest concentration (115 µM) did not achieve 
50% inhibition of plasmin. Interestingly, heparin exhibited inhibitory activity against 
plasmin at concentrations > 10 µM which was not concentration-dependent and plateaued 
around 20 % inhibition. All tripeptide thrombin inhibitors and aprotinin exhibited 
concentration-dependent anti-plasmin activity, and all were capable of maximal plasmin 
inhibition at µM concentrations. After calculating the IC50 value for each of these 
inhibitors, reported in Table 12, the most potent plasmin inhibitor was aprotinin (IC50 
0.057 µM), followed by Ac-(D)Phe-Pro-boroArg-OH (IC50 0.095 µM), Boc-D-Phe-Pro-
Arg-H (IC50 0.33 µM), D-MePhe-Pro-Arg-H (IC50 1.58 µM) and D-Phe-Pro-Arg-H (IC50 
3.2 µM). The individual % plasmin inhibitory values for each inhibitor concentration 
point are found in Tables 12g and 12h. 
6. Inhibition of Plasminogenolysis 
Since it was found that some of the thrombin inhibitors studied in the above 
described assays had inhibitory activities against serine proteases other than thrombin and 
because some of these proteases are involved in the regulation of fibrinolysis, more 
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Fig. 18. Concentration dependent inhibition of the amidolytic activity of plasmin by 
thrombin inhibitors. (•) D-Phe-Pro-Arg-H, (O) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-
Pro-Arg-H, (.A) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (0) hirudin, (+)heparin, 
( <> ) aprotinin. Each point represents a mean ± 1 SD of three individual determinations. 
The individual values at each concentration point and their gravimetric equivalents are 
given in Tables 12g-12h. 
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specifically, the activation of plasminogen to plasmin, the effect of these agents on the 
generation of plasmin was also investigated. In these assays, plasminogen was activated 
to plasmin by either streptokinase or tP A in buffered plasminogen and NHP-based assays. 
a. Pure Plasminogen System 
Fig. 19 depicts the effects of various agents on the process of plasminogenolysis 
in the assays where plasminogen is provided in a purified form. Except for argatroban, 
all thrombin inhibitors studied in these assay systems exhibited inhibitory activities in the 
process of plasminogenolysis, although to varying degrees, regardless of whether 
activation was mediated by streptokinase (Fig. 19, panel A) or tPA (Fig. 19, panel B). 
The inhibitory patterns that emerged from the two assays were parallel. 
As depicted in Fig. 19, panel A, in the streptokinase-mediated plasminogenolysis 
assay, hirudin appeared to be the weakest inhibitor (IC50 > 1.2 µM), with a maximal 
inhibition of around 20% at the highest concentration used (1 µM), concentration-
independently. On the other hand Ac-(D)Phe-Pro-boroArg-OH was the strongest 
inhibitor (IC50 < 1.97 µM) followed closely by Boc-D-Phe-Pro-Arg-H (IC50 4.9 µM). 
While the effects of D-MePhe-Pro-Arg-H (IC50 7 µM) and D-Phe-Pro-Arg-H (IC50 12.6 
µM) followed those of Ac-(D)Phe-Pro-boroArg-OH and Boc-D-Phe-Pro-Arg-H, aprotinin 
was a stronger concentration-dependent inhibitor of plasminogenolysis. The inhibitory 
pattern of heparin was weakly concentration-dependent in this assay (IC50 >0.73 µM). 
The IC50 value for each thrombin inhibitor in the streptokinase assay are reported in 
Table 13. The individual % plasminogenolysis inhibitory values for each inhibitor 
concentration point are found in Tables 13a - 13c. 
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Fig. 19. Concentration dependent inhibition of the process of plasminogenolysis by 
antithrombin agents. Panel A depicts the effects mediated by various agents in the pure 
plasminogen system, activated by streptokinase. The individual values at each 
concentration point and their gravimetric equivalents are given in Tables 13a-13c. Panel 
B depicts the effects mediated by agents in the pure plasminogen system, activated by t-
p A. The individual values at each concentration point and their gravimetric equivalents 
are given in Tables 13d-13f. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-
D-Phe-Pro-Arg-H, (Ll) Ac-(D)Phe-Pro-boroArg-OH, (0) hirudin, ( +) heparin, ( O) 
aprotinin. Each point represents a mean ± 1 SD of three individual determinations. 
Table 13 -- Inhibition of plasminogenolysis by thrombin inhibitors as -determined in biochemically defined and NHP amidolytic 
systems. 
Pure Plasminogen Assay, IC50 in [µM] NHP-Derived Plasminogen Assay, IC50 in [µM] 
Streptokinase tPA Streptokinase tPA 
D-Phe-Pro-Arg-H 12.6 ± 1.6 1.18 ± 0.02 7.0 ± 1.6 2.5 ± 0.1 
D-MePhe-Pro-Arg-H 7.0 ± 0.8 0.62 ± 0.02 5.24 ± 0.97 3.5 ± 0.1 
Boc-D-Phe-Pro-Arg-H 4.9 ± 0.5 <0.089 4.3 ± 0.7 < 1.77 
Ac-D-Phe-Pro-boroArg-OH < 1.97 <0.098 < 1.97 < 1.97 
Argatroban > 1.0 > 1.0 > 1.0 > 1.0 
Hirudin > 1.22 > 1.22 > 1.22 > 1.22 
Heparin >0.73 >0.73 >0.73 >0.73 
Aprotinin >3.84 0.355 ± 0.215 >3.84 1.92 ± 0.02 
Each value represents the mean ± 1 SD of three separate determinations. In the pure plasminogen lysed by streptokinase assay, the 
value produced by D-Phe-Pro-Arg-H was significantly different from those produced by D-MePhe-Pro-Arg-H and Boc-D-Phe-Pro-
Arg-H. In the pure plasminogen lysed by tPA assay, the value produced by Boc-D-Phe-Pro-Arg-H was significantly different from 
those produced by D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H. In the NHP-derived plasminogen lysed by streptokinase assay, non 
of the values were significantly different from each other. Similarly, in the NHP-derived plasminogen lysed by tP A assay, non of 
the values were significantly different from each other. (p < 0.05, ANOV A followed by Student-Newman-Keuls test). 
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Fig. 19, panel B depicts the inhibitory effects of various agents on the 
plasminogenolysis mediated by tPA. Hirudin was found to be again the weakest inhibitor 
(IC50 > 1.2 µM), producing a plateau at around 20% inhibition even at the highest 
concentration (1 µM). Ac-(D)Phe-Pro-boroArg-OH was found to be the strongest 
inhibitor of the tP A-induced plasminogenolysis (IC50 < 0.1 µM), followed by Boc-D-Phe-
Pro-Arg-H (IC50 < 0.09 µM), aprotinin (IC50 0.36 µM), D-MePhe-Pro-Arg-H (IC50 0.6 
µM) and D-Phe-Pro-Arg-H (IC50 1.2 µM). Heparin produced weak inhibitory effects 
which plateaued at 35 % inhibition at concentration in the nM range. The IC50 values for 
each of the antithrombin agents are reported in Table 13. The individual inhibitory 
values at each agent concentration point are given in Tables 13d - 13f. 
b. NHP System 
Fig. 20 represents the effects of various inhibitors on the process of 
plasminogenolysis in assays where the source of plasminogen is NHP. With the 
exception of argatroban and heparin, all thrombin inhibitors studied in these tests 
exhibited inhibitory activities in the process of plasminogenolysis, although to varying 
degrees, regardless of whether activation was mediated by streptokinase (Fig. 20, panel 
A) or tPA (Fig. 20, panel B). The inhibitory patterns that resulting from the two tests 
were parallel. 
In the streptokinase-induced plasminogenolysis assay (Fig. 20, panel A), heparin 
appeared to be the weakest inhibitor, with a maximal inhibition of around 25 % at the 
highest concentration used (0.73 µM), followed by hirudin with a maximal inhibition of 
30% at the highest concentration studied (1 µM). On the other hand Ac-(D)Phe-Pro-
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Fig. 20. Concentration dependent inhibition of process of plasminogenolysis by 
antithrombin agents. Panel A depicts the effects mediated by various agents in the NHP 
system, activated by streptokinase. The individual values at each concentration point and 
their gravimetric equivalents are given in Tables 13g-13i. Panel B depicts the effects 
mediated by agents in the NHP system, activated by t-PA. The individual values at each 
concentration point and their gravimetric equivalents are given in Tables 13j-131. ( •) 
D-Phe-Pro-Arg-H, ( o) D-MePhe-Pro-Arg-H, ( •) Boc-D-Phe-Pro-Arg-H, (A) Ac-(D)Phe-
Pro-boroArg-OH, (0) hirudin, ( +) heparin, ( O) aprotinin. Each point represents a 
mean ± 1 SD of three individual determinations. 
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boroArg-OH was the strongest inhibitor (IC50 < 2.0 µM), followed closely by Boc-D-
Phe-Pro-Arg-H (IC50 4.3 µM). While the concentration-dependent effects of D-MePhe-
Pro-Arg-H (IC50 5.2 µM) and D-Phe-Pro-Arg-H (IC50 7 µM) followed those of Ac-
(D)Phe-Pro-boroArg-OH and Boc-D-Phe-Pro-Arg-H, they were superimposable with 
those of aprotinin. The IC50 values for each thrombin inhibitor are given in Table 13, 
while the values for the individual concentrations of each agent are reported in Tables 
13g - 13i. 
In the tPA-induced plasminogenolysis, heparin had no effects even at the highest 
concentration studied (0. 73 µM). Hirudin was again found to be the weakest inhibitor 
of plasminogenolysis (IC50 < 1 µM) and inhibited only 33 % of the process. The 
strongest inhibitor in this assay was found to be Ac-(D)Phe-Pro-boroArg-OH (IC50 < 2 
µM), followed by Boc-D-Phe-Pro-Arg-H (IC50 < 1.8 µM), aprotinin (IC50 1.9 µM), D-
Phe-Pro-Arg-H (IC50 2.5 µM) and D-MePhe-Pro-Arg-H (IC50 2.5 µM). Table 12 reports 
the IC50 values of each thrombin inhibitor in this assay. Tables 13j - 131 contain the 
inhibitory values at each concentration for the individual antithrombin agents. 
7. Inhibition of Extrinsic Activation Systems in Fibrinogen Deficient 
Human Plasma by Thrombin Inhibitors 
Although the antithrombin and anti-Xa assays provided data on the direct 
inhibitory activities of thrombin inhibitors against thrombin and factor Xa, their effects 
on protease generation were not addressed in these assays. The coagulation cascade is 
a complex enzyme network with feedback mechanisms and amplification loops. Thus, 
it is conceivable that even if a thrombin inhibitor is effective in directly inhibiting 
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thrombin or factor Xa, it may not inhibit the generation of various proteases and 
thrombin. Therefore, the inhibitory effects of thrombin inhibitors on the generation of 
thrombin and factor Xa were studied in the fibrinogen deficient plasma where specific 
activators of the extrinsic and intrinsic assay systems were used. The human plasma 
used in these assays was fibrinogen deficient, in which clot formation was avoided to 
minimize clotting interference. 
a. Inhibition of Extrinsic Thrombin Generation 
Fig. 21. panel A depicts the data of the inhibition of thrombin generation after 
extrinsic activation by various thrombin inhibitors. All agents produced a concentration-
dependent inhibition of thrombin. While hirudin was the most potent inhibitor (IC50 
0.02µM) in this assay, the maximal inhibitory activity plateaued around 803. With the 
exception of argatroban, the rest of the thrombin inhibitors were relatively weaker 
inhibitors but were able to completely inhibit the generation of thrombin at higher 
concentrations. According to the IC50 values for each thrombin inhibitor in this test, 
reported in Table 14, after hirudin, the most potent inhibitor was heparin (IC50 0.2 µM), 
closely followed by Ac-(D)Phe-Pro-boroArg-OH (IC50 0.4 µM). The effects of D-Phe-
Pro-Arg-H (IC50 5.3 µM) and D-MePhe-Pro-Arg-H (IC50 5.1 µM) were superimposable. 
Although Boc-D-Phe-Pro-Arg-H had a similar IC50 value as the other two aldehydes (5.5 
µM), the slope of the response was steeper, indicating improved efficacy. Argatroban 
was found to be the weakest inhibitor in this test. The individual % thrombin generation 
inhibitory values for each inhibitor concentration point are found in Tables 14a - 14e. 
Table 14 -- Inhibition of generation of thrombin and factor Xa by thrombin inhibitors as determined in fibrinogen-
deficient amidolytic systems. 
Extrinsic Generation, IC50 [µM] Intrinsic Generation, IC50 [µM] 
Thrombin Factor Xa Thrombin Factor Xa 
D-Phe-Pro-Arg-H 5.3 ± 0.6 10 ± 1.5 3.8 ± 0.8 0.07 ± 0.01 
D-MePhe-Pro-Arg-H 5.1 ± 0.5 13 ± 1.5 1.4 ± 0.4 0.106 ± 0.005 
Boc-D-Phe-Pro-Arg-H 5.5 ± 0.5 2.2 ± 0.4 1.4 ± 0.2 0.16 ± 0.01 
Ac-D-Phe-Pro-boroArg-OH 0.4 ± 0.1 0.24 ± 0.06 0.14 ± 0.04 0.036 ± 0.005 
Argatroban 19 ± 3 >60 6.5 ± 0.6 0.17 ± 0.03 
Hirudin 0.02 ± 0.01 >5 0.04 ± 0.005 0.018 ± 0.002 
Heparin 0.2 ± 0.1 0.045 ± 0.01 0.032 ± 0.004 0.006 ± 0.002 
Each value represents the mean ± 1 SD of three separate determinations. In the extrinsic generation of thrombin 
assay, all values were significantly different from each other except for the following pairs: D-Phe-Pro-Arg-H vs D-
MePhe-Pro-Arg-H, D-Phe-Pro-Arg-H vs Boc-D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H vs Boc-D-Phe-Pro-Arg-H, Ac-
(D)Phe-Pro-boroArg-OH vs hirudin, Ac-(D)Phe-Pro-boroArg-OH vs heparin and hirudin vs heparin. In the extrinsic 
generation of factor Xa, the values produced by D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H were significantly 
different when compared to each other and when compared to Boc-D-Phe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH 
and heparin. In the intrinsic thrombin generation assay, all values produced by all thrombin inhibitors were 
significantly different from each other, with the exception of the following pairs: D-MePhe-Pro-Arg-H vs Boc-D-Phe-
Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH vs hirudin, Ac-(D)Phe-Pro-boroArg-OH vs heparin and hirudin vs heparin. 
In the extrinsic factor Xa generation assay, all values were significantly different from each other, except for the 
comparison between Boc-D-Phe-Pro-Arg-H and argatroban. (p < 0.05, ANOVA followed by Student-Newman-Keuls 
test). 
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Fig. 21. Concentration-dependent inhibition of the extrinsic activation of coagulation, 
by antithrombin agents, in the fibrinogen-deficient system. Panel A depicts the effects 
mediated by various agents in the extrinsic thrombin generation system. The individual 
values at each concentration point and their gravimetric equivalents are given in Tables 
14a-14e. Panel B depicts the effects mediated by agents in the extrinsic factor Xa 
generation system. The individual values at each concentration point and their 
gravimetric equivalents are given in Tables 14f-14j. (•) D-Phe-Pro-Arg-H, (o) D-
MePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H, (.6.) Ac-(D)Phe-Pro-boroArg-OH, (•) 
argatroban, (D) hirudin, (+)heparin. Each point represents a mean ± 1 SD of three 
individual determinations. 
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b. Inhibition Extrinsic Factor Xa Generation 
Fig. 21, panel B depicts the results on the inhibition of factor Xa generation after 
extrinsic activation by various agents. All inhibitors produced a concentration-dependent 
inhibition of factor Xa. Hirudin appeared to be a weak inhibitor of extrinsic factor Xa 
generation and only about 20 % of factor Xa generation was maximally inhibited at 
concentration as high as 5 µM. With the exception of argatroban, the other thrombin 
inhibitors were able to completely inhibit the generation of factor Xa. According to the 
IC50 values for each antithrombin agent in this assay reported in Table 14, the most 
potent inhibitor was heparin (IC50 0.045 µM), followed by Ac-(D)Phe-Pro-boroArg-OH 
(IC50 0.24 µM) and then by Boc-D-Phe-Pro-Arg-H (IC50 2.2 µM). The effects of D-Phe-
Pro-Arg-H (IC50 10 µM) and D-MePhe-Pro-Arg-H (IC50 13 µM) were superimposable. 
Argatroban was the weakest inhibitor in this assay system (IC50 > 62 µM). The 
individual % factor Xa generation inhibitory values for each inhibitor concentration point 
are found in Tables 14f - 14j. 
8. Inhibition of Intrinsic Activation Systems in Fibrinogen Deficient 
Human Plasma by Thrombin Inhibitors 
The extrinsic and intrinsic activation of the coagulation cascade trigger different 
sequences of clotting factor activations. Therefore, the proportions of active factors 
generated, as well as the speed at which they are generated are different. To study the 
effects of thrombin inhibitors on the coagulation cascade after intrinsic activation, their 
effects on the generation of thrombin and factor Xa were studied in the following tests, 
where human plasma was activated intrinsically and the amount of thrombin and factor 
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Xa generated was detected with specific chromogenic substrates. As with the extrinsic 
assays described earlier, fibrinogen deficient human plasma was used in these assays. 
a. Inhibition of Intrinsic Thrombin Generation 
Fig. 22, panel A depicts the inhibition of thrombin generation after intrinsic 
activation by various thrombin inhibitors. The inhibition produced by these agents was 
concentration-dependent. While heparin was found to be the most potent inhibitor in this 
test (IC50 0.032 µM), followed closely by hirudin (IC50 0.04 µM), the maximal inhibitory 
activity of both agents plateaued around 80 % . With the exception of argatroban, the 
other thrombin inhibitors appeared to be weaker than heparin and hirudin but were able 
to completely inhibit the generation of thrombin at higher concentrations. According to 
the IC50 values for each thrombin inhibitor in this assay, reported in Table 14, after 
hirudin and heparin, the most potent inhibitor was Ac-(D)Phe-Pro-boroArg-OH with an 
IC50 of 0.14 µM. The effects of D-MePhe-Pro-Arg-H (IC50 1.4 µM) and Boc-D-Phe-Pro-
Arg-H (IC50 1.4 µM) were superimposable, followed by D-Phe-Pro-Arg-H (IC50 3.8 
µM). Argatroban was found to be the weakest inhibitor in this assay system (IC50 6.5 
µM) and it also appeared to plateau around 65 % . The individual % thrombin generation 
inhibitory values for each inhibitor concentration point are found in Tables 14k - 140. 
b. Inhibition of Intrinsic Factor Xa Generation 
Fig. 22, panel B, represents the inhibition of factor Xa generation after intrinsic 
activation by various agents. The inhibition produced by these thrombin inhibitors was 
concentration-dependent and all agents were capable of completely inhibiting factor Xa 
generation at the higher concentrations. The order of potency of these antithrombin 
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Fig. 22. Concentration dependent inhibition of the intrinsic activation of coagulation, by 
antithrombin agents, in the fibrinogen-deficient system. Panel A depicts the effects 
mediated by various agents in the intrinsic thrombin generation system. The individual 
values at each concentration point and their gravimetric equivalents are given in Tables 
14k-14o. Panel B depicts the effects mediated by agents in the intrinsic factor Xa 
generation system. The individual values at each concentration point and their 
gravimetric equivalents are given in Tables 14p-14t. (•) D-Phe-Pro-Arg-H, (o) D-
MePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H, (£.) Ac-(D)Phe-Pro-boroArg-OH, (•) 
argatroban, (D) hirudin, (+)heparin. Each point represents a mean ± 1 SD of three 
individual determinations. 
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agents was heparin (IC50 0.006 µM) > hirudin (IC50 0.018 µM) > Ac-(D)Phe-Pro-
boroArg-OH (IC50 0.17 µM) > D-Phe-Pro-Arg-H (IC50 0.11 µM) > D-MePhe-Pro-Arg-H 
(IC50 0.07 µM) >Boc-D-Phe-Pro-Arg-H (IC50 0.16 µM) >argatroban (IC50 0.17 µM), 
as indicated by their IC50 values, reported in Table 14. The individual % factor Xa 
generation inhibitory values for each inhibitor concentration point are found in Tables 
14p - 14t. 
9. Inhibition of KONYNE® Based Systems by Thrombin Inhibitors 
In the extrinsic thrombin and factor Xa generation experiments described above, 
while the initial activation was provided extrinsically, the intrinsic pathway was also 
eventually activated due to the feedback loops mediated by thrombin. To devise a test 
where only extrinsic activation was present without interference from the intrinsic 
factors, a mixture of factors II, VII, IX and X purified from human plasma (KONYNE®) 
was utilized instead of fibrinogen deficient human plasma. Thus, with extrinsic 
activation only the extrinsic and common pathway were amplified. The amount of 
thrombin and factor Xa generated were detected based on their amidolytic activity on 
chromogenic substrates, specific for thrombin and factor Xa respectively. 
a. Inhibition of Thrombin Generation from KONYNE® 
Inhibition of thrombin generated from KONYNE® after extrinsic activation, by 
thrombin inhibitors was concentration-dependent, as illustrated in Fig. 23, panel A. 
Hirudin was the most potent inhibitor in this assay but the maximal inhibitory activity 
plateaued around 40 % . On the other hand, the rest of the thrombin inhibitors were 
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Fig. 23. Concentration-dependent inhibition of the extrinsic activation of coagulation in 
the KONYNE® system, by antithrombin agents. Panel A depicts the effects mediated by 
various agents in the extrinsic thrombin generation system. The individual values at each 
concentration point and their gravimetric equivalents are given in Tables 15a-15c. Panel 
B depicts the effects mediated by agents in the extrinsic factor Xa generation system. 
The individual values at each concentration point and their gravimetric equivalents are 
given in Tables 15d-15f. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-
Phe-Pro-Arg-H, (Ll) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, ( +) 
heparin. Each point represents a mean ± 1 SD of three individual determinations. 
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relatively weaker but were able to inhibit the generation of thrombin to a greater extent 
at higher concentrations. According to the IC50 values for each thrombin inhibitor in this 
assay system, reported in Table 15, the most potent inhibitor Ac-(D)Phe-Pro-boroArg-
OH with an IC50 of 0.25 µM. The effects of D-MePhe-Pro-Arg-H (IC50 1.94 µM) and 
Boc-D-Phe-Pro-Arg-H (IC50 1.59 µM) were superimposable. As with hirudin, D-Phe-
Pro-Arg-H and heparin also appeared to plateau in their inhibitory activities around 40 % . 
Argatroban was the weakest inhibitor in this test with an IC50 of 10.0 µM. The 
individual % thrombin generation inhibitory values for each inhibitor concentration point 
are found in Tables 15a - 15c. 
Table 15 -- Inhibition of generation of thrombin and factor Xa by thrombin inhibitors as 
determined in FEIBA ® and KONYNE amidolytic systems. 
KONYNE® System FEIBA ® System 
IC50 [µM] IC50 [µM] 
Thrombin Factor Xa Thrombin Factor Xa 
D-Phe-Pro-Arg-H >3.0 2.58 2.73 2.8 
D-MePhe-Pro-Arg-H 1.94 0.41 >2.9 1.68 
Boc-D-Phe-Pro-Arg-H 1.59 0.91 >2.7 2.21 
Ac-(D )Phe-Pro-boroArg-OH 0.25 0.10 0.66 0.36 
Argatroban 10.0 10.0 > 18.8 0.82 
Hirudin >2.15 1.28 0.54 0.54 
Heparin > 1.8 0.75 1.66 > 1.8 
Each value was derived from a single determination. 
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b. Inhibition of Factor Xa Generation from KONYNE® 
Inhibition of factor Xa generated from KONYNE®, after extrinsic activation, by 
thrombin inhibitors was concentration-dependent, as illustrated in Fig. 23, panel B. 
Hirudin appeared to be a weak inhibitor of factor Xa generation and only about 50 % of 
factor Xa generation was maximally inhibited at concentrations around 2.9 µM. The 
antithrombin agents were able to inhibit the generation of factor Xa to a greater extent. 
According to the IC50 values for each thrombin inhibitor in this assay reported in Table 
15, the most potent inhibitor was Ac-(D)Phe-Pro-boroArg-OH (IC50 0.1 µM), followed 
by D-MePhe-Pro-Arg-H (IC50 0.9 µM), heparin (IC50 0.8 µM), Boc-D-Phe-Pro-Arg-H 
(IC50 0.9 µM), hirudin (IC50 1.3 µM), D-Phe-Pro-Arg-H (IC50 2.6 µM) and lastly by 
argatroban (IC50 10 µM). The individual % factor Xa generation from KONYNE® 
inhibitory values for each inhibitor concentration point are found in Tables 15d - 15f. 
10. Inhibition of FEIBA ® Based Systems by Thrombin Inhibitors 
These assays are similar to the KONYNE® based reaction mixtures as described 
earlier. However, FEIBA® mainly contains factor VIia and factors II, VII, IX and X, 
in both the native and active forms. This product is purified from human plasma. In 
these studies thromboplastin C was used an activator. Thus, with this activation only the 
extrinsic and common pathway were activated. The amount of thrombin and factor Xa 
generated were detected based on their amidolytic activity on chromogenic substrates, 
specific for thrombin and factor Xa respectively. 
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Fig. 24. Concentration-dependent inhibition of the extrinsic activation of coagulation in 
the FEIBA ® system, by antithrombin agents. Panel A depicts the effects mediated by 
various agents in the extrinsic thrombin generation system. The individual values at each 
concentration point and their gravimetric equivalents are given in Tables 15g-15i. Panel 
B depicts the effects mediated by agents in the extrinsic factor Xa generation system. 
The individual values at each concentration point and their gravimetric equivalents are 
given in Tables 15j-151. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-
Phe-Pro-Arg-H, (~) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (0) hirudin, ( +) 
heparin. Each point represents a mean ± 1 SD of three individual determinations. 
190 
a. Inhibition of Thrombin Generation from FEIBA ® 
Fig. 24, panel A depicts the inhibition of thrombin generation from FEIBA ®after 
extrinsic activation by various thrombin inhibitors. All agents exhibited concentration-
dependent inhibition of thrombin generation in this assay. Hirudin was the most potent 
inhibitor in this assay (IC50 0.54 µM) but the maximal inhibitory activity plateaued 
around 90%. The effects of hirudin were closely followed by those of Ac-(D)Phe-Pro-
boroArg-OH (IC50 0.66 µM). While heparin (IC50 1.66 µM) and D-Phe-Pro-Arg-H (2. 73 
µM) had weaker inhibitory activities in this test than Ac-(D)Phe-Pro-boroArg-OH, D-
MePhe-Pro-Arg-H, Boc-D-Phe-Pro-Arg-H and argatroban where devoid of any effects 
at high concentrations (IC50 >2.9, 2.7 and 18.8 µM respectively). The IC50 values for 
each thrombin inhibitor in this assay system are reported in Table 15 and the individual 
% thrombin generation inhibitory values for each inhibitor concentration point are found 
in Tables 15g - 15i. 
b. Inhibition of Factor Xa Generation from FEIBA ® 
Inhibition of factor Xa generated from FEIBA ® after extrinsic activation, by 
thrombin inhibitors was concentration-dependent, as illustrated in Fig. 24, panel B. Ac-
(D)Phe-Pro-boroArg-OH was the most potent inhibitor in this assay (IC50 0.36 µM) 
followed by hirudin (IC50 0.54 µM), argatroban (IC50 0.82 µM), D-MePhe-Pro-Arg-H 
(IC50 1.68 µM), Boc-D-Phe-Pro-Arg-H (IC50 2.21 µM) and D-Phe-Pro-Arg-H (IC50 2.8 
µM). Heparin was devoid of any effects at high concentrations ( > 1.9 µM). The IC50 
values for all agents are reported in Table 15. The individual % factor Xa generation 
from KONYNE® inhibitory values for each inhibitor concentration point are given in 
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Tables 15j - 151. 
D. Anticoagulant Effects of Thrombin Inhibitors in NHP 
All of the results described in section C. Biochemical Assays, with the exception 
of the TT in the human fibrinogen based test, were based on the inhibition of the 
amidolytic activity of thrombin, factor Xa and other serine proteases. Furthermore, the 
TT in the fibrinogen based test was a defined assay in which no other clotting factors 
except for thrombin and fibrinogen were present. Therefore, the in vitro anticoagulant 
effects of thrombin inhibitors, based on the inhibition of thrombin clotting activity, were 
studied in the following global clotting tests, where all clotting factors were present in 
normal human plasma. Each assay was based on the activation of the coagulation in a 
distinct manner, thus providing specific data on the inhibitory actions of these 
antithrombin agents at various sites. To compare the relative anticoagulant effects of 
thrombin inhibitors in these assays, the concentrations of each inhibitor that resulted in 
prolongation of the clotting time to 100 sec (CT100) was calculated and is given in Table 
16. 
1. Prothrombin Time (PT) 
In the PT assay, thromboplastin was added to NHP to activate the coagulation 
cascade extrinsically (starting with factor VII), leading to thrombin formation which 
resulted in clot formation. The inhibitory activities of thrombin inhibitors in this assay 
system were concentration-dependent, as seen in Fig. 25. Heparin had no effects in this 
test at high concentrations ( > 0. 9 µM). When comparing the concentrations of each 
Table 16 -- Comparative anticoagulant effects of thrombin inhibitors in NHP. 
Concentrations that prolong clotting time to 100 sec in [µM] 
PT APTT TT ECT Hep test 
D-Phe-Pro-Arg-H 61 ± 2 11.9 ± 0.4 5.1 ± 0.2 0.16 ± 0.04 21.4 ± 0.8 
D-MePhe-Pro-Arg-H 33 ± 1 8.2 ± 0.2 2.7 ± 0.3 0.22 ± 0.05 11.2±0.4 
Boc-D-Phe-Pro-Arg-H 101 ± 4 7.7 ± 0.5 5.5 ± 0.2 0.89 ± 0.03 23.8 ± 0.6 
Ac-D-Phe-Pro-boroArg-OH 6.2 ± 1 0.68 ± 0.05 0.60 ± 0.02 0.095 ± 0.010 2.05 ± 0.05 
Argatroban 28 ± 1 6.90 ± 0.20 8.9 ± 0.2 0.21 ± 0.01 3.65 ± 0.10 
Hirudin 2.3 ± 0.5 1.44 ± 0.05 0.009 ± 0.006 0.065 ± 0.015 1.3 ± 0.05 
Heparin >0.9 0.22 ± 0.03 0.155 ± 0.005 >10.0 0.30 ± 0.05 
Each value represents the mean ± 1 SD of three separate determinations. In the PT assay, values produced by all 
thrombin inhibitors (except for heparin) were significantly different from each other. In the APTT assay, values 
produced by all thrombin inhibitors were significantly different from each other, with the exception of the Ac-(D)Phe-
Pro-boroArg-OH vs heparin comparison. In the 10 U ca++TT assay, values produced by all thrombin inhibitors were 
significantly different from each other, with the exception of the hirudin vs heparin comparison. In the ECT assay, 
values produced by all thrombin inhibitor (except for heparin) were significantly different from each other with the 
exception of the following pairs: D-Phe-Pro-Arg-H vs D-MePhe-Pro-Arg-H, D-Phe-Pro-Arg-H vs argatroban, D-
MePhe-Pro-Arg-H vs argatroban and Ac-(D)Phe-Pro-boroArg-OH vs hirudin. In the Heptest assay, values produced 
by all thrombin inhibitors were significantly different from each other. (p < 0.05, ANOV A followed by Student-
Newman-Keuls test). 
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Fig. 25. Comparative anticoagulant effects of antithrombin agents, after supplementation 
to NHP, as studied in the PT. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) 
Boc-D-Phe-Pro-Arg-H, (.t.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, 
(+)heparin. Each point represents a mean ± 1 SD of three individual determinations. 
The individual values at each concentration point and their gravimetric equivalents are 
given in Tables 16a-16c. 
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Fig. 26. Comparative anticoagulant effects of various agents, after supplementation to 
NHP, as studied in the APTT. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) 
Boc-D-Phe-Pro-Arg-H, (.t.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, 
(+)heparin. Each point represents a mean ± 1 SD of three individual determinations. 
The individual values at each concentration point and their gravimetric equivalents are 
given in Tables 16d-16f. 
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thrombin inhibitor that resulted in prolongation of the clotting time to 100 sec, reported 
in Table 16, it was found that the most potent inhibitor of the PT was hirudin (CT100 : 2.3 
µM) followed by Ac-(D)Phe-Pro-boroArg-OH (CT100: 6.2 µM). Both hirudin and Ac-
(D)Phe-Pro-boroArg-OH appeared to have an all-or-none effects on the PT. The effects 
of Ac-(D)Phe-Pro-boroArg-OH were followed by argatroban (CT100: 28 µM), D-MePhe-
Pro-Arg-H (CT100 : 33 µM), D-Phe-Pro-Arg-H (CT100 : 61 µM) and lastly by Boc-D-Phe-
Pro-Arg-H (CT100 : 101 µM). Even though argatroban produced a clotting time 
prolongation to 100 sec at a lower concentration than D-MePhe-Pro-Arg-H, the latter 
inhibitor prolonged the PT to over 300 sec at lower concentrations than argatroban (97 
µM versus 188 µM respectively). The individual clotting times for each thrombin 
inhibitor concentration point are reported in Tables 16a - 16c. 
2. Activated Partial Thromboplastin Time (APTT) 
In the APTT assay, a contact activator was added to NHP to activate the 
coagulation cascade intrinsically (starting with factor XII), leading to thrombin formation 
which resulted in clot formation. As seen in Fig. 26, the inhibitory activities of various 
thrombin inhibitors in this assay were concentration-dependent. When comparing the 
concentrations of each thrombin inhibitor that resulted in prolongation of the clotting time 
to 100 sec as given in Table 16, it was found that the most potent inhibitor of the APTT 
was heparin (CT100: 0.22 µM) followed by Ac-(D)Phe-Pro-boroArg-OH (CT100: 0.68 µM) 
and then closely by hirudin (CT100: 1.44 µM). The effects of hirudin were followed by 
argatroban (CT100: 6.9 µM), Boc-D-Phe-Pro-Arg-H (CT100: 7.7 µM), D-MePhe-Pro-Arg-
H (CT100: 8.2 µM) and D-Phe-Pro-Arg-H (CT100: 11.9 µM). The inhibitory profiles of 
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the last four thrombin inhibitors were superimposable. The individual clotting times for 
each thrombin inhibitor concentration point are reported in Tables 16d - 16f. 
3. Thrombin Time (TT) 
In the TT assay, thrombin was added to NHP to convert the existing fibrinogen 
to fibrin clots. Furthermore, the added thrombin activated the coagulation cascade at 
multiple points (extrinsically via factors VII and V, intrinsically via factor XI and 
common pathway via factor VIII), leading to additional thrombin formation which 
resulted in clot formation. The inhibitory activities of thrombin inhibitors in this assay 
system were concentration-dependent, as seen in Fig. 27. The concentrations of each 
thrombin inhibitor that resulted in prolongation of the clotting time to 100 sec are given 
in Table 16. The most potent inhibitor of the TT was hirudin (CT100 : 0.009 µM), 
followed by heparin (CT100 : 0.155 µM). The effects of heparin were followed by Ac-
(D)Phe-Pro-boroArg-OH (CT100: 0.6 µM) and then by D-MePhe-Pro-Arg-H (CT100: 1.7 
µM), D-Phe-Pro-Arg-H (CT100 : 5.1 µM), Boc-D-Phe-Pro-Arg-H (CT100: 5.5 µM) and 
lastly by argatroban (CT100: 8.9 µM). The inhibitory profiles of D-Phe-Pro-Arg-H and 
Boc-D-Phe-Pro-Arg-H were superimposable. The individual clotting times for each 
thrombin inhibitor concentration point are given in Tables 16g - 16i. 
4. Ecarin Clotting Time (ECT) 
In the ECT assay, ecarin was added to NHP to activate the existing prothrombin 
to meizothrombin and other intermediates with clotting activity, which led to fibrinogen 
conversion to fibrin clots. This was different from the TT, where exogenous thrombin 
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Fig. 27. Comparative anticoagulant effects of thrombin inhibitors, after supplementation 
to NHP, as studied in the TT. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) 
Boc-D-Phe-Pro-Arg-H, (.c.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, 
(+)heparin. Each point represents a mean ± 1 SD of three individual determinations. 
The individual values at each concentration point and their gravimetric equivalents are 
given in Tables 16g-16i. 
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Fig. 28. Comparative anticoagulant effects of antithrombin agents, after supplementation 
to NHP, as studied in the ECT. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) 
Boc-D-Phe-Pro-Arg-H, (.c.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, 
(+)heparin. Each point represents a mean ± 1 SD of three individual determinations. 
The individual values at each concentration point and their gravimetric equivalents are 
given in Tables 16j-16k. 
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was added to the NHP. Fig. 28 depicts the inhibitory activities of thrombin inhibitors 
in this assay system. With the exception of heparin, the inhibitory activities of the other 
agents were concentration-dependent. Table 16 shows the concentrations of each 
thrombin inhibitor that resulted in prolongation of the clotting time to 100 sec. When 
comparing these CT100s, it was found that the most potent inhibitor of the ECT was 
hirudin (CT100: 0.065 µM), followed closely by Ac-(D)Phe-Pro-boroArg-OH (CT100: 
0.095 µM). The effects of Ac-(D)Phe-Pro-boroArg-OH were followed by D-Phe-Pro-
Arg-H (CT100: 0.16 µM), Boc-D-Phe-Pro-Arg-H (CT100: 0.89 µM) and lastly by 
argatroban (CT100: 3.65 µM). In this assay, heparin was devoid of any effects at high 
concentrations ( > 0. 91 µM). The individual clotting times for each thromb in inhibitor 
concentration point are given in Tables 16j and l 6k. 
5. Heptest 
In the Hep test assay, factor Xa added to NHP activated the common pathway 
which lead to thrombin formation with subsequent fibrinogen conversion to fibrin clots. 
The inhibitory activities of antithrombin agents in this test were concentration-dependent, 
as seen in Fig. 29. When comparing the concentrations of each thrombin inhibitor that 
resulted in prolongation of the clotting time to 100 sec, as reported in Table 16, heparin 
was found to be the most potent inhibitor of the Heptest with a CT100 of 0.3 µM. The 
effects of heparin were followed closely by Ac-(D)Phe-Pro-boroArg-OH (CT100: 2.1 µM) 
and then by argatroban (CT100: 3.7 µM), D-MePhe-Pro-Arg-H (CT100 : 11.2 µM), Boc-D-
Phe-Pro-Arg-H (CT100: 23.8 µM) and lastly by D-Phe-Pro-Arg-H (CT100: 21.4 µM). The 
individual clotting times for each thrombin inhibitor concentration point are reported in 
Tables 161 - 16n. 
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Fig. 29. Comparative anticoagulant effects of various agents, after supplementation to 
NHP, as studied in the Heptest. (•) D-Phe-Pro-Arg-H, (O) D-MePhe-Pro-Arg-H, (•) 
Boc-D-Phe-Pro-Arg-H, (.t.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, 
(+)heparin. Each point represents a mean ± 1 SD of three individual determinations. 
The individual values at each concentration point and their gravimetric equivalents are 
given in Tables 161-16n. 
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E. Anticoagulant Effects of Thrombin Inhibitors in Normal Human Whole Blood 
The coagulation process in vivo takes place in whole blood, so that in addition to 
the coagulation factors present in plasma, the rest of the blood components, such as 
platelets and white cells may also play a role in the clotting process. To investigate the 
anticoagulant activities of thrombin inhibitors in normal human whole blood, the ACT 
and TEG were utilized to compare D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH, 
argatroban, hirudin and heparin. Freshly drawn blood samples were supplemented in 
vitro with various concentrations of thrombin inhibitors prior to studying their effects in 
these assay systems. 
1. Activated Clotting Time (ACT) 
The results of the concentration-dependent anticoagulant activities of thrombin 
inhibitors in whole blood, as studied in the ACT, are depicted in Fig. 30. Ac-(D)Phe-
Pro-boroArg-OH, hirudin and heparin produced similar concentration-dependent pattern 
of prolongation of the ACT with a prolongation of this assay to 300-370 sec at 
concentrations of 1 µM. D-MePhe-Pro-Arg-H and argatroban had weak anticoagulant 
activities even at the highest concentration, producing a prolongation of the ACT to 150-
180 sec at 1 µM concentrations. The individual clotting times for each inhibitor 
concentration are reported in Table 160. 
2. Thrombelastographic Analysis (TEG) 
The results of the concentration-dependent anticoagulant activities of thrombin 
inhibitors in whole blood, as studied in the TEG, are depicted in Fig. 31. As seen in this 
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Fig. 30. Comparative anticoagulant effects of thrombin inhibitors, after supplementation 
to normal human whole blood, as detected in the ACT assay. (•) D-MePhe-Pro-Arg-H, 
(•) Ac-(D)Phe-Pro-boroArg-OH, (T) argatroban, (•) hirudin, (+)heparin. Each point 
represents a mean ± 1 SD of three individual determinations. The individual values at 
each concentration point and their gravimetric equivalents are given in Table 160. 
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Fig. 31. Comparative anticoagulant effects of thrombin inhibitors, after supplementation 
to normal human whole blood, as studied in the TEG assay. (•) D-MePhe-Pro-Arg-H, 
(•) Ac-(D)Phe-Pro-boroArg-OH, (T) argatroban, (•) hirudin, (+)heparin. Each point 
represents a mean ± 1 SD of three individual determinations. The individual values at 
each concentration point and their gravimetric equivalents are given in Table 16p. 
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profile, D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin 
produced similar concentration-dependent pattern of prolongation of the r value of the 
TEG (38-47 mm) at equimolar concentrations (0.1 µM). Argatroban had weak 
anticoagulant activities even at the highest concentration, producing a prolongation of the 
TEG r value to 31 mm at 1 µM. The individual TEG r values for each inhibitor 
concentration are reported in Table 16p. 
F. Anticoagulant Effects of Thrombin Inhibitors in NRP 
Human plasma and rabbit plasma differ in their composition and the relative 
levels of clotting factors. Since it was shown in the biochemical studies that each 
thrombin inhibitor had a distinct pattern of inhibition of serine proteases and generation 
assays, it was reasonable to assume that the anticoagulant effects of these inhibitors 
would differ depending on the plasma origin. Therefore, to compare the in vitro 
anticoagulant effects of thrombin inhibitors, based on the inhibition of thrombin clotting 
activity in the following global clotting tests, D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-
boroArg-OH, hirudin and heparin were supplemented to normal rabbit plasma. As with 
the NHP tests, each assay was based on the specific activation of the coagulation system, 
thus providing different insights into the inhibitory actions of these thrombin inhibitors. 
To compare the anticoagulant effects of thrombin inhibitors in these assay systems, the 
concentrations of each inhibitor that resulted in prolongation of the clotting time to 100 
sec (CT100) was calculated and compiled in Table 17. 
Table 17 -- Comparative anticoagulant effects of thrombin inhibitors in NRP. 
Concentrations that prolong clotting time to 100 sec in [µM] 
PT APTT TT Heptest 
D-MePhe-Pro-Arg-H 107 ± 4 4.8 ± 0.4 4.5 ± 0.4 3.3 ± 0.2 
Ac-(D )Phe-Pro-boroArg-OH >20.1 0.52 ± 0.08 1.0 ± 0.2 1.1 ± 0.1 
Hirudin 3.6 ± 0.4 0.7 ± 0.1 0.18 ± 0.02 0.24 ± 0.03 
Heparin >9.3 0.38 ± 0.10 0.18 ± 0.02 0.27 ± 0.06 
Each value represents the mean ± 1 SD of three separate determinations. In the PT assay, values produced 
by D-MePhe-Pro-Arg-H and hirudin were significantly different from each other. In the APTT assay, the value 
produced by D-MePhe-Pro-Arg-H was significantly different from those produced by the other thrombin 
inhibitors. In the 10 U ca++TT assay, values produced by all thrombin inhibitors were significantly different 
from each other, with the exception of the hirudin vs heparin comparison. In the Heptest assay, as in the TT 
assay, values produced by all thrombin inhibitors were significantly different from each other, with the 
exception of the hirudin vs heparin comparison. (p <0.05, ANOVA followed by Student-Newman-Keuls test). 
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1. Prothrombin Time (PT) 
In the PT assay, thromboplastin added to NRP activated the coagulation cascade 
extrinsically (starting with factor VII), leading to thrombin formation which resulted in 
clot formation. The inhibitory activities of antithrombin agents in this assay are depicted 
in Fig. 32, panel A. Heparin and Ac-(D)Phe-Pro-boroArg-OH had minimal effects in 
this assay at high concentrations: heparin produced a pt of 17 sec at 9.4 µM, while Ac-
(D)Phe-Pro-boroArg-OH produced a PT of 24 sec at 20 µM. When comparing the 
concentrations of each thrombin inhibitor that resulted in prolongation of the clotting time 
to 100 sec, given in Table 17, it was found that the most potent inhibitor of the PT was 
hirudin (CT100: 3.6 µM) followed by D-MePhe-Pro-Arg-H (CT100 : 107 µM). Both 
hirudin and D-MePhe-Pro-Arg-H appeared to have an all-or-none effects on the PT. The 
individual clotting times for each thrombin inhibitor concentration point are reported in 
Table 17a. 
2. Activated Partial Thromboplastin Time (APTT) 
In the APTT, a contact activator mixture added to NRP activated the coagulation 
cascade intrinsically (starting with factor XII), leading to thrombin formation which 
resulted in clot formation. The inhibitory activities of thrombin inhibitors in this test 
were concentration-dependent, as seen in Fig. 32, panel B. Table 17 depicts the 
concentrations of each agent that resulted in prolongation of the clotting time to 100 sec. 
In comparing the CT 100 value for each antithrombin agent, it was found that the most 
potent inhibitor of the APTT was heparin (CT100: 0.4 µM) followed by closely by Ac-
(D)Phe-Pro-boroArg-OH (CT100: 0.5 µM), hirudin (CT100: 0.7 µM) and lastly by D-
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Fig. 32. Comparative anticoagulant effects of thrombin inhibitors, after supplementation 
to normal rabbit plasma, as studied in the global clotting tests. Panel A represents the 
effects of antithrombin agents in the PT assay. The individual values at each 
concentration point and their gravimetric equivalents are given in Table 17a. Panel B 
represents the effects of various agents in the APTT assay. The individual values at each 
concentration point and their gravimetric equivalents are given in Table 17b. Panel C 
represents the effects of agents in the TT assay. The individual values at each 
concentration point and their gravimetric equivalents are given in Table 17c. Panel D 
represents the effects of antithrombin agents in the Heptest. The individual values at 
each concentration point and their gravimetric equivalents are given in Table 17d. ( •) 
D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-Pro-boroArg-OH, (•) hirudin, (+)heparin. Each 
point represents a mean ± 1 SD of three individual determinations. 
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MePhe-Pro-Arg-H (CT100: 4.8 µM). The individual clotting times for each thrombin 
inhibitor concentration point are reported in Table 17b. 
3. Thrombin Time (TT) 
In the TT, thrombin added to NRP directly converted the existing fibrinogen to 
fibrin clots. Furthermore, the added thrombin activated the coagulation cascade at 
multiple points (extrinsically via factors VII and V, intrinsically via factor XI and 
common pathway via factor VIII), leading to additional thrombin formation which 
resulted in clot formation. Fig. 32, panel C, represents the inhibitory activities of 
antithrombin agents. In this assay, all agents produced a concentration-dependent 
prolongation of the PT. When comparing the concentrations of each thrombin inhibitor 
that resulted in prolongation of the clotting time to 100 sec, reported in Table 17, it was 
found that the most potent inhibitor of the TT was hirudin (CT100 : 0.18 µM) followed 
closely by heparin (CT100 : 0.18 µM). However, prolongation of the TT to over 300 sec 
was achieved with a lower concentration of heparin (0.47 µM) than of hirudin (0. 72 
µM). The effects of heparin were followed by Ac-(D)Phe-Pro-boroArg-OH (CT100 : 1 
µM) and then by D-MePhe-Pro-Arg-H (CT100: 4.5 µM). The individual clotting times 
for each thrombin inhibitor concentration point are reported in Table 17c. 
4. Heptest 
In the Heptest, factor Xa added to NRP activated the common pathway which lead 
to thrombin formation with subsequent fibrinogen conversion to fibrin clots. The 
inhibitory activities of antithrombin agents in this assay system were concentration-
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dependent, as seen in Fig. 32, panel D. Table 17 reports the concentrations of each 
thrombin inhibitor that resulted in prolongation of the clotting time to 100 sec. When 
comparing the CT 100 in this assay, it was found that the most potent inhibitors of the 
Heptest were heparin (CT100 : 0.27 µM) and hirudin (CT100: 0.24 µM), which exhibited 
similar effects at the same concentrations. The effects of heparin and hirudin were 
followed by Ac-(D)Phe-Pro-boroArg-OH (CT100: 1.1 µM) and then by D-MePhe-Pro-
Arg-H (CT100: 3.3 µM). The individual clotting times for each thrombin inhibitor 
concentration point are given in Table 17d. 
G. Anticoagulant Effects of Thrombin Inhibitors in Normal Rabbit Whole Blood 
Since the concentration of plasma factors differ depending on the species utilized, 
the thrombin inhibitors D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin and 
heparin were also supplemented to freshly drawn rabbit whole blood, to compare their 
anticoagulant effects to each other and to their respective effects in the normal human 
whole blood assays. The effects of these agents in the ACT and TEG assays were 
studied. 
1. Activated Clotting Time (ACT) 
The results of the anticoagulant activities of thrombin inhibitors in rabbit whole 
blood, as studied in the ACT, are depicted in Fig. 33. Ac-(D)Phe-Pro-boroArg-OH, 
hirudin and heparin produced similar prolongation of the ACT at the concentrations 
utilized, exhibiting a prolongation of the ACT of 180-230 sec from the baseline, at 
concentrations of 201, 144 and 187 nM respectively. D-MePhe-Pro-Arg-H had the 
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Fig. 33. Comparative anticoagulant effects of various agents, after supplementation to 
normal rabbit whole blood, as studied in the ACT assay. (D) D-MePhe-Pro-Arg-H at 
389 nM, ( =) Ac-(D)Phe-Pro-boroArg-OH at 201 nM, (-#-#-) hirudin at 144 nM, (•) 
heparin at 235 nM. Each point represents a mean ± 1 SD of three individual 
determinations. The individual values at each concentration point and their gravimetric 
equivalents are given in Table 17e. 
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Fig. 34. Comparative anticoagulant effects of various agents, after supplementation to 
normal rabbit whole blood, as studied in the TEG assay. (D) D-MePhe-Pro-Arg-H at 
389 nM, ( =) Ac-(D)Phe-Pro-boroArg-OH at 201 nM, (-#-#-) hirudin at 144 nM, (•) 
heparin at 235 nM. Each point represents a mean ± 1 SD of three individual 
determinations. The individual values at each concentration point and their gravimetric 
equivalents are given in Table 17f. 
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weakest anticoagulant activities, producing only a 92 sec prolongation of the ACT from 
the baseline at a concentration of 389 nM. The individual clotting times for each 
thrombin inhibitor are reported in Table 17e. 
2. Thrombelastographic Analysis (TEG) 
The results of the anticoagulant activities of thrombin inhibitors in whole rabbit 
blood, as studied in the TEG, are depicted in Fig. 34. D-MePhe-Pro-Arg-H produced 
similar prolongation of the TEG r value as Ac-(D)Phe-Pro-boroArg-OH and hirudin. 
This prolongation was 30-40 mm from the baseline value at 389, 201 and 144 µM 
respectively by the three thrombin inhibitors. Heparin produced the strongest 
prolongation of the r value of the TEG, to > 200 mm at a concentration of 187 nM. The 
individual TEG r values for each thrombin inhibitor are reported in Table 17f. 
H. Antithrombotic Effects of Thrombin Inhibitors as Studied in the 
Rabbit Stasis Thrombosis Model 
The Wessler stasis thrombosis model (Wessler et al. 1959) is a rabbit model of venous 
thrombosis and has been widely used in the evaluation of antithrombotic activity of 
various substances. Although this model has provided useful information on the 
antithrombotic activities of various anticoagulant agents, the results obtained are relative 
to the type of thrombogenic challenge used to produce the thrombotic processes. Defined 
thrombogenic agents to activate the hemostatic system of rabbits have been previously 
utilized in a standardized manner where the site of activation is controlled (Fareed et al. 
1985). In previous studies specific components of the hemostatic system were selectively 
activated with various agents such as Prothrombin Complex Concentrate (PCC) and 
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Russell's Viper Venom (RVV) (Fareed et al. 1985). However, additional activation of 
other enzymes and the presence of protein C in these activation mixtures may influence 
the results. The availability of TF in a recombinant form (Bach et al. 1986) allows for 
a specific investigation of thrombogenesis and its pathophysiological mechanisms. In this 
study, the objective was to characterize r-TF in terms of its thrombogenicity in a 
standardized model of stasis thrombosis and subsequently to compare the antithrombotic 
potential of thrombin inhibitors following I.V. or S.C. administration. In addition, the 
duration of the antithrombotic effects of thrombin inhibitors was also studied. 
Representative thrombin inhibitors compared in this model were D-MePhe-Pro-Arg-H, 
Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin. 
1. Standardization of the Rabbit Stasis Thrombosis Model 
In these studies, r-TF was injected at various doses in the procedure described in 
Chapter III, Section I. 1. After I.V. injection of r-TF, at 1.351, 0.676, 0.338, 0.169 
and 0.042 pmol/kg, followed by a 20 sec circulation time, the jugular vein segments of 
the rabbit were isolated and after 10 and 20 minutes of stasis, each of the jugular vein 
segments was dissected and the contained clots were graded on a previously established 
scale from 0 to +4 (Fareed et al. 1986). Blood samples were collected at baseline and 
after r-TF injection, for ex vivo whole blood and plasma analyses. Six rabbits were 
studied at each r-TF dose. 
a. Clot Score Analyses 
Injection of r-TF produced dose-dependent thrombotic effects, as depicted in Fig. 
210 
35. At doses of 1.35 pmol/kg the clot scores obtained were always maximal ( +4) at 
both the 10 minute and the 20 minute endpoints. The estimated ED50 from this curve for 
r-TF was about 0.34 and 0.4 pmol/kg for the 10 and 20 min stasis respectively. At 
doses as low as 42.3 fmol/kg there was always a clot of at least + 1 observed after a 20 
minute stasis time. When saline was used in place of r-TF in this procedure, there were 
no clots observed (clot score=O). A dose of 0.68 pmol/kg consistently resulted in clot 
scores of at least + 3. This was the dose selected for assessing the antithrombotic effects 
of thrombin inhibitors in this model in the following studies. The clot score value for 
each r-TF dose for both the 10 and 20 min stasis time are given in Table 18. 
Table 18 -- Standardization of the rabbit model of jugular vein stasis 
thrombosis, with r-TF: dose-dependent thrombotic effects of r-TF after 
I.V. injection, 20 sec circulation, after 10 and 20 min stasis. 
Clot Score 
Dose Dose 10 min stasis 20 min stasis 
ng/kg pmol/kg 
50 1.351 4.0±0.0 4.0±0.0 
25 0.676 3.2±0.2 3.6±0.3 
12.5 0.338 1.7±0.6 2.0±0.0 
6.25 0.169 1.2±0.4 1.8±0.4 
1.56 0.042 1.0±0.0 1.5±0.0 
0 0 0.0±0.0 0.0±0.0 
Each value represents the mean ± SEM of 6 independent determinations. 
b. Ex Vivo Analyses of Plasma and Whole Blood Samples 
The ex vivo effect of r-TF on the protease inhibition profile of rabbit plasma as 
studied by the antithrombin and anti-Xa amidolytic methods did not reveal any detectable 
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Fig. 35. Dose-dependent thrombotic effects of r-TF as studied in the rabbit model of 
jugular vein stasis thrombosis. r-TF was administered through I.V. injection and allowed 
to circulate for 20 sec prior to ligation of the jugular segments. ( •) represent clot scores 
obtained after 10 minutes stasis, ( o) represent clot scores obtained after 20 min stasis. 
Each point represents a mean ± S.E.M. (n=6). * denotes statistical significance 
(p < 0. 05) when compared to control (saline produced 0. 0 ± 0. 0, both after 10 and 20 
min stasis) as analyzed with the Kruskal-Wallis test. The individual clot score values at 
each rTF dose and their gravimetric equivalents are given in Table 18. 
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antithrombin or anti-Xa activity at any of the doses of r-TF administered. However, as 
shown in Fig. 36, comparison of the ACT values of samples obtained at baseline and 5 
minutes after r-TF administration, revealed a prolongation of the ACT. This 
prolongation was dose-dependent, which was significant at r-TF doses of 0. 68 pmol/kg 
or greater. However, at doses below 0.34 pmol/kg there was no prolongation in the 
ACT. 
Fig. 37 depicts the comparison of the measured r distance on the TEG of samples 
obtained from the rabbits which had undergone the stasis model before and after the 
administration of r-TF at various doses. A clear dose-dependent prolongation of the TEG 
r duration occurred, which became significant when a 1. 35 pmol/kg dose was 
administered. The other TEG parameters (k, rk and angle) also exhibited a parallel 
prolongation to the r value (data not shown). 
When the plasma samples collected before and after r-TF injection were 
compared, r-TF had no effects on any of the global clotting tests, as seen in Fig. 38. 
r-TF did not exhibit any effect on the PT of rabbit plasma when administered in vivo at 
doses as high as 1.35 pmol/kg, as seen in Fig. 38, panel A. Panel B of Fig. 38 depicts 
the results from the APTT analysis of the samples obtained from the stasis thrombosis 
experiments. The in vivo administration of r-TF did not appear to have any effect on the 
APTT at doses up to 1.35 pmol/kg. Similar results to those from the PT and APTT (i.e. 
no difference between baseline and post r-TF injection) were obtained from the ex vivo 
Heptest analysis of the blood samples obtained during the stasis thrombosis experiments 
(Fig. 38, panel C). In addition, r-TF appeared to have no effect on the TT profile when 
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Fig. 36. Dose-dependent pro-coagulant ex vivo effects of r-TF as studied in the rabbit 
model of jugular vein stasis thrombosis, utilizing the ACT assay. Blood samples were 
collected prior to r-TF injection and 5 min following r-TF injection. Each point 
represents a mean of the difference between baseline and post-r-TF values for each rabbit 
+ S.E.M. (n=6 at each dose). 
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Fig. 37. Dose-dependent pro-coagulant ex vivo effects of r-TF as studied in the rabbit 
model of jugular vein stasis thrombosis, utilizing the TEG assay. Blood samples were 
collected prior to r-TF injection and 5 min following r-TF injection. Each point 
represents a mean of the difference between baseline and post-r-TF values for each rabbit 
+ S.E.M. (n=6 at each dose). 
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Fig. 38. Dose-dependent pro-coagulant ex vivo effects of r-TF as studied in the rabbit 
model of jugular vein stasis thrombosis. Blood samples were collected prior to r-TF 
injection and 5 min following r-TF injection. Panel A depicts the results of the PT 
analysis. Panel B depicts the results from the APTT analysis. Panel C depicts the 
results of the Heptest analysis. Panel D depicts the results of the TT analysis. Each 
point represents a mean of the difference between baseline and post-r-TF values for each 
rabbit ± S.E.M. (n=6 at each dose). 
administered at doses as high as 1.35 pmol/kg (Fig. 38, panel D). 
2. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors 
After I. V. Administration at a Fixed Time Point 
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From the above standardization studies, an r-TF dose of 0.68 pmol/kg was chosen 
for the standard procedure as the thrombogenic source in this rabbit jugular vein stasis 
thrombosis model. The antithrombotic effects of D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-
boroArg-OH, hirudin and heparin were compared in a dose-dependent manner, after I.V. 
injection and after a 5 min circulation time prior to injection of r-TF. Twenty sec after 
injection of r-TF, the jugular segments of the rabbit were isolated and after 10 and 20 
minutes of stasis, each jugular segment was dissected and the contained clots were 
analyzed on a previously established scale from 0 to +4 (Fareed et al. 1986). Blood 
samples were collected at baseline and 5 min after thrombin inhibitor injection (prior to 
r-TF injection), for ex vivo whole blood and plasma analyses. Six rabbits were studied 
at each thrombin inhibitor dose. 
a. Clot Score Analyses 
Injection of all four thrombin inhibitors produced dose-dependent antithrombotic 
effects, after 10 and 20 min stasis time, in a dose range of 0.001 to 2 µmol/kg, as 
depicted in Fig. 39, panels A and B respectively. The strongest antithrombotic agent 
appeared to be heparin at doses in the nmol/kg range, both after 10 and 20 min stasis 
time, with ED50s of 0.008 and 0.009 µmol!kg respectively. The effects of heparin were 
closely followed by those of hirudin, with ED50s of 0.003 and 0.11 µmol/kg respectively. 
After 20 min stasis time, the antithrombotic effects of heparin and hirudin were 
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Fig. 39. Comparative dose-dependent antithrombotic effects of various agents as studied 
in the rabbit model of jugular vein stasis thrombosis. Each thrombin inhibitor was 
administered through I. V. injection and circulated for 5 minutes prior to initiation of the 
stasis procedure. The results depicted in panel A represent clot scores obtained after 10 
minutes stasis. The results depicted in panel B represent clot scores obtained after 20 
min stasis. (•) D-MePhe-Pro-Arg-H, (•) Ac-D-Phe-Pro-boroArg-OH, (•) hirudin, ( +) 
heparin. Each point represents a mean ± S.E.M. (n=6). * denotes statistical 
significance (p < 0.05) when compared to control (3.2 ± 0.2 after 10 min stasis in panel 
A, 3.6 ± 0.3 after 20 min stasis in panel B), as analyzed with the Kruskal-Wallis test. 
The individual clot score values at each antithrombin agent dose and their gravimetric 
equivalents at both the 10 and 20 min stasis end points are given in Tables 19a-19b. 
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superimposable at doses higher than 0.01 µmol/kg. The effects of heparin and hirudin 
were followed by those of Ac-(D)Phe-Pro-boroArg-OH, with ED50s of 0.032 and 0.045 
µmol/kg after 10 and 20 min stasis. D-MePhe-Pro-Arg-H was the weakest 
antithrombotic agent after both 10 and 20 min stasis time, with ED50s of 0.242 and 1.60 
µmol/kg respectively. The estimated ED50 from each thrombin inhibitor dose-response 
curve is reported in Table 19. The clot score value for each thrombin inhibitor dose 
after 10 and 20 min stasis time are found in Tables 19a - 19d. 
Table 19 -- Comparative antithrombotic potencies of thrombin inhibitors 
after I. V. injection as determined in the rabbit model of jugular vein stasis 
thrombosis. 
D-MePhe-Pro-Arg-H 
Ac-D-Phe-Pro-boroArg-OH 
Hirudin 
Heparin 
Dose of each agent that results in a clot 
score of + 2 in [µmol/kg]. 
10 min stasis time 20 min stasis time 
0.242 1.60 
0.032 0.045 
0.003 0.011 
0.008 0.009 
Each value represents a single determination from the respective dose-
response curve depicted in Fig. 39. 
b. Ex Vivo Analyses of Plasma and Whole Blood Samples 
Fig. 40 depicts the ex vivo effect of thrombin inhibitors on the protease inhibition 
profile of rabbit plasma as studied by the antithrombin and anti-Xa amidolytic methods 
revealing dose-dependent antithrombin effects but only minimal anti-Xa activities. Even 
at the highest doses administered, most of these agents produced only weak anti-Xa 
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Fig. 40. Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after I.V. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 5 min post agent injection (prior to r-TF). Panel A depicts 
the results of the amidolytic antithrombin analysis. Panel B depicts the results from the 
amidolyticanti-Xaanalysis. (•) D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-Pro-boroArg-OH, 
(•) hirudin, ( +) heparin. Each point represents a mean of the difference between 
baseline and post-agent values for each rabbit ± S.E.M. (n=6 at each dose, for each 
agent). 
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Fig. 41. Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after I. V. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 5 min post agent injection (prior to r-TF). Panel A depicts 
the results from the ACT analysis. Panel B depicts the results from the TEG r analysis. 
(•) D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-Pro-boroArg-OH, (•) hirudin, (+)heparin. 
Each point represents a mean of the difference between baseline and post-agent values 
for each rabbit ± S.E.M. (n=6 at each dose, for each agent). 
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actions. While heparin produced the strongest antithrombotic effects, as assessed by the 
clot scores, hirudin produced the most potent antithrombin effects. As in the clot score 
profiling, Ac-(D)Phe-Pro-boroArg-OH, relatively weaker than heparin and hirudin, it 
produced slightly stronger antithrombin effects in comparison to D-MePhe-Pro-Arg-H. 
A comparison of the ACT values of samples obtained at baseline and 5 minutes 
after thrombin inhibitor injection, depicted in Fig. 41 panel A, showed a dose-dependent 
prolongation of the ACT, for all thrombin inhibitors, in a pattern parallel to the one 
emerging from the clot scores. The strongest prolongation of the ACT was produced by 
heparin producing a 600 sec ACT prolongation from the baseline value at a dose of 
0.023 µmol/kg, followed by hirudin, Ac-(D)Phe-Pro-boroArg-OH and then D-MePhe-
Pro-Arg-H. While Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H produced 
similar prolongation of the ACT at the highest dose used to that of heparin, hirudin 
resulted in only a 300 sec prolongation at the highest dose injected. 
Fig. 41, panel B, depicts the comparison of the measured r distance on the TEG 
of samples obtained from the rabbits which underwent the stasis model before and after 
the administration of antithrombin agents at various doses. Dose-dependent prolongation 
of the TEG r duration occurred with all thrombin inhibitors, in a pattern similar to the 
ACT and to the clot score profile. At the highest doses injected, heparin produced the 
longest prolongation of the TEG r value, followed by Ac-(D)Phe-Pro-boroArg-OH, D-
MePhe-Pro-Arg-H and lastly by hirudin. 
When the plasma samples collected before and after thrombin inhibitor injection 
were compared, global clotting test-dependent results were obtained, as seen in Fig. 42. 
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Fig. 42. Dose-dependent ex vivo anticoagulant effects of antithrombin agents after I.V. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 5 min post agent injection (prior to r-TF). Panel A depicts 
the results of the PT analysis. Panel B depicts the results from the APTT analysis. 
Panel C depicts the results from the Heptest analysis. Panel D depicts the results from 
the TT analysis. (•) D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-Pro-boroArg-OH, (•) 
hirudin, ( +) heparin. Each point represents a mean of the difference between baseline 
and post-agent values for each rabbit ± S.E.M. (n=6 at each dose, for each agent). 
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None of the thrombin inhibitors had any effects on the PT of rabbit plasma, even at the 
highest dose injected, as seen in Fig. 42, panel A. The panel B of Fig. 42 depicts the 
results from the APTT analysis and comparison of the samples obtained from these stasis 
thrombosis experiments. The in vivo administration of heparin and D-MePhe-Pro-Arg-H 
did not appear to have any effect on the APTT, even at the highest doses injected. 
Hirudin and Ac-(D)Phe-Pro-boroArg-OH produced mild dose-dependent prolongation of 
the APTT. When the plasma samples collected before and after the injection of thrombin 
inhibitors were compared in the Heptest assay (Fig. 42, panel C), it was found that all 
agents produced dose-dependent prolongation of the Heptest. In the Heptest, heparin 
appeared to produce more potent anticoagulant effects than hirudin, followed by Ac-
(D) Phe-Pro-boroArg-0 H and then by D-MePhe-Pro-Arg-H. When the same plasma 
samples were compared in the TT (Fig. 42, panel D), all thrombin inhibitors produced 
a prolongation of the TT. Hirudin produced the most potent prolongation of the TT, 
followed closely by heparin, then by Ac-(D)Phe-Pro-boroArg-OH and lastly by D-
MePhe-Pro-Arg-H. While hirudin at the highest dose injected produced weaker 
antithrombotic activities than heparin and Ac-(D)Phe-Pro-boroArg-OH at their highest 
doses, hirudin produced the longer prolongation of the TT than the other two compounds. 
Furthermore, while D-MePhe-Pro-Arg-H at the highest dose injected produced similar 
antithrombotic effects to those of heparin and Ac-(D)Phe-Pro-boroArg-OH at the highest 
dose injected, the prolongation of the TT was longer with D-MePhe-Pro-Arg-H (about 
15 fold increase from baseline) than with heparin and Ac-(D)Phe-Pro-boroArg-OH (about 
5 fold increase from baseline). 
3. Duration of Antithrombotic Effects of Thrombin Inhibitors 
After I. V. Administration at a Fixed Dose 
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To determine the time-dependance of the antithrombotic effects of the thrombin 
inhibitors studied in this rabbit stasis thrombosis model after I.V. administration, the dose 
of each agent that produced sub-maximal antithrombotic effects was selected and studied 
at different circulation times, prior to injecting r-TF as described above. The dose of 
each thrombin inhibitor studied was: D-MePhe-Pro-Arg-H at 1.942 µmol/kg, Ac-(D)Phe-
Pro-boroArg-OH at 0.101 µmol/kg, hirudin at 0.036 µmollkg and heparin at 0.023 
µmol/kg. The circulation time points selected for studying the antithrombotic effects of 
these thrombin inhibitors at these doses were 5, 30, 60 and 90 min (prior to r-TF 
injection). Six rabbits were tested at each time point for each thrombin inhibitor. Blood 
draws were performed at baseline and prior to r-TF injection (5 or 30 or 60 or 90 min 
post thrombin inhibitor injection) and utilized in the ex vivo whole blood and plasma 
analyses. 
a. Clot Score Analyses 
Intravenous administration of all four thrombin inhibitors produced time-dependent 
antithrombotic effects, as depicted in Fig. 43, after 10 and 20 min stasis time, panels A 
and B respectively. The thrombin inhibitor which lost its antithrombotic activities at the 
fastest rate was Ac-(D)Phe-Pro-boroArg-OH (t1h about 20 min post I.V. injection, after 
both the 10 and 20 min stasis time), followed by heparin (t1h around 40 min and 25 min 
post I.V. injection, after the 10 and 20 min stasis respectively) and then by D-MePhe-
Pro-Arg-H (tl/z around 60 min and 45 min post I.V. injection after the 10 and 20 min 
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Fig. 43. Time dependance of antithrombotic effects of various agents in the rabbit model 
of jugular vein stasis thrombosis. Each agent was administered through I.V. injection 
and allowed to circulate for varying time periods prior to initiation of the stasis 
procedure. The results depicted in panel A represent clot scores obtained after 10 
minutes stasis. The results depicted in panel B represent clot scores obtained after 20 
min stasis. (•) D-MePhe-Pro-Arg-H at 1.942 µmol/kg, (•) Ac-D-Phe-Pro-boroArg-OH 
at 0.101 µmol/kg, (•) hirudin at 0.036 µmol/kg, (+)heparin at 0.023 µmol/kg. Each 
point represents a mean± S.E.M. (n=6). *denotes statistical significance (p<0.05) 
when compared to control (3.2 ± 0.2 after 10 min stasis in panel A, 3.6 + 0.3 after 20 
min stasis in panel B), as analyzed with the Kruskal-Wallis test. The individual clot 
score values for each thrombin inhibitor at each time point at both the 10 and 20 min 
stasis end points are given in Tables 19e-19f. 
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stasis respectively). Hirudin also exhibited a gradual diminution of its antithrombotic 
activities at the slowest rate ( t1h around 75 min and 65 min post I. V. injection, after 10 
and 20 min stasis respectively). The clot score values for each thrombin inhibitor at each 
circulation time are found in Tables 19e and 19f, following 10 and 20 min stasis 
respectively. 
b. Ex Vivo Analyses of Plasma and Whole Blood Samples 
The ex vivo effect of thrombin inhibitors on the protease inhibition profile of 
rabbit plasma as studied by the antithrombin and anti-Xa amidolytic methods revealed 
time-dependent antithrombin effects but minimal anti-Xa activities, as can be seen in Fig. 
44, panels A and B respectively. The antithrombin effects of heparin were minimal as 
well. D-MePhe-Pro-Arg-H and hirudin produced an antithrombin pattern indicating peak 
antithrombin activity at 30 min post I. V. injection, in contrast to their time-dependent 
antithrombotic profile, in which their peak antithrombotic activities were observed 5 min 
after I.V. injection. The antithrombin activities of Ac-(D)Phe-Pro-boroArg-OH were 
steadily lost with time. 
Comparison of the ACT values of samples obtained at baseline and 5, 30, 60 and 
90 min after thrombin inhibitor injection, depicted in Fig. 45, panel A, revealed a time-
dependent prolongation of the ACT, for all antithrombin agents, in a pattern parallel to 
the one emerging from the clot score time-dependent profile. The thrombin inhibitors 
that lost their ACT prolongation effects at the fastest rate were Ac-(D)Phe-Pro-boroArg-
OH and heparin, followed by D-MePhe-Pro-Arg-H. Hirudin lost its ACT prolongation 
effects at the slowest rate. 
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Fig. 44. Time-dependent ex vivo anticoagulant effects of thrombin inhibitors after I. V. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 5 min prior to r-TF injection. Panel A depicts the results of 
the amidolytic antithrombin analysis. Panel B depicts the results from the amidolytic 
anti-Xa analysis. (•) D-MePhe-Pro-Arg-H at 1.942 µmollkg, (•) Ac-(D)Phe-Pro-
boroArg-OH at 0.101 µmol/kg, (•) hirudin at 0.036 µmollkg, ( +) heparin at 0.023 
µmollkg. Each point represents a mean of the difference between baseline and post-agent 
values for each rabbit ± S.E.M. (n=6 at each time point, for each agent). 
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Fig. 45. Time-dependent ex vivo anticoagulant effects of thrombin inhibitors after I.V. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 5 min prior to r-TF injection. Panel A depicts the results 
from the ACT analysis. Panel B depicts the results from the TEG r analysis. (•) D-
MePhe-Pro-Arg-H at 1.942 µmollkg, (•) Ac-(D)Phe-Pro-boroArg-OH at0.101 µmollkg, 
(•) hirudin at 0.036 µmol/kg, (+)heparin at 0.023 µmollkg. Each point represents a 
mean of the difference between baseline and post-agent values for each rabbit ± S.E.M. 
(n=6 at each time point, for each agent). 
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Fig. 45, panel B, depicts the comparison of the measured r distance on the TEG 
of samples obtained from the rabbits which underwent the stasis model before and after 
the administration of thrombin inhibitors at various blood sampling times. Time-
dependent prolongation of the TEG r value was observed with all thrombin inhibitors, 
in a pattern parallel to the one emerging from the clot score time-dependent profile and 
the ACT profile. The thrombin inhibitor that lost its TEG prolongation effects at the 
fastest rate was Ac-(D)Phe-Pro-boroArg-OH, followed by heparin and then by D-MePhe-
Pro-Arg-H. Hirudin lost its TEG prolongation effects at the slowest rate. 
When the plasma samples collected before and 5, 30, 60 and 90 min after 
thrombin inhibitor injection were compared, global clotting test-dependent and time-
dependent results were obtained, as seen in Fig. 46. None of the thrombin inhibitors had 
any effects on the PT of rabbit plasma as seen in Fig. 46, panel A. Panel B of Fig. 46 
depicts the results from the APTT analysis and comparison of the samples obtained from 
these stasis thrombosis experiments. While the in vivo administration of heparin and D-
MePhe-Pro-Arg-H did not appear to have any effect on the APTT, the anticoagulant 
effects produced by hirudin and Ac-(D)Phe-Pro-boroArg-OH were time-dependent. 
When the plasma samples collected before and after the injection of thrombin inhibitors 
were compared in the Heptest assay (Fig. 46, panel C), it was found that all thrombin 
inhibitors produced time-dependent prolongation of the Heptest. While the anticoagulant 
effects in the Heptest assay steadily decreased with time for Ac-(D)Phe-Pro-boroArg-OH, 
hirudin and heparin, D-MePhe-Pro-Arg-H appeared to produce peak anticoagulant 
activities abut 30 min post I.V. injection, similarly to its effects in the antithrombin 
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Fig. 46. Time-dependent ex vivo anticoagulant effects of antithrombin agents after I. V. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 5 min prior to r-TF injection (post-thrombin inhibitor 
injection for various circulating time periods). Panel A depicts the results of the PT 
analysis. Panel B depicts the results from the APTT analysis. Panel C depicts the 
results from the Heptest analysis. Panel D depicts the results from the TT analysis. (•) 
D-MePhe-Pro-Arg-H at 1.942 µmol/kg, (•) Ac-(D)Phe-Pro-boroArg-OH at 0.101 
µmollkg, (•) hirudin at 0.036 µmol/kg, ( +) heparin at 0.023 µmol/kg. Each point 
represents a mean of the difference between baseline and post-agent values for each 
rabbit ± S.E.M. (n=6 at each time point, for each agent). 
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assay. When the same plasma samples were compared in the TT (Fig. 46, panel D), all 
thrombin inhibitors produced a steadily declining time-dependent prolongation of the TT. 
The effects of D-MePhe-Pro-Arg-H were cleared at the fastest rate, in contrast to its 
time-dependent anti thrombotic effects. 
4. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors 
After S.C. Administration at a Fixed Time Point 
As in the above studies, a r-TF dose of 0. 68 pmol/kg was chosen for the standard 
procedure as the thrombogenic source in this rabbit jugular vein stasis thrombosis model. 
The anti thrombotic effects of D-MePhe-Pro-Arg-H, Ac-(D) Phe-Pro-boroArg-0 H, hirudin 
and heparin were compared in a dose-dependent manner, after S.C. injection and after 
a 45 min circulation time prior to injection of r-TF. Twenty sec after injection of r-TF, 
the jugular segments of the rabbit were isolated and after 10 and 20 minutes of stasis, 
each jugular segment was dissected and the contained clots were analyzed on a previously 
established scale from 0 to +4 (Fareed et al. 1986). Blood samples were collected at 
baseline and 45 min after thrombin inhibitor injection (prior to r-TF injection), for ex 
vivo whole blood and plasma analyses. Six rabbits were studied at each thrombin 
inhibitor dose. 
a. Clot Score Analyses 
Injection of all four thrombin inhibitors produced dose-dependent antithrombotic 
effects, after 10 and 20 min stasis time, as depicted in Fig. 47, panels A and B 
respectively. The most potent antithrombotic agent appeared to be hirudin at doses in 
the nmol/kg range, both after 10 and 20 min stasis time, with ED50s of 0.036 and 0.07 
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Fig. 47. Comparative dose-dependent antithrombotic effects of various agents as studied 
in the rabbit model of jugular vein stasis thrombosis. Each agent was administered 
through S.C. injection and allowed to circulate for 45 minutes prior to initiation of the 
stasis procedure. The results depicted in panel A represent clot scores obtained after 10 
minutes stasis. The results depicted in panel B represent clot scores obtained after 20 
min stasis. ( •) D-MePhe-Pro-Arg-H, ( •) Ac-D-Phe-Pro-boroArg-0 H, ( •) hirudin, ( + ) 
heparin. Each point represents a mean ± S.E.M. (n=6). * denotes statistical 
significance (p < 0. 05) when compared to control (3. 2 ± 0. 2 after 10 min stasis in panel 
A, 3.6 ± 0.3 after 20 min stasis in panel B), as analyzed with the Kruskal-Wallis test. 
The individual clot score values at each thrombin inhibitor dose and their gravimetric 
equivalents at both the 10 and 20 min stasis end points are given in Tables 20a-20d. 
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µmol/kg respectively. The effects of hirudin were followed by those of Ac-(D)Phe-Pro-
boroArg-OH (ED50s of 0.152 and 0.29 µmol/kg after 10 and 20 min stasis respectively) 
and heparin (ED50s od 0.185 and 0.25 µmol/kg respectively. After 20 min stasis time, 
the antithrombotic effects of Ac-(D)Phe-Pro-boroArg-OH and heparin were 
superimposable. Similar to the antithrombotic effects after I. V. administration, D-
MePhe-Pro-Arg-H was the weakest antithrombotic agent after both 10 and 20 min stasis 
time, with ED50s of 1.22 and 2.78 µmol/kg respectively. The estimated ED50 from each 
thrombin inhibitor dose-response curve is reported in Table 20. The clot score value for 
each thrombin inhibitor dose are found in Tables 20a - 20d, for the 10 and 20 min stasis 
time. 
Table 20 -- Comparative antithrombotic potencies of thrombin inhibitors 
after S.C. injection, as determined in the rabbit model of jugular vein 
stasis thrombosis. 
D-MePhe-Pro-Arg-H 
Ac-D-Phe-Pro-boroArg-OH 
Hirudin 
Heparin 
Dose of each agent resulting in a clot score 
of + 2 in [µmol/kg] 
10 min stasis time 20 min stasis time 
1.22 2.78 
0.152 0.29 
0.036 0.07 
0.185 0.25 
Each value represents a single determination from the respective dose-
response curves depicted in Fig. 47. 
b. Ex Vivo Analyses of Plasma and Whole Blood Samples 
The ex vivo effect of thrombin inhibitors on the protease inhibition profile of 
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rabbit plasma as studied by the antithrombin and anti-Xa amidolytic methods revealed 
dose-dependent antithrombin effects but minimal anti-Xa activities even at the highest 
doses administered, as can be seen in Fig. 48, panels A and B respectively. Hirudin 
produced the strongest antithrombin effects, which corresponded to the antithrombotic 
effects. As in the clot score profiling, Ac-(D)Phe-Pro-boroArg-OH produced the second 
most potent antithrombin effects, followed by heparin and lastly by D-MePhe-Pro-Arg-H. 
Even though all thrombin inhibitors produced similar antithrombotic effects at the highest 
doses used, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H produced a markedly 
higher antithrombin effects than hirudin and heparin. 
Comparison of the ACT values of samples obtained at baseline and 45 minutes 
after thrombin inhibitor S.C. injection, depicted in Fig. 49, panel A, revealed a dose-
dependent prolongation of the ACT, for all thrombin inhibitors, in a pattern parallel to 
the one emerging from the clot scores. The strongest prolongation of the ACT was 
produced by hirudin, followed by Ac-(D)Phe-Pro-boroArg-OH and then by heparin and 
D-MePhe-Pro-Arg-H. Even though all agents produced similar antithrombotic effects 
at the highest doses used, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H 
produced a markedly longer ACT prolongation than hirudin and heparin, similar to the 
antithrombin effects. 
Fig. 49, panel B, depicts the comparison of the measured r distance on the TEG 
of samples obtained from the rabbits which underwent the stasis model before and after 
the S.C. injection of thrombin inhibitors at various doses. Dose-dependent prolongation 
of the TEG r duration occurred with all thrombin inhibitors. Unlike the antithrombotic, 
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Fig. 48. Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after S.C. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 45 min post agent injection. Panel A depicts the results of 
the amidolytic antithrombin analysis. Panel B depicts the results from the amidolytic 
anti-Xa analysis. (•) D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-Pro-boroArg-OH, (•) 
hirudin, ( +) heparin. Each point represents a mean of the difference between baseline 
and post-agent values for each rabbit ± S.E.M. (n=6 at each dose, for each agent). 
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Fig. 49. Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after S.C. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 45 min post agent injection. Panel A depicts the results from 
the ACT analysis. Panel B depicts the results from the TEG r analysis. (•) D-MePhe-
Pro-Arg-H, (•) Ac-(D)Phe-Pro-boroArg-OH, (•) hirudin, ( +) heparin. Each point 
represents a mean of the difference between baseline and post-agent values for each 
rabbit ± S.E.M. (n=6 at each dose, for each agent). 
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antithrombin and ACT effects, in the TEG r value comparisons it was found that the dose 
response effects of Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin overlapped. 
However, D-MePhe-Pro-Arg-H consistently resulted in the weakest effects on the TEG 
r value. 
When the plasma samples collected before and after thrombin inhibitor S.C. 
injection were compared, global clotting test-dependent results were obtained, as seen in 
Fig. 50. None of the thrombin inhibitors had any effects on the PT of rabbit plasma, 
even at the highest dose injected, as seen in Fig. 50, panel A. Panel B of Fig. 50 depicts 
the results from the APTT analysis and comparison of the samples obtained from these 
stasis thrombosis experiments. All thrombin inhibitors produced dose-dependent 
anticoagulant effects after S.C. injection. Similar to the effects that these agents had on 
the TEG r value, the anticoagulant effects of Ac-(D)Phe-Pro-boroArg-OH, hirudin and 
heparin after S.C. administration overlapped. Even though all thrombin inhibitors 
produced similar antithrombotic effects at the highest doses used, the anticoagulant 
effects of heparin were markedly higher than those produced by the other agents. When 
the plasma samples collected before and 45 min after the S.C. injection of thrombin 
inhibitors were compared in the Heptest assay (Fig. 50, panel C), it was found that all 
agents produced dose-dependent prolongation of the Heptest. As seen in the 
antithrombotic profile, in the Heptest hirudin appeared to produce the strongest 
anticoagulant effects. These effects were followed by those produced by heparin and 
then by Ac-(D)Phe-Pro-boroArg-OH. Consistently with all other effects produced by D-
MePhe-Pro-Arg-H after S.C. injection, this agent was the least potent anticoagulant in 
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Fig. 50. Dose-dependent ex vivo anticoagulant effects of antithrombin agents after S.C. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 45 min post thrombin inhibitor injection (prior to r-TF). 
Panel A depicts the results of the PT analysis. Panel B depicts the results from the 
APTT analysis. Panel C depicts the results from the Heptest analysis. Panel D depicts 
the results from the TT analysis. (•) D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-Pro-
boroArg-OH, (•) hirudin, (+)heparin. Each point represents a mean of the difference 
between baseline and post-agent values for each rabbit ± S.E.M. (n=6 at each dose, for 
each agent). 
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the Heptest assay as well. As observed with the anticoagulant effects in the APTT, even 
though all thrombin inhibitors produced similar antithrombotic effects at the highest doses 
used, the anticoagulant effects of heparin in the Heptest assay were markedly higher than 
those produced by Ac-(D)Phe-Pro-boroArg-OH and hirudin. Like heparin, D-MePhe-
Pro-Arg-H also produced higher anticoagulant effects in the Heptest than Ac-(D)Phe-Pro-
boroArg-OH and hirudin, at the highest doses injected. When the same plasma samples 
were compared in the TT (Fig. 50, panel D), all thrombin inhibitors produced a 
prolongation of the TT in manner parallel to their antithrombotic effects, so that hirudin 
produced the most potent prolongation of the TT, followed closely by heparin, then by 
Ac-(D)Phe-Pro-boroArg-OH and lastly by D-MePhe-Pro-Arg-H. While all thrombin 
inhibitors at the highest dose injected produced similar antithrombotic activities, hirudin 
and Ac-(D)Phe-Pro-boroArg-OH produced longer prolongation of the TT than the other 
two compounds. 
5. Duration of Antithrombotic Effects of Thrombin Inhibitors 
After S.C. Administration at a Fixed Dose 
To determine the time-dependance of the antithrombotic effects of the thrombin 
inhibitors studied in this rabbit stasis thrombosis model after S.C. administration, the 
dose of each agent that produced sub-maximal antithrombotic effects in the dose-
dependent S.C. studies was selected and studied at different circulation times, prior to 
injecting r-TF as described above. The dose of each antithrombin agent studied was: D-
MePhe-Pro-Arg-H at 4.854 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 0.503 µmol/kg, 
hirudin at 0.144 µmol/kg and heparin at 0.455 µmol/kg. The circulation time points 
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selected for studying the antithrombotic effects of these thrombin inhibitors at these doses 
were 15, 45 and 90 min (prior to r-TF injection). Six rabbits were tested at each time 
point for each thrombin inhibitor. Blood samples were collected at baseline and prior 
to r-TF injection (15, 30, 45, 60 and 90 min post thrombin inhibitor injection) and 
utilized in the ex vivo whole blood and plasma analyses. 
a. Clot Score Analyses 
Subcutaneous administration of all four thrombin inhibitors produced a time-
dependent antithrombotic effects, as depicted in Fig. 51, after 10 and 20 min stasis time, 
panels A and B respectively. In the 10 min stasis clot score results (Fig. 51, panel A), 
it was observed that while Ac-(D)Phe-Pro-boroArg-OH lost its antithrombotic activities 
progressively with time after 15 min post S.C. injection, the effects of D-MePhe-Pro-
Arg-H and hirudin started to diminish after 45 min post S.C. injection. In contrast to 
the antithrombotic effects produced by the other thrombin inhibitors, the effects of 
heparin steadily increased with time, with the maximal antithrombotic effects achieved 
90 min post S.C. injection. 
The duration of the antithrombotic effects of thrombin inhibitors after S.C. 
injection, as assessed by the clot scores obtained after 20 min stasis time (Fig. 51, panel 
B), differed only slightly from those obtained after 10 min stasis time. The 
antithrombotic effects of Ac-(D)Phe-Pro-boroArg-OH appeared to have steady 
antithrombotic effects over the 90 min period studied, rather than being progressively lost 
with time after 15 min post S.C. injection, as observed in the 10 min stasis panel. D-
MePhe-Pro-Arg-H appeared to time-dependently lose its antithrombotic activities starting 
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Fig. 51. Time dependance of antithrombotic effects of various agents in the rabbit model 
of jugular vein stasis thrombosis. Each agent was administered through S.C. injection 
and allowed to circulate for varying time periods prior to initiation of the stasis 
procedure. The results depicted in panel A represent clot scores obtained after 10 
minutes stasis. The results depicted in panel B represent clot scores obtained after 20 
min stasis. (•) D-MePhe-Pro-Arg-H at 4.854 µmol/kg, (•) Ac-D-Phe-Pro-boroArg-OH 
at 0.503 µmol/kg, (•) hirudin at 0.144 µmol/kg, ( +) heparin at 0.455 µmol/kg. Each 
point represents a mean± S.E.M. (n=6). *denotes statistical significance (p<0.05) 
when compared to control (3.2 ± 0.2 after 10 min stasis in panel A, 3.6 + 0.3 after 20 
min stasis in panel B), as analyzed with the Kruskal-Wallis test. The individual clot 
score values for each thrombin inhibitor at each time point at both the 10 and 20 min 
stasis end points are given in Tables 20e-20f. 
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at 15 min post S.C. injection, as opposed to 45 min post S.C. injection, as observed in 
the 10 min stasis panel. Hirudin, like Ac-(D)Phe-Pro-boroArg-OH, appeared to have 
steady antithrombotic effects over the 90 min period studied, rather than being 
progressively lost with time after 45 min post S.C. injection, as observed in the 10 min 
stasis panel. Heparin time-dependently increased its antithrombotic effects, reaching a 
maximum around 60 min post S.C. injection, as opposed to 90 min post S.C. injection, 
as observed in the 10 min stasis panel. The clot score values for each thrombin inhibitor 
at each circulation time are found in Tables 20e and 20f, following 10 and 20 min stasis 
respectively. 
b. Ex Vivo Analyses of Plasma and Whole Blood Samples 
The ex vivo effect of thrombin inhibitors on the protease inhibition profile of 
rabbit plasma as studied by the antithrombin amidolytic method revealed time-dependent 
antithrombin effects, as can be seen in Fig. 52, panel A. While the antithrombin effects 
of D-MePhe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH were steady over the 90 min 
period monitored, the effects of hirudin and heparin steadily increased with time, 
reaching a maximum at 60 min post S.C. injection. Heparin exhibited time-dependent 
anti-Xa effects, as measured in the amidolytic assay, depicted in Fig. 52, panel B. These 
effects reached a maximum about 60 min post S.C. injection of heparin. The other three 
agents had weak effects on the inhibition factor Xa, as measured in this assay. 
Comparison of the ACT values on samples obtained at baseline and 5, 30, 60 and 
90 min after thrombin inhibitor injection, depicted in Fig. 53, panel A, revealed a time-
dependent prolongation of the ACT, for all thrombin inhibitors. Parallel to the 
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Fig. 52. Time-dependent ex vivo anticoagulant effects of thrombin inhibitors after S.C. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 5 min prior to r-TF injection. Panel A depicts the results of 
the amidolytic antithrombin analysis. Panel B depicts the results from the amidolytic 
anti-Xa analysis. (•) D-MePhe-Pro-Arg-H at 4.854 µmol/kg, (•) Ac-(D)Phe-Pro-
boroArg-OH at 0.503 µmol/kg, (•) hirudin at 0.144 µmol/kg, ( +) heparin at 0.455 
µmollkg. Each point represents a mean of the difference between baseline and post-agent 
values for each rabbit ± S.E.M. (n=6 at each time point, for each agent). 
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Fig. 53. Time-dependent ex vivo anticoagulant effects of thrombin inhibitors after S.C. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 5 min prior to r-TF injection. Panel A depicts the results 
from the ACT analysis. Panel B depicts the results from the TEG r analysis. (•) D-
MePhe-Pro-Arg-H at4.854 µmol/kg, (•) Ac-(D)Phe-Pro-boroArg-OHat0.503 µmol/kg, 
(•) hirudin at 0.144 µmol/kg, (+)heparin at 0.455 µmollkg. Each point represents a 
mean of the difference between baseline and post-agent values for each rabbit ± S.E.M. 
(n=6 at each time point, for each agent). 
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antithrombotic effects, D-MePhe-Pro-Arg-H gradually lost its anticoagulant effects in the 
ACT. In contrast to their antithrombotic effects, Ac-(D)Phe-Pro-boroArg-OH and 
hirudin time-dependently increased their anticoagulant activities in the ACT during the 
90 min following S.C. injection. Heparin, parallel to its antithrombotic effects after S.C. 
injection, also time-dependently increased its anticoagulant actions in the ACT. 
Fig. 53, panel B depicts the comparison of the measured r distance on the TEG 
of samples obtained from the rabbits which underwent the stasis model before and after 
the S.C. injection of thrombin inhibitors at various blood sampling times. Time-
dependent prolongation of the TEG r value was observed with hirudin and heparin. The 
effects of both agents were maximal at 60 min post S.C. injection, parallel to their 
antithrombotic effects. D-MePhe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH produced 
maximal TEG r value prolongation from the first blood sampling time at 15 min, and 
these effects were steady throughout the 90 min post S.C. injection period, even though 
their respective antithrombotic effects were slowly diminishing. 
When the plasma samples collected at the baseline and 5, 30, 60 and 90 min after 
thrombin inhibitor injection were compared, global clotting test-dependent and time-
dependent results were obtained, as seen in Fig. 54. With the exception of D-MePhe-
Pro-Arg-H, none of the thrombin inhibitors had any effects on the PT of rabbit plasma 
as seen in Fig. 54, panel A. The effects of D-MePhe-Pro-Arg-H on the PT were 
noticeable only 45 min post S.C. injection. Panel B of Fig. 54 depicts the results from 
the APTT analysis and comparison of the samples obtained from these stasis thrombosis 
experiments. D-MePhe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH produced maximal 
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Fig. 54. Time-dependent ex vivo anticoagulant effects of antithrombin agents after S.C. 
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples 
were collected prior to and 5 min prior to r-TF injection (post-agent S.C. injection for 
various circulating time periods). Panel A depicts the results of the PT analysis. Panel 
B depicts the results from the APTT analysis. Panel C depicts the results from the 
Heptest analysis. Panel D depicts the results from the TT analysis. (•) D-MePhe-Pro-
Arg-H at 4.854 µmol/kg, (•) Ac-(D)Phe-Pro-boroArg-OH at 0.503 µmol/kg, (•) hirudin 
at 0.144 µmol/kg, (+)heparin at 0.455 µmol/kg. Each point represents a mean of the 
difference between baseline and post-agent values for each rabbit ± S.E.M. (n=6 at 
each time point, for each agent). 
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prolongation of the APTT throughout the 90 min post S.C. injection period, even though 
the corresponding antithrombotic effects slowly decreased with time. The anticoagulant 
effects of hirudin on the APTT increased with time and plateaued around 60 min after 
S.C. injection, similarly to its antithrombotic effects. The anticoagulant effects of 
heparin on the APTT closely paralleled the antithrombotic effects after S.C. injection, 
20 min stasis time. Time-dependent increase in the antithrombotic and anticoagulant 
activity of heparin was observed until 60 min post S.C. injection, after which time point, 
both activities declined. When the plasma samples collected prior to and after the 
injection of thrombin inhibitors were compared in the Heptest assay (Fig. 54, panel C), 
it was found Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin produced time-dependent 
prolongation of the Heptest. D-MePhe-Pro-Arg-H produced maximal prolongation of the 
Heptest throughout the 90 min period post S.C. injection. The anticoagulant effects of 
the other three inhibitors in the Heptest, steadily increased with time, reaching a peak 
at 60 min post S.C. injection, after which the anticoagulant effects started to decrease. 
When the same plasma samples were compared in the TT (Fig. 54, panel D), hirudin and 
heparin produced a steadily increasing time-dependent prolongation of the TT. The 
anticoagulant effects of D-MePhe-Pro-Arg-H reached a maximum at 30 min post S.C. 
injection, which started to decrease 45 min post S.C. injection. Ac-(D)Phe-Pro-boroArg-
OH also produced time-dependent prolongation of the TT after S.C. injection, similar to 
its anticoagulant effects in the APTT and Heptest, reaching a maximum at 60 min post 
S.C. injection and then declining with time. 
I. Antithrombotic Effects of Thrombin Inhibitors as Studied in the 
Rat Model of Laser-Induced Thrombosis 
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The rabbit jugular vein stasis thrombosis model used in the previous experiments 
is venous model of thrombosis that results in fibrin-rich clots. Since veins and arteries 
have different physiologic make ups (hemodynamics, smooth muscle, size) and exhibit 
distinct pathophysiologic responses, it is probable that thrombin inhibitors have different 
antithrombotic effects depending on the type of blood vessel studied and the thrombotic 
injury. Therefore, in the following studies, a rat model of laser-induced thrombosis was 
utilized to compare the antithrombotic effects of D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-
boroArg-OH, hirudin and heparin. This model of arterial thrombosis is based on the 
development of a platelet-rich thrombus in response to focused laser-mediated thermal 
injuries to the vascular wall. The endpoint in this model was the number of standardized 
laser exposures required to produce either a clot completely occluding the arteriole 
injured or a semi-occluding clot with a length equal to 1.5 x the vessel diameter. 
Thrombin inhibitors were injected at various concentrations through the rat tail vein 5 
min prior to induction of the laser injury. 
The results of these studies are depicted in Fig. 55. In control rats (injected with 
saline) 3 laser shots were needed to reach an endpoint. All thrombin inhibitors produced 
dose-dependent antithrombotic effects in this model. In comparing the dose of each agent 
required to extend the endpoint to 6 laser shots, as given in Table 21, heparin was the 
most potent antithrombotic agent (0.08 µmol/kg), followed by Ac-(D)Phe-Pro-boroArg-
OH (0.154 µmol/kg) and then by hirudin (0.28 µmol/kg). Consistent with the rabbit 
jugular vein stasis thrombosis model, D-MePhe-Pro-Arg-H had the weakest effects in the 
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Fig. 55. Comparative dose-dependent antithrombotic effects of various agents as studied 
in the rat laser-induced thrombosis model. Each thrombin inhibitor was injected through 
the rat tail vein circulated for 5 minutes prior to initiation of the laser injury procedure. 
(•) D-MePhe-Pro-Arg-H, (•) Ac-D-Phe-Pro-boroArg-OH, (•) hirudin, ( +) heparin. 
Each point represents a mean ± S.E.M. (n=6). * denotes statistical significance 
(p < 0.05) when compared to control (2.9 ± 0.1) as analyzed with ANOVA followed by 
the Student-Newman-Keuls test. The individual values for each thrombin inhibitor dose 
and their gravimetric equivalents are given in Tables 21a-2ld. 
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rat laser-induced thrombosis model as well (2 µmol/kg). In this model, the ceiling for 
heparin and hirudin appeared to be around 8 laser exposures. However, in the case of 
Ac-(D)Phe-Pro-boroArg-OH, this ceiling was extended to about 10 laser shots. 
Furthermore, D-MePhe-Pro-Arg-H produced dose-dependent antithrombotic effects up 
to a dose of 3. 4 µmol/kg, while with higher doses the anti thrombotic effects were 
weaker. In the rats that received D-MePhe-Pro-Arg-H at doses higher than 3.4 µmol/kg, 
it was visually observed that the blood flow was reduced within 3-10 min after injection 
of the thrombin inhibitor. Similar observations were made in the rats that received Ac-
(D)Phe-Pro-boroArg-OH at doses higher than 0.2 µmollkg. These results were not 
reported, since the blood flow completely stopped prior to induction of laser injury. The 
number of laser exposures required to achieve the endpoint for each thrombin inhibitor 
at each dose are reported in Tables 21a - 2ld. 
Table 21 -- Comparative antithrombotic potencies of thrombin inhibitors, 
as determined in the rat model of laser-induced thrombosis in isolated 
mesenterial arterioles. 
D-MePhe-Pro-Arg-H 
Ac-D-Phe-Pro-boroArg-OH 
Hirudin 
Heparin 
Dose of each agent that results in 
increase of laser shots to 6 in [µmol/kg]. 
2.0 
0.15 
0.28 
0.08 
Each value represents a single determination from the respective dose-
response curves depicted in Fig. 53. Saline, as the control, required 2.9 
± 0.1 laser shots for occlusive thrombus formation. 
J. Hemorrhagic Effects of Thrombin Inhibitors as Studied in the 
Rabbit Ear Bleeding Model 
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Thrombin inhibitors can be potent antithrombotic agents, as seen in the previous 
results on the thrombosis models. While species-dependent, their antithrombotic actions 
are mediated mainly through their inhibitory actions against thrombin. However, the 
same process is involved in normal hemostasis, where the primary hemostatic plug is 
formed by activated platelets (which thrombin can activate) and reinforced by fibrin 
deposition (formed by the catalytic action of thrombin). Inhibition of these processes 
may lead to hemorrhage. To compare the hemorrhagic potential of thrombin inhibitors, 
D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin were studied in 
a rabbit model of ear bleeding (Cade et al. 1984). The thrombin inhibitors were 
administered to rabbits at various doses and following varying circulation times, 5 
standardized cuts were made into their ears. The blood released from the punctured sites 
for the ensuing 10 min was collected and measured. To compare the hemorrhagic 
potential of these agents, an index was devised, whereby the dose of the antithrombin 
agent that produced bleeding of 2 · 109 RBC/L was estimated as the BD2• Six rabbits 
were tested at each thrombin inhibitor dose and circulation time studied. 
1. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors 
After I. V. Administration at Fixed Time Points 
The dose-dependent hemorrhagic effects of thrombin inhibitors after I.V. 
injection, as assessed in the rabbit ear bleeding model are depicted in Fig. 56. In panel 
A, the hemorrhagic procedure was initiated 5 min after I.V. injection of the thrombin 
inhibitor, while in panel B, the hemorrhagic procedure was initiated following 20 min 
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Fig. 56. Comparative dose-dependent hemorrhagic effects of thrombin inhibitors as 
studied in the rabbit ear bleeding model. In panel A, each agent was administered 
through I. V. injection and allowed to circulate for 5 minutes prior to initiation of the 
incision procedure. In panel B, each agent was administered through I.V. injection and 
circulated for 20 minutes prior to initiation of the incision procedure. ( •) D-MePhe-Pro-
Arg-H, (•) Ac-D-Phe-Pro-boroArg-OH, (•) hirudin, ( +) heparin. Each point 
represents a mean± S.E.M. (n=6). *denotes statistical significance (p<0.05) when 
compared to control (0.100 ± 0.060) as analyzed with ANOVA followed by the Student-
Newman-Keuls test. The individual values for each thrombin inhibitor dose and their 
gravimetric equivalents for both the 5 an 10 min post I. V. end points are given in Tables 
22a-22d. 
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I. V. injection of the thrombin inhibitor. Except for heparin, the other thrombin 
inhibitors resulted in dose-dependent hemorrhagic effects. The agent with the strongest 
hemorrhagic effects was hirudin, 5 min post and 10 min post I. V. injection, with BD2 
of 0.11 and 0.30 µmol/kg respectively. The effects of hirudin were followed by Ac-
(D)Phe-Pro-boroArg-OH (BD2s of 0.55 and 0.54 µmol/kg after 5 and 20 min injection) 
and then by D-MePhe-Pro-Arg-H (BD2s of 2.82 and >4.85 µmol/kg, after 5 and 20 min 
post injection). Heparin exhibited minimal hemorrhagic effects, as seen in both the 5 
min and 20 min post I. V. injection panels (BD2s of > 0 .45 µmol/kg in both cases). 
While the hemorrhagic effects of D-MePhe-Pro-Arg-H and hirudin were decreased 20 
min post I. V. injection when compared to 5 min post I. V. injection, the effects of Ac-
(D)Phe-Pro-boroArg-OH appeared to increase with time. The dose of each thrombin 
inhibitor that resulted in bleeding of 2 · 1()9 RBC/L, 5 min and 20 min post I. V. injection, 
is reported in Table 22. The amount of RBCs released at each thrombin inhibitor dose 
is reported in Tables 22a - 22d for the 5 min and 10 min post I. V. injection. 
Table 22 -- Comparative hemorrhagic potencies of thrombin inhibitors after I.V. 
injection, as determined in the rabbit model of ear bleeding. 
D-MePhe-Pro-Arg-H 
Ac-D-Phe-Pro-boroArg-OH 
Hirudin 
Heparin 
Dose of each agent that resulted in bleeding of 
2 · 109 RBC/L in [µmol/kg]. 
5 min post I. V injection 20 min post I. V. injection 
2.82 
0.55 
0.11 
>0.45 
>4.85 
0.54 
0.30 
>0.45 
Each value represents a single determination from the respective dose-response curves 
depicted in Fig. 56. Saline produced bleeding of 0.100 ± 0.070 109 RBC/L. 
2. Duration of Hemorrhagic Effects of Thrombin Inhibitors 
After I. V. Administration at a Fixed Dose 
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To determine the duration of the hemorrhagic effects of thrombin inhibitors, the 
dose of each agent that produced sub-maximal hemorrhagic effects in the above studies 
was selected and the hemorrhagic procedure was initiated at different times post I. V. 
injection of these agents. The individual doses for these studies were 4.85 µmol/kg for 
D-MePhe-Pro-Arg-H, 0.50 µmol/kg for Ac-(D)Phe-Pro-boroArg-OH, 0.36 µmol/kg for 
hirudin and 0.46 µmol/kg for heparin. The hemorrhagic process was initiated 5, 20, 30, 
45, 60 and 90 min post I.V. injection of each thrombin inhibitor. Six rabbits were 
studied at each circulation time point. 
The data of the comparative hemorrhagic effects are depicted in Fig. 57. All 
thrombin inhibitors exhibited time-dependent hemorrhagic profiles which generally 
diminished within 45 min post I.V. injection. D-MePhe-Pro-Arg-H lost its hemorrhagic 
effects at the fastest rate (t1/2 around 15 min), while Ac-(D)Phe-Pro-boroArg-OH (t1h 
around 35 min) and hirudin (t1/2 around 25 min) showed a decrease in their hemorrhagic 
effects only after 20 min post I. V. injection. The individual data on the hemorrhagic 
effects of each antithrombin agent at each time point are found in Table 22e. 
3. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors 
After S.C. Administration at Fixed Time Points 
The dose-dependent hemorrhagic effects of thrombin inhibitors after S.C. 
injection, as assessed in the rabbit ear bleeding model are depicted in Fig. 58. In panel 
A, the hemorrhagic procedure was initiated 45 min after S.C. injection of the thrombin 
inhibitor, while in panel B, the hemorrhagic procedure was initiated following 60 min 
250 
8 
~ 7 
_J 6 
' m 5 w 
0 4 T""" 
...._, 3 
() 2 CD 
a:::: 1 * 
0 
0 10 20 30 40 50 60 70 80 90 
Circulation Time (minutes) 
Fig. 57. Time dependance of hemorrhagic effects of antithrombin agents in the rabbit 
ear bleeding model. Each agent was administered through I. V. injection and allowed to 
circulate for varying time periods prior to initiation of the incision procedure. ( •) D-
MePhe-Pro-Arg-H at 4.85 µmol/kg, (•) Ac-D-Phe-Pro-boroArg-OH at 0.50 µmol/kg, 
(•) hirudin at 0.36 µmol/kg, ( +) heparin at 0.46 µmol/kg. Each point represents a 
mean+ S.E.M. (n=6). *denotes statistical significance (p<0.05) when compared to 
control (0.100 ± 0.060) as analyzed with ANOV A followed by Student-Newman-Keuls 
test. The individual values for each thrombin inhibitor at each time point are given in 
Table 22e. 
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Fig. 58. Comparative dose-dependent hemorrhagic effects of various agents as studied 
in the rabbit ear bleeding model. In panel A, each agent was administered through S.C. 
injection and allowed to circulated for 45 minutes prior to initiation of the incision 
procedure. In panel B, each agent was administered through S.C. injection and 
circulated for 60 minutes prior to initiation of the incision procedure. ( •) D-MePhe-Pro-
Arg-H, ( .. ) Ac-D-Phe-Pro-boroArg-OH, (•) hirudin, ( +) heparin. Each point 
represents a mean± S.E.M. (n=6). *denotes statistical significance (p<0.05) when 
compared to control (0.100 ± 0.060) as analyzed with ANOVA followed by the Student-
Newman-Keuls test. The individual values for each thrombin inhibitor dose and their 
gravimetric equivalents for both the 5 an 10 min post I. V. end points are given in Tables 
23a-23d. 
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S.C. injection of the antithrombin agent. Similar to the hemorrhagic effects following 
I. V. administration, except for heparin, the other thrombin inhibitors resulted in dose-
dependent hemorrhagic effects. As observed after I.V. injection, the agent with the 
strongest hemorrhagic effects 45 min post S.C. administration, was hirudin (BD2 0.80 
µmol/kg), followed by Ac-(D)Phe-Pro-boroArg-OH (BD2 1.13 µmol/kg) and then by D-
MePhe-Pro-Arg-H (BD2 > 9. 7 µmol/kg). Heparin had minimal hemorrhagic effects, as 
seen in both the 45 min and 60 min post S.C. injection panels, with BD2 of >0.9 
µmollkg in both cases. Except for Ac-(D)Phe-Pro-boroArg-OH, none of the other 
inhibitors appeared to have any hemorrhagic effects 60 min post S.C. injection, as seen 
in panel B of Fig. 58. However, the effects of Ac-(D)Phe-Pro-boroArg-OH were lower 
at 60 min post S.C. injection, when compared to the effects produced 45 min post S.C. 
injection. The dose of each thrombin inhibitor that resulted in bleeding of 2 · 109 RBC/L, 
45 min and 60 min post S.C. injection, is reported in Table 23. The amount of RBCs 
released at each thrombin inhibitor dose is reported in Tables 23a - 23d, for the 45 min 
and 60 min post S.C. injection. 
4. Duration of Hemorrhagic Effects of Thrombin Inhibitors 
After S.C. Administration at a Fixed Dose 
To determine the duration of the hemorrhagic effects of thrombin inhibitors after 
S.C. injection, the dose of each agent that produced sub-maximal hemorrhagic effects in 
the above studies was selected and the hemorrhagic procedure was initiated at different 
times post S.C. injection of these agents. The dose of each thrombin inhibitor selected 
was: D-MePhe-Pro-Arg-H at 9.71 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 2.01 
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µmollkg, hirudin at 0.77 µmol/kg and heparin at 0.91 µmol/kg. The hemorrhagic 
procedure was initiated 15, 30, 45, 60 and 90 min post S.C. injection of each thrombin 
inhibitor. Six rabbits were studied at each circulation time point. 
Table 23 -- Comparative hemorrhagic potencies of thrombin inhibitors after S.C. 
injection, as determined in the rabbit model of ear bleeding. 
D-MePhe-Pro-Arg-H 
Ac-D-Phe-Pro-boroArg-OH 
Hirudin 
Heparin 
Dose of each agent that resulted in bleeding of 
2 · 109 RBC/L in [µmol/kg]. 
45 min circulation 
>9.71 
1.13 
0.80 
>0.91 
60 min circulation 
>9.7 
1.57 
>0.7 
>0.9 
Each value represents a single determination from the respective dose-response curves 
depicted in Fig. 58. Saline produced bleeding of 0.100 ± 0.070 109 RBC/L. 
The results of these studies are depicted in Fig. 59. Except for heparin, the other 
thrombin inhibitors had time-dependent hemorrhagic effects. For Ac-(D)Phe-Pro-
boroArg-OH and hirudin, their hemorrhagic effects became maximal at 45 min post S.C. 
injection. While both thrombin inhibitors progressively lost their hemorrhagic activities 
after 45 min, the effects of hirudin were abolished at 60 min post S.C. injection. D-
MePhe-Pro-Arg-H lost its hemorrhagic effects progressively with time, similar to its 
time-dependent hemorrhagic effects after I. V. injection. Heparin, as in all other 
hemorrhagic studies, had minimal effects at all time points. The hemorrhagic effects of 
each thrombin inhibitor at each time point are found in Table 23e. 
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Fig. 59. Time dependance of hemorrhagic effects of thrombin inhibitors in the rabbit 
ear bleeding model. Each agent was administered through S.C. injection and allowed 
to circulate for varying time periods prior to initiation of the incision procedure. ( •) D-
MePhe-Pro-Arg-H at 9.71 µmol/kg, (•) Ac-D-Phe-Pro-boroArg-OH at 2.01 µmol/kg, 
(•) hirudin at 0. 77 µmol/kg, ( +) heparin at 0.91 µmol/kg. Each point represents a 
mean± S.E.M. (n=6). *denotes statistical significance (p<0.05) when compared to 
control (0.100 ± 0.060) as analyzed with ANOVA followed by the Student-Newman-
Keuls test. The individual values for each thrombin inhibitor at each time point are given 
in Table 23e. 
K. Effects of Thrombin Inhibitors on Blood Pressure 
After I. V. Administration in Rabbits 
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Thrombin inhibitors may mediate vascular effects independent of their 
antithrombin activities. To asses whether the thrombin inhibitors used in the rabbit 
model of ear blood loss had any effects on the blood pressure of rabbits, the blood 
pressure during the stasis thrombosis procedure was monitored for the highest dose of 
each thrombin used after I.V. injection (D-MePhe-Pro-Arg-H at 1.942 µmol/kg, Ac-
(D)Phe-Pro-boroArg-OH at 0.101 µmol/kg, hirudin at µmol/kg and heparin at 0.023 
µmol/kg). 
The blood pressure monitoring of the rabbits during the stasis thrombosis 
procedure, in the studies where the dose-dependent effects of r-TF were also studied. 
These studies revealed a slight transient drop in the blood pressure lasting 5 ± 1 minutes 
after the first baseline blood draw and the subsequent infusion of saline (Fig. 60, panel 
A). Similar results were obtained when r-TF was used in place of saline, as seen in Fig. 
60, panel B. The results obtained with each of the thrombin inhibitors (injected 5 min 
prior to the r-TF injection) were similar to those obtained with r-TF alone. 
Representative graphs from a rabbit treated with hirudin and Ac-(D)Phe-Pro-boroArg-OH 
are seen in Fig. 60, panels C and D respectively. Panel E shows the effect of D-MePhe-
Pro-Arg-H on the blood pressure response. Consistent with the results obtained with the 
other agents, this peptide derivative did not produce any significant effects on the blood 
pressure. 
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Fig. 60. Intra-arterial blood pressure monitoring of rabbits during in vivo investigation 
with rTF and anti thrombotic agents. Five min following the I. V. injection of each agent, 
9 ml of blood was collected via the carotid artery. Panel A depicts the effects of rTF 
at 1.35 pmol/kg, I.V. Panel B depicts the effects of saline. Panel C depicts the effects 
of hirudin at 0.04 µmol/kg, I.V. Panel D depicts the effects of Ac-(D)Phe-Pro-boroArg-
0 H at 0. 1 µmol/kg, I. V. Panel E depicts the effects of D-MePhe-Pro-Arg-H at 1. 9 
µmol/kg, I.V. 
CHAPTER V 
DISCUSSION 
This dissertation represents an integrated account of the pharmacological 
properties of several thrombin inhibitors which are not different only in their structural 
characteristics, but also exhibit varying degrees of specificity towards thrombin. The 
experimental approaches are designed to test the hypothesis that the inhibition of 
thrombin may not be the sole determinant of their endogenous antithrombotic and 
hemorrhagic actions. It is likely that several other endogenous factors are responsible 
for their pharmacologic effects. These effects include both the plasmatic and cellular 
sites. Furthermore, metabolic transformations of the individual thrombin inhibitors could 
also contribute to their endogenous pharmacodynamics. 
In this dissertation, heparin has been used as a reference anticoagulant. However, 
unlike all of the antithrombin agents used, this drug produces its actions through 
potentiation of antithrombin and HC-II. Furthermore, this agent exhibits poly-
pharmacologic behavior and targets several plasmatic and vascular sites (Lindahl et al. 
1991, Jeske et al. 1995). On the other hand, the synthetic and recombinant thrombin 
inhibitors included in this study represent chemically pure homogeneous agents. A 
comparison of the biochemical and pharmacological characteristics of heparin and 
thrombin inhibitors is given in Table 24. 
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Table 24 -- Comparative properties of heparin and thrombin inhibitors. 
Thrombin inhibition 
Clot-bound thrombin 
Inhibition of other serine 
proteases 
Fibrinolytic interactions 
Serpin interactions 
Platelet interactions 
Endothelial interactions 
Hemodynamic modulation 
Immunogenicity 
Bioavailability 
Liver toxicity 
Antagonists 
Heparin Thrombin Inhibitors 
Indirect 
No interaction 
Indirect, Xa and to a lesser 
extent XIIa, Xla, Xa and IXa. 
Activation 
Requires antithrombin, 
potentiates HC-II, releases TFPI 
Inhibition 
t vascular permeability, release 
of TFPI, binds endothelial lining 
Activation 
HIT 
20-30% S.C., <5% oral 
t liver enzymes 
Protamine, PF4, several serpins 
Direct 
Inactivation 
Variable 
Variable 
None 
Inhibition only of thrombin-
induced aggregation 
Unknown 
Unknown 
Barely immunogenic 
80-100% S.C., 5-30% oral 
None 
None 
N 
Vl 
00 
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Beside the antithrombin mediated inhibition of thrombin, heparin produces its 
overall antithrombotic effects through various mechanisms, while thrombin inhibitors are 
believed to act only through the inhibition of thrombin. Thus, while heparin is capable 
of inhibiting other coagulation factors via antithrombin and HC-II, antithrombin agents 
antagonize the final stages of coagulation. In addition, heparin interacts ionically with 
the vascular lining to mediate a series of antithrombotic and pro-fibrinolytic effects, such 
as release of tP A, TFPI and anti thrombotic glycosaminoglycans from the endothelial 
lining (Verstraete and Zoldelhyi 1995). Heparin is also capable of inhibiting platelet 
functions, while antithrombin agents only inhibit thrombin-induced aggregation. On the 
other hand, most of the antithrombin agents are smaller in size and therefore are capable 
of inhibiting clot-bound thrombin, which may be important in clot stabilization and its 
subsequent lysis (Gast et al. 1994, Berry et al. 1994). The main reason for clinical 
interest in antithrombin agents as a potential replacement for heparin is due to the fact 
that heparin has certain limitations, which include wide subject-to-subject variability, 
poor response and allergic manifestations. One of the most serious adverse effects with 
heparin is heparin induced thrombocytopenia (HIT), a deleterious immune reaction where 
the patient's platelets aggregate in response to heparin to form white clots. Both heparin 
and the higher molecular weight thrombin inhibitors (hirudin) exhibit immunogenicity 
(Eichler and Greinacher 1996). The clinical implications of the anti-hirudin antibodies 
are not clear at this time. Another reason for evaluating alternative antithrombotic agents 
to heparin is the limited S.C. bioavailability of heparin. Heparin exhibits S.C. bio-
availability of 20-303 whereas the thrombin inhibitors have 80-100% S.C. 
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bioavailability. The oral bioavailability of the thrombin inhibitors ranges from 5-30 3 
whereas heparin has a rather limits absorption ( < 5 3) by this route. Another major a 
problem that needs to be addressed for all direct thrombin inhibitors is their 
pharmacologic neutralization. While heparin is readily neutralizable by protamine, 
currently, there is no available pharmacologic antagonist for any of the direct thrombin 
inhibitors. 
Thrombin inhibitors as a class of new anticoagulants represents compounds with 
significant structural variations. Recombinant hirudin represents a protein analog of 
natural hirudin with absolute specificity for thrombin. The peptide arginals represent low 
molecular weight peptide derivatives with strong antithrombin potency. However, they 
also exhibit varying degrees of inhibitory actions towards other serine proteases. The 
boronic acid tripeptide Ac-(D)Phe-Pro-boroArg-OH represents a transition state analogue 
with a high degree of reactivity and broad serine protease inhibitory spectrum. The 
peptidomimetic agent argatroban, represents a relatively weaker inhibitor of thrombin, 
with a high degree of specificity. 
While the antiprotease spectrum of these agents has been extensively investigated, 
very little is known regarding their interactions with the cellular components of blood and 
vasculature. It is generally perceived that the antithrombin actions of these agents 
correlate directly with their in vivo pharmacologic effects. Theoretically, this hypothesis 
appears logical, however, experimental validation of this widely accepted concept is not 
available until now. The data reported in this dissertation represent the first 
comprehensive account where the different antithrombin agents are compared in defined 
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biochemical systems mimicking thrombogenesis and valid pharmacological models are 
utilized to investigate the relative antithrombotic and bleeding actions of these agents. 
This research provides an integrated account of the biochemical and pharmacologic 
actions of these agents, that may be useful in predicting the relative therapeutic index 
of these new anticoagulants. 
Despite the extensive trials on the use of the new thrombin inhibitors in 
appropriately chosen clinical indications, supportive studies on their biochemical and 
pharmacologic influences of these agents have been rather limited. Due to the absence 
of this important fundamental information, both the safety and efficacy problems have 
been obvious during the newer clinical trials. The comparative studies reported in this 
dissertation address the following key questions: 
1. Is the sole inhibition of thrombin sufficient to control thrombogenesis in various 
thrombotic states? 
2. Are thrombin inhibitors similar to heparin in their pharmacologic actions? 
3. Are there any differences among the currently available thrombin inhibitors? 
4. Do thrombin inhibitors manifest non-thrombin mediated pharmacologic actions? 
This dissertation therefore attempts to address some of the previously unresolved 
issues in carefully designed biochemical and pharmacologic studies. A direct comparison 
of thrombin inhibitors as a new class of drugs with conventional heparin provides an 
important database for the relative antithrombotic and hemorrhagic profiles of these 
drugs, which will be helpful in their clinical development. 
A. Molecular and Structural Characterization of 
Heparin and Antithrombin agents 
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The peptide aldehyde D-Phe-Pro-Arg-H has been reported to be unstable in 
solution (Bajusz et al. 1990). The peptides D-MePhe-Pro-Arg-H and Boc-D-Phe-Pro-
Arg-H were developed to minimize cyclization and racemization. To determine the 
extent of cyclization and racemization in all of these agents, the HPLC studies were 
undertaken. All peptides resulted in elution profiles composed of more than one peaks. 
The identity of the structure which was represented by each one of the background-
adjusted peaks was deciphered by isolating the material represented by each peak and 
then analyzing it with NMR techniques, which have been previously published (Bajusz 
et al. 1990). The HPLC studies revealed that almost 903 of the D-Phe-Pro-Arg-H, 95 % 
of the D-MePhe-Pro-Arg-H and 100% of the Boc-D-Phe-Pro-Arg-H remained in the 
active form, in three equilibrium structures, after reconstitution in distilled H20. 
The HPLC analysis of the boronic acid peptide derivative Ac-(D)Phe-Pro-
boroArg-OH revealed that this compound eluted in several peaks. However, the identity 
of the structures represented by each one of these peaks is not known at this time. 
Furthermore, in contrast to the peptide arginals, the elution profile of this agent was 
rather complex. Because of the highly reactive nature of this agent, molecular 
interactions and other structural transformations may be responsible for this complex 
behavior. The boronic acid residue is highly reactive and the unusual HPLC elution 
profile may also be attributable to the interaction of this reactive peptide to the column. 
The heparin preparation employed in these studies is a polycomponent mixture 
of glycosaminoglycans of different molecular weights. To determine the homogeneity 
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of this preparation of porcine origin, the GPC studies were carried out. The heparin 
preparation was examined by using two different detectors, the UV and the RI. The 
peaks resolved in the UV detector are generally due to the amount of sulfation and the 
presence of double bonds in the heparin. The peaks detected with the RI are due to the 
mass of the material studied. The results obtained from both detectors were in close 
agreement. The molecular weight average of this particular heparin preparation was 
determined to be approximately 10,700 and about half of the material was determined to 
be in the 8,000-12,000 range. While no analytical studies were carried out on the 
recombinant hirudin, this preparation was certified to be homogeneous and 95 3 pure by 
the manufacturer. It is apparent that the agents used in this investigation represent wide 
differences in their physicochemical and structural characteristics. While hirudin is a 
recombinant protein and the synthetic thrombin inhibitors represent structurally distinct 
peptidomimetics, heparin is a complex mixture of sulfated glycosaminoglycans. 
Therefore, molar conversions of the effects of heparin in these reported studies were 
based on the apparent molecular weight of heparin. In contrast, the molecular weights 
of all other agents were based on their formula molecular weights. 
B. Relative Antithrombin Potencies of Thrombin Inhibitors 
Thrombin inhibitors are being extensively investigated for a variety of clinical 
applications. As the number of thrombin inhibitors is increasing, there is a growing need 
for the development of a method for the potency standardization of these agents. 
Currently, outside the structural characterization using HPLC methods and the 
biochemical characterization of these agents measuring inhibitory constants for thrombin 
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(Bajusz et al. 1978, Bagdy et al. 1994, Kettner et al. 1990, Kikumoto et al. 1984, Braun 
et al. 1988), no other valid methods are available for the direct comparison of the 
antithrombin potency of these agents. Furthermore, a study where antithrombin potency 
for a specific antithrombin agent is directly compared with its pharmacologic actions is 
not available. 
In the thrombin titration studies, where the amidolytic effect of thrombin on a 
chromogenic substrate was used to determine the inhibitory activities of antithrombin 
agents, an attempt was made to evaluate and compare various thrombin inhibitors in 
terms of ATU potencies. The order of potency of the thrombin inhibitors was found to 
be hirudin> Ac-(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-OH > D-Phe-Pro-Arg-
H > Boc-D-Phe-Pro-Arg-H > argatroban. With the exception of argatroban, the order 
of potencies of the other agents matched the order of their respective Ki values. Even 
though all of these thrombin inhibitors interact with thrombin on a 1: 1 stoichiometric 
ratio, these agents form complexes with thrombin in kinetically distinct manners. More 
specifically, the tripeptide aldehydes (D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and Boc-
D-Phe-Pro-Arg-H) are slowly reversible thrombin inhibitors with Ki values of around 80 
nM (Bajusz et al. 1978, Bagdy et al. 1994), Ac-(D)Phe-Pro-boroArg-OH is a transition 
state analogue with a Ki of 41 pM, which means a tight-binding and slowly reversible 
competitive thrombin inhibitor (Kettner et al. 1990), argatroban is a fast reversible 
antithrombin agent with a Ki of 39 nM (Kikumoto et al. 1984), while hirudin is a tight-
binding inhibitor with a Ki of 21 fM (Stiirzebecher and Walzman 1991). To overcome 
these kinetic differences, prior to the addition of the substrate, each of the thrombin 
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inhibitors was pre-incubated with thrombin, to achieve steady-state kinetics. Despite this 
pre-incubation period, the activity of argatroban in this amidolytic assay in relationship 
to the other thrombin inhibitors was not correlated with the order of their Ki values. 
The amidolytic activity of thrombin is not predictive of the clotting activity of 
thrombin. The amidolytic activity of thrombin may be unaffected even if the clotting 
activity of this enzyme is diminished (Sonder and Fenton 1986). Furthermore, the 
affinity (Km) and the specificity constant (k.:,,/Km) of thrombin for the chromogenic 
substrate used in this method (51 · 106 M-1s-1) are different from those of the natural 
substrates for thrombin (Sonder and Fenton 1986), such as factor V (3.26 · 106 M-1s-1, 
Monkovic and Tracy 1990), factor XI (0.0026 · 106 M-1s-1, Gailiani and Broze 1991), 
factor XIII (0.12 · 106 M-1s-1, Janus et al. 1983), protein C (Esmon et al. 1983) and 
fibrinogen (3.8 · 106 M-1s-1 and 1.1·106 M-1s-1, for fibrinopeptides A and B, De Cristofaro 
and Di Cera 1992, Picozzi et al. 1994). Therefore, a competition between the 
chromogenic substrate and each of the thrombin inhibitors cannot be readily related to 
and be predictive of pathophysiologic events. 
To determine the relative antithrombin effects of these inhibitory agents utilizing 
the functional property of thrombin to cleave fibrinogen into fibrin, the fibrinogen-based 
clotting systems were developed. In these assays, the order of potency of the 
antithrombin agents was found to be hirudin> Ac-(D)Phe-Pro-boroArg-OH > D-MePhe-
Pro-Arg-H > argatroban> D-Phe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H. As with their 
respective Ki values, hirudin and Ac-(D)Phe-Pro-boroArg-OH were the strongest 
thrombin inhibitors in this test, while Boc-D-Phe-Pro-Arg-H was the weakest. However, 
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the order of potencies of D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and argatroban were 
of a different sequence in this assay than the order of their Ki values. Furthermore, 
argatroban exhibited more potent activities in relationship to the rest of the antithrombin 
agents in this clot-based system, unlike its weak effects in the amidolytic systems. 
As published previously (Iyer and Fareed, 1995), the amidolytic thrombin titration 
assay is a rapid and reproducible method that can be used for the in vitro potency 
evaluation and quality assurance purposes for a specific thrombin inhibitor. However, 
the value of this method in screening all new thrombin inhibitors for their anticoagulant 
and antithrombotic potential may be limited and can be applied only to the agents that 
are known to be tight, slowly reversible thrombin inhibitors. In this method, only the 
IC50 values are comparable and doubling of this value may not give the correct number 
for 100% thrombin inactivation (Dr. J. Fenton II and Ms. Brezniak, New York State 
Department of Health, personal communication). The example of argatroban illustrates 
this point: argatroban is found to be 100 fold weaker than hirudin (on a molar basis) in 
this assay. However, in the fibrinogen-based method, where the end-point is clot 
formation and is also a rapid and reliable screening method for antithrombin activities 
of agents, argatroban exhibited comparable antithrombin potencies to those of D-MePhe-
Pro-Arg-H and D-Phe-Pro-Arg-H. Furthermore, argatroban has been used clinically for 
a variety of indications in Japan (Kario et al. 1995) and is in clinical trials in both 
Europe and the U.S., with promising efficacy and beneficial outcomes. Thus, the in 
vitro potency evaluation of these agents may or may not be relevant to the in vivo 
actions. This chromogenic method may be useful in the comparison of various batches 
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of the same thrombin inhibitor, or even in the comparison of different thrombin inhibitors 
with the exact mechanism of thrombin inhibition. The fibrinogen-based method may be 
more relevant in comparing thrombin inhibitors that differ in their mechanisms of 
actions. As demonstrated recently by Bagdy et al. 1994, it is important to utilize a 
battery of several different methods to assess relative potencies of thrombin inhibitors, 
since it appears that different methods may be more suitable for evaluating one agent in 
comparison with other thrombin inhibitors. 
C. Antithrombin and Anti-Xa Activities of Thrombin Inhibitors 
in Plasmatic Systems 
While defined assay systems, such as the amidolytic tests discussed earlier, can 
provide useful information on the relative antithrombin potency of various agents, these 
assays are based on buffered conditions where thrombin is the only enzyme present. To 
examine the matrix effect that plasma has on the antithrombin activities of thrombin 
inhibitors, the human plasma-based amidolytic antithrombin assay was utilized. The 
order of potency of the antithrombin agents was found to be hirudin> Ac-(D)Phe-Pro-
boroArg-OH > D-Phe-Pro-Arg-H > D-MePhe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H > 
argatroban. In this system, heparin was also studied and was found to be an even more 
potent antithrombin agent than hirudin. The effects of heparin in this system are 
mediated through the antithrombin contained within the plasma and therefore the 
antithrombin effects exhibited by this drug are a reflection of the potentiation of 
antithrombin and not of direct effects of heparin on thrombin. Since the previously 
discussed thrombin titration systems are devoid of antithrombin, heparin had no 
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antithrombin effect and comparisons with the other thrombin inhibitors were not possible. 
When rabbit plasma was used instead of human plasma in the same assay, heparin 
was again found to be the strongest thrombin inhibitor. However, the order of potencies 
of hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H were reversed, 
although very close in absolute value. This difference in the order of potency in the 
human and rabbit plasma systems is probably a reflection of the differences in the plasma 
matrices and the concentrations of various factors. Rabbit plasma contains higher 
concentrations than human plasma of most coagulation factors, with the exception of 
prekallikrein, factor X, prothrombin and fibrinogen (Walenga 1987). In addition, rabbit 
plasma contains about the same amount of antithrombin as human plasma (Walenga 
1987). Since rabbit plasma contains 18 fold higher concentrations of factor V than 
human plasma, which serves as a cofactor for factor Xa, and since addition of thrombin 
to plasma activates the coagulation cascade via multiple feedback mechanisms, it may be 
that direct inhibition of factor Xa in the rabbit plasma-based assay by such agents as Ac-
(D )Phe-Pro-boroArg-OH may be more important in the generation and subsequent 
inhibition of generated thrombin than in the human plasma-based system. On the other 
hand, in the human plasma-based test, the direct inhibition of the added thrombin may 
mask any effects that thrombin inhibitors may have on the generation of thrombin from 
the endogenous factors by inhibiting other coagulation factors. Thus, the inhibitory 
constants for thrombin, as represented by the reported Ki values, may be more relevant 
in predicting the antithrombin potency of these agents. 
An automated method for the determination of hirudin in plasma has been recently 
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published (Hafner et al. 1995). This method is also based on the amidolytic activity of 
thrombin on a chromogenic substrate. However, in this method bovine thrombin is used 
instead of human enzyme as is in the studies described in this dissertation. This may 
also influence the comparative effects of various thrombin inhibitors on the amidolytic 
activity of this thrombin. Furthermore, the chromogenic substrate is added to the plasma 
before thrombin, therefore decreasing the possibility that low reaction velocity thrombin 
inhibitors, such as heparin/antithrombin complex, will have an effect on this assay. The 
comparative effects of hirudin in the chromogenic assay and the APTT results reported 
by Hafner et al. 1996 are in agreement with the results reported in this dissertation, 
where no correlation was found between the antithrombin amidolytic activities of various 
thrombin inhibitors and their effects in the APTT assay. 
To examine the specificity of the antithrombin agents compared in these studies 
for thrombin, the amidolytic anti-Xa assays were also utilized. These assays were 
plasma-based systems and it was found that with the exception of heparin and Ac-(D)Phe-
Pro-boroArg-OH, the other thrombin inhibitors were devoid of anti-Xa activity. As 
expected, heparin exhibited measurable anti-Xa activity in this assay which is mediated 
by plasmatic antithrombin. Antithrombin also inhibits most of the factors in the 
coagulation cascade, especially thrombin and factor Xa. 
The effects of Ac-(D)Phe-Pro-boroArg-OH validate the observation that this 
compound is not a specific thrombin inhibitor, even though its potency for factor Xa 
inhibition is lower than that of heparin. When the same inhibitors were studied in the 
rabbit plasma-based assay, similar results were obtained: except for heparin ·and Ac-
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(D)Phe-Pro-boroArg-OH, none of the other agents had any anti-Xa effects. Even though 
heparin was again found to be a more potent factor Xa inhibitor than Ac-(D)Phe-Pro-
boroArg-OH, its anti-Xa potency in the human plasma in comparison to the rabbit plasma 
was 10 fold stronger, while Ac-(D)Phe-Pro-boroArg-OH's potency was only 3 fold 
stronger in the human plasma than in the rabbit plasma. This difference in the ratios is 
most likely reflective of the limiting factor in heparin's activity, namely the antithrombin 
concentration in each plasma system in relation to the factor Xa/factor Va levels. 
Another plasma-based assay that provides data on the antithrombin and anti-Xa 
effects of various agents is the Heptest, which is a clot-based method, unlike the 
previously discussed plasma-based assays, which are amidolytic methods. In this assay, 
activated factor Xa is added to the plasma, which results in direct activation of the 
common pathway and generation of thrombin. The order of potency of thrombin 
inhibitors in the human plasma-based Heptest assay was heparin> hirudin > Ac-(D)Phe-
Pro-boroArg-OH > argatroban > D-MePhe-Pro-Arg-H > D-Phe-Pro-Arg-H > Boc-D-
Phe-Pro-Arg-H. With the exception of heparin, and the change in the rank order of 
argatroban and D-MePhe-Pro-Arg-H, this potency order closely followed that obtained 
in the fibrinogen-based antithrombin assay. In addition, the order of potency of the 
antithrombin agents in the Heptest closely followed the order of their respective Ki 
values. When rabbit plasma was used instead of human plasma in the Heptest assay, 
hirudin was found to be more potent than heparin. This difference is probably due to the 
difference in antithrombin concentration in relation to factor Xa/factor Va concentration 
in the two plasmas, which limits the heparin antithrombin and anti-Xa activity. 
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In all of the systems discussed earlier, argatroban was found to be a weak 
inhibitor in the amidolytic assays, while in the clotting assays its activity appeared to be 
more potent in relation to the tripeptide aldehydes, corresponding to their respective Ki 
values. Since argatroban is the most reversible of all thrombin inhibitors examined, this 
indicates that an agent's antithrombin potency as measured by a Ki value rather than its 
amidolytic potential may be more predictive of its anticoagulant effects. 
D. Antiprotease Spectrum of Various Thrombin Inhibitors 
The objective of adjunctive therapy of anticoagulants with fibrinolytics is to 
simultaneously control thrombogenesis and facilitate thrombolysis. However, the specific 
agents which are to be combined should be carefully selected. Many of the new 
antithrombin agents target the catalytic site of thrombin, which is similar in many blood-
borne enzymes, including most of the enzymes involved in coagulation and fibrinolysis. 
Thus, it is possible that some of these catalytic site directed thrombin inhibitors may 
inhibit other enzymes, involved in both coagulation and fibrinolysis, regardless of their 
relative affinity for thrombin. In addition, highly specific thrombin inhibitors without 
additional antiprotease activities, such as hirudin, may also impair physiological 
fibrinolysis by inactivating thrombomodulin-bound thrombin. Since thrombomodulin-
bound thrombin has an anticoagulant action and no procoagulant activities, by activating 
protein C, which in turn inhibits the coagulation cascade by inactivating cofactors Va and 
VIIIa and promotes the fibrinolytic system by inactivating one of its inhibitors (P AI-1), 
inhibition of this bound thrombin would compromise the endogenous fibrinolytic system. 
These experimental studies, where the inhibitory effects of various thrombin 
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agents on the amidolytic activities of purified enzymes were studied and designed to 
assess the inhibitory range of several thrombin inhibitors on pro-fibrinolytic enzymes. 
In the defined enzyme systems, it was evident that Ac-D-Phe-Pro-boroArg-OH was the 
thrombin inhibitor with the widest and strongest range of antiprotease actions. Boc-D-
Phe-Pro-Arg-H also had a wide range of antiprotease activities, although these were 
achieved at higher concentrations (0.24 - 15 µM). D-Phe-Pro-Arg-H and D-MePhe-Pro-
Arg-H did not affect kallikrein and urokinase but did inhibit the other enzyme systems 
at concentrations comparable to those of Ac-D-Phe-Pro-boroArg-OH or Boc-D-Phe-Pro-
Arg-H. In contrast to these tripeptide derived thrombin inhibitors, argatroban, a 
peptidomimetic of comparable mass, hirudin and heparin/antithrombin had minimal 
activities on the enzymes systems examined. Heparin was used in conjunction with 
antithrombin, since heparin mediates its inhibitory activities through potentiation of 
antithrombin. Aprotinin, an anti-fibrinolytic agent, followed the inhibitory profile of Ac-
(D)Phe-Pro-boroArg-OH at equivalent concentrations. This agent however is devoid of 
antithrombin activity at this concentration range. It should be noted that the inhibition 
of these purified enzymes by thrombin inhibitors is competitive utilizing a substrate 
which is different than the natural ones for each enzyme, e.g. the natural substrates of 
APC are factors Va and VIiia and their Ki values are different from that of the 
chromogenic substrate used in the amidolytic assay. Therefore, the in vivo and clinical 
relevance of these data is questionable and will depend among other factors on the local 
concentrations of the antithrombin agent, the endogenous and exogenous enzymes and 
the natural substrates. A valid approach to demonstrate the inhibitory effects of thrombin 
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inhibitors on APC is to utilize an animal model in which the regulatory physiologic 
effects of this anticoagulant protein can be assessed (::::; 100 µM). Nevertheless, these 
results suggest that agents such as the tripeptide derivatives may exhibit direct 
interactions with these enzymes and they may show varying degrees of compatibility with 
fibrinolytic agents since they can directly interact and compromise these actions. Agents 
such as argatroban, hirudin and heparin that lack direct inhibitory activities against the 
fibrinolytic enzymes, are expected to behave differently when administered with 
thrombolytic agents. 
The relationship of these in vitro non-thrombin effects of the antithrombin agents 
to the in vivo process of fibrinolysis was examined in a rabbit model of jugular vein 
thrombolysis (Callas et al. 1995). In contrast to most animal models of thrombolysis 
used by other investigators where the clots formed are platelet-rich and are designed to 
detect thrombolytic facilitation, the clots formed and lysed in this model are fibrin-rich 
clots and the model is designed to detect thrombolytic compromise. The studies on the 
effects of thrombin inhibitors on this thrombolytic model confirm the results from the in 
vitro studies. The antithrombin agent with the broadest and strongest spectrum of 
activity against the fibrinolytic enzymes, Ac-D-Phe-Pro-boroArg-OH, also compromised 
thrombolysis the most. D-MePhe-Pro-Arg-H and aprotinin also had marked anti-
fibrinolytic activities in this animal model. In contrast, argatroban, hirudin and heparin 
had minimal effects, correlating with their narrow spectrum of activity. Interestingly, 
the last three agents did have some activity, which may be due to inhibition of the 
thrombomodulin-bound thrombin. Although the doses used in this rabbit model of 
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jugular clot lysis were higher than those required for antithrombotic effects of these 
thrombin inhibitors, these levels may be relevant to those achieved clinically in localized 
delivery in procedures such as coronary thrombolysis. Preliminary results of a clinical 
trial where patients with acute myocardial infarction were administered adjunctive therapy 
of strep to kinase and hirulog-I indicate that lower doses of hirulog-1 are more beneficial 
than higher concentrations (Theroux 1995). This unexpected effect may be attributed to 
inhibition of thrombomodulin-bound thrombin at higher doses of hirulog-1, so that 
inhibition of the activation of protein C and subsequent compromise of the physiological 
anticoagulant and fibrinolytic system is strong enough to manifest a clinical impact. 
Several investigators have published experimental studies on the interactions of 
various thrombin inhibitors with thrombolytic processes. A summary of these studies is 
given in the last section of the literature review. The difference between the previous 
studies and those reported in this dissertation is that these assays were developed so that 
only inhibitory effects on pro-fibrinolytic enzymes were detected, while any potential 
facilitating activities were not accountable. 
Currently there are several thrombin inhibitors in clinical development as 
anticoagulants for the management of vascular and cardiovascular disorders. Hirudin, 
hirulog-1, efegatran are being developed for the management of abrupt closure during 
coronary angioplasty. The on-site concentrated delivery of these agents has also been 
advocated. In such clinical applications a direct fibrinolytic compromise by the inhibition 
of tPA and plasmin may seriously impair thrombolytic processes. An indirect fibrinolytic 
deficit due to the inhibition of thrombin's regulatory effect on activated protein C 
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formation can also lead to impaired fibrinolysis. Thus, prophylactic antithrombotic use 
of newly developed antithrombin drugs may also lead to an impairment of physiologic 
fibrinolysis which can manifest itself into various forms of thrombotic syndromes. 
Therefore, it is important to determine the relative fibrinolytic compromising actions of 
these agents to achieve optimal clinical results. 
E. Inhibitory Actions of Thrombin Inhibitors in Protease Generating Systems 
While in the previously discussed assays, the direct inhibitory activities of various 
agents on serine proteases was examined, the effects of the same agents on more complex 
assays, where activation of one factor leads to the generation of another was studied in 
a series of appropriately designed assays. Three different assays were used to study 
different aspects of coagulation and fibrinolysis: 
1. Extrinsic generation systems, where the coagulation cascade was activated with 
thromboplastin and the source of clotting factors ranged from fibrinogen-deficient 
plasma to prothrombin complexes. 
2. Intrinsic generation systems, where coagulation was activated by a contact 
activator and the source of clotting factors was fibrinogen-deficient plasma. 
3. Plasminogenolysis systems, where streptokinase or tPA mediated plasmin 
generation from either human plasma derived or purified plasminogen. 
In the first two types of assays, the detection of generation of both factor Xa and 
thrombin was possible. Thus, data was obtained on the importance of inhibition of 
thrombin versus factor Xa and the impact of these inhibitions on the further amplification 
of each system. 
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1. Extrinsic Activation Systems 
In the fibrinogen deficient plasma-based assay where thrombin and factor Xa are 
generated after extrinsic activation, the order of potency of the various thrombin 
inhibitors studied varied depending on whether thrombin or factor Xa were detected. 
Thus, with regards to thrombin, the order of potency was hirudin> heparin> Ac-
(D )Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H > D-Phe-Pro-Arg-H > Boc-D-Phe-Pro-
Arg-H > argatroban. Hirudin however, plateaued at about 803 inhibition of thrombin 
generation, while the other antithrombin agents were able to completely block this 
process, with the exception of argatroban. When considering the factor Xa generated in 
the same system, the order of potency of the various agents changed to heparin> Ac-
(D )Phe-Pro-boroArg-OH > Boc-D-Phe-Pro-Arg-H, D-Phe-Pro-Arg-HandD-MePhe-Pro-
Arg-H. Hirudin and argatroban had minimal inhibitory activities in the generation of 
factor Xa, never exceeding about 20 3 inhibition. Considering the hirudin results and 
knowing that hirudin inhibits only thrombin, it seems that the feedback activation of 
factor Xa by the generated thrombin accounts for about 20 3 of the generated factor Xa 
in this system, or the amount that hirudin is able to block through thrombin inhibition. 
Alternatively, hirudin maximally inhibits 80 3 of the generated thrombin, which indicates 
that the remaining 20 3 of thrombin is responsible for 80 3 of factor Xa generation, after 
extrinsic activation. These explanations on the differential activities of hirudin do not 
contradict the results obtained with heparin and Ac-(D)Phe-Pro-boroArg-OH, which are 
capable of completely inhibiting the generation of both thrombin and factor Xa, probably 
due in part to their ability to directly inhibit factor Xa. However, when considering the 
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activities of the tripeptide aldehydes, it is difficult to understand why these thrombin 
inhibitors, unlike hirudin, are capable of completely blocking both thrombin and factor 
Xa generation. The differences in the kinetics of thrombin inhibition may be accountable 
for these differences from hirudin, so that if hirudin binds thrombin relatively slower as 
it is generated, enough thrombin 11 escapes 11 to perpetuate the feedback amplifications and 
further generation of thrombin. In addition, while the tripeptide aldehydes do not inhibit 
factor Xa, they may have inhibitory activities on other coagulation factors in addition to 
thrombin, since as seen in the pro-fibrinolytic enzyme assay studies, the tripeptide 
aldehydes are capable of inhibiting other serine proteases to varying degrees. These 
explanations are in accordance with the actions of argatroban, the other monospecific 
thrombin inhibitor which, like hirudin, is not capable of completely inhibiting the 
generation of either thrombin or factor Xa. The comparative effects of heparin and 
hirudin utilizing this system have been previously published (Kaiser et al. 1992) and are 
in agreement with the results described in this dissertation. 
In the fibrinogen deficient plasma assays, the intrinsic pathway is also activated 
at some point via the feedback actions of thrombin. However, in the KONYNE® and 
FEIBA ® based tests, only factors involved in the extrinsic and common pathways of 
coagulation are present. In these systems, heparin exhibited markedly weaker inhibitory 
activities in relation to the other thrombin inhibitors, in contrast to its profile in the 
fibrinogen-deficient plasma-based assays. This difference in the actions of heparin are 
probably due to the absence of antithrombin from the KONYNE® and FEIBA ® 
preparations. Trace amounts of antithrombin or HC-11 must exist however, since heparin 
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has some effects. The comparative effects of hirudin and heparin and Ac-(D)Phe-Pro-
boroArg-OH in the KONYNE® system have been recently published (Kaiser et al. 1994). 
In this publication, addition of antithrombin is shown to potentiate the inhibitory activities 
of heparin. However, addition of factor V does not influence the inhibitory activities of 
any of the three studied agents, indicating that the factor V concentration in the 
KONYNE® preparation and consequently in this system, is not a rate limiting a factor. 
The difference between the KONYNE® and FEIBA ®preparations is that FEIBA ® 
contains factor VIIa in addition to factors II, VII, IX and X. In the KONYNE® based 
assays, Ac-(D)Phe-Pro-boroArg-OH was the only inhibitor that was capable of 
completely inhibiting the generation thrombin and factor Xa, while the other antithrombin 
agents exhibited activities similar to those of hirudin in the fibrinogen deficient plasma-
based systems. The difference in activity between Ac-(D)Phe-Pro-boroArg-OH and the 
other agents is probably due to the ability of Ac-(D)Phe-Pro-boroArg-OH to directly 
inhibit both thrombin and factor Xa. Furthermore, since the tripeptide aldehydes also 
lose their ability to inhibit the generation of both thrombin and factor Xa in this assay, 
in contrast to their activities in the fibrinogen deficient plasma systems, the previous 
hypothesis that these aldehydes may exert their inhibitory effects via inhibition of other 
coagulation factors can be narrowed to the intrinsic coagulation factors. 
In the FEIBA® based assay, while Ac-(D)Phe-Pro-boroArg-OH remains a potent 
inhibitor of both the thrombin and factor Xa generation, hirudin is also a potent inhibitor 
of this generation test. In this assay, hirudin is capable of almost completely blocking 
the generation of both thrombin and factor Xa, in contrast to the previous systems. 
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These results suggest that the relative speed or the activation status of coagulation at 
which thrombin is generated is important in the activity of thrombin inhibitors. The 
results obtained from the KONYNE® and FEIBA ®assays are difficult to interpret in light 
of the fact that thrombin and factor Xa are generated even in the absence of cofactors 
VIII and V, according to the specification sheets of the products. This indicates that 
either both products or thromboplastin which is added to extrinsically activate the 
coagulation system retain trace amounts of these cofactors. 
2. Intrinsic Activation Systems 
To examine the effects of antithrombin agents on the inhibition of the intrinsic 
generation of thrombin and factor Xa, the fibrinogen deficient plasma was activated with 
a contact activator and the generated thrombin and factor Xa were detected with 
chromogenic substrates. With the exception of heparin, all antithrombin agents inhibited 
the intrinsic generation of thrombin in a manner parallel to their inhibitory profiles in the 
extrinsic generation of thrombin and similar explanations for their activities can be 
offered. However, in contrast to its extrinsic thrombin activation profile, the activities 
of heparin plateaued around 80 3 inhibition of intrinsic thrombin generation. Similarly, 
argatroban and hirudin also produced comparable results to heparin in both systems. The 
difference in the activities of heparin is probably due to the differences in the inhibition 
of various clotting factors by antithrombin, through which heparin exerts its actions. 
When examining the effects of antithrombin agents on the generation of factor Xa in the 
same system, all agents including heparin, hirudin and argatroban, were capable of 
completely inhibiting the generation of factor Xa. Thus, it appears that none of the 
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factor Xa generated is a result of feedback activation through thrombin. These results 
are in agreement with the comparative effects of hirudin and heparin in these systems 
reported in a previous publication (Kaiser et al. 1992). 
3. Plasminogenolysis Systems 
Since various antithrombin agents were found to inhibit various fibrinolytic 
enzymes, to assess their effects on the process of activation of plasminogen, the in vitro 
plasminogenolysis experiments were carried out. Activation of plasminogen to plasmin 
was also inhibited to various degrees by the different agents, with the activities of hirudin 
and heparin being always minimal. The inhibitory profile of the thrombin inhibitors 
remained the same regardless of activators, streptokinase and tPA, or source of 
plasminogen, purified or human plasma. Therefore, the inhibitory effects of the 
antithrombin agents on these processes are probably due to direct inhibition of plasmin, 
while direct inhibition of the plasminogen activators may also contribute to the overall 
inhibitory effects of each agent in this system. These results are in agreement with the 
published effects of thrombin inhibitors on fibrinolytic enzymes (Barabas et al. 1993), 
where it was shown that the tripeptide aldehydes D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H 
and Boc-D-Phe-Pro-Arg-H, produced concentration-dependent antifibrinolytic effects in 
the fibrin plate assay and the TEG. However, according to these published studies, while 
these thrombin inhibitors produce clear inhibitory effects on TEG measured fibrinolysis, 
they also decrease the elasticity of the clots formed, which is suggested to be a pro-
fibrinolytic effect. The results of these studies reinforce the importance of the specificity 
of antithrombin agents for thrombin. 
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F. Global Anticoagulant Effects of Thrombin Inhibitors: 
PT, APTT, ACT and TEG 
The information provided by the antiprotease and protease generation assays is 
valuable in understanding the mechanism of action of each agent in more global settings, 
such as in plasma and whole blood clotting processes. The PT and APTT are the 
plasmatic clot-based assays that are the equivalents of the extrinsic and intrinsic 
fibrinogen deficient plasma amidolytic-based assays respectively. 
In the PT assay, heparin has no anticoagulant effects in contrast to its effects in 
the extrinsic generation system. The differences in the plasma dilutions and the 
concentrations of the activator (thromboplastin) in the two systems may be responsible 
for this difference in heparin's action. With the exception of heparin and hirudin, the 
order of potency of the anticoagulant effects of the other antithrombin agents was the 
same as in the extrinsic thrombin generation system and similar to their Ki value rank 
order: hirudin > Ac-(D )Phe-Pro-boroArg-OH > argatroban > D-MePhe-Pro-Arg-H > 
D-Phe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H. The observations on the effects of 
argatroban reinforce the concept that the effects of an agent on the clotting activity of 
thrombin correlate better with its Ki value than its effects on the amidolytic activity of 
thrombin. 
In the APTT assay, the order of potency of the antithrombin agents was found to 
be heparin> Ac-(D)Phe-Pro-boroArg-OH > hirudin> argatroban> Boc-D-Phe-Pro-Arg-
H > D-MePhe-Pro-Arg-H > D-Phe-Pro-Arg-H. This rank order does not correspond to 
the one obtained from the intrinsic thrombin generation system, or to any other obtained 
from the rest of the assays. This is the only test where Ac-(D)Phe-Pro-boroArg-OH was 
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found to be a more potent anticoagulant than hirudin. However, heparin was the most 
effective anticoagulant overall in this assay, as it was in the Heptest and the intrinsic and 
extrinsic generation of factor Xa in the fibrinogen deficient plasma-based assays. This 
is probably reflective of the importance of generation of factor Xa in the coagulation 
pathway after intrinsic activation, which is the rate limiting step in the generation of 
thrombin. 
Species differences between human and rabbit plasma affect the anticoagulant 
activities of thrombin inhibitors, as seen when studying the effects of heparin, hirudin, 
Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H in the rabbit plasma-based PT 
assay. In this assay, while hirudin was a stronger anticoagulant than D-MePhe-Pro-Arg-
H and heparin exhibited no anticoagulant effects, Ac-(D)Phe-Pro-boroArg-OH also 
exhibited no anticoagulant effects, in contrast to its activities in the human plasma-based 
PT. However, when examining the anticoagulant effects of the same inhibitors in the 
rabbit plasma-based APTT, the rank order of anticoagulant potencies of these agents was 
the same as in the human plasma-based APTT. 
The ACT and TEG assays provide tools for studying the anticoagulant effects of 
thrombin inhibitors in whole blood, so that clot formation is the composite result of the 
intrinsic activation of the coagulation cascade and its interactions with other blood 
components. When heparin, hirudin, Ac-(D)Phe-Pro-boroArg-OH, D-MePhe-Pro-Arg-H 
and argatroban were compared in these assays, both of these tests provided comparable 
results. In both systems, hirudin, heparin and Ac-(D)Phe-Pro-boroArg-OH appeared to 
be stronger anticoagulants than D-MePhe-Pro-Arg-H and argatroban. However,.the TEG 
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assay appeared to be more sensitive to the anticoagulant effects of these agents, in that 
their differences in the extent of anticoagulation were more pronounced. Similar results 
were obtained when heparin, hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-
Arg-H were compared in rabbit whole blood, where again the TEG assay appeared to be 
more sensitive to the anticoagulant effects of these agents than the ACT assay. 
G. Specific Measurements of Antithrombin Actions: TT and ECT 
The plasma-based amidolytic antithrombin assay gives useful information on the 
relative antithrombin activities of various agents. However, as seen from the previous 
studies, the results of the amidolytic assays are not always correlated with the Ki values 
of thrombin inhibitors and the anticoagulant effects of these compounds depends on the 
assay end-point, amidolysis versus clotting. The clot-based equivalent test of this 
antithrombin assay is the TT, where a specific amount of thrombin is added to plasma 
to stimulate clot production. The relative activities of various agents in this clotting 
assay revealed that they all exhibited concentration-dependent anticoagulation with a rank 
order of potency of hirudin> heparin> Ac-(D)Phe-Pro-boroArg-OH> D-MePhe-Pro-
Arg-H > D-Phe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H > argatroban. This rank order is 
quite different from that obtained in the amidolytic plasma-based antithrombin assay, 
where heparin was found to be the strongest antithrombin agent. Interestingly, the TT 
derived order of potency of thrombin inhibitors was exactly the same as that obtained 
from the thrombin titration assays where the A TU potency for each agent was 
determined. Similarly, the TT derived rank potency order paralleled that obtained from 
the extrinsic generation of thrombin in the fibrinogen deficient plasma-based system. 
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Another interesting observation in the TT assay was that this was the only clot-based 
assay in which argatroban was the weakest anticoagulant, similar to its inhibitory 
amidolytic actions in the previous studies. 
The ECT assay is a newly developed assay that utilizes the snake venom derived 
enzyme ecarin to activate prothrombin in the plasma to procoagulant thrombin 
intermediates, rather than adding exogenous thrombin as in the TT assay. This assay 
was developed as a plasma clotting test that is specific for direct thrombin inhibitors. 
Since heparin inhibits thrombin only through potentiation of the activities of antithrombin 
and HC-11 and since the thrombin resulting from ecarin activation is not fully formed and 
the antithrombin recognition sites are not exposed, heparin has no effects in this assay. 
Hirudin and Ac-(D)Phe-Pro-boroArg-OH had the strongest anticoagulant effects in this 
assay, as seen in all other tests. However, the effects of the other antithrombin agents 
had the following rank order of potency: D-Phe-Pro-Arg-H > D-MePhe-Pro-Arg-H > 
argatroban> Boc-D-Phe-Pro-Arg-H, which did not correlate with the results of any of 
the other assays apart from Boc-D-Phe-Pro-Arg-H being the weakest agent in some 
assays. 
Even though the ECT may not be an optimal assay to compare the anticoagulant 
effects of antithrombin agents in relationship to their Ki values for thrombin, this test 
may be of clinical usefulness in the monitoring of thrombin inhibitor levels in patients 
receiving antithrombin drugs in conjunction with other anticoagulant agents, eg. in a 
patient receiving hirudin while on oral anticoagulants or heparin. In a recent report 
(Callas et al. 1996), it was shown that when plasma from patients on oral anticoagulants 
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or heparin was supplemented with hirudin or other thrombin inhibitors, the ECT assay 
was not affected, as compared with their effects after supplementation to normal human 
plasma. Furthermore, two recent publications (Riibsamen et al. 1996, Radziwon et al. 
1996) report on the effectiveness of the ECT test in patient bedside monitoring of PEG-
hirudin. Both studies show that the ECT is not influenced by other anticoagulant 
treatments such as aspirin, low molecular weight heparins and unfractionated heparin. 
In addition, the ECT results correlated with the absolute PEG-hirudin concentration in 
the plasma of the patients systemically administered with PEG-hirudin. However, the 
results obtained with the APTT and the ACT assays did not produce a similar 
correlation. The wide range of sensitivity of this assay is an added advantage (Radziwon 
et al. 1996). 
Most of the patients treated with antithrombin agents are simultaneously 
administered with heparin or oral anticoagulant drugs. The conventional clotting tests 
such as the PT, APTT and TT are not reliable measures of the specific effects of 
antithrombin agents in these circumstances. The results reported in this dissertation 
suggest that ECT can be used for the absolute monitoring of the antithrombin agents in 
the presence of other anticoagulants. Therefore, this test is of major value in the specific 
monitoring of antithrombin drugs during PTCA, thrombolysis and stenting. 
H. Comparative Antithrombotic Actions of Various Thrombin Inhibitors 
The in vitro antithrombin and anticoagulant actions of various agents did not 
correlate with their in vivo antithrombotic effects. To examine the relative antithrombotic 
effects of selected thrombin inhibitors, four of the agents studied in the in vitro assays 
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were compared in the modified rabbit model of jugular vein stasis thrombosis. rTF was 
used as a thrombogenic challenge to determine the relative antithrombotic effects of 
various thrombin inhibitors. Unlike the previously reported studies, this thrombogenic 
trigger provided a more defined activation approach. This is also more relevant to the 
interventional cardiovascular procedures where TF is generated. The agents selected 
were heparin, hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H. Heparin 
was studied because it has been the traditional antithrombotic agent used clinically, in 
addition to being the target for replacement by some of the newer antithrombin agents. 
Since hirudin is currently in many clinical trials for various indications and is the 
strongest and specific thrombin inhibitor, it was also used in these comparative studies. 
Based on the broad anti-serine protease profile of Ac-(D)Phe-Pro-boroArg-OH, this agent 
was suitable for examining the relative contribution of thrombin inhibition in relation to 
inhibition of other clotting factors and serine proteases in antithrombotic efficacy. D-
MePhe-Pro-Arg-H was compared with the previous antithrombin agents since its 
inhibitory spectrum is narrower than Ac-(D)Phe-Pro-boroArg-OH but not as specific as 
hirudin. During the course of these experiments, several ex vivo whole blood and plasma 
analyses were made, in an attempt to determine which test would be optimal and 
correlate best with the observed antithrombotic effects of each agent. 
1. Standardization of rTF as a Thrombogenic Trigger in the 
Rabbit Stasis Thrombosis Model 
The Wessler stasis thrombosis model (Wessler et al. 1959) is a rabbit model of 
venous thrombosis and has been widely used in the evaluation of antithrombotic activity 
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of various substances. Although this model has provided useful information on the 
antithrombotic activities of various anticoagulant agents, the results obtained are relative 
to the type of thrombogenic trigger used to produce the thrombotic processes (Fareed et 
al. 1985). Defined thrombogenic agents to activate the hemostatic system of rabbits have 
been previously utilized in a standardized manner where the site of activation is 
controlled (Fareed et al. 1985). In previous studies, specific components of the 
hemostatic system were selectively activated with various agents such as Prothrombin 
Complex Concentrate (PCC) and Russell's Viper Venom (RVV) (Fareed et al. 1985). 
The availability of TF in a recombinant form (Bach et al. 1986) allows for an in-depth 
investigation of the activation of hemostasis and its pathophysiological mechanisms. 
TF is a 37,000 MW protein that is required for the activation of factor VII 
(Nemerson 1988). This TF/VIIa complex is then capable of converting factor X to Xa 
directly or via activation of factor IX to IXa (Osterud and Rapaport 1977). Activated 
factor Xa can then form a complex with factor V and this complex catalyzes the 
conversion of prothrombin to active thrombin, which then in turn converts fibrinogen to 
fibrin. The concentration of factor V in plasma is lower than that of factor X (Nesheim 
et al. 1981, Miletich et al. 1981) and without TF available, as under normal conditions, 
only the VIIIa/IXa complex can catalyze the activation of factor X (Moshier 1990). 
Thus, as in the PT assay, the supplementation of large exogenous TF, after complexation 
with factor VII, causes a direct activation of factor X that is then able to saturate all of 
the available factor V. The generated factor Xa can then further catalyze the activation 
of factor VII, thus resulting in an amplified response of the extrinsic pathway of 
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coagulation, leading to generation of massive amounts of thrombin with the end result 
of formation of thrombi. The effectiveness of TF in initiating this amplified cascade is 
evident in the clotting results of the modified stasis thrombosis model as demonstrated 
in these studies, where rTF was capable of producing clots in this model at doses as low 
as 0.04 pmol/kg. 
From the ex vivo analysis of the blood samples collected before and after 
administration of rTF in this rabbit model, a decrease in the clotting times of the global 
clotting tests would have been expected after the rTF administration. However, in the 
ex vivo studies performed in the rTF treated animals, no shortening of any of the plasma 
clotting assays (PT, APTT, TT and Heptest) was observed. This may be due to assay 
limitations, since these tests have been designed to detect anticoagulant effects in plasma 
samples and they may not be sensitive to procoagulant states. Another possible 
explanation is that rTF may bind to the cellular components of blood and vasculature, 
so that in preparing and testing the plasma fraction all rTF is removed. Furthermore, 
it is also conceivable that the administered rTF may have been neutralized by TFPI at 
the endothelial or plasmatic sites. The possibility that rTF may not exert any 
procoagulant effects in plasma systems has been excluded, since in a previous publication 
of these studies (Callas et al. 1995), the in vitro effects of rTF on plasma were studied 
in the PT assay in place of thromboplastin and it was observed that r-TF produced 
concentration-dependent shortening of the PT test. 
The ex vivo ACT and TEG methods of monitoring the degree of whole blood 
coagulation in these experiments revealed unexpected results at the higher doses of rTF 
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(0.68 and 1.35 pmol/kg), where a significant prolongation of these tests was observed, 
in contrast to what was indicated from the clot scores obtained from the same animals. 
While the ex vivo analyses of plasma samples obtained after rTF administration in rabbits 
revealed no procoagulant effects in comparison to the baseline plasma samples, none of 
the plasma samples were found to be in an anticoagulant state either. This was in 
contrast to the ex vivo whole blood TEG and ACT results. Thus, prolongation of the 
whole blood clotting parameters is not due to hypofibrinogenemia or coagulation factor 
depletion effect due to excessive amounts of circulating TF since decrease in fibrinogen 
would result in prolongation of the plasma clotting assay results as well. 
There are several possible explanations for this apparent ex vivo anticoagulant 
activity of rTF at the higher doses. The biological actions of TF, outside from its role 
in the coagulation cascade have been poorly characterized and it may well be that TF 
interacts with other cells, maybe endothelial cells or platelets, and through signal 
transduction mechanisms TF may promote fibrin formation and deposition so that even 
though in the end there is clot formation, it is not due to extrinsic pathway activation of 
blood coagulation alone and activation of coagulation may not be the only rTF mediated 
effect. 
Another explanation for this ACT and TEG prolongation may be related to tissue 
factor pathway inhibitor (TFPI) which is present in plasma in different molecular forms 
which are primarily determined by its association with circulating lipoproteins. TFPI is 
a Kunitz-type protease inhibitor (Wun et al. 1988, Girard et al. 1989). One domain of 
this protease binds to the factor VII/TF complex while the other binds to factorXa, thus 
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blocking both the extrinsic pathway leading to thrombin formation and the amplification 
of the same pathway by factor Xa (Broze 1989, Broze et al. 1988). TFPI is present in 
the plasma at ng/ml concentrations (Gramzinski et al. 1989) and thus it may inactivate 
all the factor VII/TF complexes more so when TF is available at higher concentrations, 
thus leaving only the factor IXa/factor VIII complex available for initiation of coagulation 
procedures. The vascular endothelium secretes TFPI in culture (Broze and Miletich 
1987, Warr et al. 1989) but the mechanisms that lead to release or increase in plasma 
TFPI are not well defined and neither is their mode of action. Also, there is evidence 
that intravenous heparin may cause the release of TFPI bound to the luminal surface of 
the vascular endothelium (Sandset et al. 1988). It may be that rTF at higher doses 
displaces TFPI bound to the endothelium. Normal plasma levels of TFPI are unable to 
protect rabbits against DIC and glomerular thrombosis after 4 hours infusion of rabbit 
brain TF (Warr et al. 1990). Rapaport reported that the ability of TFPI to protect 
against lower concentrations of TF in the rabbits is under study (Rapaport 1991). 
However, no defined studies on the thrombogenic effects of rTF have been reported, 
where any simultaneous measurements of TFPI have been obtained. 
In addition to cofactors, ca++ and the coagulation factors, the following steps in 
the coagulation cascade require a phospholipid surface: activation of factors IX and X by 
factor VIIa in the presence of TF, factor X activation by factor IXa in the presence of 
factor VIIIa, and thrombin formation (from prothrombin) by factor Xa in the presence 
of factor Va. In each reaction both the factor acting as the activator (protease) as well 
as the inactive zymogen form of the factor to be activated bind to the phospholipid 
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matrix. The cofactors have specific domains for binding to proteases, zymogens, ca++ 
and phospholipids (Moshier 1990). This phospholipid matrix is normally supplied by the 
platelets. However, in these studies the rTF used is already packaged in phospholipid 
vesicles. It is thus possible that the large doses of rTF provide a phospholipid surface 
which can sufficiently bind cofactors and the other components of the previously listed 
steps in a manner that they are less likely to produce procoagulant effects which are 
measurable by TEG and ACT methods. On the other hand, in the tests performed on 
plasma samples, a procoagulant effect as measured by the shortening of the clotting time 
may not be detectable due to assay limitations. In order to fully assess the effects of 
rTF, measurements of markers of protease activation such as the F1+2 fragment, 
fibrinopeptide A and thrombin-antithrombin complex may have been useful. However, 
these tests are only available for the human markers and it was not possible to perform 
these tests in the rabbit stasis thrombosis model. 
Thus, the in vivo hypercoagulable state (formation of thrombi) as observed with 
the modified stasis model, cannot be correlated with either the ex vivo whole blood 
clotting tests (ACT and TEG) or the ex vivo plasma clotting tests (PT, APTT, Heptest, 
TT). Furthermore, while the two whole blood clotting tests correlate well with each 
other, they do not correlate with the plasma clotting tests. 
As reported in the previous publication of this study (Callas et al. 1995), when 
the surface of clots generated in this animal model were examined under electron 
microscopy, the clots generated were found to be dense fibrin-rich clots with few other 
cellular components entrapped. When these clots were compared to the clots obtained 
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from the FEIBA ® treated rabbits, the morphologic characteristics of these clots differed, 
with the rTF clots appearing denser and of finer fibrin structure. Therefore, activation 
of the coagulation pathway at different levels influences the quality of the generated clot. 
This may be of clinical relevance and may aid in understanding qualitative differences 
in various thrombotic states. 
The current model used for the study of the thrombogenic effects of rTF 
represents a defined pathophysiologic model in which the cumulative clot formation is 
dependent on both the rTF and vascular stasis. Although in the whole blood system the 
suggested evidence on the release of TFPI or a TFPI-like substance is observed, the 
created thrombogenic event in the isolated jugular segment is strong enough to overpower 
the anticoagulant effects observed in the whole blood clotting assays. 
2. Comparative Antithrombotic Actions of Thrombin Inhibitors 
From the studies of the dose-dependent thrombogenic effects of rTF in the rabbit 
model of jugular vein stasis thrombosis, a dose of 0.68 pmol/kg was selected for the 
subsequent studies in which the antithrombotic effects of various agents were compared. 
This dose was selected because it consistently resulted in clot scores of at least + 3, both 
after 10 and 20 min stasis. The following thrombin inhibitors were compared in this 
model: heparin, hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H. 
a. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors After I. V. 
Administration 
All agents produced dose-dependent anti thrombotic effects after I. V. injection. 
The clots obtained after 10 min stasis revealed that the order of anti thrombotic potency 
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of these agents was hirudin> heparin> Ac-(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-
Arg-H. However, the shape of the dose-response curve for each agent was different and 
while heparin and Ac-(D)Phe-Pro-boroArg-OH produced sigmoid responses, hirudin and 
D-MePhe-Pro-Arg-H resulted in more linear responses indicating a decreased efficacy 
in comparison to heparin and Ac-(D)Phe-Pro-boroArg-OH. When examining the results 
from the 20 min stasis, again all antithrombin agents produced dose-dependent 
antithrombotic effects. The order of potency of these agents was different from the 10 
min results in that the dose-response curves obtained with hirudin and heparin were 
almost superimposable, indicating that heparin retains its antithrombotic effects relatively 
longer than hirudin. The dose-response relationships by all thrombin inhibitors were 
linear, indicating decreased efficacy in comparison to their 10 min stasis effects. This 
decreased efficacy may be due to the clots becoming more stable with time via the cross-
linking activities of factor XIIIa. 
The comparative antithrombotic effects of heparin, hirudin, hirulog and argatroban 
in a rat model of jugular vein thrombosis have been recently published (Hayes et al. 
1996). In this report, consistent with the earlier described results, on a molar basis 
hirudin was found to be a stronger antithrombotic agent than heparin after I.V. injection. 
The ex vivo analyses of blood samples obtained before and after the administration 
of each of the antithrombins, revealed that the relative effects of each agent were assay-
dependent. In the amidolytic antithrombin assay, all agents produced dose-dependent 
thrombin inhibition and their order of potency in this assay correlated with their relative 
antithrombotic responses. However, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-
294 
Arg-H produced 30 and 503 thrombin inhibition at the lowest doses injected, even 
though their corresponding antithrombotic effects were minimal. In the anti-Xa assay 
heparin and Ac-(D)Phe-Pro-boroArg-OH produced dose-dependent effects, but these 
never exceeded 40 and 303 inhibition respectively. These anti-Xa effects produced by 
heparin and Ac-(D)Phe-Pro-boroArg-OH are not surprising since both agents produced 
concentration-dependent anti-Xa effects in the in vitro studies, which were also weaker 
than their amidolytic antithrombin effects. Their relative ex vivo anti-Xa activities also 
corresponded with their relative in vitro anti-Xa effects. Minimal anti-Xa effects were 
also produced by hirudin and D-MePhe-Pro-Arg-H and these were probably indirect and 
due to inhibition of thrombin and subsequent suppression of feedback amplifications. 
The ex vivo whole blood analyses of the samples obtained prior and post thrombin 
inhibitor administration revealed that all agents resulted in dose-dependent prolongation 
of both assays, which correlated with each other although they did not correlate with the 
relative antithrombotic effects of these agents. With the exception of hirudin which was 
weaker than heparin, the other agents retained the rank order of potency in the whole 
blood clotting assays. While both the ACT and the TEG were sensitive to the 
anticoagulant effects of heparin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H, 
neither assay was sensitive to the effects of hirudin: at the highest doses that each agent 
was administered, hirudin produced the weakest ex vivo ACT and TEG prolongation, 
even though the antithrombotic effects produced by each agent were similar. The 
anticoagulant responses of heparin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-
H at the higher concentrations were similar only in the ACT, correlating to the similarity 
295 
of their antithrombotic effects at these doses. Furthermore, the inter-animal variations 
were less pronounced in the ACT than in the TEG, as measured by the S.E.M. 
The ex vivo anticoagulant effects of antithrombin agents as measured in the plasma 
clotting assays revealed that these effects were assay-dependent. None of the thrombin 
inhibitors produced any effects in the PT, while the dose-dependent effects produced in 
the APTT were minimal. On the other hand, the Heptest and the TT revealed clear 
dose-dependent anticoagulant effects of all thrombin inhibitors after I.V. injection. The 
rank order of potency of these effects in the Heptest was heparin> hirudin > Ac-(D)Phe-
Pro-boroArg-OH > D-MePhe-Pro-Arg-H, which was similar to the whole blood assay 
results but different from the antithrombotic effects. The TT appeared to be the most 
sensitive test in detecting the anticoagulant effects of all thrombin inhibitors, as 
determined by the fold increase from baseline values. At the highest doses used, none 
of the thrombin inhibitors resulted in more than a 5-fold increase in the Heptest, while 
in the TT, hirudin and D-MePhe-Pro-Arg-H exceeded 10-fold increase from baseline 
values. Furthermore, the rank order of potency of these agents in the TT followed that 
observed in the antithrombotic effects: hirudin> heparin> Ac-(D)Phe-Pro-boroArg-
OH> D-MePhe-Pro-Arg-H. However, the extent of the TT anticoagulant effects 
achieved with the highest dose of each thrombin inhibitor was different and did not 
correspond to the extent of their antithrombotic actions. 
b. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors After S.C. 
Administration 
The relative antithrombotic actions of antithrombin agents are dependent on the 
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route of administration, as seen in the rabbit stasis thrombosis studies where all agents 
were injected subcutaneously. While all agents produced dose-dependent antithrombotic 
effects and the rank order of antithrombotic actions was similar to those obtained after 
I. V. administration of these agents in the same model, the dose-response curve of heparin 
was close to that of Ac-(D)Phe-Pro-boroArg-OH in the S.C. studies after 10 min stasis 
and was the same after 20 min stasis. This was different from the response observed in 
the I. V. studies, where the effects of heparin were closer to those of hirudin. A possible 
explanation for this relative decrease in the activities of heparin is that this agent, being 
a multi-component drug of varying molecular weights, does not cross the subcutaneous 
barrier entirely, so that the higher molecular weight components do not reach the 
circulation. Based on the molecular weight of hirudin (6963 DA), this compound is 
expected to have weaker antithrombotic effects after S.C. administration, as opposed to 
I. V. administration, relative to Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H. 
Taking into consideration the ratio of the ED50 values for each agent in the I.V. and S.C. 
studies, while there was a 5-fold decrease in the absolute value for Ac-(D)Phe-Pro-
boroArg-OH and D-MePhe-Pro-Arg-H, for hirudin this decrease was 12-fold and for 
heparin it was 23-fold, which supports the view regarding the S.C. barrier influence on 
the transport of heparin and hirudin. Another difference in the two studies (I. V. versus 
S.C. administration) was that the dose-response relationship for all thrombin inhibitors 
was linear after both 10 and 20 min stasis. As seen in the I. V. studies, after 20 min 
stasis, all agents decreased in efficacy (the slope of the dose-response curves decreased) 
in comparison to their 10 min stasis effects. 
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The ex vivo amidolytic antithrombin effects of the same agents after S.C. 
administration were dose-dependent. However, the extent of antithrombin activity did 
not correlate with the extent of antithrombotic effects, as seen when comparing these 
agents at the highest doses administered. With the exception of heparin which produced 
weak dose-dependent anti-Xa effects, none of the other three agents had any apparent 
dose-dependent effects on the amidolytic anti-Xa assay. The effects of heparin can be 
explained by the ability of antithrombin, through which heparin mediates its anticoagulant 
effects, to inhibit factor Xa in addition to thrombin. The whole blood clotting analyses 
of blood samples obtained before and after thrombin inhibitor S.C. injection revealed that 
all agents produced dose-dependent anticoagulant effects. The potency order of the 
anticoagulant effects of these agents was similar to their antithrombotic order of potency. 
The TEG assay appeared to be more sensitive to the anticoagulant effects of these agents 
than the ACT, where hirudin and heparin produced about 25 3 and 35 3 of the 
anticoagulant effects of Ac-(D)Phe-Pro-boroArg-OH at the highest doses where their 
antithrombotic effects where equivalent. 
The anticoagulant effects of antithrombin agents after S.C. administration, as 
detected in the plasma-based clotting assays revealed that, as with the I.V. studies, the 
effects were test-dependent. As seen in the I.V. studies, none of these agents produced 
any effects in the PT assay. The effects on the APTT, Heptest and TT were dose-
dependent. Hirudin exhibited the strongest effects, correlating with the antithrombotic 
effects produced by this agent. However, the TT was the most sensitive assay to the 
effects of hirudin at the highest injected dose in comparison with the other agents. 
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c. Time-Dependance of Anti thrombotic Effects of Thrombin Inhibitors After I. V. 
Administration 
The studies on the time-dependance of the antithrombotic effects of heparin, 
hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H after I.V. administration 
showed that the effects of all agents decreased with time, both after 10 and 20 min stasis. 
Ac-(D)Phe-Pro-boroArg-OH and heparin lost their antithrombotic activities at a faster 
rate than hirudin and D-MePhe-Pro-Arg-H, as determined by the slopes of their time-
dependent responses. The ex vivo antithrombin analyses of the plasma samples obtained 
before and after the injection of each antithrombin agent, showed that with exception of 
heparin which had minimal antithrombin activities, the antithrombin effects of the other 
agents where time-dependent. While the effects of Ac-(D)Phe-Pro-boroArg-OH 
decreased steadily with time, the effects of D-MePhe-Pro-Arg-H where maximal at 30 
min and those of hirudin where maximal around 45 min. The antithrombotic effects of 
D-MePhe-Pro-Arg-H were steadily maximal for the first 30 min after administration 
(correlating with the antithrombin effects) but the antithrombotic effects of hirudin 
steadily declined after I. V. injection. This dichotomy in the antithrombotic/ antithrombin 
effects of hirudin may be due to compartmentalization of hirudin and subsequent slow 
release of this agent so that the ex vivo antithrombin effects are sustained, even though 
the antithrombotic effects are diminished. As seen in the previous studies, none of the 
agents had any substantial effects on the anti-Xa assay. In contrast to the plasma 
amidolytic antithrombin and anti-Xa assays, the whole blood clotting tests, ACT and 
TEG, showed that all agents produced time-dependent anticoagulant effects that paralleled 
their antithrombotic effects, with heparin and Ac-(D)Phe-Pro-boroArg-OH exhibiting the 
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fastest rates of decrease of their anticoagulant activities, similar to their antithrombotic 
activities. 
As observed in the previous studies, none of the antithrombin agents had any 
effects on the PT assay after I. V. administration during the observation period. In 
contrast, the other plasma-based clotting assays revealed a time-dependent decrease of 
the anticoagulant activities of all thrombin inhibitors, with one notable exception: D-
MePhe-Pro-Arg-H produced a time-dependent increase in the Heptest assay until 30 min 
post I. V. injection, after which these effects started to rapidly decrease. This particular 
effect of D-MePhe-Pro-Arg-H is similar to that seen in the antithrombin amidolytic assay 
and is consistent with the antithrombotic effects of this agent, which are maximally 
sustained for the first 30 min post I. V. administration. Overall, as seen in the previous 
studies, the TT was the most sensitive assay to the anticoagulant effects produced by 
thrombin inhibitors. 
d. Time-Dependent Antithrombotic Effects of Thrombin Inhibitors After S.C. 
Administration 
The studies on the time dependance of the anti thrombotic effects of various agents 
after S.C. administration revealed the differences in the ability of each agent to cross 
through the S. C. barrier. When examining the comparative antithrombotic effects of 
heparin, hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H in the rabbit 
stasis thrombosis model after 10 min stasis, it was observed that the agents that exhibited 
the maximal antithrombotic effects at the shortest interval after S.C. injection were 
hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H, in that order. . The two 
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tripeptide derivatives have similar low molecular weights (496.8 and 514.6 DA 
respectively), which probably allows them to cross rapidly through to the circulation. 
While the effects of Ac-(D)Phe-Pro-boroArg-OH steadily and slowly declined with time 
after 15 min, the effects of D-MePhe-Pro-Arg-H remained maximal up to 45 min after 
S.C. administration before declining, indicating perhaps a difference in the clearance 
rates of the two agents. Similar to the effects of D-MePhe-Pro-Arg-H, hirudin also 
exhibited steady maximal antithrombotic effects for 45 min after S.C. injection, before 
these effects started to subside. The molecular weight difference between the two 
tripeptides and hirudin is 14-fold, but this does not compromise the ability of hirudin to 
cross the S.C. barrier. In contrast to the time-dependent effects of these agents, heparin 
exhibited a steady increase in its antithrombotic effects after S.C. administration up to 
the last time point examined at 90 min post injection. This is to be expected considering 
the multi-component nature of this drug and expecting the smaller antithrombotic 
components to cross the S.C. barrier earlier than the heavier counterparts. 
The time-dependent effects of these agents are also dependent on the duration of 
stasis, so that at the 20 min stasis end point, the time-dependent antithrombotic profile 
of each agent changed. While the effects of D-MePhe-Pro-Arg-H were maximal 15 min 
post S.C. administration, these effects steadily declined, rather than remaining constant 
for 45 min as observed in the 10 min stasis. On the other hand, the effects of Ac-
(D)Phe-Pro-boroArg-OH and hirudin remained constant over the 90 min period following 
post S.C. injection, in contrast to their 10 min stasis effects which slowly declined after 
15 min. The effects of hirudin after 20 min stasis were steady over the 90 min period 
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studied as well and this was again in contrast to the effects of this agent after 10 min 
stasis, where a decline was observed after 45 min post S.C. administration. However, 
the sustained effects of both Ac-(D)Phe-Pro-boroArg-OH and hirudin after 20 min stasis 
were decreased when compared to the maximal effects at the 10 min stasis end point, 
indicating that these agents had decreased antithrombotic effects against cross-linked 
fibrin. Heparin exhibited a gradual and continual increase in its antithrombotic effects 
over the 90 min observation period, following S.C. injection and 10 min stasis. This 
was also in contrast to its effects after 20 min stasis, where heparin increased its 
antithrombotic effects until 45 min post S.C. administration, after which these 
antithrombotic activities gradually decreased. This may also be indicative of the limited 
antithrombotic potential of heparin on cross-linked fibrin. 
The time-dependent ex vivo amidolytic antithrombin effects of heparin after S.C. 
injection, revealed a correlation with its antithrombotic effects, as did the amidolytic anti-
Xa test and the whole blood clotting tests (ACT and TEG). As seen previously, none 
of the other thrombin inhibitors had any effects on the anti-Xa amidolytic assay. The 
antithrombin, ACT and TEG effects of hirudin correlated with its antithrombotic effects 
after 10 min stasis, with the ACT being the most sensitive assay. Ac-(D)Phe-Pro-
boroArg-OH produced sustained maximal antithrombin and TEG effects, correlating with 
its 20 min stasis antithrombotic effects, while in the ACT results correlated more with 
its 10 min stasis antithrombotic effects (a steady increase with time over the 90 min 
period). D-MePhe-Pro-Arg-H also exhibited sustained maximal antithrombin and TEG 
effects, throughout the 90 min observation time after S.C. administration. However, in 
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the ACT, a time-dependent decline in this agent's anticoagulant activity was observed, 
correlating well with its effects after 20 min stasis. The assay that was most sensitive 
to all of the agents' effects without reaching the upper limit was the ACT, while the 
amidolytic antithrombin and TEG results often approached the upper limits of the assays, 
with the exception of hirudin. 
When examining the time-dependent ex vivo anticoagulant effects of these agents, 
as studied in the plasma-based clotting assays, once again, it was observed that none of 
these agents had any effects on the PT. The results of heparin on the APTT, Heptest and 
TT correlated well with its antithrombotic effects after 20 min stasis. Hirudin produced 
minimal effects on the APTT and the Heptest, while its effects on the TT increased with 
time throughout the 90 min observation period post S.C. injection. The effects of Ac-
(D)Phe-Pro-boroArg-OH on the APTT were always maximal, while the time-dependent 
anticoagulant effects in the Heptest and the TT paralleled the antithrombotic effects of 
this agent. D-MePhe-Pro-Arg-H produced sustained maximal effects in the APTT and 
the Heptest, while its effects in the TT correlated with its antithrombotic effects. Thus, 
the TT appeared to be the most sensitive plasma clotting assay for these agents, without 
exceeding the upper limits at the doses producing maximal antithrombotic effects. 
Another observation was that at 75 min post S.C. administration at 10 min stasis and 35 
min post S.C. injection at 20 min stasis, all agents produced similar antithrombotic 
results. However, of all ex vivo analyses, only the TT assay results converged around 
the 75 time point. 
To date, a comparison of the duration of action of the four agents investigated 
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after S.C. administration in any animal models is not available. The duration of in vivo 
antithrombotic actions may therefore have relevance to the prophylactic use of these 
agents. 
I. Comparative Hemorrhagic Profile of Thrombin Inhibitors 
The rabbit ear bleeding model used in these studies was introduced by Cade in 
1959. This model has been extensively utilized to profile the hemorrhagic effects of 
various drugs and is based on the ability of superficial minor vessels to occlude after 
transection within minutes. The primary hemostatic plug is formed by platelets, which 
is then reinforced by fibrin deposition resulting from activation of coagulation. The 
clotting process is triggered by the exposure of blood to TF on the subendothelial sites 
of the transected vessels, resulting in thrombin formation which mediates platelet 
activation. Therefore, inhibitors of the coagulation cascade as well as platelet inhibitors 
are expected to have dose-dependent hemorrhagic effects in this model, which manifest 
by increased blood loss in a specified period of time. This model was used to compare 
the relative hemorrhagic effects of heparin, hirudin Ac-(D)Phe-Pro-boroArg-OH and D-
MePhe-Pro-Arg-H, to allow for comparison of these effects with the antithrombotic 
effects, discussed previously, in the same species. During the course of the rabbit ear 
bleeding experiments blood samples were not obtained for concomitant ex vivo analysis 
to minimize blood loss and to avoid hemodynamic alterations in this model. 
1. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors 
After I. V. Administration 
When the dose-dependent hemorrhagic effects of thrombin inhibitors were 
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examined in the rabbit ear blood loss model, heparin produced weak but steady 
hemorrhagic effects at all doses studied, 5 min after I. V. administration. The 
hemorrhagic effects of heparin after 20 min of I. V. injection were diminished. These 
weak bleeding effects of heparin may be attributed to the fact that heparin works through 
potentiating the anticoagulant effects of circulating antithrombin and HC-II. Therefore, 
the available amount of antithrombin and HC-II can be saturated by heparin and beyond 
a dose of 0.1 mg/kg I.V. heparin no additional anticoagulant effects can be achieved. 
Hirudin and D-MePhe-Pro-Arg-H produced dose-dependent hemorrhagic effects both 
after 5 and 20 min post I. V. administration and similar to heparin their effects were 
diminished after 20 min. Because of their mechanism of action, these direct thrombin 
inhibitors do not achieve a ceiling effect as seen with heparin. While Ac-(D)Phe-Pro-
boroArg-OH also produced dose-dependent hemorrhagic effects after 5 and 20 min post 
I. V. injection, the effects of this agent after 20 min post I. V. administration were 
potentiated, in contrast to the bleeding effects of the other agents. This enhancement of 
the bleeding effects of Ac-(D)Phe-Pro-boroArg-OH with time may be due to vascular 
binding and subsequent slow release of this agent, or more likely, to non-anticoagulant 
effects of this agent and may involve vascular compromise. The observation 
substantiating the latter hypothesis is that at the 1 µmol/kg I. V. dose tested, 3 rabbits 
presented with respiratory depression within the first 5 min after I. V. injection, became 
cyanotic and expired within 30 min after the administration. Necroscopic examination 
of vital organs did not reveal any unusual findings. These rabbits were substituted to 
maintain the rabbit group size at 6 animals. 
2. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors 
After S.C. Administration 
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The hemorrhagic effects of thrombin inhibitors after S.C. injection were also 
examined. Heparin was found to have significant bleeding effects only at the highest 
dose administered (0.9 µmol/kg) and only after 45 min post S.C. administration. At 60 
min post S.C. injection, this effect was diminished. These minimal bleeding effects after 
S.C. administration are also likely to be due to inability of all heparin fractions to pass 
the S.C. barrier. Hirudin produced dose-dependent hemorrhagic effects, 45 min post 
S.C. injection, but similar to the effects of heparin, these effects were also diminished 
60 min post S.C. administration. In contrast to the relatively weak bleeding effects of 
hirudin and heparin, the dose-dependent effects of Ac-(D)Phe-Pro-boroArg-OH were 
maximal 45 min post S.C. injection and although they decreased 60 min post S.C. 
administration, these remained stronger than any effects produced by the other thrombin 
inhibitors. This observation supports the previous hypothesis that the hemorrhagic effects 
produced by Ac-(D)Phe-Pro-boroArg-OH may be due in part to additional non-thrombin 
related activities of this agent. D-MePhe-Pro-Arg-H exhibited a bleeding profile similar 
to that produced by hirudin, in that 45 min post S.C. injection it produced dose-
dependent effects which were diminished 60 min post S.C. administration. Since Ac-
(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H are of similar molecular weights and 
probably cross the S.C. barrier at similar rates, the limited effects of D-MePhe-Pro-Arg-
H after S.C. injection further support the possibility of Ac-(D)Phe-Pro-boroArg-OH 
exhibiting hemorrhagic effects through non-thrombin mediated actions. 
3. Time-Hemorrhagic Effects of Thrombin Inhibitors After 
I.V. and S.C. Administration 
306 
The time-dependent hemorrhagic effects of these thrombin inhibitors revealed a 
progressive agent specific decrease in the hemorrhagic activities. However, after S.C. 
administration, heparin, hirudin and Ac-(D)Phe-Pro-boroArg-OH produced increasing 
hemorrhagic effects with time with a maximal effect at 45 min post administration, after 
which these started to decline. In contrast to the S.C. hemorrhagic effects of heparin, 
hirudin and Ac-(D)Phe-Pro-boroArg-OH, S.C. injection of D-MePhe-Pro-Arg-H resulted 
in gradually decreasing bleeding effects from the first time point observed (15 min post 
S.C. administration). This suggests that D-MePhe-Pro-Arg-H is capable of crossing the 
S.C. barrier in less than 15 min post injection, further supporting the hypothesis that the 
maximal hemorrhagic effects produced by Ac-(D)Phe-Pro-boroArg-OH 45 min post S.C. 
administration are due to additional non-coagulation related effects of this agent. 
J. Integration of Data on Antithrombotic and Hemorrhagic Effects 
of Thrombin Inhibitors 
In comparing the dose-dependent antithrombotic and hemorrhagic effects of 
various thrombin inhibitors, it was found that even though overall hirudin was the 
strongest antithrombotic agent in the stasis thrombosis model after both 1.V. and S.C. 
administration, it also had the strongest bleeding effects in the rabbit ear blood loss 
model, with the exception of the 60 min post S.C. injection results, where Ac-(D)Phe-
Pro-boroArg-OH was the strongest agent. On the other hand, heparin produced strong 
antithrombotic effects, which were weaker than hirudin, after l.V. and S.C. 
administration, while producing the weakest hemorrhagic effects of all agents after both 
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I.V and S.C. administration. The effects of Ac-(D)Phe-Pro-boroArg-OH were 
consistently stronger than those produced by D-MePhe-Pro-Arg-H in both animal models 
after both I.V. and S.C. injection. 
The comparison of the antithrombotic and hemorrhagic effects of each thrombin 
inhibitor can be best illustrated by comparing the ED50 value of the effects that each 
agent produced in the stasis model to the dose that resulted in bleeding of 2 · 1 D9 RBC/L 
in the rabbit ear blood loss model. When comparing the ED50 values of each thrombin 
inhibitor derived in the stasis model after I.V. administration and 10 min stasis, and the 
doses the produced 2 · 109 RBC/L blood loss 5 min post I. V. injection, it was found that 
D-MePhe-Pro-Arg-H had the lowest ratio of the two respective parameters, with the 
bleeding dose being about 12-fold greater than the antithrombotic dose. Ac-(D)Phe-Pro-
boroArg-OH closely followed with a 17-fold difference in its bleeding/antithrombotic 
values. Hirudin, on the other hand, producing less hemorrhagic effects than D-MePhe-
Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH at high doses, had a 37-fold difference of 
its respective hemorrhagic/antithrombotic indices. Heparin, producing minimal 
hemorrhagic effects at all doses had a ratio of > 56-fold of the respective indices. These 
differences indicate that while hirudin is a more potent antithrombotic agent than heparin, 
as assessed in the rabbit stasis thrombosis model, heparin has a wider safety margin. 
This is most likely attributable to the fact that heparin mediates its actions through 
potentiation of a limiting amount of antithrombin and HC-11 in plasma, which imposes 
a ceiling on its maximal effects, whether antithrombotic or hemorrhagic. 
The relative antithrombotic/hemorrhagic effects of antithrombin agents after I.V. 
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administration depend on the time period studied. Thus, when the ED50 of each thrombin 
inhibitor in the stasis thrombosis model after I. V. injection and 20 min stasis is compared 
with the bleeding effects produced 20 min post I. V. administration, it was found that 
because D-MePhe-Pro-Arg-H exhibited a decrease in its hemorrhagic effects the ratio to 
the antithrombotic effects could be determined only as > 3. The bleeding/antithrombotic 
index for Ac-(D)Phe-Pro-boroArg-OH was found to decrease from 17 to 12, which may 
be explained by increased non-thrombin related hemorrhagic effects of this agent with 
time. When comparing the hemorrhagic/antithrombotic effects of hirudin at these time 
points, the ratio decreased to 27, which could be attributed to sequestration of this drug 
and subsequent slow release, resulting in high enough circulating concentrations to 
produce an antiplatelet effect (through thrombin inhibition) but not sufficient for an 
antithrombotic effect. The bleeding/antithrombotic ratio of heparin remained high at 
> 50, suggesting that this drug has the widest safety/efficacy window. 
The ratios of the hemorrhagic and antithrombotic effects of various thrombin 
inhibitors after S.C. injection is not as clear, since in most cases these agents produced 
minimal hemorrhagic effects. Thus, for Ac-(D)Phe-Pro-boroArg-OH, the ratio of the 
ED50 from the 45 min post S.C. administration and 10 min stasis dose-response compared 
with the dose that results in 2 · 109 RBC/L bleeding was 7, and the ratio of the ED50 after 
20 min stasis to the bleeding effects after 60 min post S.C. injection was 5. These ratios 
for the safety/efficacy of Ac-(D)Phe-Pro-boroArg-OH are lower than the ratios observed 
after I. V. administration. Hirudin had a safety /efficacy ratio of 22, when comparing the 
ED50 from the 45 min post S.C. injection and 10 min stasis antithrombotic dose-response 
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compared with the dose that results in 2 · 109 RBC/L 45 min post S.C. administration, 
which was also lower than the ratio produced after I.V. injection. The lower 
safety/efficacy ratios after S.C. administration as compared to those after I.V. injection, 
for both inhibitors may be attributable mostly to decreased antithrombotic effects after 
S.C. administration, as discussed earlier. 
It is interesting to note that these experimental observations on the relative 
bleeding/antithrombotic effects of antithrombin agents are consistent with the recently 
available clinical data where increased risk of hemorrhage was found to be associated 
with the use of antithrombin agents such as hirudin (Antman and TIMI 9A Investigators, 
1994, GUSTO Ila Investigators, 1994, GUSTO Ilb Investigators, 1996). In the 
experimental studies, a dose-response for both the hemorrhagic and antithrombotic 
actions was evident. Such relationships in the clinical trials have not been established. 
These observations clearly suggest the need of individual dose-response investigation for 
different antithrombin agents. To obtain valid results, these studies should be optimally 
carried out in the same species. 
K. Rat Laser-Induced Thrombosis Model 
The comparative antithrombotic effects of thrombin inhibitors, as studied in the 
rabbit stasis thrombosis model, provide information on the antithrombotic activities of 
these agents in the venous system. Since the pathophysiology of thrombotic processes 
in the arterial and the venous systems differ, these compounds were also compared in a 
rat model of laser-induced arterial thrombosis as performed in the mesenteric arterioles. 
This model is standardized so that exposure of an arteriole to 2-3 sequential laser shots 
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results in thrombus formation that is either occluding or is of a length 1.5 x vessel 
diameter. The thrombi formed with this procedure are platelet-rich clots that do not 
stabilize unless continued laser exposure occurs. The laser exposures are directed 
towards the vessel wall. The laser injury is thermal in nature and after histologic 
examination of these vessels, it appears that only endothelial cells are affected (Dr. Klaus 
Breddin, personal communication). The injury is concentrated enough so that usually 
only the surface membrane of the endothelial cells is detached. However, in some 
instances the whole cell appears to be "dehydrated". This indicates that exposure of TF 
from sub-endothelial sites triggers local coagulation to generate enough thrombin to 
activate platelets, or it may be that coagulation is triggered by contact activation through 
exposed sub-endothelial matrices. 
Heparin, hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H 
exhibited dose-dependent antithrombotic effects in this animal model. The order of 
antithrombotic potencies was heparin> Ac-(D)Phe-Pro-boroArg-OH > hirudin> D-
MePhe-Pro-Arg-H. This order of potencies was different from those observed in the 
rabbit stasis thrombosis model. While D-MePhe-Pro-Arg-H was consistently the weakest 
antithrombotic agent in both the rabbit venous stasis model and the rat arterial thrombosis 
model, hirudin was the strongest antithrombotic agent in the rabbit stasis thrombosis 
model and in this rat model it ranked third. The fact that heparin was found to be the 
strongest antithrombotic agent in the rat arterial thrombosis model, in contrast to its 
effects in the rabbit venous thrombosis model suggest that heparin is more effective than 
hirudin in inhibiting the formation of thrombus in this model. On the other hand, when 
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coagulation is activated extrinsically with greater amounts of TF, as is the case with the 
rabbit stasis thrombosis procedure, the endogenous levels of antithrombin may not be 
sufficient or as effective as hirudin in inhibiting coagulation. Since Ac-(D)Phe-Pro-
boroArg-OH was also found to be a stronger antithrombotic agent than hirudin in the rat 
model, and both heparin and Ac-(D)Phe-Pro-boroArg-OH exhibit both antithrombin and 
anti-Xa effects, it may be that inhibition of coagulation at multiple sites is more effective 
in preventing platelet activation due to generation of thrombin. 
While D-MePhe-Pro-Arg-H dose-dependently prevented clot formation in the rat 
model in a dose-dependent fashion, a ceiling effect was reached at about a dose of 2 
µmol/kg. This ceiling effect was of about 6 laser shots, which is lower than that of 8 
laser shots observed with heparin and hirudin. Furthermore, at D-MePhe-Pro-Arg-H 
doses higher than 3.4 µmol/kg, the antithrombotic effects of this agent progressively 
decreased. It was visually observed that the blood flow markedly decreased at these 
higher doses, so that the thrombus formation could be an indirect effect of altered 
hemodynamics. Similar decreases in blood flow were observed with Ac-(D)Phe-Pro-
boroArg-OH at doses above 0.2 µmol/kg, I.V. These effects by both D-MePhe-Pro-Arg-
H and Ac-(D)Phe-Pro-boroArg-OH on the rat blood flow are indicative of the non-
thrombin related effects that these agents may produce. Another interesting finding is 
that the ceiling effect of Ac-(D)Phe-Pro-boroArg-OH was about 10 laser shots which is 
higher than that produced by heparin and hirudin. Since Ac-(D)Phe-Pro-boroArg-OH 
is a direct thrombin and factor Xa inhibitor and is not limited by endogenous amounts 
of antithrombin as is heparin, the higher ceiling effect for this agent is not surprising. 
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Although the differences in the potency orders in the rabbit venous stasis 
thrombosis model and the rat laser-induced arterial thrombosis model are most likely due 
to the differences in the pathophysiologic processes, the possibility of species dependance 
cannot be excluded. 
When the bleeding results of the 1.V. administered heparin and antithrombin 
agents were compared with the observed antithrombotic actions in the rat laser model of 
arterial thrombosis, there was no relevance that could be established. Although the 
vascular sites are the primary trigger for the laser model and vascular compromise could 
also contribute to bleeding, the lack of any relationship between these two findings may 
be due to the species differences. 
L. Species Dependence of Antithrombotic and Anticoagulant Effects 
of Thrombin Inhibitors 
To compare the relative anticoagulant actions of newer agents, whole blood and 
plasma-based assays have been performed in rat, rabbit, dog, monkey and human blood 
and plasma (Schlam et al. 1975). In this dissertation, the in vitro studies are primarily 
carried out in the human and rabbit plasma and whole blood. In comparing the baseline 
coagulation profile of whole blood and plasma, it was evident that rabbit plasma and 
whole blood clotted faster in various assays. This may be due to the compositional 
variations in the coagulation pathways and number of blood cells. Interestingly, this 
trend was not followed when individual antithrombin agents were tested in several assays. 
In other words, each of the inhibitors exhibited a distinct assay-dependent profile in both 
the human and rabbit studies. These observations reinforce the notion that while 
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antithrombin agents primarily target thrombin in mediating their anticoagulant effects in 
plasma, these agents may exhibit complex interactions in different activation states and 
therefore exhibit variable responses which are both species and activation dependent. 
Species dependent antithrombotic actions also play an important role in the 
determination of the antithrombotic potency of various antithrombin agents. In this 
investigation, a rabbit model of venous stasis thrombosis was employed to compare the 
relative antithrombotic actions of these agents. To investigate the comparative effects of 
these agents in arterial thrombosis, a laser model of rat arterial thrombosis was used. 
Although the model-dependent variations are predictable, the ED50 for each of the 
inhibitors were markedly higher in the rat laser model (5-10 fold) in contrast to the rabbit 
stasis thrombosis model. This observation may be partly dependent on the species used. 
In this research dissertation, the primary intent was to compare the relative potency of 
various thrombin inhibitors with heparin. In a consistent fashion such comparisons where 
carried out to determine the rank order of potency. The relevance of the ED50s obtained 
in different models to projected human responses may be questionable. Regardless, such 
an exercise is of crucial value in the preclinical profile of a new antithrombin drug. 
Beside the measurable anticoagulant actions of heparin and antithrombin agents, 
species dependent variations in the pharmacokinetic and pharmacodynamics effects may 
also contribute to the different responses noted during this research. Thus, it is clear that 
both the in vitro and ex vivo profile of various agents are not only dependent on the 
blood/plasma matrix but also on the endogenous transformations and interactions with the 
cellular and vascular sites. 
M. Integration of in vitro Studies with Observed 
Phannacologic Actions of Thrombin Inhibitors 
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The general order of potency of the antithrombotic effects of thrombin inhibitors 
in the rabbit stasis thrombosis model was hirudin> heparin> Ac-(D)Phe-Pro-boroArg-
OH> D-MePhe-Pro-Arg-H. This order correlated well in a number of in vitro assays. 
Specifically, the antithrombotic effects of hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-
MePhe-Pro-Arg-H correlated with their published Ki values, the amidolytic thrombin 
potency evaluation results and the fibrinogen-based clotting assay results. The 
antithrombotic effects of all four thrombin inhibitors in the rabbit model correlated with 
their respective results in the extrinsic and intrinsic thrombin generation from fibrinogen 
deficient plasma results, as well as with the in vitro PT and TT clotting assays. 
The order of potency of the four antithrombin agents in the rat laser model 
correlated with only one of the in vitro assay profiles of these agents, namely the APTT. 
This observation supports the hypothesis that platelet activation and clot formation in this 
model may not be due to intrinsic activation of coagulation. 
The overall order of potency of the bleeding effects of antithrombin agents, as 
observed in the rabbit model of ear blood loss, was hirudin> Ac-(D)Phe-Pro-boroArg-
OH> D-MePhe-Pro-Arg-H > heparin. The order of the three first agents followed the 
same trend with the order of their Ki values, the results of the amidolytic thrombin 
potency evaluation studies, the fibrinogen-based clotting results, the PT assay and the 
ECT test. However, when the antithrombotic effects of heparin are also considered, 
none of the in vitro assays correlate with the hemorrhagic results, indicating the necessity 
of in vivo evaluation of the hemorrhagic effects of antithrombin agents. 
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The above observations point to the usefulness of standardization of various 
thrombin inhibitors. Caution should be taken to compare various agents in the same 
system though, and with agents such as heparin which are not direct thrombin inhibitors, 
standardization is not possible in the same manner as with the direct antithrombin agents. 
Furthermore, it may be that some in vitro assays are not suitable for comparison of 
agents with different mechanisms of thrombin inhibition, as is the case with argatroban 
and its effects on the amidolytic assays. For the same reason, while the amidolytic 
protease generation assays provide useful information on the mechanisms of action of 
thrombin inhibitors and their relative efficacies and potencies, argatroban cannot be 
compared with the other agents in these systems in a manner that can be related to its 
effects in clot-based assays or to its in vivo antithrombotic effects. Therefore, apart from 
the Ki comparison of agents for thrombin, clot-based assays may be more applicable in 
comparing these thrombin inhibitors. 
While concomitant ex vivo analyses were not carried out in the rat arterial 
thrombosis model due to animal weight and methodological limitations, the rabbit venous 
thrombosis ex vivo analyses indicate that the whole blood clotting assays (ACT and TEG) 
and the TT plasma clotting assay are the optimal tests for correlating antithrombotic with 
anticoagulant effects, since in the other tests (with the exception of the PT), while all 
agents produced dose-dependent anticoagulant effects, the relative extent of their ex vivo 
effects did not correlate with the relative extent of their antithrombotic effects. Similar 
observations have been recently reported (Carteaux et al. 1995). In this publication, the 
comparative antithrombotic effects of hirudin, heparin and Ro 46-6240 (low molecular 
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weight direct thrombin inhibitor) correlated with the ex vivo ACT effects but not with the 
ex vivo APTT results. It should be noted that the relative extent of ex vivo anticoagulant 
effects of hirudin in all tests utilized did not correlate to the relative extent of 
antithrombotic effects when compared to the other agents, pointing to the need for 
development of assays that correspond to antithrombotic effects and the importance of 
comparing thrombin inhibitors in a battery of assays both in vitro and in vivo. 
In terms of therapeutic monitoring of an individual thrombin inhibitor, the ECT 
assay may be useful since the range of sensitivity of this test is wider than any other 
assay. Furthermore, this assay is not affected by the presence of indirect thrombin 
inhibitors, which makes this test ideal for thrombin inhibitor monitoring in situations 
where additional antithrombotic agents may have been used. However, the suitability of 
this assay for comparison of various anticoagulants and extrapolation of these relative in 
vitro effects to their relative in vivo antithrombotic effects is unclear at the time. 
N. Significance of Studies in Understanding the 
Pharmacology of Thrombin Inhibitors 
The relative potency of the thrombin inhibitors included in this investigation is 
usually expressed in terms of Ki or IC50 values which are carried out in defined in vitro 
systems, in which thrombin titration is used. Whether or not the assigned inhibitory 
constants translate into pharmacologic effects is not known. This investigation represents 
the first comprehensive study to simultaneously compare the biochemical and 
pharmacologic actions of heparin and antithrombin agents. An agent may show strong 
antithrombin potency, however, due to its complex pharmacodynamics and other 
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endogenous interactions, its behavior may not be predictable simply by assigning to it an 
antithrombin potency. For example, hirudin exhibited the strongest antithrombin 
potency, however, in the laser model of arterial thrombosis, its potency was relatively 
weaker in relation to thrombin inhibitors such as Ac-(D)Phe-Pro-boroArg-OH. This 
observation clearly suggests that beside the inhibition of thrombin, additional factors 
contribute to the observed pharmacologic actions of antithrombin agents. 
Heparin is a complex polypharmacologic agent with multiple plasmatic and 
vascular sites of action. Although the overall anticoagulant activity of this drug is 
usually standardized in anticoagulant units (USP assays), the potency designation of 
antithrombin agents may not be directly comparable to that assigned to heparin and 
related drugs. Thus, an APTT elevation to 3 or 4 times the baseline level by a thrombin 
inhibitor may or may not be relevant to the overall anticoagulant/antithrombotic response 
observed with heparin. This investigation has provided clear evidence on this hypothesis. 
At equivalent levels of APTT, the relative antithrombotic actions of these agents are not 
the same. This is not just true for the comparison of heparin and antithrombin agents 
but thrombin inhibitors at equivalent prolongation of clotting tests exert different degrees 
of antithrombotic and/or hemorrhagic effects. This dissertation therefore provides 
evidence that the bioequivalence of these agents is not predictable by any of the ex vivo 
tests available at this time. 
Significant difference in the pharmacodynamic effects of these agents are found 
regardless of the potency, molarity and gravimetric adjustments. Thus, each 
antithrombin agent exhibits its own unique biochemical and pharmacologic profile. The 
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data obtained in various studies is readily transformed into molar values which may have 
a closer relevance to the observed pharmacologic actions. An in-depth analysis of the 
dose and the time-dependent pharmacodynamics of each of these agents can therefore be 
useful in projecting some of the clinical effects of these agents. This dissertation 
therefore has addressed some of the pharmacologic and biochemical parameters in molar 
terms which can be applied for limited direct comparisons. 
One of the most significant questions regarding the relative importance of 
thrombin in the mediation of thrombogenesis and its inhibition as the main target for 
controlling the thrombotic events has been objectively addressed in this dissertation. 
From the experimental evidence provided, it is clear that the sole inhibition of thrombin 
is not the primary determinant of the antithrombotic actions of antithrombin agents and 
heparin. In the case of thrombin inhibitors, additional plasmatic and non-plasmatic 
processes also contribute to the control of thrombogenesis by these agents. In the case 
of heparin, it is obvious that the antithrombin mediated inhibition of thrombin is only one 
of the multiple mechanisms for the pharmacologic action of this drug. 
Another significant observation in this dissertation is related to the dichotomy 
between the in vitro and in vivo behavior of these agents. It is commonly believed that 
antithrombin agents are usually inert. If this was true, a steady decrease in the observed 
antithrombotic and bleeding effects after I.V. administration would have been noted. 
This certainly does not hold true for some of these agents, therefore, endogenous 
transformations and other cellular and vascular interactions contribute to their observed 
effects. 
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Therefore, a classification of thrombin inhibitors can be proposed on the basis of 
the spectrum of their pharmacologic actions, as depicted on Table 25. Antithrombin 
agents can be grouped into three major categories. Hirudin, hirulog and their analogues 
are clearly agents with plasmatic actions only, solely targeting the generated thrombin 
and its regulatory functions. On the other end, agents such as heparin and aptamers 
mediate diverse pharmacologic actions including vascular, anti-inflammatory, anti-platelet 
and anti-proliferative effects. Agents such as the tripeptide and peptidomimetic thrombin 
inhibitors possess vascular effects in addition to their plasmatic actions, placing these in 
a category between the two described above. 
Table 25 -- Classification of Thrombin Inhibitors Based on their Pharmacologic Actions 
Agents with plasmatic actions only Hirudin, hirulog 
Agents with dual mechanisms of action (plasmatic and Peptides, 
vascular) peptidomimetics 
Agents with additional regulatory effects (anti-
proliferative, platelet interactions, anti-inflammatory) 
Heparin, aptamers 
An additional significant observation during this investigation relates to the fact 
that antithrombin agents are considered inhibitors which only target thrombin. However, 
their effects on other serine proteases and modified forms of thrombin are not taken into 
account. Many of the thrombin inhibitors such as D-MePhe-Pro-Arg-H and Ac-(D)Phe-
Pro-boroArg-OH, significantly inhibit non-thrombin serine proteases and this may have 
a complex outcome. In addition, most of the thrombin inhibitors inhibit thrombomodulin 
bound thrombin, which can have significant implications in the management of 
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thrombotic and cardiovascular disorders. This dissertation has provided an additional 
insight on the potential clinical implications due to the non-specificity of these agents. 
Another classification of thrombin inhibitors can thus be generated based on the 
spectrum of their serine protease activities, as depicted on Table 26. Hirudin, hirulog 
and their analogues, argatroban, HC-II and aptamers are monospecific agents that interact 
solely with thrombin. On the other hand, agents such as Ac-(D)Phe-Pro-boroArg-OH 
interact with almost every serine proteases involved in systems other than coagulation and 
including the fibrinolytic system. Agents with limited serine protease inhibitory activities 
but not restricted to thrombin are included in the narrow spectrum class of thrombin 
inhibitors. These agents include napsagatran, inogatran and antithrombin and beside their 
antithrombin activities, these also exhibit weaker inhibition of other coagulation factors. 
Table 26 -- Classification of Thrombin Inhibitors Based on their Serine Protease 
Inhibitory Spectrum 
Monospecific 
Narrow spectrum 
Broad spectrum 
Hirudin, hirulog, argatroban, HC-II, 
aptamers 
Napsagatran, inogatran, antithrombin 
Ac-(D)Phe-Pro-boroArg-OH, peptide arginals 
While preclinical screening of new antithrombin agents have mostly relied on 
thrombin titration methods to assign relative potency for antithrombin derived drugs, such 
potency designation has not been very useful in the prediction of the in vivo 
pharmacologic behavior of these drugs. One of the most important contributions of this 
research is based on the fact that it provides the first comprehensive database for the 
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comparative biochemical profile, in vitro anticoagulant actions and pharmacologic 
information relevant to their efficacy and safety. It is also for the first time that these 
agents are compared at a molar level. Table 27 shows the data on the comparative rank 
order of potencies of heparin and these antithrombin agents in several biochemically 
defined assays. It is interesting to note that heparin and hirudin exhibit the strongest 
potency profiles while the rank order for other agents varies depending on the type of 
assay used. Similarly, when heparin and these agents are tabulated in terms of their 
anticoagulant potency ranking, assay dependent rank order variations were obvious as 
shown on Table 28. While heparin and hirudin once again showed strong effects, Ac-
(D)Phe-Pro-boroArg-OH exhibited relatively comparable effects. The rank order of 
other antithrombin agents varied with the type of test used. Of notable interest was the 
behavior of these agents in the ECT assay, where heparin failed to show any 
anticoagulant effects and hirudin remained the strongest anticoagulant agent tested. 
Interestingly, argatroban in this assay was found to have comparable effects to the 
peptide arginal derivatives. 
The animal models of thrombosis and bleeding provided a useful preclinical 
approach to compare the in vivo effects of heparin, hirudin and other antithrombin agents 
and relate these results to the biochemical and anticoagulant studies. These results are 
tabulated on Table 29. These studies were carried out only on heparin, hirudin, Ac-
(D )Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H. While hirudin was found to be 
strongest in most of these in vivo studies, heparin and Ac-(D)Phe-Pro-boroArg-OH also 
exhibited comparable or stronger effects in some models. To a large extent, the order 
Table 27 -- Comparative rank order of potencies of various antithrombin agents in various biochemical assays. 
1 2 
Ki hirudin Ac-FPboroR 
ATU potency hirudin Ac-FPboroR 
Fibrinogen-based hirudin Ac-FPboroR 
clotting 
Amidolytic anti-Ila heparin hirudin 
in NHP 
Amidolytic anti-Xa Heparin Ac-FPboroR 
inNHP 
Fibrinogen-deficient hirudin heparin 
assay: thrombin 
generation 
Fibrinogen-deficient heparin Ac-FPboroR 
assay: factor Xa 
generation 
FPR = D-Phe-Pro-Arg-H 
Me-FPR = D-MePhe-Pro-Arg-H 
Boc-FPR = Boc-D-Phe-Pro-Arg-H 
Ac-FPboroR = Ac-(D)Phe-Pro-boroArg-OH 
3 4 5 6 
argatroban FPR Me-FPR Boc-FPR 
Me-FPR FPR Boc-FPR argatroban 
Me-FPR argatroban FPR Boc-FPR 
Ac-FPboroR FPR Me-FPR Boc-FPR 
Ac-FPboroR Me-FPR Ac-FPboroR Boc-FPR 
FPR, Me-FPR, 
Boc-FPR 
7 
argatroban 
argatroban 
Table 28 -- Comparative rank order of potencies of various antithrombin agents in in vitro anticoagulant assays. 
1 2 3 4 5 6 7 
PT hirudin Ac-FPboroR 
APTT heparin Ac-FPboroR 
TT hirudin heparin 
ECT hirudin Ac-FPboroR 
Hep test heparin hirudin 
ACT Ac-FPboroR, Me-FPR, 
hirudin, heparin argatroban 
TEG Ac-FPboroR, Me-FPR 
hirudin, heparin 
FPR = D-Phe-Pro-Arg-H 
Me-FPR = D-MePhe-Pro-Arg-H 
Boc-FPR = Boc-D-Phe-Pro-Arg-H 
Ac-FPboroR = Ac-(D)Phe-Pro-boroArg-OH 
argatroban Me-FPR FPR Boc-FPR 
hirudin argatroban Boc-FPR Me-FPR FPR 
Ac-FPboroR Me-FPR FPR Boc-FPR argatroban 
FPR Me-FPR argatroban Boc-FPR 
Ac-FPboroR argatroban Me-FPR FPR Boc-FPR 
argatroban 
Table 29 -- Comparative rank order of potencies of various antithrombin agents in in vivo pharmacologic models. 
1 2 3 4 
Rabbit stasis thrombosis, hirudin heparin Ac-FPboroR Me-FPR 
I. V. 10 min stasis 
Rabbit stasis thrombosis, heparin hirudin Ac-FPboroR Me-FPR 
I.V. 20 min stasis 
Rabbit stasis thrombosis, hirudin Ac-FPboroR heparin Me-FPR 
S.C. 10 min stasis 
Rabbit stasis thrombosis, hirudin heparin Ac-FPboroR Me-FPR 
S.C. 20 min stasis 
Rat laser induced heparin Ac-FPboroR hirudin Me-FPR 
thrombosis 
Rabbit hemorrhagic model, hirudin Ac-FPboroR Me-FPR heparin 
I.V., 5 and 20 min 
Rabbit hemorrhagic hirudin Ac-FPboroR Me-FPR, heparin 
model, S.C., 45 min 
Rabbit hemorrhagic Ac-FPboroR Me-FPR, hirudin, 
model, S.C., 60 min heparin 
FPR = D-Phe-Pro-Arg-H 
Me-FPR = D-MePhe-Pro-Arg-H 
Boc-FPR = Boc-D-Phe-Pro-Arg-H 
Ac-FPboroR = Ac-(D)Phe-Pro-boroArg-OH 
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of potency in the rabbit model of thrombosis followed consistent patterns. This order 
followed a different ranking pattern for the rat laser model of thrombosis, where heparin 
was found to be strongest and hirudin was relatively weaker than both heparin and Ac-
(D )Phe-Pro-boroArg-OH. Similarly, in the bleeding model, the order of hemorrhagic 
effects followed a different pattern, which was also route dependent. Heparin was found 
to be relatively weaker in comparison to all other antithrombin agents. These studies 
clearly warrant the necessity of evaluating the results of the in vitro and in vivo screening 
in a multiparametric integrated fashion. The data presented here is therefore of crucial 
importance in projecting the biochemical and pharmacological actions of newly developed 
antithrombin agents. 
This dissertation therefore emphasizes the importance of pharmacologic profiling 
for new antithrombin agents as the direct antithrombin effects and other plasmatic or 
vascular actions of these agents can only be evaluated in valid pharmacologic studies. 
It is important to point out that some of the recent adjustments of clinical trials and the 
reported adverse events due to both the safety and efficacy compromise were largely 
based on incomplete preclinical pharmacological information. 
0. Developmental Perspectives 
The current developmental perspectives on various thrombin inhibitors are 
summarized in Table 30. Site-directed antithrombin agents such as recombinant hirudin, 
hirulog and synthetic tripeptides are currently undergoing various phases of clinical trials. 
These agents were initially developed with the premise that sole targeting of thrombin 
may be the most important step in the development of anticoagulants and antithrombotic 
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drugs to treat thrombotic and cardiovascular disorders (Lefkovits and Topol 1994, 
Verstraete and Zoldhelyi 1995). It is nearly five years that these agents have undergone 
clinical trials. Hirudin and hirulog have completed several phase II trials, whereas the 
peptide D-MePhe-Pro-Arg-H, marketed under the generic name efegatran sulfate, has 
recently entered a phase II trial. The primary focus of these trials has been in 
cardiovascular areas such as pretreatment of ischemic heart disorders, anticoagulation 
during coronary angioplasty, treatment of post-interventional abrupt closure and late 
reocclusion (restenosis) and adjunct usage during thrombolysis. It is too early to suggest 
that these agents have a definitive advantage over heparin. However, in heparin 
compromised patients, these new anticoagulants may be useful on a compassionate basis. 
The cost of hirudin therapy is relatively higher than heparin. The relative cost for the 
synthetic antithrombin agents may be lower than hirudin, however, the true cost analysis 
can only be valid after a comprehensive pharmacoeconomic analysis for specific 
prophylactic and therapeutic indications. 
Several peptidomimetic antithrombin agents are also currently in clinical 
development for both cardiovascular and therapeutic indications. These include 
argatroban (Mitsubishi, Japan), inogatran (Astra, Sweden) and napsagatran (Roche), 
Switzerland). The results of some of these clinical trials are expected later this year. 
In addition, many other antithrombin agents are now in active preclinical development. 
Of the various peptide derived antithrombin agents, efegatran is the only agent 
which is currently developed for cardiovascular indications. Many other agents 
developed by different companies were initially developed in various preclinicaLstudies, 
Table 30 -- Developmental Status of Site-Directed Thrombin Inhibitors 
Hirudin and its analogues 
Hirulogs 
Peptidomimetics 
Peptides and their derivatives 
Aptamers 
Plasma derived antithrombin 
Chemical Nature 
Recombinant protein 
Developmental Status 
Developed for both arterial and venous 
thrombosis 
Synthetic bifunctional oligopeptides Several clinical studies are completed; additional 
studies are planned in various indications 
Synthetic heterocyclic derivatives Phase II clinical development in the USA; used 
(argatroban, inogatran, napsagatran) in Japan 
Peptide arginals (efegatran) Phase II clinical development 
DNA and RNA derived oligonucleotides with Preclinical stage; limited animal data available 
thrombin-binding domains (defibrotide) 
Natural proteins and their recombinant 
equivalent products 
Antithrombin (AT-III) is currently used. HC-II 
is still in developmental status 
Transition state peptide analogues Oligopeptides and synthetic organic agents Preclinical screening is being completed 
(boronic acid derivatives) 
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but due to problematic developmental issues, their clinical development was discontinued. 
Aptamers represent both DNA and RNA derived oligonucleotides with weaker 
anticoagulant effects. As such, these agents are not developed for the purpose of 
anticoagulation. However, some of these agents show antithrombin actions in the in vitro 
settings. A mammalian DNA derived product, defibrotide (Crinos, Italy), has been used 
as an anti-ischemic drug, however, its actions are not solely attributed to the inhibition 
of thrombin. This agent, like heparin, produces multiple pharmacologic effects on 
platelets, endothelial cells and also release of TFPI (Fareed et al. 1995). 
Despite the isolation and characterization of various antithrombin proteins from 
human plasma and development of their recombinant equivalent, antithrombin obtained 
by the fractionation of human plasma remains the only thrombin inhibitor for clinical use 
(Menache 1991, Fourrier et al. 1993). Several products are currently available for the 
treatment of congenital thrombophilia and acquired hypercoagulable state including DIC. 
HC-11 has also become available but is not currently used. 
Many other synthetic and recombinant approaches have been used to develop 
antithrombin agents at this time. Of these, the development of the transition state 
analogues has been pursued. Despite developing very potent antithrombin agents using 
this approach, these agents have not been clinically developed due to toxic effects. 
From the studies reported in this dissertation and the published data, it is clear 
that the currently available thrombin inhibitors are not solely specific for thrombin. With 
the exception of hirudin, most of the other thrombin inhibitors are capable of producing 
several additional effects including inhibition of non-thrombin serine proteases, 
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interacting with vascular sites and modulating various regulatory processes. Some of 
these effects are depicted in Fig. 61. 
Most antithrombin agents have been designed and developed as specific inhibitors 
of thrombin. However, these agents exhibit variable interactions with the serine protease 
network, including the fibrinolytic, kallikrein and complement system. Since thrombin 
belongs to the serine protease family of enzymes, as do most of the coagulation factors 
and the fibrinolytic enzymes, developing an inhibitor with strong affinity for thrombin 
and none for the other enzymes remains a challenge to the pharmaceutical industry. 
While aptamers, hirudin and hirulog have inhibitory activities only towards thrombin due 
to their unique mode of action (they recognize and inhibit sites on thrombin other than 
the catalytic site, which are unique for thrombin), the other thrombin inhibitors, which 
are designed to bind to the catalytic site of thrombin have weaker inhibitory activities 
against other enzymes as well. Thus, at high doses, these agents may interfere with the 
fibrinolytic system and with APC. This interaction may have some safety compromise 
in patients who are treated with these drugs, especially at high dosages (Theroux 1995). 
Another important issue is the inhibition of thrombomodulin-bound thrombin by 
the low molecular weight thrombin inhibitors. While thrombomodulin-bound thrombin 
is devoid of procoagulant effects, it retains its anticoagulant effects since it is still capable 
of activating protein C (which functions both as an anticoagulant by inactivating factor 
Va and factor VIIIa and as a pro-fibrinolytic by inactivating PAI-1 and PAI-3). The 
importance of thrombomodulin-bound thrombin inhibition remains to be clarified. 
However, as reported in clinical trial results with hirudin, the lack of dose-dependency 
Inhibition of 
fibrinolytic pathwa 
Activated Protein 
C Inhibition 
Feedback 
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Fig. 61. Sites of Actions of Thrombin Inhibitors. Beside the inhibition of thrombin, 
these agents are also capable of inhibiting some of the regulatory actions of thrombin, 
such as the activation of protein C through thrombomodulin bound thrombin, stabilization 
of clot through factor XIIIa and primary hemostatic activation of platelets. The non-
thrombin mediated activities of these agents include the inhibition of fibrinolytic and 
kallikrein related enzymes, feedback amplification of proteases (thrombin and non-
thrombin), modulation of complement esteroproteases and potential modulation of nitric 
oxide pathways. 
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after a threshold dose of hirudin, indicate that thrombomodulin-bound thrombin plays an 
significant role in the overall anticoagulant response (Theroux 1995). 
Some of the thrombin inhibitors also possess direct vasodilatory effects, 
independent of their activity on thrombin. These effects are believed to be mediated 
through metabolic products containing guanidino groups which result in the increase of 
nitric oxide generation (Fareed and Callas 1995). Depending on the specific indication 
for which the thrombin inhibitor is developed, this vascular effect may be desirable. 
Nevertheless, this type of effect should be investigated and considered. 
The pathophysiologic role of thrombin extends beyond coagulation and platelet 
activation. Thrombin also has direct effects on other cell types and functions, ranging 
from mitogenesis and contraction of smooth muscle cells to adhesion and metastasis of 
tumor cells to neurite growth regulation to endothelial cell stimulation (Tapparelli et al. 
1993). Although the functions of thrombin in such processes as atherogenesis and cancer 
metastasis have not been fully characterized, a thrombin inhibitor will interfere with all 
of thrombin's bioregulatory functions. These observations may have some impact on the 
development of thrombin inhibitors in cancer and cardiovascular indications. 
Ever since their introduction, most of the clinical indications for these new 
anticoagulants have been in the interventional cardiovascular areas (Herrman and Serruys 
1994). Initial focus has been on the prevention of abrupt closure during coronary 
angioplasty (Topol et al. 1993, Topol 1995). These agents have also been tried for the 
post-PTCA prevention of both the early and late reocclusion (Suzuki et al. 1995). In 
addition, some of the thrombin inhibitors have been used for the treatment of unstable 
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angina (Topol 1995). More recently, some of these agents have been tested for their 
efficacy in stenting (Sternberger et al. 1996, van Beusekom et al. 1994, Buchwald et al. 
1993). Although several reports on the experimental use of these antithrombin agents 
have been made available on their use in cardiovascular surgery in animal models, only 
isolated reports in human studies are available (Riess et al. 1995). Since a known 
antagonist to neutralize the effects of antithrombin agents is not available, concerns over 
the use of these agents have been expressed (Edmunds 1995). Currently, no 
pharmacologic antagonists exist for hirudin or any of the other direct thrombin inhibitors, 
making the managing of precipitated hemorrhagic effects problematic. Current hirudin 
reversal strategies employed include prothrombin complex concentrate to neutralize the 
circulating antithrombin agents (Irani et al. 1995) or dialysis to remove an antithrombin 
agent from the blood (Fareed et al. 1991). Strategies that are under development of 
effective neutralizing agents are production of mutant thrombin molecules that are devoid 
of clotting activity but for which antithrombin agents retain a high affinity, thus 
saturating circulating levels of these agents (Fischer et al. 1996). 
Thrombin inhibitors are attractive to both clinicians and surgeons as substitute 
anticoagulants in heparin compromised patients in particular. For patients exhibiting 
heparin induced thrombocytopenia and requiring anticoagulation, several trials are 
currently in progress to test the efficacy of new antithrombin agents (Edmunds 1995, 
Chamberlin et al. 1995). 
Although thrombin inhibitors are potent anticoagulants and unlike heparin do not 
require any endogenous cofactors for their actions, their development as· surgical 
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anticoagulants has been rather slow due to the non-availability of a pharmacologic 
antagonist. Only when such an antagonist is available and clinically validated, these 
agents may find their way into surgical applications. 
There is a growing interest in the use of these agents in the prevention and 
treatment of DVT (Bridey et al. 1995). A recent study (Eriksson et al. 1996) reported 
on the successful use of recombinant hirudin in the prophylaxis of post-orthopaedic 
surgery. In this study unfractionated heparin (5000 IU s.c. t.i.d.) was compared with 
hirudin (15 mg s.c. b.i.d.), which was found to be superior. Several additional trials are 
currently being conducted on different antithrombin agents. 
Current clinical trends also point to polypharmacologic approaches for the 
treatment and management of cardiovascular disorders. Combination modalities of 
anticoagulants with other drug classes such as antiplatelet and fibrinolytic drugs has been 
employed (Theroux et al. 1995, Lee 1995, Cannon and Braunwald 1995). While 
clinically developed thrombin inhibitors are reportedly specific for thrombin inhibition, 
these agents exhibit interactions with other drugs. Antiplatelet drugs such as aspirin and 
ticlopidine have additive or synergistic actions when used in conjunction with thrombin 
inhibitors (O'Donnell et al. 1995). Similar interactions would be expected when 
thrombin inhibitors would be used with heparin and low molecular weight heparins or 
antithrombin III concentrates (Biemond et al. 1994). On the other hand, adjunct usage 
of thrombin inhibitors with thrombolytic agents, at an optimized dose, could result in the 
facilitation of thrombolysis or, if the thrombin inhibitor dose is not adjusted, in 
thrombolytic compromise. Some of these agents may also directly inhibit activated 
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protein C, or inhibit activated protein C formation by neutralizing thrombomodulin-bound 
thrombin (Theroux et al. 1995, Callas et al 1995, Callas and Fareed 1995). Furthermore, 
thrombin inhibitors may neutralize the coagulant actions of factor VIia and prothrombin 
complex concentrates (Biemond et al. 1994). Therefore, it is desirable that the 
interactions of thrombin inhibitors are well studied and considered when designing drug 
combination protocols for clinical applications, as such interactions may have both safety 
and efficacy implications. 
The development of thrombin inhibitors has added a new dimension in the 
management of thrombotic and vascular disorders. While the major clinical indications 
for these agents include interventional cardiovascular procedures and DVT prophylaxis, 
little is known for their use in the area of surgical and therapeutic anticoagulation. It is 
projected that many of the newer thrombin inhibitors, such as hirulog and hirudin, will 
be developed as anticoagulants and may be substituted for heparin. Synthetic tripeptides 
with broader serine protease inhibitory spectrum offer unique tools to control thrombo-
genesis at different levels and may prove to be more useful in chronic indications, 
including prophylactic usage. The usefulness of various thrombin inhibitors in a given 
medical or surgical indication can be proven only in properly designed clinical trials. 
CHAPTER VI 
SUMMARY 
A. In Vitro Studies 
1. The molecular profile was investigated in the case of the peptide arginals, Ac-
(D)Phe-Pro-boroArg-OH and unfractionated heparin. The specifications on hirudin and 
argatroban indicated these agents to be > 903 pure and homogeneous. The peptide 
arginals and Ac-(D)Phe-Pro-boroArg-OH exhibited hydrate form transformations. As 
expected, heparin was determined to be polycomponent and exhibited similar molecular 
weight profile in both the UV and RI analyses. 
2. The relative antithrombin potency (ATU) for each thrombin inhibitor as 
measured by an amidolytic method was found to widely vary in the range of 2,000-
200,000 ATU/mg (1,000-156,000 ATU/nmol). These unit potency values were not 
consistent with the published Ki and IC50 values. This may be due to differences in the 
experimental methods, the choice of thrombin preparations and the mathematical analyses 
of the generated data. 
3. When the thrombin titration was carried out on the natural substrate of 
thrombin, fibrinogen, against the commercially available human thrombin preparation, 
all of the thrombin inhibitors exhibited different degrees of antithrombin potency. 
However, heparin did not exhibit any antithrombin potency in these assays. The rank 
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order for the relative antithrombin actions of these agents is given as follows: hirudin> 
Ac-(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H > argatroban > D-Phe-Pro-Arg-H > 
Boc-D-Phe-Pro-Arg-H. 
4. The amidolytic antithrombin potencies were also measured for heparin and 
various antithrombin agents in normal human plasma and normal rabbit plasma based 
assays. In these assays, heparin was found to be the strongest inhibitor (IC50 of 6.1-9.6 
nM). Species dependent variations were noted. The various thrombin inhibitors exhibited 
the following rank order of potency: heparin> hirudin > Ac-(D)Phe-Pro-boroArg-OH > 
D-Phe-Pro-Arg-H > D-MePhe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H > argatroban. 
5. In the amidolytic anti-Xa assays performed in the normal human plasma and 
normal rabbit plasma assays, except for heparin and Ac-(D)Phe-Pro-boroArg-OH, none 
of the other thrombin inhibitors produced any anti-Xa effects. Heparin in both systems 
was found to be an efficient inhibitor of factor Xa. 
6. The antiprotease profile for each of the individual thrombin inhibitors and 
heparin/antithrombin complex was investigated utilizing chymotrypsin, trypsin, activated 
protein C, glandular kallikrein, tPA, urokinase and plasmin. Aprotinin was also included 
as a reference inhibitor. None of the thrombin inhibitors produced any inhibition of 
chymotrypsin. With the exception of hirudin and argatroban, all of the thrombin 
inhibitors produced varying degrees of inhibition of these stated enzymes with IC50 values 
in the µM range. These studies clearly indicate that different thrombin inhibitors are 
capable of producing measurable inhibition of non-thrombin serine proteases of the 
fibrinolytic and kallikrein system, at concentrations which are least one .order of 
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magnitude greater than those observed for the inhibition of thrombin. 
7. The thrombin and factor Xa generation studies were carried out in fibrinogen 
deficient plasma to compare the relative ability of heparin and these thrombin inhibitors 
on the generation of these enzymes after extrinsic and intrinsic activation. All agents 
produced varying degrees of the inhibition of thrombin and factor Xa generation, 
following the order of hirudin > heparin> Ac-(D) Phe-Pro-boroArg-OH > D-MePhe-Pro-
Arg-H > D-Phe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H > argatroban for extrinsic and 
intrinsic thrombin generation and with the following order for extrinsic factor Xa 
generation: heparin> Ac-(D)Phe-Pro-boroArg-OH > D-Phe-Pro-Arg-H, D-MePhe-Pro-
Arg-H and Boc-D-Phe-Pro-Arg-H. 
8. The influence of these agents on the generation of factor Xa and thrombin was 
also carried out in activated and native prothrombin complex concentrates. After 
extrinsic activation, varying degrees of inhibition of both of these enzymes was noted. 
Activation and system variations were evident and each inhibitor showed an individual 
profile. In comparison to heparin, thrombin inhibitors produced relatively stronger anti-
Xa than antithrombin effects. Ac-(D)Phe-Pro-boroArg-OH was found to be the strongest 
inhibitor in most of these assays. 
9. Each of the thrombin inhibitors and heparin exhibited a distinct inhibitory 
profile in the norman human plasma based clotting assays, such as the PT, APTT, TT, 
Heptest and ECT. The relative anticoagulant potency was also both agent and assay 
dependent. In each test, the following potency rank orders were observed: 
PT: hirudin, Ac-(D)Phe-Pro-boroArg-OH > argatroban > D-MePhe-Pro-Arg-H > D-Phe-
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Pro-Arg-H > Boc-D-Phe-Pro-Arg-H 
APTT: heparin> Ac-(D)Phe-Pro-boroArg-OH > hirudin > argatroban > Boc-D-Phe-Pro-
Arg-H > D-MePhe-Pro-Arg-H > D-Phe-Pro-Arg-H 
TT: hirudin> heparin> Ac-(D)Phe-Pro-boroArg-OH> D-MePhe-Pro-Arg-H> D-Phe-
Pro-Arg-H > Boc-D-Phe-Pro-Arg-H > argatroban 
Heptest: heparin> hirudin> Ac-(D)Phe-Pro-boroArg-OH > argatroban> D-MePhe-Pro-
Arg-H > D-Phe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H 
ECT: hirudin> Ac-(D)Phe-Pro-boroArg-OH > D-Phe-Pro-Arg-H > D-MePhe-Pro-Arg-
H > argatroban > Boc-D-Phe-Pro-Arg-H 
10. The relative anticoagulant effects of heparin and various inhibitors were also 
investigated in the whole blood ACT and TEG assays. In both assays, a concentration-
dependent anticoagulant effect was evident in the ACT (rank order: hirudin, heparin, Ac-
(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H, argatroban) and the TEG (rank order: 
hirudin, heparin, Ac-(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H > argatroban). 
11. For the comparative anticoagulant effects in the normal rabbit plasma based PT, 
APTT, TT and Heptest, heparin, hirudin, D-MePhe-Pro-Arg-H and Ac-(D)Phe-Pro-
boroArg-OH exhibited distinct profiles. The relative anticoagulant potency was also both 
agent and assay dependent. In each test, the following rank orders were observed: 
PT: hirudin, Ac-(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H 
APTT: heparin> Ac-(D)Phe-Pro-boroArg-OH> hirudin> D-MePhe-Pro-Arg-H 
TT: hirudin> heparin> Ac-(D)Phe-Pro-boroArg-OH> D-MePhe-Pro-Arg-H 
Heptest: heparin> hirudin> Ac-(D)Phe-Pro-boroArg-OH> D-MePhe-Pro-Arg-H 
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12. Heparin and various thrombin inhibitors also produced varying degrees of 
anticoagulant actions in the ACT and TEG assays performed in the native rabbit whole 
blood. The relative anticoagulant effects were both assay and agent dependent. Thus, 
each method provided a different degree of anticoagulant potency. 
B. In Vivo Studies 
1. Recombinant TF was found to produce dose-dependent thrombogenic effects 
in a rabbit jugular vein stasis thrombosis model. The apparent ED50 for producing the 
thrombogenic response at 10 min was determined to be 0.34 pmol/kg. At 20 min, the 
ED50 was about 4 pmol/kg. The relative thrombogenic response of rTF at 10 and 20 min 
did not appear to be significantly different. At dosages of up to 1 pmol/kg I. V. 
administration, rTF did not produce any alterations in the clot based tests such as the PT, 
APTT, TT and Heptest. However, in the ACT and TEG tests, at doses ranging from 
0 .1-1 pmol/kg, a dose-dependent anticoagulant effect was noted. The mechanism for this 
rTF produced effect on ACT and TEG was not explored. 
2. Heparin, hirudin, D-MePhe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH 
produced dose-dependent antithrombotic effects at both the 10 and 20 min end points. 
The order of potency for these agents was found to be hirudin > heparin> Ac-(D)Phe-
Pro-boroArg-OH > D-MePhe-Pro-Arg-H at the 10 min end point and heparin> 
hirudin> Ac-(D)Phe-Pro-boroArg-OH> D-MePhe-Pro-Arg-H at the 20 min endpoint. 
The ex vivo analyses of the blood revealed sizeable antithrombin activities. However, 
the relative anti-Xa activities were markedly lower. The ACT and TEG test also showed 
individual anticoagulant profiles for each of these agents. In the plasmatic clotting tests, 
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while the PT remained unaffected, agent specific anticoagulant effects were noted in the 
APTT, TT and Heptest. 
anticoagulant effects. 
Ac-(D)Phe-Pro-boroArg-OH produced the strongest 
3. In the S.C. studies, a dose-dependent and agent specific antithrombotic action 
was noted with all four agents. The order of potency was found to be hirudin > Ac-
(D )Phe-Pro-boroArg-OH > heparin> D-MePhe-Pro-Arg-H and hirudin > heparin> Ac-
(D )Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H at both the 10 and 20 min end points 
respectively. Dose-dependent antithrombin effects were also evident with all four agents. 
However, relatively weaker anti-Xa activities were observed. The ex vivo ACT and TEG 
analyses also revealed agent and dose-dependent effects. The ex vivo analyses of plasma 
revealed a dose-dependent prolongation of the APTT, TT and Heptest. However, no 
effects were observed in the PT assay. On a molar basis, hirudin was found to be the 
strongest antithrombotic agent in these studies. 
4. At a fixed I.V. dosage, each of these agents produced a time-dependent 
antithrombotic action. Regardless of the anti thrombotic potency, each of these agents 
showed varying duration of the antithrombotic and ex vivo effects as measured by various 
tests. The duration of action followed the order of hirudin> D-MePhe-Pro-Arg-H > 
heparin> Ac-(D)Phe-Pro-boroArg-OH. With the exception of the PT, the other ex vivo 
tests showed time-dependent agent specific effects. 
5. In the S.C. studies, fixed doses of each of these inhibitors also produced time-
dependent antithrombotic and assay-dependent ex vivo effects on various parameters. In 
contrast to the I.V. studies, the subcutaneously administered agents produced sustained 
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antithrombotic actions. Heparin and hirudin exhibited relatively longer duration of 
actions in contrast to the peptides used. 
6. Heparin and antithrombin agents also produced dose-dependent antithrombotic 
actions in a rat model of laser-induced arterial thrombosis. The antithrombotic potency 
in this model was determined to be heparin> Ac-(D)Phe-Pro-boroArg-OH> hirudin> 
D-MePhe-Pro-Arg-H. 
7. The hemorrhagic actions of heparin and thrombin inhibitors were investigated 
in a rabbit model of ear blood loss at 5 and 20 min post agent administration. Each of 
these agents produced a dose-dependent hemorrhagic effect. The hemorrhagic potential 
for these agents is graded in the following order: hirudin> Ac-(D)Phe-Pro-boroArg-
OH > D-MePhe-Pro-Arg-H > heparin. The duration of the hemorrhagic action for each 
of these agents was also investigated at a fixed dosage. The hemorrhagic actions of these 
agents followed different time courses and were cleared within 60 min. 
8. Subcutaneously administered heparin and antithrombin agents were also found 
to produce hemorrhagic effects in the rabbit ear blood loss model at 45 and 60 min 
circulation times. Hirudin and Ac-(D)Phe-Pro-boroArg-OH produced a dose-dependent 
effect. However, heparin and D-MePhe-Pro-Arg-H produced relatively weaker effects. 
At a fixed dosage, the time course of the hemorrhagic actions of D-MePhe-Pro-Arg-H 
decreased with time, whereas hirudin and Ac-(D)Phe-Pro-boroArg-OH showed biphasic 
responses. The hemorrhagic actions of these agents peaked at 45 min. While the effect 
produced by hirudin reverted to baseline, the action of Ac-(D)Phe-Pro-boroArg-OH 
remained elevated at 90 min. 
CHAPTER VII 
CONCLUSIONS 
Antithrombin agents represent a chemically and functionally diverse variety of 
pharmacologic agents with different degrees of specificity for the inhibition of thrombin. 
As a class, these agents have been found to be distinct from heparin in terms of their 
mechanism of action and pharmacodynamic effects. Independent of the antithrombin 
potency for each of the individual agents as measured by either the Ki or the IC50 based 
titration of the antithrombin actions, these agents exhibit several endogenous effects 
which are not completely attributable to their relative inhibitory action on thrombin. 
Furthermore, each of the thrombin inhibitors exhibits a distinct anti-serine protease and 
protease generation inhibitory profile which also contributes to its biochemical and 
pharmacologic identity. This research also provided experimental evidence that sole 
targeting of thrombin is not enough in the control of thrombogenesis and additional 
endogenous factors which contribute to these processes. Furthermore, indiscriminate 
inhibition of thrombin may compromise the regulatory roles of thrombin, such as the 
activation of protein C, clot stabilization through factor Xllla, hemostatic process 
mediated through platelets and other cellular functions. It is concluded that beside 
distinct differences amongst various thrombin inhibitors, these agents also exhibit non-
thrombin mediated biochemical and pharmacologic actions which may not be related to 
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their actions on thrombin. Even in the case of highly specific thrombin inhibitors such 
as hirudin, several distinct actions of this agent are responsible for some of the additional 
biochemical and pharmacologic effects which can contribute to its therapeutic index. 
Thus, a comprehensive profile for each agent is a prerequisite for an objective 
development of these new anticoagulant and antithrombotic drugs. Furthermore, for the 
clinical development in specific vascular and thrombotic indications, these drugs should 
not be developed mimicking the approaches which have been used for heparin, rather 
each agent should be considered as a distinct pharmacologic agent with its own profile 
and be developed as such. Biochemical and pharmacologic modelling approaches can be 
used to mimic specific thrombotic and cardiovascular disorders where each of these new 
antithrombin agents can be profiled. On the basis of these investigations, some 
projections can be made. Such an approach may be more cost-effective and will 
minimize the necessity for large scale, costly and time consuming clinical trials where 
the safety issues are not always clear. 
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Project Title: Consent Form for Volunteer 31ood Donors 
VOLUNTEER INFORMATION 
A sample of your blood is to be drawn from a vein for tne puroose of being 
used as a contra 1 for procedures perfor:ned in the Her:ia. '.:J ~ og:1 /He~·os :as is Research 
Labora:ories. The amount of blood dra1·m frc::i you, the ty~e of test performed 
on this sample (as a control) is marked on the following lists: 
TE37 
_Platelet Aggregation Study 
_Osmotic Fragility Studies 
_ Autohemolysis 
NBT Test (White cell 
- function test) 
_ Leucocyte Chemotaxis 
_ Who 1 e Bl cod Vi seas i ty Studies 
For the Preparation of Nonnal 
- Human Pool Plasma and other 
Blood Components 
A>~CUi:T OF BLOOD RE'.:;U IREJ 
9 mi citrate~ bleed 
(Butterfly Syringe method) 
5 m; blood (Plas:ic syringe) 
5 ml blood (syringe method) 
10 ml heparinized blood 
(Vacutainer method} 
10 ml heoarinizec blood 
(Syringe' method) 
10 ml heoarinizec blood 
{Syringe' method) 
10 ml citrated blood 
{Syringe method} 
For these tests there is no commercially available control at this time. 
For the proper interpretation of these tests, fresh normal human blood is 
needed. The drawing of your blood from the vein is a well established 
procedure which has very little risk. Slight pain and a small amount of 
bleeding may occur. Occasionally, a blood clot may fonn in the vein, but 
this is rare and seldom produces permanent damage. 
{over) 
VOLUNTEER INFORMATION (continued) 
No direct benefit is expected to any one individua1, but it may eventua11y 
improve the quality of tests done on blood in the future, and may identify 
certain diseases more accurate1y. There is no a1ternative procedure at this 
time which would pennit us to obtain the a~ount of human blood we need for 
the· test. 
CONSENT 
I have fully exp1ained to----------------------
Name: Volunteer 
the nat:Jre and purpose of the above described procedure and the risks that 
are involved in its perfor:nance. I have ans'..iered and 't1il 1 ans;·1er a11 questions 
to the best of my abi 1 i ty. 
351 · 
(Si gna ::Jre: Spec i a 1 r:ema to 1 ogy Personnel) 
I have been fully infor:ned of the abo•1e described proc:~dure l'lith its possible 
benefits and risks. I give permission for my participation in this study. I 
know that or his/her associates wi11 be 
avai1able to ans1-1er any questions r may ha·1e. If, at any time, I fee1 my 
questions have not been adequately answered, I may request to speak with a 
member of the ~'1edica1 Center Institutiona~ Revie'..i Soard. I understand that 
I am free to withdraw this consent and discontinue participation in this 
project at any time without prejudice to my care. I have received a copy of 
this informed consent document. 
(Signature: Volunteer) 
Signature: Witness to Signatures) 
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#A. STATE OF NEW YORK 
,., DEPARTMENT OF HEAL TH 
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Wadsworth Center The Governor Nelson A. Rockefeller Empire State Plaza P.O. Box 509 Albany, New York 12201·0509 
Barbara A. DeBuono, M.D .• M.P.H. 
Commissioner 
Ms. Demetra Callas 
Department of Pathology 
Loyola University Medical Center 
2160 South First Ave. 
Maywood, IL 60153 
Fax: 708-216-6660 
Dear Ms. Callas: 
Karen Schimke 
Executive Deputy Commissioner 
February 5, 1996 
As far as I am concerned, I have no objections to you using figures from a previous 
publication by D.H. Bing and myself(Thromb. Hemost. 14: 234-240, 1988). However, I do not 
know if the publisher of the journal require written permission for reproduction of such materials. 
JWF/lrnj 
~incerely, J .· _ 
A ' .) I . -;-i'---- / /J1.Y,l ~, {< - ;~At VyL£-ohn W. Fenton, II, Ph.D., FACB 
Phone: 518-486-256212119 
Fax: 518-474-7992 
02/l4/l9S5 1~: '.3 
February 13, 1996 
Mr. Chris Hall 
Thi=: M:dical Publisb.m 
381 Park Ave 
New York, NY 
Dear Mr. Hail. i I 
i 
2160 So .. th l'inr A..:nuc: 
~od, !llmois 60153 
Pc.Gi:: 01 
!tki>hc.nc:: (:-OS) 215-JUI 
Fa: (708) 2l6~396 
Thank: you fer your wi3tm:= rCprdmg my ~ about ;;:pr~ a tiguI'l! publliht!d in 
Se::ninarl in Thrombolis and H::moswi3. I am a graduati: smdci:tt in die Ph.:0. prog:-am of the 
Oeparm:.elll: of Ph.arma.c:ology at Loyola Univer3ity Chicago, in t.h.e fii:al. stages of my ~. 
under the guidance af Dr. J~wied. Fareed.. The figore r would Im lD get ~ion to r~roduce 
is Fig. l ("A 3..Cimc:nsinaal model ofliuman a-tbrombin") published in Se:ni..n.m in inro.cibosis 
mi Hemostasi3, 14(3):m, 1988, in the article at.'.tllorcd by Dr. Femcu.. My imenrlon is ta 
reproduce this ~in my~ in tile lln:ratu;e r=vicw section. fur visual apreseritation 
and claf.fication of the !truame 'or thrombin. If there is my ocher in.~on that you ·:leed. 
do llOt hesiuu: to ccm:act me. · 
Sincerely 
rflernef.~~ 
Demetra Callas 
Phone: 708-216-5587 
Fax= 708-216-6660 . I 
E-mail: dctllas@wpo.iLlm;.ad'G : 
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Table 8a -- Antithrombin Activity of Antithrombin Agents, as 
Studied in the Thrombin Titration Assay. 
D-Phe-Pro-Arg-H 
ng/ml nM 
21.28 4.25 
15.96 3.19 
13.83 2.76 
12.77 2.55 
11.70 2.34 
10.64 2.13 
10.11 2.02 
9.57 1.91 
9.31 1.86 
9.04 1.81 
8.78 1.75 
8.51 1.70 
8.24 1.65 
7.98 1.59 
7.71 1.54 
6.91 1.38 
6.38 1.28 
5.85 1.17 
5.59 1.12 
5.32 1.06 
5.05 1.01 
4.79 0.96 
4.52 0.90 
3.99 0.80 
3.72 0.74 
3.46 0.69 
3.19 0.64 
2.66 0.53 
2.39 0.48 
2.13 0.43 
1.86 0.37 
1.60 0.32 
1.06 0.21 
0.80 0.16 
0.53 0.11 
0.27 0.05 
0.00 0.00 
% Residual 
Thrombin Activity* 
7.7 ± 0.9 
9.6 ± 1.8 
11.0±3.6 
11.9±3.0 
13.9 ± 2.9 
15.4 ± 0.9 
16.5 ± 4.4 
17.8 ± 6.9 
18.8 ± 2.4 
20.2 ± 4.9 
21.4 ± 2.9 
22.7 ± 4.5 
23.3 ± 4.5 
25.6 ± 3.4 
25.8 ± 3.8 
26.1 ± 3.7 
31.3 ± 3.6 
33.8 ± 5.4 
35.0± 3.3 
39.1 ± 1.2 
41.4 ± 5.0 
46.5 ± 6.7 
51.3 ± 5.6 
53.3 ± 5.2 
57.3 ± 5.7 
61.9 ± 3.9 
64.6± 3.5 
66.5 ± 5.7 
72.2 ± 6.4 
72.9 ± 3.0 
77.3 ± 6.1 
85.0 ± 3.3 
89.2 ± 2.3 
91.8 ± 5.4 
94.7 ± 6.8 
98.8±6.1 
100.0± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
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Table 8b -- Antithrombin Activity of Antithrombin Agents, 
as Studied in the Thrombin Titration Assay. 
ng/ml 
21.28 
19.15 
17.02 
15.96 
14.89 
13.83 
12.77 
11.70 
11.17 
10.64 
10.11 
9.57 
9.04 
8.51 
7.98 
7.45 
6.91 
6.38 
5.85 
5.32 
4.79 
4.26 
3.72 
3.19 
2.66 
2.13 
1.60 
1.06 
0.96 
0.85 
0.74 
0.64 
0.53 
0.43 
0.21 
0.11 
0.00 
D-MePhe-Pro-Arg-H 
nM 
41.35 
37.21 
33.08 
31.01 
28.94 
26.87 
24.81 
22.74 
21.71 
20.67 
19.64 
18.61 
17.57 
16.54 
15.50 
14.47 
13.44 
12.40 
11.37 
10.34 
9.30 
8.27 
7.24 
6.20 
5.17 
4.13 
3.10 
2.07 
1.86 
1.65 
1.45 
1.24 
1.03 
0.83 
0.41 
0.21 
0.00 
% Residual 
Thrombin Activity* 
10.4 ± 0.5 
10.9 ± 0.8 
11.8± 1.1 
12.8 ± 1.2 
13.2 ± 2.5 
15.7 ± 0.6 
18.9 ± 3.8 
17.7 ± 0.8 
18.2 ± 2.2 
19.7 ± 3.3 
22.7 ± 1.9 
23.5 ± 1.7 
26.4 ± 2.7 
26.1 ± 5.2 
29.1 ± 3.1 
30.7 ± 3.9 
30.3 ± 4.5 
37.7 ± 3.0 
43.1 ± 4.2 
46.0 ± 1.3 
51.7± 8.5 
57.6 ± 0.7 
63.2 ± 10.4 
69.1 ± 7.9 
73.4 ± 2.0 
76.6 ± 5.8 
81.2 ± 1.9 
88.3 ± 6.3 
89.8 ± 5.2 
89.6 ± 5.0 
90.8 ± 3.1 
91.6 ± 2.7 
95.4 ± 1.8 
95.7 ± 3.5 
98.7 ± 4.3 
98.0 ± 0.7 
100.0± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
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Table 8c -- Antithrombin Activity of Antithrombin Agents, 
as Studied in the Thrombin Titration Assay. 
ng/ml 
1063.83 
957.45 
851.06 
744.68 
638.30 
531.91 
425.53 
319.15 
212.77 
106.38 
95.74 
85.11 
74.47 
63.83 
53.19 
47.87 
42.55 
37.23 
31.91 
29.26 
26.60 
23.94 
21.28 
18.62 
15.96 
13.30 
10.64 
9.57 
8.51 
7.45 
6.38 
5.32 
4.26 
3.19 
2.13 
1.06 
0.00 
Boc-D-Phe-Pro-Arg-H 
nM 
1928.63 
1735.76 
1542.90 
1350.04 
1157.18 
964.31 
771.45 
578.59 
385.73 
192.86 
173.58 
154.29 
135.00 
115.72 
96.43 
86.79 
77.15 
67.50 
57.86 
53.04 
48.22 
43.39 
38.57 
33.75 
28.93 
24.11 
19.29 
17.36 
15.43 
13.50 
11.57 
9.64 
7.71 
5.79 
3.86 
1.93 
0.00 
% Residual 
Thrombin Activity* 
12.5 ± 1.4 
12.9 ± 1.8 
14.2 ± 1.0 
14.2± 1.0 
16.2 ± 2.5 
17.1±1.2 
18.2 ± 4.8 
19.2 ± 4.2 
24.4 ± 6.0 
30.8 ± 3.4 
32.8 ± 0.5 
31.7 ± 2.5 
32.9 ± 2.6 
35.2 ± 3.8 
36.2 ± 3.5 
38.1±4.3 
35.7 ± 2.5 
37.1±0.9 
38.5 ± 2.0 
36.6 ± 0.4 
39.2 ± 5.6 
40.3 ± 5.7 
40.3 ± 2.3 
43.9 ± 7.8 
44.2 ± 4.3 
52.7 ± 3.0 
55.2 ± 1.8 
56.5 ± 2.2 
64.4 ± 4.8 
68.1 ± 1.9 
72.4 ± 6.4 
77.0 ± 1.4 
80.7 ± 3.0 
86.5 ± 4.7 
88.5 ± 5.1 
97.0± 6.1 
100.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
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Table 8d -- Antithrombin Activity of Antithrombin Agents, 
as Studied in the Thrombin Titration Assay. 
Ac-(D)Phe-Pro-boroArg-OH 
% Residual 
ng/ml nM Thrombin Activity* 
6.38 12.85 8.4± 4.2 
5.85 11.78 9.1 ± 4.8 
5.32 10.71 15.8 ± 4.4 
5.05 10.17 20.0 ± 16.8 
4.79 9.64 18.7 ± 5.8 
4.52 9.10 17.9± 4.2 
4.26 8.57 19.8 ± 2.0 
3.99 8.03 23.4± 3.4 
3.72 7.49 32.8± 0.9 
3.46 6.96 39.8± 2.9 
3.19 6.42 39.5± 3.3 
2.93 5.89 44.4± 1.6 
2.66 5.35 49.0± 3.3 
2.39 4.82 53.2± 5.0 
2.13 4.28 59.0± 3.7 
1.86 3.75 60.8± 3.7 
1.60 3.21 65.9± 3.0 
1.33 2.68 74.4± 1.3 
1.06 2.14 77.2± 1.4 
0.96 1.93 78.1 ± 1.3 
0.85 1.71 81.5 ± 1.3 
0.74 1.50 86.2± 3.4 
0.64 1.28 91.3 ± 4.8 
0.53 1.07 88.3± 1.4 
0.43 0.86 94.9± 5.1 
0.32 0.64 94.8± 5.3 
0.21 0.43 97.3± 4.8 
0.11 0.21 97.0± 5.0 
0.00 0.00 100.0 ± 0.0 
* Each value represents the mean ± SD of three 
independent determinations. 
Table 8e -- Antithrombin Activity of Antithrombin Agents, 
as Studied in the Thrombin Titration Assay. 
ng/ml 
2127.66 
1861.70 
1489.36 
1276.60 
1063.83 
957.45 
851.06 
744.68 
638.30 
531.91 
478.72 
425.53 
372.34 
319.15 
265.96 
212.77 
159.57 
106.38 
101.06 
95.74 
85.11 
74.47 
63.83 
58.51 
53.19 
47.87 
42.55 
37.23 
31.91 
26.60 
21.28 
15.96 
10.64 
5.32 
0.00 
Argatroban 
nM 
3999.36 
3499.44 
2799.55 
2399.62 
1999.68 
1799.71 
1599.74 
1399.78 
1199.81 
999.84 
899.86 
799.87 
699.89 
599.90 
499.92 
399.94 
299.95 
199.97 
189.97 
179.97 
159.97 
139.98 
119.98 
109.98 
99.98 
89.99 
79.99 
69.99 
59.99 
49.99 
39.99 
30.00 
20.00 
10.00 
0.00 
% Residual 
Thrombin Activity* 
9.3 ± 0.7 
10.7 ± 0.7 
12.8 ± 1.0 
14.2 ± 1.0 
17.3 ± 0.9 
19.2±1.1 
20.6 ± 1.0 
22.6 ± 2.7 
24.3 ± 1.0 
27.5 ± 1.0 
28.9 ± 1.6 
32.0 ± 2.4 
35.1 ± 2.2 
38.6 ± 2.8 
40.2 ± 2.5 
47.6 ± 3.7 
51.2 ± 3.2 
61.3±3.1 
65.2 ± 4.2 
69.2 ± 3.1 
71.9 ± 0.8 
73.1 ± 2.8 
74.3 ± 4.6 
77.5 ± 4.7 
81.7± 1.1 
84.8 ± 2.5 
85.0 ± 1.6 
85.2± 2.0 
89.0 ± 1.6 
91.4 ± 4.1 
91.9 ± 1.7 
95.3 ± 5.8 
97.6 ± 3.9 
98.7 ± 2.3 
100.0 ± 0.0 
* Each value represents the mean ± SD of three 
independent determinations. 
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Table Sf -- Antithrombin Activity of Antithrombin Agents, 
as Studied in the Thrombin Titration Assay. 
ng/ml 
58.51 
50.53 
47.87 
45.21 
42.55 
41.49 
40.43 
39.36 
38.30 
37.23 
36.17 
35.11 
34.04 
32.98 
31.91 
30.85 
29.79 
28.72 
27.66 
26.60 
24.47 
22.34 
21.28 
20.21 
19.15 
18.09 
17.02 
15.96 
14.89 
13.83 
11.70 
9.57 
8.51 
6.38 
5.32 
4.26 
3.19 
1.06 
0.00 
nM 
8.40 
7.26 
6.88 
6.49 
6.11 
5.96 
5.81 
5.65 
5.50 
5.35 
5.19 
5.04 
4.89 
4.74 
4.58 
4.43 
4.28 
4.13 
3.97 
3.82 
3.51 
3.21 
3.06 
2.90 
2.75 
2.60 
2.44 
2.29 
2.14 
1.99 
1.68 
1.38 
1.22 
0.92 
0.76 
0.61 
0.46 
0.15 
0.00 
Hirudin 
% Residual 
Thrombin Activity* 
5.5 ± 0.2 
7.2 ± 1.4 
8.4 ± 1.0 
12.0 ± 3.5 
14.5 ± 0.1 
16.6±2.1 
17.7 ± 2.5 
20.0 ± 2.0 
21.8 ± 2.9 
26.1±3.4 
25.8 ± 3.6 
26.0 ± 1.1 
31.8 ± 4.7 
35.1±7.8 
34.8 ± 1.9 
37.0 ± 1.3 
39.0± 2.6 
41.7±2.3 
46.9 ± 6.9 
48.0 ± 3.9 
48.5 ± 4.4 
50.9 ± 1.4 
49.8 ± 0.9 
51.5 ± 1.4 
58.6 ± 2.4 
58.2 ± 0.7 
63.6 ± 3.4 
67.9 ± 4.1 
74.3 ± 1.0 
75.0± 4.6 
76.5 ± 0.8 
80.9 ± 2.5 
84.3 ± 0.3 
86.9 ± 1.3 
87.7 ± 1.1 
91.2 ± 1.0 
93.1±3.2 
98.9 ± 5.9 
100.0± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
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Table 9a -- 10 U TT of Various Thrombin Inhibitors in the Human Fibrinogen Based 
System. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H 
ng/ml nM sec* nM sec* nM sec* 
800.000 1450.3 > 300.0 
400.000 725.2 124.8 ± 76.9 
200.000 399.5 > 300.0 388.7 > 300.0 362.6 59.0±32.5 
100.000 199.8 115.8 ± 1.3 194.3 210.0 ± 75.7 181.3 36.5 ±26.1 
50.000 99.9 27.9 ± 7.2 97.2 33.9± 19.0 90.6 20.7 ± 7.2 
25.000 49.9 18.1 ± 5.4 48.6 28.7± 19.6 45.3 18.6± 6.1 
12.500 25.0 17.9 ± 5.3 24.3 24.6± 15.8 22.7 18.2 ± 4.5 
6.250 12.5 17.2 ± 4.7 12.1 16.6± 4.1 
3.125 6.2 19.3 ± 7.1 6.1 17.8 ± 4.3 
0.000 0.0 18.7 ± 1.7 0.0 18.7 ± 1.7 0.0 18.7 ± 1.7 
* Each value represents the mean ± SD of three independent determinations. 
Table 9b -- 10 UTT of Various Thrombin Inhibitors in the 
Human Fibrinogen Based System. 
Ac-(D)Phe-Pro-boroArg-OH 
ng/ml nM sec* 
40.000 80.5 > 300.0 
20.000 
10.000 
5.000 
2.500 
1.250 
0.000 
40.3 
20.1 
10.1 
5.0 
2.5 
0.0 
44.0 ± 10.0 
25.1 ± 5.9 
17.5± 3.1 
22.3 ± 10.5 
18.7 ± 4.6 
18.7 ± 1.7 
* Each value represents the mean ± SD of three 
independent determinations. 
Table 9c -- 10 U TT of Various Thrombin Inhibitors in the Human 
Fibrinogen Based System. 
Argatroban Hirudin 
ng/ml nM sec* nM sec* 
500.000 939.8 > 300.0 71.8 >300.0 
250.000 469.9 294.9 ± 8.8 35.9 42.9 ± 34.0 
125.000 235.0 165.6 ± 39.0 18.0 24.8± 5.8 
62.500 117.5 83.1 ± 18.7 9.0 24.6 ± 12.1 
31.250 58.7 40.0± 15.4 4.5 21.7 ± 8.4 
15.625 29.4 30.8 ± 13.4 2.2 17.1 ± 3.4 
7.813 14.7 21.3 ± 5.1 
3.906 7.3 17.5 ± 2.5 
1.953 3.7 19.4 ± 2.2 
0.000 0.0 18.7 ± 1.7 0.0 18.7 ± 1.7 
* Each value represents the mean ± SD of three independent 
determinations. 
Table 9d -- 10 UTT of Various Thrombin Inhibitors in the 
Human Fibrinogen Based System. 
Heparin 
ng/ml nM sec* 
100000 9090.9 32.6 ± 12.1 
50000 4545.5 27.0± 0.9 
10000 909.1 22.8± 5.5 
0 0.0 18.7 ± 1.7 
* Each value represents the mean ± SD of three 
independent determinations. 
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Table 9e -- 10 U Ca++TT of Various Thrombin Inhibitors in the Human Fibrinogen 
Based System. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-OH Boc-D-Phe-Pro-Arg-H 
ng/ml nM sec* nM sec* nM sec* 
1600.00 2900.7 242.3 ± 71.8 
800.000 1554.6 >300.0 1450.3 72.7± 3.6 
400.000 799.0 >300.0 777.3 174.1 ± 54.8 725.2 29.3± 5.4 
200.000 399.5 21.5 ± 3.5 388.7 16.6± 7.7 362.6 13.2 ± 3.1 
100.000 199.8 12.2 ± 1.7 194.3 10.6± 0.5 181.3 9.3 ± 0.1 
50.000 99.9 10.4 ± 3.0 97.2 8.4 ± 0.4 90.6 7.7± 1.1 
25.000 49.9 8.7 ± 1.5 48.6 8.2± 0.5 45.3 9.5 ± 2.0 
12.500 25.0 8.4 ± 0.7 24.3 8.1 ± 0.6 22.7 8.1 ± 0.3 
6.250 12.5 8.5 ± 0.4 12.1 7.6± 0.5 
3.125 6.2 8.5 ± 0.4 6.1 7.7± 0.3 
0.000 0.0 7.6±0.1 0.0 7.6± 0.1 0.0 7.6± 0.1 
* Each value represents the mean ± SD of three independent determinations. 
Table 9f -- 10 U Ca++TT of Various Thrombin Inhibitors 
in the Human Fibrinogen Based System. 
Ac-(D)Phe-Pro-boroArg-OH 
ng/ml nM sec* 
80.000 161.0 > 300.0 
40.000 80.5 34.8 ± 22.0 
20.000 40.3 25.4 ± 25.2 
10.000 20.1 9.0± 0.3 
5.000 10.1 8.5± 0.6 
2.500 5.0 8.3± 0.1 
1.250 2.5 8.1 ± 0.6 
0.000 0.0 7.6± 0.1 
* Each value represents the mean ± SD of three 
independent determinations. 
Table 9g -- 10 U ca++TT of Various Thrombin Inhibitors in the Human 
Fibrinogen Based System. 
Argatroban Hirudin 
ng/ml nM sec* nM sec* 
1000.000 1879.7 > 300.0 143.6 > 300.0 
500.000 939.8 221.7 ± 34.3 71.8 169.9 ± 123.3 
250.000 469.9 109.3 ± 22.7 35.9 15.3 ± 7.9 
125.000 235.0 59.2 ± 22.6 18.0 19.4 ± 18.0 
62.500 117.5 33.8 ± 17.3 9.0 16.9± 14.1 
31.250 58.7 21.6 ± 15.0 4.5 15.1 ± 12.1 
15.625 29.4 7.7± 3.5 2.2 8.7± 0.7 
7.813 14.7 6.2 ± 3.1 
3.906 7.3 7.5 ± 0.7 
1.953 3.7 8.1 ± 0.3 
0.000 0.0 7.6± 0.1 0.0 7.6± 0.1 
* Each value represents the mean ± SD of three independent 
determinations. 
Table 9h -- 10 U Ca+ +TT of Various Thrombin Inhibitors 
in the Human Fibrinogen Based System. 
Heparin 
ng/ml nM sec* 
100000 9090.9 15.9± 11.2 
50000 4545.5 9.6± 0.9 
10000 909.1 8.7± 0.6 
0 0.0 7.6± 0.1 
* Each value represents the mean ± SD of three 
independent determinations. 
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Table lOa -- Inhibition of the Amidolytic Activity of Thrombin by Various Agents in 
NHP. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H 
ng/ml nM % Inhibition* nM % Inhibition* nM % Inhibition* 
6666.67 13317.35 97.3± 0.3 12955.05 96.4± 0.2 12086.05 93.3 ± 0.0 
3333.33 6658.68 96.0± 0.4 6477.52 94.5± 0.9 6043.03 89.5±0.1 
1666.67 3329.34 94.5± 0.5 3238.76 92.3± 0.5 3021.51 83.1±0.3 
666.67 1331.74 92.4 ± 0.7 1295.50 89.4 ± 1.3 1208.61 75.4 ± 3.1 
333.33 665.87 90.1 ± 0.9 647.75 85.6± 1.4 604.30 67.8 ± 3.3 
166.67 332.93 87.1 ± 1.3 323.88 82.6± 1.2 302.15 61.0 ± 2.5 
83.33 166.47 85.5 ± 1.5 161.94 79.6± 1.3 151.08 54.0 ± 2.9 
41.67 83.23 82.0± 2.0 80.97 75.2± 2.6 75.54 42.3 ± 6.7 
20.83 41.62 67.3± 10.2 40.48 58.7± 9.5 37.77 25.8 ± 7.4 
10.42 20.81 36.3 ± 10.7 20.24 31.3 ± 10.2 18.88 11.4 ± 4.5 
5.21 10.40 16.6± 2.8 10.12 13.9± 3.4 9.44 5.5 ± 1.2 
2.60 5.20 8.8± 1.8 5.06 7.1 ± 1.3 4.72 2.9±1.1 
1.30 2.60 5.9± 1.9 2.53 4.5 ± 0.6 2.36 2.6 ± 0.8 
0.00 0.00 0.0± 0.0 0.00 0.0± 0.0 0.00 0.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 1 Ob -- Inhibition of the Amidolytic Activity of 
Thrombin by Various Agents in NHP. 
Ac-D-Phe-Pro-boroArg-OH 
ng/ml nM % Inhibition* 
666.67 1341.92 97.1 ± 0.4 
333.33 670.96 96.5 ± 0.2 
166.67 335.48 95.4 ± 0.2 
66.67 134.19 94.6 ± 0.4 
33.33 67.10 90.7 ± 1.1 
16.67 33.55 63.1 ± 9.5 
8.33 16.77 28.3 ± 3.4 
4.17 8.39 11.9± 1.4 
2.08 4.19 3.6± 0.5 
0.00 0.00 0.0± 0.0 
* Each value represents the mean ± SD of three 
independent determinations. 
Table 1 Oc -- Inhibition of the Amidolytic Activity of Thrombin by Various 
Agents in NHP. 
Argatroban Hirudin 
ng/ml nM % Inhibition* nM % Inhibition* 
6666.67 12531.33 84.8± 2.9 957.44 90.7± 1.2 
3333.33 6265.66 79.1 ± 3.9 478.72 90.6± 1.1 
1666.67 3132.83 67.9± 5.5 239.36 90.5± 1.3 
666.67 1253.13 49.6± 10.6 95.74 89.9± 1.0 
333.33 626.57 26.3± 6.4 47.87 86.0± 1.9 
166.67 313.28 8.4± 4.6 23.94 57.8 ± 16.7 
83.33 156.64 0.0± 0.5 11.97 22.8± 5.2 
41.67 5.98 8.3± 0.8 
20.83 2.99 2.5± 1.1 
0.00 0.00 0.0± 0.0 0.00 0.0± 0.0 
* Each value represents the mean ± SD of three independent 
determinations. 
Table lOd -- Inhibition of the Amidolytic Activity of 
Thrombin by Various Agents in NHP. 
Heparin 
ng/ml nM % Inhibition* 
66666.67 6060.61 70.1 ± 1.9 
33333.33 3030.30 68.6 ± 1.3 
16666.67 1515.15 68.9± 2.7 
6666.67 606.06 71.0 ± 2.2 
3333.33 303.03 70.9 ± 1.5 
1666.67 151.52 72.3 ± 1.0 
666.67 60.61 78.4 ± 1.6 
333.33 30.30 79.9 ± 1.7 
166.67 15.15 68.5 ± 2.3 
83.33 7.58 40.4 ± 2.3 
41.67 3.79 17.4±0.8 
20.83 1.89 5.5 ± 0.6 
10.42 0.95 2.6 ± 1.6 
0.00 0.00 0.0± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
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Table lOe -- Inhibition of the Amidolytic Activity of Thrombin by Various Agents in NRP. 
D-MePhe-Pro-Arg-H Ac-(D )Phe-Pro-boroArg-OH Hirudin Heparin 
ng/ml nM % Inhibition* nM % Inhibition* nM % Inhibition* nM % Inhibition* 
6666.1 606.l 77.l ± 6.3 
2666.7 5182.0 95.4 ± 0.4 383.0 93.1 ± 0.5 242.4 75.8 ± 2.5 
1333.3 2591.0 93.6± 0.7 191.5 92.6 ± 0.7 121.2 77.2 ± 2.5 
666.7 1295.5 91.1 ± 0.8 1342.0 98.9 ± 0.0 95.7 91.1 ± 0.9 60.6 79.6 ± 0.9 
333.3 647.8 86.4 ± 4.7 671.0 98.3 ± 0.5 47.9 81.9 ± 4.9 30.3 78.6± 4.0 
166.7 323.9 86.7 ± 0.9 335.0 97.8 ± 0.1 23.9 47.4 ± 7.3 15.2 70.5 ± 6.6 
83.3 161.9 85.1 ± 0.7 168.0 97.1 ± 0.0 12.0 23.3 ± 5.9 7.6 57.9± 6.3 
41.3 80.3 82.3 ± 0.5 83.9 95.6 ± 0.6 5.9 13.5 ± 5.6 3.8 31.5 ± 8.0 
20.7 40.2 75.8 ± 3.9 41.9 85.5 ± 2.7 3.0 7.2 ± 1.9 1.9 17.1 ± 2.0 
10.7 20.7 53.7±10.8 21.0 47.3 ± 4.0 1.5 4.7± 2.5 1.0 9.2 ± 2.0 
5.3 10.4 22.3±19.4 10.5 21.4 ± 2.4 0.8 3.5 ± 2.1 
2.7 5.2 17.7 ± 6.8 5.2 11.9 ± 0.9 0.4 4.7± 2.7 
1.3 2.6 6.3 ± 1.4 
0.7 1.3 5.4 ± 0.8 
0.0 0.0 0.0± 0.0 0.0 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 0.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 1 la -- Inhibition of the Amidolytic Activity of 
Factor Xa by Various Agents in NHP. 
Ac-D-Phe-Pro-boroArg-OH 
ng/ml nM 3 Inhibition* 
540.54 1088.04 72.1 ± 2.5 
270.27 
135.14 
54.05 
27.03 
13.51 
6.76 
3.38 
0.00 
544.02 
272.01 
108.80 
54.40 
27.20 
13.60 
6.80 
0.00 
58.3 ± 2.8 
40.6 ± 5.0 
26.3 ± 3.6 
12.9 ± 1.2 
8.4 ± 2.1 
2.5 ± 0.4 
0.0± 0.7 
0.0 ± 0.0 
* Each value represents the mean ± SD of three 
independent determinations. 
Table llb -- Inhibition of the Amidolytic Activity 
of Factor Xa by Various Agents in NHP. 
Heparin 
ng/ml nM 3 Inhibition* 
54054.05 4914.00 45.6 ± 9.5 
27027.03 2457.00 49.4±10.3 
13513.51 1228.50 56.7± 9.3 
5405.41 491.40 66.5 ± 5.3 
2702.70 245.70 75.2± 3.2 
1351.35 122.85 87.6± 2.2 
540.54 49.14 89.1 ± 1.2 
270.27 24.57 90.4 ± 0.7 
135.14 12.29 81.4 ± 4.1 
67.57 6.14 55.8 ± 7.4 
33.78 3.07 26.6± 2.5 
16.89 1.54 10.9± 0.9 
8.45 0.77 5.0± 1.3 
4.22 0.38 0.0± 2.7 
0.00 0.00 0.0± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
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Table 11 c -- Inhibition of the Amidolytic Activity of Thrombin by Various Agents in NRP. 
D-MePhe-Pro-Arg-H Ac-(D)Phe-Pro-boroArg-OH Hirudin Heparin 
ng/ml nM 3 Inhibition* nM 3 Inhibition* nM 3 Inhibition* nM 3 Inhibition* 
6666.7 606.1 77.1 ± 6.3 
2666.7 5182.0 95.4 ± 0.4 383.0 93.1±0.5 242.4 75.8 ± 2.5 
1333.3 2591.0 93.6 ± 0.7 191.5 92.6 ± 0.7 121.2 77.2 ± 2.5 
666.7 1295.5 91.1 ± 0.8 1341.9 98.9 ± 0.0 95.7 91.1±0.9 60.6 79.6 ± 0.9 
333.3 647.8 86.4 ± 4.7 671.0 98.3 ± 0.5 47.9 81.9 ± 4.9 30.3 78.6 ± 4.0 
166.7 323.9 86.7 ± 0.9 335.5 97.8 ± 0.1 23.9 47.4 ± 7.3 15.2 70.5 ± 6.6 
83.3 161.9 85.1 ± 0.7 167.7 97.1 ± 0.0 12.0 23.3 ± 5.9 7.6 57.9 ± 6.3 
41.7 80.3 82.3 ± 0.5 83.9 95.6 ± 0.6 5.9 13.5 ± 5.6 3.8 31.5 ± 8.0 
20.8 40.2 75.8 ± 3.9 41.9 85.5 ± 2.7 3.0 7.2 ± 1.9 1.9 17.1 ± 2.0 
10.4 20.7 53.7± 10.8 21.0 47.3 ± 4.0 1.5 4.7 ±2.5 1.1 9.2 ± 2.0 
5.2 10.4 22.3 ± 19.4 10.5 21.4 ± 2.4 0.8 3.5±2.1 
2.6 5.2 17.7 ± 6.8 5.2 11.9 ± 0.9 0.4 4.7 ± 2.7 
1.3 2.6 6.3 ± 1.4 
0.7 1.3 5.4 ± 0.8 
0.0 0.0 0.0± 0.0 0.0 0.0 ± 0.0 0.0 0.0 ±0.0 0.0 0.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 12a -- Inhibition of the Amidolytic 
Activity of Chymotrypsin by Various 
Inhibitors. 
Aprotinin 
µglml µM % Inhibition* 
30.71 4.72 87.6 ± 0.5 
15.36 2.36 82.1 ± 0.4 
7.68 1.18 71.4 ± 1.2 
3.84 0.59 34.3 ± 3.5 
1.92 0.29 28.6 ± 0.7 
0.96 0.15 11.6 ± 0.5 
0.48 0.07 5.0 ± 0.4 
0.24 0.04 3.9 ± 0.3 
0.12 0.02 0.9 ± 0.6 
0.00 0.00 0.0 ± 0.0 
* Each value represents the mean ± SD of 
three independent determinations. 
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Table 12b -- Inhibition of the Amidolytic Activity of Trypsin by Thrombin Inhibitors. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H Ac-(D) Phe-Pro- Aprotinin 
boroArg-OH 
µglml µM % Inhibition* µM % Inhibition* µM % Inhibition* µM % Inhibition* µM % Inhibition* 
13.333 26.635 95.3 ± 1.1 25.910 97.7 ± 0.1 24.172 99.1 ± 0.2 26.838 99.4 ± 0.3 2.048 98.7 ± 0.9 
6.667 13.317 93.8 ± 1.0 12.955 95.9 ± 0.1 12.086 98.8 ± 0.2 13.419 99.4 ± 0.2 1.024 92.2 ± 10.0 
3.333 6.659 91.8 ± 1.2 6.478 93.1 ± 1.5 6.043 97.7 ± 0.1 6.710 99.2 ± 0.1 0.512 66.8 ± 27.5 
1.667 3.329 88.6 ± 0.6 3.239 88.6 ± 0.1 3.022 97.0± 0.6 3.355 99.4 ± 0.2 0.256 29.5 ± 12.6 
0.833 1.665 86.1 ± 3.0 1.619 86.5 ± 1.3 1.511 94.2 ± 3.5 1.677 99.1 ± 0.2 0.128 30.9 ± 17.3 
0.417 0.832 79.8 ± 0.4 0.810 86.3 ± 3.8 0.755 95.7± 0.7 0.839 99.0± 0.3 0.064 24.4 ± 6.9 
0.208 0.416 44.0±12.5 0.405 79.1 ± 9.7 0.378 81.9 ± 6.1 0.419 98.6 ± 0.9 0.032 19.9 ± 1.5 
0.104 0.208 26.3 ± 3.0 0.202 54.1 ±22.8 0.189 38.0 ± 3.8 0.210 82.9 ±22.6 0.016 20.1 ± 6.6 
0.052 0.104 17.5 ± 9.8 0.101 28.6 ± 21.1 0.094 26.9± 6.3 0.105 54.1±53.1 
0.026 0.052 16.4 ± 12.2 0.051 17.9±17.8 0.047 19.2 ± 9.4 0.052 27.6±15.1 
0.013 0.026 12.9 ± 10.4 0.025 9.9 ± 5.9 0.024 19.2 ± 0.1 0.026 20.9 ± 22.1 
0.007 0.013 7.7 ± 14.8 0.013 16.3 ± 7.5 0.012 18.0 ± 5.7 0.013 11.9±17.4 
0.003 0.007 8.7 ± 4.0 0.006 7.4 ± 3.5 0.006 15.3 ± 6.6 0.007 14.4 ± 7.8 
0.002 0.003 7.1±15.6 0.003 4.0± 5.1 0.003 6.8 ± 1.3 0.003 12.1 ±26.3 
0.001 0.002 14.1± 2.8 0.002 6.5 ± 15.6 0.001 9.7 ± 4.5 0.002 15.7±11.4 
0.000 0.001 3.3 ± 4.7 0.001 13.4 ± 0.5 0.001 12.4 ± 2.5 0.001 9.3 ± 14.4 
0.000 0.000 0.0 ± 0.0 0.000 0.0 ± 0.0 0.000 0.0± 0.0 0.000 0.0 ± 0.0 0.000 0.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 12c -- Inhibition of the Amidolytic Activity of APC by Thrombin Inhibitors. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H Ac-(D)Phe-Pro- Aprotinin 
boroArg-OH 
µg/ml µM % Inh* µM % Inh* µM % Inh* µM % Inh* µM % Inh* 
125.000 19.195 55.0 ± 1.2 
62.500 124.850 96.4 ± 0.6 121.454 93.3 ± 0.8 113.307 86.4 ± 1.3 125.805 97.9 ± 0.3 9.598 36.6 ± 1.4 
31.250 62.425 93.9 ± 0.6 60.727 86.4 ± 1.5 56.653 72.0 ± 7.2 62.903 96.1 ± 0.2 4.799 25.8 ± 1.9 
15.625 31.213 89.2 ± 0.7 30.363 76.4 ± 4.3 28.327 58.4 ± 9.3 31.451 92.6 ± 1.1 2.399 13.8 ± 1.4 
7.813 15.606 80.2 ± 1.5 15.182 63.1 ± 3.4 14.163 49.6 ± 5.3 15. 726 86.4 ± 0.2 1.200 10.1 ± 0.3 
3.906 7.803 66.8 ± 3.2 7.591 47.4 ± 4.5 7.082 32.5 ± 4.7 7.863 73.6 ± 1.3 0.600 3.7 ± 0.4 
1.953 3.902 48.1 ± 3.4 3.795 31.3 ± 2.9 3.541 16.7 ± 2.9 3.931 53.0 ± 0.9 0.300 1.9 ± 0.9 
0.977 1.951 28.9 ± 4.1 1.898 17.4 ± 2.5 1.770 9.3 ± 1.4 1.966 30.0 ± 2.7 
0.488 0.975 15.2 ± 4.6 0.949 10.4 ± 1.1 0.885 4.2 ± 2.8 0.983 12.9 ± 2.4 
0.244 0.488 5.5 ± 4.9 0.474 6.8 ± 3.2 0.443 3.9 ± 1.7 0.491 5.5 ± 1.5 
0.000 0.000 0.0 ± 0.0 0.000 0.0 ± 0.0 0.000 0.0 ± 0.0 0.000 0.0± 0.0 0.000 0.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 12d -- Inhibition of the Amidolytic Activity of Glandular Kallikrein 
by Thrombin Inhibitors. 
Ac-(D)Phe-Pro-boroArg-OH Aprotinin 
µg/ml µM % Inhibition* µM % Inhibition* 
66.667 5.119 95.0 ± 4.5 
33.333 67.096 79.8 ±4.6 2.559 96.8 ± 3.8 
16.667 33.548 68.8 ±7.5 1.280 87.7 ± 8.4 
8.333 16.774 49.2 ± 6.9 0.640 72.5 ± 2.9 
4.167 8.387 34.9 ± 9.5 0.320 42.0 ± 2.8 
2.083 4.194 20.6 ±2.3 0.160 21.0 ± 4.6 
1.042 2.097 11.4 ± 3.2 0.080 8.3 ± 3.3 
0.521 1.048 3.0 ± 3.5 0.040 1.6 ± 4.3 
0.260 0.524 4.3 ± 1.6 0.020 2.1 ± 6.2 
0.000 0.000 0.0 ± 2.3 0.010 0.5 ± 2.8 
* Each value represents the mean ± SD of three independent 
determinations. 
Table 12e -- Inhibition of the Amidolytic 
Activity of Glandular Kallikrein by 
Thrombin Inhibitors. 
Heparin 
µg/ml µM % Inhibition* 
66.667 6.231 44.6 ± 27.8 
33.333 3.115 38.6 ± 30.9 
16.667 1.558 28.7 ± 33.6 
8.333 0.779 13.7 ± 22.3 
4.167 0.389 6.1 ± 14.4 
2.083 0.195 1.3 ± 8.0 
1.042 0.097 0.0 ± 7.7 
0.000 0.000 0.0 ± 1.0 
* Each value represents the mean ± SD of 
three independent determinations. 
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Table 12f -- Inhibition of the Amidolytic Activity oft-PA by Thrombin Inhibitors. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H Ac-(D)Phe-Pro-boroArg-OH 
µg/ml µM %Inhibition* µM %Inhibition* µM %Inhibition* µM %Inhibition* 
33.333 66.587 56.2 ± 2.9 64.775 64.2 ± 2.1 60.430 94.1±1.0 67.096 99.5 ± 0.8 
16.667 33.293 39.7 ± 1.2 32.388 50.0 ± 4.0 30.215 86.8 ± 1.8 33.548 99.5 ± 0.8 
8.333 16.647 25.2 ± 2.0 16.194 30.7 ± 2.7 15.108 68.4 ± 2.5 16.774 98.8 ± 0.7 
4.167 8.323 13.3 ± 3.2 8.097 17.7 ± 4.8 7.554 44.8 ± 7.0 8.387 48.9±7.1 
2.083 4.162 9.4 ± 4.6 4.048 10.8 ± 0.9 3.777 22.6 ± 5.5 4.194 20.3 ± 3.4 
1.042 2.081 2.5 ± 5.7 2.024 6.7 ± 1.8 1.888 12.2 ± 5.5 2.097 6.8 ± 1.7 
0.521 1.040 3.3 ± 7.4 1.012 4.6 ± 1.3 0.944 5.9 ± 2.7 1.048 5.4 ± 4.4 
0.260 0.520 2.6± 4.1 0.506 3.3 ± 4.1 0.472 5.9 ± 2.3 0.524 1.2 ± 5.2 
0.130 0.260 2.1 ± 3.6 0.253 3.2± 3.8 0.236 2.4 ± 3.6 0.262 0.4 ± 5.2 
0.065 0.130 1.9 ± 5.6 0.127 1.5 ± 2.9 0.118 0.0± 4.0 0.131 0.0± 7.9 
* Each value represents the mean ± SD of three independent determinations. 
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Table 12g -- Inhibition of the Amidolytic Activity of Urokinase by Thrombin 
Inhibitors. 
Boc-D-Phe-Pro-Arg-H Ac-(D )Phe-Pro-boroArg-OH 
µg/ml µM %Inhibition* µM %Inhibition* 
33.333 60.430 76.9 ± 1.2 67.096 98.6± 1.3 
16.667 30.215 61.8 ± 3.2 33.548 97.8± 1.2 
8.333 15.108 47.1 ± 0.9 16.774 95.6± 1.2 
4.167 7.554 35.4 ± 2.8 8.387 92.0± 0.6 
2.083 3.777 23.6 ± 5.6 4.194 83.4 + 2.6 
1.042 1.888 15.2 ± 4.6 2.097 62.9± 4.1 
0.521 0.944 8.0± 2.2 1.048 31.1 ± 1.8 
0.260 0.472 5.7 ± 4.0 0.524 14.8 ± 1.8 
0.130 0.236 2.5 ± 9.0 0.262 6.5 ± 1.1 
0.065 0.118 5.2 ± 4.5 0.131 4.0± 1.6 
0.033 0.059 2.6 ± 3.4 0.066 3.3 ± 3.2 
0.016 0.030 1.6 ± 2.9 0.033 3.1 ± 2.0 
* Each value represents the mean ± SD of three independent determinations. 
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Table 12h -- Inhibition of the Amidolytic Activity of Plasmin by Thrombin Inhibitors. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H 
µg/ml µM %Inhibition* µM %Inhibition* µM %Inhibition* 
33.333 66.587 93.6± 4.3 64.775 96.6 ± 4.1 60.430 99.4 ± 1.0 
16.667 33.293 88.8 ± 4.6 32.388 94.3 ± 3.7 30.215 99.2 ± 1.3 
8.333 16.647 80.2 ± 2.1 16.194 88.3 ± 4.6 15.108 97.9 ± 1.7 
4.167 8.323 66.3 ± 3.0 8.097 79.0 ± 6.4 7.554 95.9 ± 1.4 
2.083 4.162 52.1 ± 2.2 4.048 68.0 ± 4.6 3.777 90.8 ± 1.3 
1.042 2.081 35.2 ± 2.2 2.024 50.7 ± 4.0 1.888 82.8 ± 1.6 
0.521 1.040 22.1±1.7 1.012 34.1±2.0 0.944 71.4 ± 2.8 
0.260 0.520 11.7±2.9 0.506 22.0 ± 2.8 0.472 55.3 ± 5.5 
0.130 0.260 7.2 ± 0.4 0.253 13.1 ± 2.3 0.236 35.7±6.1 
0.065 0.130 3.5 ± 1.6 0.127 6.2 ± 0.6 0.118 19.6 ± 3.3 
0.033 0.065 1.7 ± 0.7 0.063 2.6 ± 1.2 0.059 12.0 ± 2.1 
0.016 0.033 0.1 ± 2.4 0.032 0.0 ± 1.8 0.030 3.3 ± 3.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 12i -- Inhibition of the Amidolytic Activity of Plasmin by Thrombin Inhibitors. 
Ac-(D)Phe-Pro-boroArg-OH Heparin Aprotinin 
µg/ml µM %Inhibition* µM %Inhibition* µM %Inhibition* 
66.667 6.231 22.2± 10.2 
33.333 67.096 100.0 ± 0.0 3.115 21.3 ± 9.6 5.119 99.0 ± 8.4 
16.667 33.548 100.0 ± 0.0 1.558 20.2± 14.9 2.559 99.0 ± 1.4 
8.333 16.774 100.0± 0.0 0.779 17.2± 16.8 1.280 99.1 ± 1.4 
4.167 8.387 100.0± 0.0 0.389 18.0± 16.8 0.640 99.3 ± 1.5 
2.083 4.194 100.0± 0.0 0.195 19.3 ± 17.8 0.320 98.9 ± 1.1 
1.042 2.097 99.8 ± 0.4 0.097 4.1 ± 7.2 0.160 85.8 ± 1.9 
0.521 1.048 97.2 ± 0.3 0.049 8.1 ± 5.4 0.080 58.4 ± 4.5 
0.260 0.524 92.5 ± 0.9 0.024 6.2± 2.1 0.040 26.1 ± 3.8 
0.130 0.262 78.9± 3.1 0.012 1.8 ± 2.5 0.020 13.8 ± 4.4 
0.065 0.131 53.8 ± 2.6 0.006 2.0± 2.0 0.010 3.4± 3.8 
0.033 0.066 30.2 ± 2.2 0.003 2.3 ± 0.9 0.005 1.4 ± 3.4 
0.016 0.033 15.3 ± 1.0 0.002 0.5 ± 1.9 0.002 1.9 ± 1.3 
0.008 0.016 7.4 ± 1.0 0.001 1.1 ± 1.3 0.001 1.7 ± 2.7 
0.004 0.008 1.4 ± 1.0 0.000 1.4 ± 0.0 0.001 0.2 ± 1.7 
* Each value represents the mean ± SD of three independent determinations. 
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Table 13a -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: Pure Plasminogen 
Lysed by Streptokinase. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H 
µg/ml µM %Inhibition* µM %Inhibition* µM %Inhibition* 
7.813 15.606 71.7 ± 3.0 15.182 73.9 ± 3.0 14.163 80.4 ± 2.0 
3.906 7.803 47.8 ± 2.0 7.591 54.3 ± 2.0 7.082 65.2 ± 2.0 
1.953 3.902 41.3 ± 2.0 3.795 47.8 ± 2.0 3.541 52.2 ± 1.5 
0.977 1.951 15.2 ± 1.5 1.898 17.4±1.5 1.770 39.1 ± 1.5 
0.000 0.000 0.0 ± 0.0 0.000 0.0 ± 0.0 0.000 0.0± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 13b -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: Pure Plasminogen 
Lysed by Streptokinase. 
Ac-(D)Phe-Pro-boroArg-OH Hirudin Heparin 
µg/ml µM %Inhibition* µM %Inhibition* µM %Inhibition* 
7.813 15.726 91.3 ± 1.0 1.122 28.3 ± 1.0 0.730 47.8 ± 
3.906 7.863 87.0 ± 1.5 0.561 19.6 ± 1.5 0.365 34.8 + 
1.953 3.931 78.3 ± 2.0 0.281 19.6 ± 1.0 0.183 34.8 ± 
0.977 1.966 63.0 ± 1.5 0.140 8.7± 0.5 0.091 26.1 ± 
0.000 0.000 0.0 ± 0.0 0.000 0.0± 0.0 0.000 0.0± 
* Each value represents the mean ± SD of three independent determinations. 
Table 13c -- Inhibition of Plasminogenolysis by Thrombin 
Inhibitors: Pure Plasminogen Lysed by Streptokinase. 
Aprotinin 
µg/ml µM %Inhibition* 
25.000 3.839 47.8 ± 1.0 
12.500 1.920 37.0 ± 2.0 
6.250 0.960 23.9 ± 1.5 
3.125 0.480 21.7 ± 1.0 
0.000 0.000 0.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
1.0 
0.5 
0.5 
1.0 
0.0 
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Table 13d -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: Pure Plasminogen 
Lysed by t-PA. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-HBoc-D-Phe-Pro-Arg-H 
µg/ml µM %Inhibition* µM %Inhibition* µM %Inhibition* 
0.781 1.561 68.2 ± 2.0 1.518 72.7 ± 2.0 1.416 90.9± 0.5 
0.391 0.780 45.5 ± 1.5 0.759 59.1 ± 1.5 0.708 90.9± 2.0 
0.195 0.390 45.5 ± 2.0 0.380 45.5 ± 2.0 0.354 81.8 ± 1.0 
0.098 0.195 45.5 ± 1.0 0.190 45.5 ± 1.0 0.177 72.7 ± 1.5 
0.049 0.098 45.5 ± 1.0 0.095 22.7 ± 1.0 0.089 63.6 ± 1.0 
0.024 0.049 0.0± 0.0 0.047 0.0± 0.0 0.044 0.0± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 13e -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: Pure Plasminogen 
Lysed by t-PA. 
Ac-(D)Phe-Pro-boroArg-OH Hirudin Heparin 
µg/ml µM % Inhibition* µM % Inhibition* µM %Inhibition* 
0.781 1.573 90.9 ± 0.5 0.112 18.2 ± 2.0 0.073 36.4 ± 
0.391 0.786 90.9± 0.0 0.056 18.2 ± 1.0 0.037 36.4 ± 
0.195 0.393 90.9± 1.0 0.028 18.2 ± 1.5 0.018 36.4 ± 
0.098 0.197 81.8 ± 1.0 0.014 18.2 ± 1.0 0.009 31.8 ± 
0.049 0.098 68.2 ± 1.5 0.007 9.1 ± 0.5 0.005 9.1 ± 
0.024 0.049 0.0± 0.0 0.004 0.0 ± 0.0 0.002 0.0± 
* Each value represents the mean ± SD of three independent determinations. 
Table 13f -- Inhibition of Plasminogenolysis by Thrombin 
Inhibitors: Pure Plasminogen Lysed by t-PA. 
Aprotinin 
µg/ml µM %Inhibition* 
25.000 3.839 54.5 ± 2.0 
12.500 1.920 36.4 ± 1.0 
6.250 0.960 31.8 ± 1.0 
3.125 0.480 31.8 ± 1.5 
1.563 0.240 18.2 ± 1.5 
0.781 0.120 0.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
1.0 
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Table 13g -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: NHP-Derived 
Plasminogen Lysed by Streptokinase. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H 
µglml µM %Inhibition* µM %Inhibition* µM % Inhibition* 
7.813 15.606 68.9 ± 4.0 15.182 81.1 ± 4.0 14.163 85.1 ± 3.0 
3.906 7.803 58.1 ± 3.0 7.591 64.9 ± 4.0 7.082 73.0± 3.0 
1.953 3.902 41.9 ± 3.0 3.795 48.6 ± 3.0 3.541 51.4 ± 2.5 
0.977 1.951 27.0± 2.0 1.898 33.8 ± 2.0 1.770 27.0 ± 2.0 
0.000 0.000 0.0± 0.0 0.000 0.0 ± 0.0 0.000 0.0± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 13h -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: NHP-Derived 
Plasminogen Lysed by Streptokinase. 
Ac-(D )Phe-Pro-boroArg-OH Hirudin Heparin 
µglml µM %Inhibition* µM %Inhibition* µM %Inhibition* 
7.813 15.726 98.6 ± 1.0 1.122 24.3 ± 1.0 0.730 25.7 ± 2.0 
3.906 7.863 97.3 ± 1.0 0.561 16.2 ± 1.5 0.365 21.6 ± 1.0 
1.953 3.931 89.2 ± 2.0 0.281 8.1 ± 1.0 0.183 16.2 ± 1.5 
0.977 1.966 82.4 ± 2.0 0.140 5.4 ± 1.0 0.091 8.1 ± 1.0 
0.000 0.000 0.0 ± 0.0 0.000 0.0± 0.0 0.000 0.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 13i -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: 
NHP-Derived Plasminogen Lysed by Streptokinase. 
Aprotinin 
µM % Inhibition* 
25.000 3.839 48.6± 1.5 
12.500 1.920 27.0± 1.0 
6.250 0.960 18.9 ± 0.5 
3.125 0.480 16.2 ± 0.5 
0.000 0.000 0.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
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Table 13j -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: NHP-Derived 
Plasminogen Lysed by t-PA. 
µg/ml 
7.813 
3.906 
1.953 
0.977 
0.000 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H 
µM %Inhibition* 
15.606 83.3 ± 2.0 
7.803 66.7 ± 2.0 
3.902 58.3 ± 2.5 
1.951 50.0± 2.0 
0.000 0.0 ± 0.0 
µM %Inhibition* 
15.182 79.2 ± 3.0 
7.591 66.7 ± 2.5 
3.795 58.3 ± 3.0 
1.898 41.7 ± 2.0 
0.000 0.0± 0.0 
µM % Inhibition* 
1.770 79.2 ± 2.0 
0.000 0.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 13k -- Inhibition of Plasminogenolysis by Thrombin 
Inhibitors: NHP-Derived Plasminogen Lysed by t-PA. 
Ac-(D)Phe-Pro-boroArg-OH Hirudin 
µglml µM %Inhibition* µM %Inhibition* 
7.813 1.122 33.3 ± 1.0 
3.906 0.561 25.0 ± 1.5 
1.953 3.931 87.5 ± 2.0 0.281 25.0 ± 1.5 
0.977 1.966 87.5 ± 2.0 0.140 16.7 ± 1.0 
0.000 0.000 0.0 ± 0.0 0.000 0.0 ± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
Table 131 -- Inhibition of Plasminogenolysis by Thrombin 
Inhibitors: NHP-Derived Plasminogen Lysed by t-PA. 
Aprotinin 
µg/ml µM %Inhibition* 
25.000 3.839 75.0± 2.0 
12.500 1.920 50.0± 2.0 
6.250 0.960 41.7 ± 1.5 
3.125 0.480 25.0± 1.0 
0.000 0.000 0.0± 0.0 
* Each value represents the mean ± SD of three independent determinations. 
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Table 14a -- Inhibition of Thrombin Generation After Extrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Argatroban 
µg/ml µM %Inhibition* µM %Inhibition* µM %Inhibition* 
33.333 66.587 97.4 ± 1.5 64.775 97.5 ± 1.0 62.657 79.4 ± 5.4 
26.667 53.269 96.7± 1.6 51.820 96.9 ± 1.3 50.125 75.3 ± 8.9 
20.000 39.952 95.3 ± 1.1 38.865 95.7± 1.6 37.594 71.4 ± 12.1 
13.333 26.635 93.9± 2.3 25.910 93.7± 2.4 25.063 63.9 ± 19.8 
10.000 19.976 92.1 ± 2.0 19.433 91.9± 2.9 18.797 59.6 ± 21.7 
8.333 16.647 90.8± 2.2 16.194 90.5 ± 3.1 15.664 51.9 ± 26.2 
6.667 13.317 88.9± 2.7 12.955 88.4 ± 3.5 12.531 46.4 ± 31.3 
6.000 11.986 88.1 ± 2.5 11.660 86.4 ± 4.3 11.278 43.1±31.4 
5.333 10.654 85.4 ± 3.6 10.364 85.5 ± 2.9 10.025 40.7 ± 30.3 
4.667 9.322 83.8± 4.4 9.069 82.9± 2.8 8.772 38.6 ± 28.4 
4.000 7.990 81.1 ± 5.5 7.773 75.5 ± 2.5 7.519 36.9 ± 26.8 
3.333 6.659 72.1 ± 9.0 6.478 53.1 ± 10.8 6.266 29.3 ± 24.4 
3.000 5.993 56.9 ± 11.6 5.830 50.8± 2.4 5.639 20.2 ± 20.8 
2.667 5.327 49.1 ± 14.2 5.182 42.9± 4.5 5.013 14.5 ± 14.5 
2.333 4.661 43.7± 9.8 4.534 33.9± 3.8 4.386 12.0 ± 14.9 
2.000 3.995 38.1 ± 12.8 3.887 23.5 ± 11.6 3.759 10.9 ± 15.4 
1.833 3.662 33.7± 10.1 3.563 22.9± 5.8 3.446 8.9 ± 12.9 
1.667 3.329 33.2± 8.1 3.239 28.8 ± 2.7 3.133 18.3 ± 14.7 
1.500 2.996 34.2± 9.0 2.915 25.0± 2.2 2.820 11.0 ± 13.4 
1.333 2.663 24.0 ± 13.5 2.591 18.9± 4.1 2.506 10.0 ± 12.5 
1.167 2.331 21.2± 12.1 2.267 15.3 ± 2.2 2.193 8.1 ± 12.4 
1.000 1.998 18.0± 7.6 1.943 9.9± 1.8 1.880 6.1 ± 12.1 
0.833 1.665 10.9± 6.8 1.619 4.7± 3.3 1.566 5.6± 11.7 
0.667 1.332 6.3± 4.9 1.296 2.2± 1.8 1.253 4.7± 11.2 
* All values represent the mean ± SD of three independent determinations. 
Table 14b -- Inhibition of Thrombin 
Generation After Extrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
Boc-D-Phe-Pro-Arg-H 
µg/ml µM %Inhibition* 
16.667 30.215 95.9 ± 2.5 
13.333 24.172 95.5 ± 2.3 
10.000 18.129 95.0± 2.4 
6.667 12.086 92.7± 2.2 
5.000 9.065 89.4± 2.0 
4.167 7.554 83.5 ± 4.5 
3.333 6.043 70.9± 9.6 
2.667 4.834 17.1 ± 12.4 
2.000 3.626 2.4 ± 5.0 
* All values represent the mean ± SD of 
three independent determinations. 
Table 14c -- Inhibition of Thrombin 
Generation After Extrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
Ac-(D )Phe-Pro-boroArg-OH 
µg/ml µM %Inhibition* 
3333.330 6709.610 98.3 ± 2.1 
2500.000 5032.210 98.3 ± 2.2 
1666.670 3354.800 98.3± 2.3 
833.330 1677.400 97.8± 2.5 
333.330 670.960 93.3± 3.3 
250.000 503.220 90.2± 4.5 
166.670 335.480 48.0± 23.8 
83.330 167.740 0.1 ± 0.7 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 14d -- Inhibition of Thrombin 
Generation After Extrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
µg/ml 
33.333 
26.667 
20.000 
13.333 
10.000 
6.667 
5.000 
4.167 
3.333 
2.500 
1.667 
0.833 
0.333 
0.250 
0.167 
0.083 
Hirudin 
µM 
4787.210 
3829.770 
2872.330 
1914.880 
1436.160 
957.440 
718.080 
598.400 
478.720 
359.040 
239.360 
119.680 
47.870 
35.900 
23.940 
11.970 
%Inhibition* 
80.3 ± 8.3 
80.5 ± 8.1 
80.3 ± 8.3 
80.7 ± 8.1 
80.5 ± 8.0 
80.3 ± 8.3 
80.1 ± 8.3 
80.2 ± 8.2 
80.1 ± 8.3 
79.8 ± 8.4 
79.7 ± 8.7 
79.5 ± 8.5 
78.5 ± 9.4 
76.3 ± 12.1 
54.2 ± 46.7 
0.6 ± 3.6 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 14e -- Inhibition of Thrombin 
Generation After Extrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
µg/ml 
333.333 
250.000 
166.667 
133.333 
100.000 
66.667 
33.333 
26.667 
20.000 
13.333 
10.000 
6.667 
5.000 
4.167 
3.333 
2.667 
2.000 
1.667 
1.333 
1.000 
Heparin 
µM 
30303.000 
22727.300 
15151.500 
12121.200 
9090.900 
6060.600 
3030.300 
2424.200 
1818.200 
1212.100 
909.100 
606.100 
454.500 
378.800 
303.000 
242.400 
181.800 
151.500 
121.200 
90.900 
% lnhib ition * 
96.7 ± 2.9 
96.5 ± 3.0 
98.0 ± 1.9 
98.4± 1.7 
97.8 ± 2.5 
98.8 ± 1.3 
98.6 ± 1.6 
99.0 ± 1.8 
99.1 ± 1.2 
98.8 ± 1.8 
98.0 ± 1.9 
94.7 ± 1.4 
90.1 ± 3.1 
81.8 ± 9.3 
72.5 ± 14.2 
54.7 ± 25.5 
20.0± 7.8 
5.7 ± 8.5 
4.0± 7.1 
3.0 ± 5.6 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 14f -- Inhibition of Factor Xa Generation After Extrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Argatroban 
µg/ml µM % Inhibition* µM %Inhibition* µM % Inhibition* 
33.333 66.587 88.2± 6.1 64.775 91.0± 4.5 62.657 36.1 ± 6.0 
26.667 53.269 86.7± 7.0 51.820 88.4± 6.2 50.125 33.6 ± 6.2 
20.000 39.952 81.0± 9.4 38.865 84.4 ± 8.3 37.594 31.8 ± 6.5 
13.333 26.635 76.4 ± 8.0 25.910 76.4 ± 13.3 25.063 28.2± 5.1 
10.000 19.976 69.8 ± 10.8 19.433 71.2± 13.7 18.797 27.2 ± 6.8 
8.333 16.647 64.9± 12.4 16.194 66.6± 13.2 15.664 26.4 ± 7.1 
6.667 13.317 58.0± 12.9 12.955 61.9± 15.4 12.531 24.8 ± 7.0 
6.000 11.986 57.9± 9.0 11.660 59.6± 14.9 11.278 23.8 ± 7.0 
5.333 10.654 50.2± 12.4 10.364 57.4± 15.0 10.025 23.9 ± 7.4 
4.667 9.322 49.1 ± 13.8 9.069 53.0± 18.8 8.772 22.6 ± 7.2 
4.000 7.990 46.8± 13.4 7.773 51.6± 16.7 7.519 21.8 ± 7.6 
3.333 6.659 29.0± 29.3 6.478 44.3± 20.6 6.266 21.5 ± 7.5 
3.000 5.993 38.6± 13.4 5.830 46.9± 16.2 5.639 21.0±8.1 
2.667 5.327 36.5 ± 16.7 5.182 45.3 ± 16.2 5.013 20.9 ± 6.6 
2.333 4.661 32.0± 12.3 4.534 43.1 ± 16.5 4.386 20.0 ± 7.7 
2.000 3.995 30.9± 12.6 3.887 41.4 ± 16.0 3.759 19.6± 7.7 
1.833 3.662 21.2 ± 19.5 3.563 40.2± 15.9 3.446 21.4 ± 7.7 
1.667 3.329 31.6 ± 5.6 3.239 32.2± 7.4 3.133 16.5 ± 7.3 
1.500 2.996 30.8± 5.1 2.915 31.0± 6.9 2.820 16.0 ± 6.5 
1.333 2.663 29.2± 7.7 2.591 30.6± 6.4 2.506 15.4 ± 7.0 
1.167 2.331 27.5 ± 6.1 2.267 29.0± 6.6 2.193 15.5 ± 6.7 
1.000 1.998 25.5 ± 5.7 1.943 26.0± 6.2 1.880 15.4 ± 6.5 
0.833 1.665 23.6± 6.8 1.619 24.7± 5.2 1.566 15.1 ± 6.1 
0.667 1.332 21.5 ± 5.7 1.296 23.2± 5.6 1.253 14.7 ± 5.7 
0.500 0.999 19.3 ± 4.6 0.972 21.0± 4.1 0.940 13.6 ± 5.5 
0.333 0.666 17.0± 3.9 0.648 19.8 ± 4.2 0.627 11.6± 5.6 
0.250 0.499 16.7 ± 4.4 0.486 17.5 ± 4.0 0.470 10.4 ± 4.6 
0.167 0.333 15.1 ± 4.5 0.324 16.1 ± 4.3 0.313 7.9± 3.0 
0.083 0.166 14.1 ± 3.1 0.162 8.4 ± 3.0 0.157 4.3 ± 1.7 
0.033 0.067 6.8± 3.0 0.065 0.6± 1.8 0.063 0.4 ± 0.9 
*All values represent the mean ± SD of three independent determinations. 
Table 14g -- Inhibition of Factor Xa 
Generation After Extrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
Boc-D-Phe-Pro-Arg-H 
µg/ml µM %Inhibition* 
16.667 30.215 96.7 ± 0.2 
13.333 
10.000 
6.667 
5.000 
4.167 
3.333 
2.667 
2.000 
1.333 
1.000 
0.833 
0.667 
0.583 
0.500 
0.417 
0.333 
0.250 
0.167 
0.083 
24.172 
18.129 
12.086 
9.065 
7.554 
6.043 
4.834 
3.626 
2.417 
1.813 
1.511 
1.209 
1.058 
0.906 
0.755 
0.604 
0.453 
0.302 
0.151 
95.6 ± 0.5 
94.0 ± 0.6 
89.5 ± 2.4 
86.1± 4.0 
82.0 ± 6.2 
78.5 ± 4.8 
68.5 ± 5.3 
61.8 ± 5.3 
51.9 ± 7.6 
44.5 ± 6.0 
42.4 ± 5.7 
35.1± 6.4 
36.2 ± 7.0 
32.3 ± 7.3 
28.1 ± 5.2 
22.3 ± 6.9 
18.3 ± 8.7 
12.7 ± 8.7 
4.5 ± 5.0 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 14h -- Inhibition of Factor Xa 
Generation After Extrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
Ac-(D)Phe-Pro-boroArg-OH 
µg/ml µM %Inhibition* 
3333.330 6709.610 99.6 ± 0.4 
2500.000 5032.210 99.4 ± 0.5 
1666.670 3354.800 99.1 ± 0.8 
833.330 1677.400 96.1 ± 0. 7 
333.330 670.960 79.3 ± 1.1 
250.000 503.220 71.2 ± 6.3 
166.670 335.480 60.4 ± 8.5 
83.330 167. 740 40.0 ± 12.0 
33.330 67.100 17.8 ± 7.0 
26.670 53.680 9.2 ± 4.2 
20.000 40.260 1.5 ± 2.5 
* All values represent the mean ± SD of 
three independent determinations. 
Table 14i -- Inhibition of Factor Xa 
Generation After Extrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
µg/ml 
33.333 
26.667 
20.000 
13.333 
10.000 
6.667 
5.000 
4.167 
3.333 
2.500 
1.667 
0.833 
0.333 
Hirudin 
µM 
4787.210 
3829.770 
2872.330 
1914.880 
1436.160 
957.440 
718.080 
598.400 
478.720 
359.040 
239.360 
119.680 
47.870 
% Inhibition* 
24.9± 5.5 
26.2 ± 8.0 
26.7 ± 8.6 
26.9± 8.6 
26.7 ± 9.0 
26.8 ± 9.0 
25.6 ± 7.0 
26.8 ± 9.8 
27.0 ± 9.6 
25.3 ± 7.5 
24.8 ± 7.8 
23.7± 8.1 
4.4 ± 8.6 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 14j -- Inhibition of Factor Xa 
Generation After Extrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
µglml 
333.333 
250.000 
166.667 
133.333 
100.000 
66.667 
33.333 
26.667 
20.000 
13.333 
10.000 
6.667 
5.000 
4.167 
3.333 
2.667 
2.000 
1.667 
1.333 
1.000 
0.667 
0.583 
0.500 
0.417 
0.333 
0.250 
0.167 
Heparin 
µM 
30303.000 
22727.300 
15151.500 
12121.200 
9090.900 
6060.600 
3030.300 
2424.200 
1818.200 
1212.100 
909.100 
606.100 
454.500 
378.800 
303.000 
242.400 
181.800 
151.500 
121.200 
90.900 
60.600 
53.000 
45.500 
37.900 
30.300 
22.700 
15.200 
%Inhibition* 
91.5 ± 7.0 
94.8 ± 3.2 
95.2 ± 2.9 
95.2 ± 2.3 
94.7 ± 1.9 
95.4 ± 2.1 
95.3 ± 2.4 
95.4 ± 2.0 
95.5 ± 2.1 
95.5 ± 2.3 
95.6 ± 2.8 
95.0 ± 2.2 
94.8 ± 2.2 
94.0 ± 1.4 
93.0 ± 2.2 
90.4 ± 2.3 
87.0 ± 4.8 
27.2 ± 47.1 
52.8 ±46.2 
48.5 ±42.7 
42.1 ±38.3 
35.8 ± 31.8 
32.9 ± 29.1 
29.5 ±26.3 
25.4 ±22.8 
17.7±15.7 
7.8 ± 6.9 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 14k -- Inhibition of Thrombin Generation After Intrinsic Stimulation of Fibrinogen-
Deficient Human Plasma. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Argatroban 
µglml µM %Inhibition* µM %Inhibition* µM %Inhibition* 
33.333 62.657 64.2 ± 11.0 
26.667 51.820 100.0 ± 0.0 50.125 64.6 ± 13.7 
20.000 38.865 99.9± 0.2 37.594 54.9 ± 16.5 
13.333 25.910 99.1 ± 1.6 25.063 60.8 ± 15.9 
10.000 19.976 100.0 ± 0.0 19.433 98.6± 2.4 18.797 57.4 ± 12.4 
8.333 16.647 99.3 ± 1.3 16.194 97.7± 4.0 15.664 55.5 ± 17.0 
6.667 13.317 98.4 ± 2.8 12.955 96.8 ± 5.5 12.531 51.6 ± 20.7 
6.000 11.986 98.5 ± 2.6 11.660 96.8± 5.5 11.278 50.9 ± 23.5 
5.333 10.654 97.6± 4.1 10.364 95.9± 7.0 10.025 47.3 ± 20.0 
4.667 9.322 97.0± 5.2 9.069 91.4 ± 15.0 8.772 50.1 ± 19.9 
4.000 7.990 96.1 ± 6.8 7.773 92.5 ± 13.0 7.519 50.1 ± 18.1 
3.333 6.659 94.0± 10.3 6.478 90.8± 15.2 6.266 40.3 ± 13.2 
3.000 5.993 92.2± 13.5 5.830 89.6± 16.9 5.639 36.1 ± 22.4 
2.667 5.327 90.5 ± 16.4 5.182 84.1 ± 25.8 5.013 31.8 ± 18.9 
2.333 4.661 87.3 ± 21.9 4.534 79.3 ± 32.6 4.386 25.3 ± 17.7 
2.000 3.995 82.2± 30.0 3.887 77.2± 34.6 3.759 22.0 ± 17.3 
1.833 3.662 80.0 ± 32.7 3.563 75.7 ± 35.1 3.446 20.6 ± 16.5 
1.667 3.329 80.0 ± 32.2 3.239 74.6 ± 37.2 3.133 13.3 ± 6.9 
1.500 2.996 76.8± 33.5 2.915 71.9± 39.5 2.820 11.1 ± 3.9 
1.333 2.663 75.1 ± 36.3 2.591 64.3 ± 38.6 2.506 7.7± 2.6 
1.167 2.331 69.3± 36.2 2.267 61.3 ± 42.4 2.193 6.1 ± 2.1 
1.000 1.998 57.8± 33.6 1.943 50.8 ± 40.4 1.880 2.1 ± 0.6 
0.833 1.665 52.9 ± 35.0 1.619 42.5 ± 40.3 1.566 1.0 ± 1.2 
0.667 1.332 35.9 ± 24.3 1.296 27.5 ± 27.4 1.253 0.3 ± 0.7 
0.500 0.999 20.3± 12.4 0.972 16.2 ± 18.8 
0.333 0.666 5.9± 6.6 0.648 2.7 ± 5.0 
0.250 0.499 2.8± 3.9 
* All values represent the mean ± SD of three independent determinations. 
Table 141 -- Inhibition of Thrombin 
Generation After Intrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
Boc-D-Phe-Pro-Arg-H 
µglml µM %Inhibition* 
13.333 24.172 100.0 ± 0.0 
10.000 
6.667 
5.000 
4.167 
3.333 
2.667 
2.000 
1.333 
1.000 
0.833 
0.667 
0.583 
0.500 
18.129 
12.086 
9.065 
7.554 
6.043 
4.834 
3.626 
2.417 
1.813 
1.511 
1.209 
1.058 
0.906 
99.1 ± 1.5 
97.8 ± 3.8 
97.2 ± 4.8 
95.7 + 7.1 
92.7 ± 11.3 
85.5 ± 19.9 
67.2 ± 48.1 
61.6 ± 50.8 
58.0 ± 49.2 
50.2 ± 43.0 
13.4 ± 11.0 
13.8 ± 10.7 
1.9 ± 2.0 
* All values represent the mean ± SD of 
three independent determinations. 
Table 14m -- Inhibition of Thrombin 
Generation After Intrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
Ac-(D)Phe-Pro-boroArg-OH 
µglml 
166.670 
83.330 
33.330 
µM %Inhibition* 
335.480 100.0 ± 0.1 
167. 740 83.4 ± 12.5 
67.100 0.0 ± 0.4 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 14n -- Inhibition of Thrombin 
Generation After Intrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
µg/ml 
33.333 
26.667 
20.000 
13.333 
10.000 
6.667 
5.000 
4.167 
3.333 
2.500 
1.667 
0.833 
0.333 
0.250 
0.167 
Hirudin 
µM 
4787.210 
3829.770 
2872.330 
1914.880 
1436.160 
957.440 
718.080 
598.400 
478.720 
359.040 
239.360 
119.680 
47.870 
35.900 
23.940 
%Inhibition* 
79.6 ± 3.7 
79.2± 4.1 
79.6 ± 3.9 
79.5 ± 3.7 
79.6 ± 3.9 
79.4 ± 3.9 
79.3 ± 3.8 
79.3 ± 4.0 
79.3 ± 3.8 
78.9± 4.2 
79.1 ± 4.3 
78.9± 3.9 
45.4 ± 41.0 
20.5 ± 31.4 
0.0 ± 0.8 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 140 -- Inhibition of Thrombin 
Generation After Intrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
µg/ml 
333.333 
250.000 
166.667 
133.333 
100.000 
66.667 
33.333 
26.667 
20.000 
13.333 
10.000 
6.667 
5.000 
4.167 
3.333 
2.667 
2.000 
1.667 
1.333 
1.000 
0.667 
0.583 
0.500 
0.417 
0.333 
0.250 
0.167 
Heparin 
µM 
30303.000 
22727.300 
15151.500 
12121.200 
9090.900 
6060.600 
3030.300 
2424.200 
1818.200 
1212.100 
909.100 
606.100 
454.500 
378.800 
303.000 
242.400 
181.800 
151.500 
121.200 
90.900 
60.600 
53.000 
45.500 
37.900 
30.300 
22.700 
15.200 
%Inhibition* 
75.1±16.5 
73.8±16.4 
73.2±16.2 
73.0±17.8 
74.3±17.8 
74.0±15.3 
71.8 ± 7.5 
71.6± 2.7 
71.4 ± 2.6 
69.9± 6.1 
71.0 ± 7.2 
73.2 ± 4.8 
76.5± 1.7 
77.1 ± 1.9 
78.3 ± 4.2 
77.9 ± 5.6 
78.0 ± 4.9 
51.8 ±45.7 
52.2 ±45.3 
51.9 ±44.9 
51.4 ±44.3 
50.8 ±44.8 
50.6 ±44.4 
47.3 ±42.9 
29.1 ±34.2 
18.0 ±35.8 
0.0± 2.0 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 14p -- Inhibition of Factor Xa Generation After Intrinsic Stimulation of Fibrinogen-
Deficient Human Plasma. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Argatroban 
µg/ml µM %Inhibition* µM %Inhibition* µM %Inhibition* 
33.333 66.587 99.2± 1.4 62.657 97.0± 4.0 
26.667 53.269 99.2± 1.4 50.125 98.0± 2.1 
20.000 39.952 99.2± 1.4 37.594 94.4 ± 5.0 
13.333 26.635 99.1 ± 1.5 25.063 95.6± 4.9 
10.000 19.976 99.1 ± 1.5 18. 797 96.8± 5.6 
8.333 16.647 99.1 ± 1.6 15.664 97.1 ± 5.1 
6.667 13.317 99.0± 1.7 12.531 95.9± 7.1 
6.000 11.986 99.0± 1.7 11.278 97.7± 4.0 
5.333 10.654 98.9± 1.9 10.025 95.3 ± 8.1 
4.667 9.322 98.9± 1.9 8.772 97.1 ± 5.0 
4.000 7.990 98.8± 2.0 7.519 94.3 ± 9.8 
3.333 6.659 98.8 ± 2.1 6.266 96.2± 6.6 
3.000 5.993 98.7± 2.2 5.639 96.0± 7.0 
2.667 5.327 98.7± 2.3 5.013 96.1 ± 6.7 
2.333 4.661 98.5 ± 2.7 4.386 96.1 ± 6.7 
2.000 3.995 98.3 ± 2.9 3.887 100.0 ± 0.0 3.759 95.7± 7.5 
1.833 3.662 97.9± 3.2 3.563 99.9± 0.1 3.446 95.5 ± 7.8 
1.667 3.329 98.0± 3.5 3.239 100.0± 0.0 3.133 86.6 ± 15.0 
1.500 2.996 97.8± 3.8 2.915 99.8 ± 0.3 2.820 86.4± 14.7 
1.333 2.663 96.7± 3.9 2.591 99.5 ± 0.5 2.506 84.8± 14.5 
1.167 2.331 96.1 ± 3.9 2.267 99.2 ± 0.8 2.193 84.9± 14.7 
1.000 1.998 96.6± 4.7 1.943 98.7± 1.1 1.880 84.6± 15.0 
0.833 1.665 95.1 ± 4.7 1.619 97.9± 1.7 1.566 84.1 ± 14.7 
0.667 1.332 94.1 ± 5.6 1.296 97.2± 1.4 1.253 83.4 ± 14.2 
0.500 0.999 93.4 ± 5.4 0.972 96.0± 1.6 0.940 81.1 ± 13.0 
0.333 0.666 92.3 ± 5.9 0.648 93.8± 1.7 0.627 78.2± 13.3 
0.250 0.499 91.2 ± 5.6 0.486 91.5± 1.1 0.470 73.9± 13.7 
0.167 0.333 89.1 ± 5.5 0.324 86.4 ± 0.8 0.313 66.0± 12.6 
0.083 0.166 81.1± 5.2 0.162 69.3 ± 5.5 0.157 47.4 ± 15.0 
0.033 0.067 43.2± 12.7 0.065 28.2± 3.1 0.063 17.5 ± 13.7 
0.025 0.050 25.1 ± 13.9 0.049 17.5 ± 2.4 0.047 11.4 ± 12.5 
0.017 0.033 10.7± 7.5 0.032 5.5 ± 1.1 0.031 5.2± 6.8 
0.008 0.017 1.8 ± 2.5 0.016 0.1 ± 0.3 0.016 0.4 ± 2.1 
*All values represent the mean ± SD of three independent determinations. 
Table 14q -- Inhibition of Factor Xa 
Generation After Intrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
Boc-D-Phe-Pro-Arg-H 
µglml µM %Inhibition* 
2.000 3.626 100.0 ± 0.0 
1.333 
1.000 
0.833 
0.667 
0.583 
0.500 
0.417 
0.333 
0.250 
0.167 
0.083 
0.033 
0.025 
0.017 
2.417 
1.813 
1.511 
1.209 
1.058 
0.906 
0.755 
0.604 
0.453 
0.302 
0.151 
0.060 
0.045 
0.030 
99.8 ± 0.3 
99.2 ± 1.5 
98.6 ± 2.5 
97.7 ± 4.0 
97.7 ± 4.0 
96.7 ± 4.6 
94.4 ± 7.7 
91.8 ± 7.3 
85.4 ± 5.1 
73.1 ± 4.8 
46.8 ± 5.9 
11.9± 6.1 
2.8 ± 1.5 
0.6 ± 1.2 
* All values represent the mean ± SD of 
three independent determinations. 
Table 14r -- Inhibition of Factor Xa 
Generation After Intrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
Ac-(D)Phe-Pro-boroArg-OH 
µglml µM %Inhibition* 
83.330 167.740 100.0 ± 0.0 
33.330 67.100 89.0± 8.5 
26.670 53.680 77.7± 25.6 
20.000 40.260 60.7± 27.6 
13.330 26.840 22.1 ± 11.3 
6.670 13.420 1.0 ± 1.5 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 14s -- Inhibition of Factor Xa 
Generation After Intrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
Hirudin 
µg/ml µM %Inhibition* 
0.833 119.680 100.0± 0.0 
0.333 47.870 97.1 ± 2.0 
0.250 35.900 80.7± 9.6 
0.167 23.940 56.9± 21.1 
0.083 11.970 5.9± 5.4 
0.033 4.790 0.9± 1.1 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 14t -- Inhibition of Factor Xa 
Generation After Intrinsic Stimulation of 
Fibrinogen-Deficient Human Plasma. 
Heparin 
µg!ml µM %Inhibition* 
333.333 30303.000 93.6± 4.4 
250.000 22727.300 93.7± 3.9 
166.667 15151.500 93.6± 4.1 
133.333 12121.200 93.5± 4.0 
100.000 9090.900 93.8± 3.8 
66.667 6060.600 93.8± 3.9 
33.333 3030.300 93.7± 3.9 
26.667 2424.200 93.9± 3.8 
20.000 1818.200 93.8± 3.9 
13.333 1212.100 94.2± 4.0 
10.000 909.100 94.2± 4.1 
6.667 606.100 94.6± 3.9 
5.000 454.500 94.5± 4.4 
4.167 378.800 94.9± 4.4 
3.333 303.000 94.8± 4.5 
2.667 242.400 95.2± 4.3 
2.000 181.800 95.0± 4.3 
1.667 151.500 96.1 ± 5.6 
1.333 121.200 95.3 ± 4.1 
1.000 90.900 95.6± 3.9 
0.667 60.600 96.3± 3.4 
0.583 53.000 97.0± 2.9 
0.500 45.500 97.4± 2.9 
0.417 37.900 97.4 ± 3.2 
0.333 30.300 96.5± 4.5 
0.250 22.700 93.6 ± 7.8 
0.167 15.200 86.0 ± 14.1 
0.083 7.600 55.3 ± 25.3 
0.033 3.000 19.3 ± 13.2 
0.025 2.300 7.4± 7.4 
0.017 1.500 1.7 ± 1.9 
0.008 0.800 0.1 ± 0.2 
* All values represent the mean ± SD of 
three independent determinations. 
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Table 15a -- Inhibition of Thrombin Generation from KONYNE® by Thrombin 
Inhibitors. 
D-Phe- D-MePhe- Boc-D-Phe- Ac-(D)Phe-Pro-
Pro-Arg-H Pro-Arg-H Pro-Arg-H boroArg-OH 
µg/ml µM %In µM %In µM %In µM %In 
1.500 2.915 53.6 2.719 59.8 
1.000 1.998 44.8 1.943 49.8 1.813 53.3 2.013 80.5 
0.500 0.999 29.5 0.972 38.2 0.906 35.5 0.999 68.3 
0.250 0.499 15.9 0.486 24.2 0.453 18.7 0.499 57.7 
0.125 0.250 2.3 0.243 14.5 0.227 8.0 0.250 50.2 
0.063 0.125 2.9 0.121 8.7 0.113 5.6 0.125 39.6 
0.031 0.062 0.0 0.061 1.6 0.057 5.2 0.062 28.3 
0.016 0.031 1.6 0.030 1.8 0.028 1.3 0.031 19.2 
0.000 0.000 0.0 0.000 0.0 0.000 0.0 0.000 0.0 
Table 15b -- Inhibition of Thrombin 
Generation from KONYNE® by Thrombin 
Inhibitors. 
Argatroban 
µg/ml µM %In 
5.000 9.398 62.6 
2.500 4.699 42.0 
1.250 2.350 38.0 
0.625 1.175 35.0 
0.313 0.587 23.0 
0.156 0.294 14.0 
0.078 0.147 11.0 
0.039 0.073 8.0 
0.020 0.037 8.0 
0.010 0.018 1.0 
0.000 0.000 0.0 
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Table 15c -- Inhibition of Thrombin Generation from 
KONYNE® by Thrombin Inhibitors. 
Hirudin Heparin 
µglml µM %In µM %In 
20.000 2.872 36.7 
15.000 1.402 43.2 
10.000 1.436 35.1 0.935 39.1 
5.000 0.467 25.3 
2.500 0.359 44.6 0.234 9.8 
1.000 0.144 43.4 0.093 0.0 
0.500 0.072 40.2 
0.250 0.036 28.2 
0.125 0.018 19.7 
0.063 0.009 6.1 
0.031 0.004 2.9 
0.000 0.000 0.0 0.000 0.0 
Table 15d -- Inhibition of Factor Xa Generation from KONYNE® by Thrombin 
Inhibitors. 
D-Phe- D-MePhe- Boc-D-Phe- Ac-(D) Phe-Pro-
Pro-Arg-H Pro-Arg-H Pro-Arg-H boroArg-OH 
µg/ml µM % In µM % In µM % In µM % In 
1.500 2.996 50.6 2.719 75.3 
1.000 1.998 48.0 1.943 58.6 1.813 70.7 2.013 99.3 
0.500 0.999 34.3 0.906 49.8 0.999 98.1 
0.250 0.499 0.0 0.486 58.3 0.453 21.7 0.499 94.1 
0.125 0.250 0.0 0.243 14.5 0.227 1.6 0.250 89.3 
0.063 0.125 0.0 0.121 0.0 0.113 0.9 0.125 74.7 
0.031 0.062 0.0 0.061 0.0 0.057 1.6 0.062 8.5 
0.016 0.031 0.0 0.030 0.0 0.028 1.4 0.031 0.0 
0.000 0.000 0.0 0.000 0.0 0.000 0.0 0.000 0.0 
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Table 15e -- Inhibition of Factor Xa 
Generation from KONYNE® by Thrombin 
Inhibitors. 
Argatroban 
µg/ml µM %In 
10.000 18.797 56.0 
5.000 9.398 52.0 
2.500 4.699 50.0 
1.250 2.350 49.0 
0.625 1.175 49.0 
0.313 0.587 45.0 
0.156 0.294 39.0 
0.078 0.147 33.0 
0.039 0.073 22.0 
0.020 0.037 13.0 
0.010 0.018 0.0 
Table 15f -- Inhibition of Factor Xa Generation from 
KONYNE® by Thrombin Inhibitors. 
Hirudin Heparin 
µg/ml µM %In µM %In 
20.000 2.872 51.7 
15.000 2.154 52.8 1.402 69.1 
10.000 1.436 53.1 0.935 60.1 
5.000 0.467 28.1 
2.500 0.359 48.7 0.234 14.1 
1.000 0.144 46.5 0.093 0.0 
0.500 0.072 19.6 0.047 0.9 
0.250 0.036 0.0 0.023 0.0 
0.125 0.018 5.9 
0.063 0.009 6.2 
0.031 0.004 2.3 
0.016 0.002 0.0 
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Table 15g -- Inhibition of Thrombin Generation from FEIBA ®by Thrombin Inhibitors. 
D-Phe- D-MePhe- Boc-D-Phe- Ac-(D)Phe-Pro-
Pro-Arg-H Pro-Arg-H Pro-Arg-H boroArg-OH 
µg/ml µM %In µM %In µM %In µM %In 
1.500 2.996 69.4 2.915 1.1 2.719 0.2 
1.000 1.998 10.9 1.943 3.1 1.813 0.0 96.8 99.3 
0.500 0.999 7.6 0.972 16.2 0.906 1.9 81.7 98.1 
0.250 0.499 5.1 0.486 0.0 0.453 0.0 28.0 94.1 
0.125 0.250 7.0 0.243 4.9 0.227 0.0 13.9 89.3 
0.063 0.125 5.1 0.121 2.1 0.113 0.0 10.3 74.7 
0.031 0.062 5.0 0.061 4.0 0.057 0.0 11.3 8.5 
0.016 0.031 6.6 0.030 3.2 0.028 5.3 13.2 0.0 
Table 15h -- Inhibition of Thrombin 
Generation from FEIBA® by Thrombin 
Inhibitors. 
Argatroban 
µg/ml µM %In 
10.000 18.797 49.0 
5.000 9.398 14.0 
2.500 4.699 11.0 
1.250 2.350 8.0 
0.625 1.175 3.0 
0.313 0.587 0.0 
0.156 0.294 1.0 
0.078 0.147 0.0 
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Table 15i -- Inhibition of Thrombin Generation from 
FEIBA ® by Thrombin Inhibitors. 
Hirudin Heparin 
µg/ml µM %In µM %In 
20.000 2.872 93.8 1.869 56.9 
15.000 2.154 91.7 1.402 34.2 
10.000 1.436 90.4 0.935 5.2 
5.000 0.718 83.7 0.467 0.0 
2.500 0.359 0.0 
1.000 0.144 2.4 
0.500 0.072 5.5 
0.250 0.036 2.9 
0.125 0.018 4.2 
0.063 0.009 10.6 
0.031 0.004 4.7 
0.016 0.002 0.0 
Table 15j -- Inhibition of Factor Xa Generation from FEIBA ®by Thrombin Inhibitors. 
D-Phe- D-MePhe- Boc-D-Phe- Ac-(D) Phe-Pro-
Pro-Arg-H Pro-Arg-H Pro-Arg-H boroArg-OH 
µg/ml µM %In µM %In µM %In µM %In 
1.500 2.996 66.4 2.915 85.4 2.719 73.3 
1.000 1.998 0.0 1.943 65.7 1.813 33.2 2.013 99.8 
0.500 0.999 0.0 0.972 0.5 0.906 2.6 1.006 99.1 
0.250 0.499 0.0 0.486 0.0 0.453 0.0 0.503 94.4 
0.125 0.250 0.0 0.243 1.5 0.227 0.0 0.252 2.8 
Table 15k -- Inhibition of Factor Xa 
Generation from FEIBA ® by Thrombin 
Inhibitors. 
µglml 
10.000 
5.000 
2.500 
1.250 
0.625 
0.313 
0.156 
0.078 
0.039 
0.020 
Argatroban 
µM 
18. 797 
9.398 
4.699 
2.350 
1.175 
0.587 
0.294 
0.147 
0.073 
0.037 
Table 151 -- Inhibition of Factor Xa 
FEIBA ®by Thrombin Inhibitors. 
Hirudin 
µglml µM %In 
20.000 2.872 88.4 
15.000 2.154 82.5 
10.000 1.436 87.8 
5.000 0.718 84.7 
2.500 0.359 0.0 
%In 
91.0 
90.0 
85.0 
78.0 
66.0 
33.0 
1.0 
1.0 
2.0 
0.0 
Generation from 
Heparin 
µM %In 
1.869 0.0 
1.402 2.3 
0.935 2.6 
0.467 0.0 
0.234 0.0 
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Table 16a -- Comparative anticoagulant effects of thrombin inhibitors in the NHP based PT assay. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H Ac-(D)Phe-Pro-boroArg-OH 
µg/ml µM Clotting µM Clotting µM Clotting µM Clotting 
Time (sec) Time (sec) Time (sec) Time (sec) 
100.00 199.76 >300.0 181.29 > 300.0 
50.00 99.88 186.5± 2.0 97.16 > 300.0 90.65 74.5± 4.7 
25.00 49.94 75.9± 2.2 48.58 162.1± 36.3 45.32 26.8± 0.2 
10.00 19.98 26.1± 0.6 19.43 49.4± 1.4 18.13 30.4± 0.8 
5.00 9.99 17.5± 0.3 9.72 23.4± 0.5 9.06 18.8± 0.3 10.06 > 300.0 
2.50 4.99 14.8± 0.5 4.86 17.1± 0.8 4.53 14.8± 0.3 5.03 39.9± 2.1 
1.25 2.50 13.0± 0.6 2.43 14.4± 0.5 2.27 12.3± 1.2 2.52 22.0± 1.5 
0.63 1.25 13.3± 0.5 1.21 13.2± 0.3 1.13 12.6± 0.2 1.26 16.7± 1.4 
0.31 0.62 12.6± 0.3 0.61 12.6± 0.3 0.57 12.6± 0.2 0.63 15.2± 1.7 
0.16 0.31 12.0± 1.8 0.30 12.4± 1.0 0.28 12.5± 0.9 0.31 13.3± 1.3 
0.00 0.00 12.0± 1.8 0.00 12.0± 1.8 0.00 12.0± 1.8 0.00 12.0± 1.8 
Each clotting time value represents the mean ± SD of three independent determinations. 
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Table 16b -- Comparative anticoagulant effects of thrombin 
inhibitors in the NHP based PT assay. 
Argatroban Heparin 
µg/ml µM Clotting µM Clotting 
Time (sec) Time (sec) 
100.00 187.97 > 300.0 
50.00 93.98 219.9± 4.0 
25.00 46.99 139.9± 3.0 
10.00 18.80 89.3± 3.0 0.93 20.5± 3.6 
5.00 9.40 58.3± 2.0 0.47 13.8± 0.6 
2.50 4.70 37.9± 1.0 0.23 12.3± 0.3 
1.25 2.35 26.4± 0.7 0.12 12.1± 0.3 
0.63 1.17 20.4± 0.5 0.06 11.8± 0.3 
0.31 0.59 15.9± 0.3 0.03 12.3± 0.9 
0.16 0.29 13.7± 0.3 0.01 12.2± 1.2 
0.00 0.00 11.6± 0.3 0.00 12.0± 1.8 
Each clotting time value represents the mean ± SD of 
three independent determinations. 
Table 16c -- Comparative anticoagulant effects of thrombin 
inhibitors in the NHP based PT assay. 
Hirudin 
µg/ml µM Clotting 
Time (sec) 
25.00 3.59 >300.0 
12.50 1.80 18.4± 1.0 
6.25 0.90 15.7± 1.0 
3.13 0.45 13.9± 1.0 
1.56 0.22 12.9± 0.5 
0.78 0.11 12.4± 0.5 
0.39 0.06 12.3± 0.5 
0.20 0.03 11.9± 0.3 
0.00 0.00 11.4± 0.3 
Each clotting time value represents the mean ± SD of 
three independent determinations. 
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Table l 6d -- Comparative anticoagulant effects of thrombin inhibitors in the NHP based APTT assay. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H Ac-(D )Phe-Pro-boroArg-OH 
µglml µM Clotting µM Clotting µM Clotting µM Clotting 
Time (sec) Time (sec) Time (sec) Time (sec) 
50.00 90.65 > 300.0 
25.00 49.94 > 300.0 48.58 > 300.0 45.32 191.2± 9.8 
10.00 19.98 145.8± 1.6 19.43 186.0± 3.0 18.13 198.1 ± 4.7 
5.00 9.99 88.4± 1.0 9.72 110.7± 1.1 9.06 112.0± 3.8 
2.50 4.99 64.7± 1.8 4.86 75.5± 0.6 4.53 70.1± 3.3 
1.25 2.50 49.5± 0.7 2.43 59.5± 3.5 2.27 51.4± 0.5 2.52 >300.0 
0.63 1.25 40.7± 1.5 1.21 45.7± 0.3 1.13 42.4± 1.0 1.26 218.0± 14.0 
0.31 0.62 38.3± 1.3 0.61 40.3± 0.6 0.57 37.7± 0.3 0.63 90.1± 8.0 
0.16 0.31 34.7± 0.3 0.30 36.2± 0.6 0.28 35.0± 0.3 0.31 68.3± 1.8 
0.00 0.00 34.7± 0.3 0.00 34.7± 0.3 0.00 34.7± 0.3 0.00 34.7± 0.3 
Each clotting time value represents the mean ± SD of three independent determinations. 
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Table 16e -- Comparative anticoagulant effects of thrombin 
inhibitors in the NHP based APTT assay. 
Argatroban Heparin 
µg/ml µM Clotting µM Clotting 
Time (sec) Time (sec) 
50.00 93.98 > 300.0 
25.00 46.99 216.6± 5.0 
10.00 18.80 157.9± 4.0 
5.00 9.40 123.2± 4.0 0.47 >300.0 
2.50 4.70 94.4± 3.0 0.23 98.0± 3.9 
1.25 2.35 79.0± 3.0 0.12 51.0± 1.3 
0.63 1.17 63.4± 2.0 0.06 35.7± 0.3 
0.31 0.59 53.4± 2.0 0.03 36.4± 4.6 
0.16 0.29 46.8± 1.0 0.01 32.7± 0.6 
0.00 0.00 29.4± 0.5 0.00 34.7± 0.3 
Each clotting time value represents the mean ± SD of 
three independent determinations. 
Table 16f -- Comparative anticoagulant effects of thrombin 
inhibitors in the NHP based APTT assay. 
Hirudin 
µg/ml µM Clotting 
Time (sec) 
25.00 3.59 >300.0 
12.50 1.80 105.9± 3.0 
6.25 0.90 89.3± 3.0 
3.13 0.45 74.9± 3.0 
1.56 0.22 63.0± 2.0 
0.78 0.11 56.0± 2.0 
0.39 0.06 48.5± 1.0 
0.20 0.03 42.7± 1.0 
0.00 0.00 29.4± 0.5 
Each clotting time value represents the mean ± SD of 
three independent determinations. 
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Table 16g -- Comparative anticoagulant effects of thrombin inhibitors in the NHP based TT assay. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H Ac-(D)Phe-Pro-boroArg-OH 
µg/ml µM Clotting µM Clotting µM Clotting µM Clotting 
Time (sec) Time (sec) Time (sec) Time (sec) 
10.00 19.98 > 300.0 18.13 > 300.0 
5.00 9.99 207.4± 41.7 9.72 >300.0 9.06 190.5± 37.6 
2.50 4.99 96.5± 2.0 4.86 161.3± 20.4 4.53 75.2± 2.0 
1.25 2.50 32.5± 2.3 2.43 91.4± 4.8 2.27 23.2± 2.0 
0.63 1.25 8.7± 3.0 1.21 48.0± 6.0 1.13 10.2± 0.8 1.26 >300.0 
0.31 0.62 9.3± 0.5 0.61 16.0± 0.7 0.57 7.0± 0.3 0.63 106.9± 4.7 
0.16 0.31 7.2± 0.4 0.30 8.0± 1.5 0.28 6.5± 0.3 0.31 20.2± 3.3 
Each clotting time value represents the mean ± SD of three independent determinations. 
Table 16h -- Comparative anticoagulant effects of thrombin 
inhibitors in the NHP based TT assay. 
Hirudin Heparin 
µg/ml µM Clotting µM Clotting 
Time (sec) Time (sec) 
5.00 0.72 >300.0 0.47 >300.0 
2.50 0.36 288.4± 16.3 0.23 137.0± 2.0 
1.25 0.18 204.1± 24.0 0.12 78.0± 0.2 
0.63 0.09 93.2± 4.7 0.06 6.7± 0.4 
0.31 0.04 54.8± 1.0 0.03 6.0± 0.3 
0.16 0.02 8.2± 2.3 0.01 5.4± 0.6 
Each clotting time value represents the mean ± SD of 
three independent determinations. 
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Table 16i -- Comparative anticoagulant effects of thrombin 
inhibitors in the NHP based TT assay. 
Argatroban 
µglml µM Clotting 
Time (sec) 
50.00 93.98 >300.0 
25.00 46.99 239.9± 5.0 
12.50 23.50 181.9± 3.0 
6.25 11.75 118.2± 3.0 
3.13 5.87 79.5± 2.0 
1.56 2.94 64.9± 2.0 
0.78 1.47 44.6± 1.0 
0.39 0.73 33.7± 1.0 
0.20 0.37 24.2± 1.0 
0.10 0.18 12.2± 1.0 
Each clotting time value represents the mean ± SD of 
three independent determinations. 
Table 16j -- Comparative anticoagulant effects of thrombin inhibitors in the NHP based ECT assay. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H 
µg/ml µM Clotting µg/ml µM Clotting µg/ml µM Clotting 
Time (sec) Time (sec) Time (sec) 
0.00 0.00 43.1 ± 0.0 0.00 0.00 41.5 ± 1.5 0.00 0.00 40.9 ± 2.7 
0.01 0.02 51.7 ± 1.3 0.01 0.02 46.9± 4.0 0.05 0.09 50.7 ± 1.3 
0.05 0.10 75.4 ± 6.6 0.05 0.10 64.6± 6.3 0.10 0.18 57.0 ± 2.2 
0.10 0.20 114.0 ± 9.7 0.10 0.19 92.5 ± 13.4 0.50 0.91 100.7 ± 7.4 
0.25 0.50 233.4 ± 18.6 0.25 0.49 178.0 ± 33.3 1.00 1.81 149.1 ± 15.8 
0.50 1.00 361.0 ± 75.1 0.50 0.97 306.7 ± 81.3 2.00 3.63 225.1 ± 27.0 
0.75 1.50 587.7 ±34.6 0.75 1.46 437.0 ± 100.4 3.00 5.44 295.8 ± 29.0 
1.00 2.00 768.9 ± 71.7 1.00 1.94 553.5 ± 121.1 4.00 7.25 356.0 ± 37.3 
1.25 2.50 887.2 ±24.8 1.25 2.43 694.1 ± 161.6 5.00 9.06 406.6 ± 51.5 
1.50 2.91 719.0 ± 102.8 6.00 10.88 585.5 ± ERR 
1.75 3.40 798.4 ± 124.9 7.50 13.60 575.1 ± 120.2 
10.00 18.13 663.7 ± 194.7 
12.50 22.66 742.8 ± 104.2 
Each clotting time value represents the mean ± SD of three independent determinations. 
Table 16k -- Comparative anticoagulant effects of thrombin inhibitors in the NHP based ECT assay. 
Ac-(D)Phe-Pro-boroArg-OH Argatroban Hirudin 
µg/ml µM Clotting µg/ml µM Clotting µg/ml µM Clotting 
Time (sec) Time (sec) Time (sec) 
0.00 0.00 42.1 ± 3.8 0.00 0.00 43.7 ± 2.4 0.00 0.00 43.1 ± 3.5 
0.01 0.02 48.8 ± 2.7 0.01 0.02 71.6 ± 30.9 0.10 0.01 59.3 ± 4.0 
0.01 0.02 52.6 ± 2.9 0.05 0.09 73.5 ± 1.0 0.25 0.04 73.8 ± 9.2 
0.05 0.10 104.5 ± 14.8 0.10 0.19 96.0 ± 3.6 0.50 0.07 105.5 ± 21.0 
0.10 0.20 188.7 ± 19.9 0.25 0.47 147.6 ± 9.4 1.00 0.14 173.5 ± 38.9 
0.20 0.40 378.1 ± 29.4 0.50 0.94 213.7 ± 13.3 2.00 0.29 325.5 ± 70.5 
0.30 0.60 577.9 ± 42.5 0.75 1.41 282.4 ± 12.0 3.00 0.43 457.3 ± 148.4 
0.40 0.81 755.3 ± 50.9 1.00 1.88 329.0 ± 9.3 4.00 0.57 632.4 ± 183. 7 
1.25 2.35 373.7 ± 4.0 5.00 0.72 698.1 ± 96.0 
1.50 2.82 420.2 ± 2.5 6.00 0.86 796.4 ± 143.0 
1.75 3.29 454.5 ± 6.7 
2.00 3.76 475.9 ± 39.1 
3.00 5.64 600.8 ± 9.4 
4.00 7.52 694.3 ± 11.5 
5.00 9.40 793.6 ± 0.0 
Each clotting time value represents the mean ± SD of three independent determinations. 
Table 161 -- Comparative anticoagulant effects of thrombin inhibitors in the NHP based Heptest assay. 
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H Ac-(D)Phe-Pro-boroArg-OH 
µg/ml µM Clotting µM Clotting µM Clotting µM Clotting 
Time (sec) Time (sec) Time (sec) Time (sec) 
50.00 99.88 > 300.0 
25.00 49.94 240.5± 6.2 45.32 >300.0 
10.00 19.98 90.5± 5.1 19.43 > 300.0 18.13 44.2± 7.3 
5.00 9.99 34.8± 3.2 9.72 65.4± 7.2 9.06 75.1± 0.7 
2.50 4.99 25.5± 0.7 4.86 38.7± 2.9 4.53 33.0± 0.8 5.03 >300.0 
1.25 2.50 21.8± 2.1 2.43 28.4± 0.7 2.27 24.8± 1.0 2.52 125.4± 0.8 
0.63 1.25 19.1± 1.2 1.21 22.2± 0.3 1.13 20.1± 0.7 1.26 59.0± 0.3 
0.31 0.62 17.8± 0.5 0.61 19.2± 0.3 0.57 17.4± 0.5 0.63 37.3± 2.0 
0.16 0.31 16.6± 0.6 0.30 16.9± 0.5 0.28 17.1± 0.8 0.31 24.3± 0.5 
0.00 0.00 16.6± 0.6 0.00 16.6± 0.6 0.00 15.6± 0.3 0.00 16.6± 0.6 
Each clotting time value represents the mean ± SD of three independent determinations. 
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Table 16m -- Comparative anticoagulant effects of 
thrombin inhibitors in the NHP based Heptest assay. 
Argatroban Hirudin 
µg/ml µM Clotting µM Clotting 
Time (sec) Time (sec) 
25.0 3.59 >300.0 
12.5 23.50 > 300.0 1.80 127.4± 3.0 
6.3 11.75 221.7± 4.0 0.90 77.3± 2.0 
3.1 5.87 131.7± 3.0 0.45 30.7± 2.0 
1.6 2.94 89.9± 3.0 0.22 26.1± 1.0 
0.8 1.47 63.3± 2.0 0.11 21.8± 0.7 
0.4 0.73 44.8± 2.0 0.06 21.4± 0.5 
0.2 0.37 34.7± 1.0 0.03 20.8± 0.5 
0.0 0.00 20.7± 0.5 0.00 20.7± 0.3 
Each clotting time value represents the mean ± SD of 
three independent determinations. 
Table 16n -- Comparative anticoagulant effects of thrombin 
inhibitors in the NHP based Heptest assay. 
Heparin 
µglml µM Clotting 
Time (sec) 
10.00 2.34 >300.0 
5.00 0.93 274.5± 14.2 
2.50 0.47 123.7± 0.7 
1.25 0.23 84.0± 0.2 
0.63 0.12 57.0± 2.3 
0.31 0.06 28.9± 0.9 
0.16 0.03 19.5± 1.0 
0.08 0.01 17.0± 0.0 
0.00 0.00 16.3± 0.3 
Each clotting time value represents the mean ± SD of 
three independent determinations. 
417 
Table l 60 -- Comparative anticoagulant effects of thrombin inhibitors after supplementation into normal human whole blood, in the 
ACT assay. 
D-MePhe-Pro-Arg-H Ac-(D) Phe-Pro- Argatroban Hirudin Heparin 
boroArg-OH 
µM ng/ml Clotting ng/ml Clotting µg/ml Clotting µg/ml Clotting µg/ml Clotting 
Time (sec) Time (sec) Time (sec) Time (sec) Time (sec) 
1.00 514.6 156.0 ± 27.9 496.8 307 ±23.8 532 183.3 ± 25.0 6963 366.0 ± 19.7 10700 326.3 ± 21.0 
0.10 51.46 134.3 ± 2.5 49.68139.7±11.6 53.2 145.7 ± 65.0 696.3 184.3 ± 10.6 1070 160.7 ± 32.8 
0.01 5.146 128.7 ± 2.1 4.968 132.3 ± 6.7 5.32 139.0 ± 2.8 69.63 136.0 ± 5.7 107 127.3 ± 7.4 
0.00 0 130.0 ± 4.2 
Each clotting time value represents the mean ± SD of three independent determinations. 
Table 16p -- Comparative anticoagulant effects of thrombin inhibitors after supplementation into normal human whole blood, in the 
TEG assay. 
D-MePhe-Pro-Arg-H Ac-(D)Phe-Pro-
boroArg-OH 
µM ng/ml TEG R Value ng/ml TEGR 
(mm) Value (mm) 
1.00 
0.10 51.46 38 49.68 43.3 ± 17.7 
0.01 5.146 22 4.968 26.3 ± 2.5 
Argatroban 
µg/ml TEG R Value 
(mm) 
532 31.2 ± 1.6 
53.2 25.2± 2.5 
5.32 25.7 ± 1.0 
Hirudin 
µg/ml TEG R Value 
(mm) 
696.3 42.8 ± 3.9 
69.63 27.0 ± 4.2 
Each TEG R value represents the mean ± SD of three independent determinations. 
Heparin 
µg/ml TEG R Value 
(mm) 
1070 46.5 ± 3.0 
107 26. 7 ± 3.3 
Table 17a -- Comparative anticoagulant effects of thrombin inhibitors in the NRP based PT assay. 
D-MePhe-Pro-Arg-H Ac-(D)Phe-Pro-boroArg-OH Hirudin Heparin 
µg/ml µM Clotting µM Clotting µM Clotting µM Clotting 
Time (sec) Time (sec) Time (sec) Time (sec) 
100.00 194.33 > 300.0 9.35 16.5 ± 0.7 
40.00 77.73 32.2 ± 4.1 5.745 >300.0 3.74 10.7 ± 1.4 
20.00 38.87 15.9 ± 2.0 2.872 48.3 ± 25.6 1.87 8.8 ± 1.0 
10.00 19.43 11.0 ± 1.4 20.13 23.7 ± 5.5 1.436 14.1 ± 1.2 0.94 7.4 ± 0.9 
5.00 9.72 8.8 ± 0.3 10.06 13.8 ± 3.2 0.718 10.3 ± 2.9 0.47 7.1±0.4 
2.50 4.86 7.9 ± 0.4 5.03 10.3 ± 0.6 0.359 8.7 ± 0.5 0.23 7.0 ± 0.5 
1.25 2.43 7.4 ± 0.1 2.52 8.3 ± 0.3 0.180 8.3 ± 0.6 0.12 6.6 ± 0.3 
0.62 1.21 6.7 ± 0.1 1.26 7.5 ± 0.5 0.089 7.4 ± 0.5 0.06 6.8 ± 0.6 
0.31 0.60 6.6 ± 0.7 0.63 7.0 ± 0.2 0.045 7.3 ± 0.2 0.03 6.8 ± 0.3 
0.16 0.31 6.9 ± 0.2 0.32 6.6 ± 0.3 0.023 6.8 ± 0.2 0.02 6.7± 0.1 
0.08 0.16 6.8 ± 0.3 0.16 6.8 ± 0.2 0.011 6.9± 0.4 
0.04 0.08 6.5 ± 0.6 0.08 6.5 ± 0.3 0.006 7.1 ± 0.2 
0.02 0.04 7.0 ± 0.1 
0.01 0.02 6.7 ± 0.4 
0.00 0.00 6.9 ± 0.3 0.00 6.8 ± 0.4 0.000 7.3 ± 0.1 0.00 7.0 ± 0.3 
Each clotting time value represents the mean ± SD of three independent determinations. 
Table 17b -- Comparative anticoagulant effects of thrombin inhibitors in the NRP based APTT assay. 
D-MePhe-Pro-Arg-H Ac-(D)Phe-Pro-boroArg-OH Hirudin Heparin 
µg/ml µM Clotting µM Clotting µM Clotting µM Clotting 
Time (sec) Time (sec) Time (sec) Time (sec) 
40.00 5.745 >300.0 
20.00 38.87 > 300.0 2.872 167.2 ± 21.1 
10.00 19.43 273.2 ±46.4 1.436 130.6 ± 45.8 0.94 >300.0 
5.00 9.72 195.7 ± 35.5 0.718 101.6 ±40.5 0.47 132.7 ± 36.2 
2.50 4.86 101.5 ± 6.1 0.359 72.7 ± 19.3 0.23 76.8 ± 16.7 
1.25 2.43 74.9 ± 7.7 2.52 >300.0 0.180 64.0 ± 21.9 0.12 57.7 ± 11.3 
0.62 1.21 54.6 ± 1.8 1.26 263.5 ± 63.3 0.089 56.2 ± 15.3 0.06 52.2 ± 8.6 
0.31 0.60 52.8 ± 7.6 0.63 124.7 ± 7.9 0.045 45.7 ± 5.7 0.03 44.4 ± 8.9 
0.16 0.31 42.2± 2.9 0.32 82.1±14.1 0.023 39.2± 4.7 0.02 37.7 ± 6.0 
0.08 0.16 39.8 ± 3.1 0.16 63.6 ± 7.7 0.011 39.8 ± 3.9 
0.04 0.08 36.9± 5.7 0.08 50.2 ± 8.6 0.006 34.9 ± 3.6 
0.02 0.04 44.0 ± 8.9 
0.01 0.02 37.4 ± 4.7 
0.00 0.00 39.4 ± 5.8 0.00 37.5 ± 4.3 0.000 36.1 ± 6.0 0.00 38.2 ± 4.3 
Each clotting time value represents the mean ± SD of three independent determinations. 
Table 17c -- Comparative anticoagulant effects of thrombin inhibitors in the NRP based TT assay. 
D-MePhe-Pro-Arg-H Ac-(D)Phe-Pro-boroArg-OH Hirudin 
µg/ml µM Clotting µM Clotting µM Clotting 
Time (sec) Time (sec) Time (sec) 
20.00 38.87 > 300.0 
10.00 19.43 298.6 ± 2.4 
5.00 9.72 176.8 ± 29.3 0.718 > 300.0 
2.50 4.86 106.8 ± 19.9 0.359 172.1 ±26.0 
1.25 2.43 59.0 ± 10.5 2.52 >300.0 0.180 100.7 ± 4.4 
0.62 1.21 44.7 ± 4.9 1.26 131.7 ± 7.0 0.089 66.7 ± 2.5 
0.31 0.60 29.2 ± 9.1 0.63 71.6 ± 3.8 0.045 41.0 ± 8.7 
0.16 0.31 17.9 ± 6.2 0.32 37.5 ± 6.5 0.023 23.6 ± 6.1 
0.08 0.16 13.6 ± 6.3 0.16 20.7 ± 4.5 0.011 13.8 ± 5.5 
0.04 0.08 11.5 ± 3.2 0.08 16.2 ± 7.5 0.006 11.3 ± 3.1 
0.02 0.04 12.8 ± 4.6 
0.01 0.02 11.0 ± 2.0 
0.00 0.00 12.3 ± 3.2 0.00 10.9 ± 3.0 0.000 11.9 ± 3.2 
Each clotting time value represents the mean ± SD of three independent determinations. 
Heparin 
µM Clotting 
Time (sec) 
0.47 >300.0 
0.23 59.3 ± 14.9 
0.12 26.3 ± 10.0 
0.06 18.3 ± 2.6 
0.03 13.7 ± 0.6 
0.02 11.8 ± 2.5 
0.00 11.9 ± 3.0 
.J::.. 
N 
N 
Table 17d -- Comparative anticoagulant effects of thrombin inhibitors in the NRP based Heptest assay. 
D-MePhe-Pro-Arg-H Ac-(D)Phe-Pro-boroArg-OH Hirudin Heparin 
µg/ml µM Clotting µM Clotting µM Clotting µM Clotting 
Time (sec) Time (sec) Time (sec) Time (sec) 
10.00 19.43 > 300.0 
5.00 9.72 215.3 ± 32.0 0.718 >300.0 0.47 >300.0 
2.50 4.86 133.9 ± 44.2 5.03 >300.0 0.359 169.8 ± 8.0 0.23 80.5 ± 55.6 
1.25 2.43 83.7 ± 4.5 2.52 290.6±16.3 0.180 76.9 ± 9.9 0.12 45.5 ± 7.1 
0.62 1.21 56.6 ±20.5 1.26 133.4 ± 17.6 0.089 54.1±16.5 0.06 31.3 ± 2.7 
0.31 0.60 38.4 ± 9.0 0.63 64.6 ± 2.8 0.045 38.0±14.9 0.03 26.0± 1.6 
0.16 0.31 29.6 ± 4.9 0.32 43.3 ± 5.9 0.023 30.3 ± 3.8 0.02 22.6 ± 2.5 
0.08 0.16 25.5 ± 5.0 0.16 29.0±10.3 0.011 26.7 ± 2.7 
0.04 0.08 21.8 ± 6.2 0.08 22.6 ± 8.0 0.006 21.4 ± 2.2 
0.02 0.04 18.7 ± 6.6 
0.01 0.02 17.6 ± 7.1 
0.00 0.00 22.0 ± 2.5 0.00 17.9 ± 7.3 0.000 23.0 ± 2.3 0.00 21.3 ± 2.1 
Each clotting time value represents the mean ± SD of three independent determinations. 
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Table 17e -- Comparative anticoagulant effects of thrombin inhibitors after 
supplementation into normal whole rabbit blood, as assessed by the ACT assay. 
µg/ml 
D-MePhe-Pro-Arg-H 0.2 
Ac-(D)Phe-Pro-boroArg-OH 0.1 
Hirudin 1.0 
Heparin 2.0 
nM 
389 
201 
144 
187 
Clotting Time 
Difference from 
Baseline (sec) 
92 ± 28 
179 ± 58 
215 ± 32 
235 ± 4 
Each clotting time value represents the mean ± SD of three independent determinations. 
Table 17f -- Comparative anticoagulant effects of thrombin inhibitors after 
supplementation into normal whole rabbit blood, as assessed by the TEG assay. 
µg/ml nM R Value Difference 
from Baseline (mm) 
D-MePhe-Pro-Arg-H 0.2 389 32.0± 8.0 
Ac-(D )Phe-Pro-boroArg-OH 0.1 201 40.3 ± 23.6 
Hirudin 1.0 144 30.0 ± 13.0 
Heparin 2.0 187 >200 
Each TEG R value represents the mean ± SD of three independent determinations. 
Table 19a -- Comparative dose-dependent antithrombotic 
effects of thrombin inhibitors as studied in the rabbit model 
of jugular vein stasis thrombosis, after I. V. injection, 5 
min prior to r-TF injection, after 10 and 20 min stasis. 
D-Me-Phe-Pro-Arg-H 
Dose Dose Clot Score After Clot Score After 
µg/kg µmol!kg 10 min Stasis* 20 min Stasis* 
0 0.00 3.2±0.2 3.6±0.3 
50 0.10 3.0±0.4 3.6±0.3 
100 0.19 2.4±0.3 2.8±0.2 
250 0.49 0.6±0.4 2.2±0.4 
500 0.97 0.8±0.3 2.3±0.4 
1000 1.94 0.2±0.2 0.8±0.4 
*Each value represents the mean± SEM of 6 independent 
determinations. 
Table 19b -- Comparative dose-dependent antithrombotic 
effects of thrombin inhibitors as studied in the rabbit model 
of jugular vein stasis thrombosis, after I.V. injection, 5 
min prior to r-TF injection, after 10 and 20 min stasis. 
Ac-D-Phe-Pro-boroArg-OH 
Dose Dose Clot Score After Clot Score After 
µglkg µmol!kg 10 min Stasis* 20 min Stasis* 
0 0.00 3.2±0.2 3.6±0.3 
5 0.01 3.6±0.3 3.4±0.3 
12.5 0.03 2.8±0.2 2.8±0.2 
25 0.05 0.6±0.3 1.8±0.4 
50 0.10 0.0±0.0 0.2±0.2 
*Each value represents the mean± SEM of 6 independent 
determinations. 
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Table 19c -- Comparative dose-dependent antithrombotic 
effects of thrombin inhibitors as studied in the rabbit model 
of jugular vein stasis thrombosis, after I. V. injection, 5 
min prior to r-TF injection, after 10 and 20 min stasis. 
Hirudin 
Dose Dose Clot Score After Clot Score After 
µg/kg µmo I/kg 10 min Stasis* 20 min Stasis* 
0 0.000 3.2±0.2 3.6±0.3 
10 0.001 3.0±0.4 3.4±0.3 
25 0.004 1.3±0.4 2.7±0.2 
50 0.007 1.6±0.3 2.2±0.2 
100 0.014 0.6±0.3 1.4±0.3 
250 0.036 0.2±0.2 0.0±0.0 
*Each value represents the mean± SEM of 6 independent 
determinations. 
Table l 9d -- Comparative dose-dependent antithrombotic 
effects of thrombin inhibitors as studied in the rabbit model 
of jugular vein stasis thrombosis, after I. V. injection, 5 
min prior to r-TF injection, after 10 and 20 min stasis. 
Heparin 
Dose Dose Clot Score After Clot Score After 
µg/kg µmol/kg 10 min Stasis* 20 min Stasis* 
0 0.000 3.2±0.2 3.6±0.3 
25 0.002 4.0±0.0 3.8±0.3 
50 0.005 2.5±0.3 2.8±0.3 
100 0.009 1.8±0.3 2.0±0.3 
250 0.023 0.0±0.0 0.6±0.4 
* Each value represents the mean ± SEM of 6 independent 
determinations. 
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Table 19e -- Time dependance of antithrombotic effects of thrombin inhibitors in the 
rabbit model of jugular vein stasis thrombosis, after I.V. injection and 10 minutes stasis. 
Time 
(min) 
5 
30 
60 
90 
Clot Scores After 10 min Stasis* 
D-Me-Phe-Pro-Arg-H 
0.2±0.2 
0.2±0.2 
2.0±0.0 
3.3±0.5 
Ac-D-Phe-Pro-
boroArg-OH 
0.0±0.0 
2.6±0.3 
3.0±0.3 
Hirudin 
0.2±0.2 
1.3±0.2 
3.0±0.4 
Heparin 
0.0±0.0 
1.5±0.4 
3.8±0.2 
D-MePhe-Pro-Arg-H was injected at 1.94 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 0.10 
µmol/kg, hirudin at 0.04 µmol/kg and heparin at 0.02 µmol/kg. *Each value represents 
the mean ± SEM of 6 independent determinations. 
Table 19f -- Time dependance of antithrombotic effects of thrombin inhibitors in the 
rabbit model of jugular vein stasis thrombosis, after I.V. injection and 20 minutes stasis. 
Time D-Me-Phe-Pro-Arg-H 
(min) 
5 0.8±0.4 
30 1.0±0.5 
60 2.8±0.2 
90 3.0±0.4 
Clot Score After 20 min Stasis* 
Ac-D-Phe-Pro-
boroArg-OH 
0.2±0.2 
2.6±0.3 
3.3±0.4 
Hirudin 
0.0±0.0 
1.8±0.3 
3.2±0.4 
Heparin 
0.6±0.4 
2.2±0.6 
3.2±0.4 
D-MePhe-Pro-Arg-H was injected at 1.94 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 0.10 
µmol/kg, hirudin at 0.04 µmol/kg and heparin at 0.02 µmol/kg. *Each value represents 
the mean ± SEM of 6 independent determinations. 
Table 20a -- Comparative dose-dependent antithrombotic effects of 
thrombin inhibitors as studied in the rabbit model of jugular vein stasis 
thrombosis, after S.C. injection, 45 min prior to r-TF injection and after 
10 and 20 min stasis. 
D-Me-Phe-Pro-Arg-H 
Dose Dose Clot Score After Clot Score After 
µg/kg µmol/kg 10 min Stasis* 20 min Stasis* 
0 0.00 3.2±0.2 3.6±0.3 
100 0.19 3.6±0.3 3.8±0.2 
250 0.49 2.8±0.2 3.6±0.3 
500 0.97 2.4±0.3 2.8±0.2 
1000 1.94 1.2±0.4 2.3±0.5 
2500 4.85 0.0±0.0 1.2±0.4 
* Each value represents the mean ± SEM of 6 independent 
determinations. 
Table 20b -- Comparative dose-dependent antithrombotic effects of 
thrombin inhibitors as studied in the rabbit model of jugular vein stasis 
thrombosis, after S.C. injection, 45 min prior to r-TF injection and after 
10 and 20 min stasis. 
Ac-D-Phe-Pro-boroArg-OH 
Dose Dose Clot Score After Clot Score After 
µglkg µmol/kg 10 min Stasis* 20 min Stasis* 
0 0.00 3.2±0.2 3.6±0.3 
25 0.05 3.1±0.1 3.4±0.2 
50 0.10 2.4±0.3 3.2±0.4 
100 0.20 1.7±0.4 2.5±0.4 
250 0.50 0.0±0.0 0.8±0.4 
* Each value represents the mean ± SEM of 6 independent 
determinations. 
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Table 20c -- Comparative dose-dependent antithrombotic effects of 
thrombin inhibitors as studied in the rabbit model of jugular vein stasis 
thrombosis, after S.C. injection, 45 min prior to r-TF injection and after 
10 and 20 min stasis. 
Hirudin 
Dose Dose Clot Score After Clot Score After 
µg/kg µmol/kg 10 min Stasis* 20 min Stasis* 
0 0.000 3.2±0.2 3.6±0.3 
25 0.004 4.0±0.0 3.8±0.2 
50 0.007 2.8±0.2 3.2±0.2 
100 0.014 2.5±0.2 2.7±0.2 
250 0.036 2.0±0.3 2.3±0.5 
500 0.072 1.3±0.5 2.0±0.4 
1000 0.144 0.4±0.3 1.0±0.6 
* Each value represents the mean ± SEM of 6 independent determinations. 
Table 20d -- Comparative dose-dependent antithrombotic effects of 
thrombin inhibitors as studied in the rabbit model of jugular vein stasis 
thrombosis, after S.C. injection, 45 min prior to r-TF injection and after 
10 and 20 min stasis. 
Heparin 
Dose Dose Clot Score After Clot Score After 
µg/kg µmol/kg 10 min Stasis* 20 min Stasis* 
0 0.000 3.2±0.2 3.6±0.3 
500 0.046 3.6±0.2 3.8±0.2 
1000 0.091 3.3±0.2 3.1 ±0.2 
2750 0.250 1.3±0.5 2.0±0.6 
5000 0.455 0.7±0.2 0.8±0.3 
* Each value represents the mean ± SEM of 6 independent determinations. 
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Table 20e -- Time dependance of antithrombotic effects of thrombin inhibitors in the 
rabbit model of jugular vein stasis thrombosis, after S.C. injection and 10 minutes stasis. 
Clot Scores After 10 min Stasis* 
Time D-Me-Phe-Pro-Arg-H Ac-D-Phe-Pro- Hirudin Heparin 
(min) boroArg-OH 
15 0.0±0.0 0.0±0.0 0.4±0.3 1.2±0.2 
45 0.0±0.0 0.3±0.4 0.4±0.3 0.7±0.2 
90 0.6±0.4 0.2±0.2 0.7±0.5 0.3±0.2 
D-MePhe-Pro-Arg-H was injected at 4.86 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 0.50 
µmol/kg, hirudin at 0.14 µmol/kg and heparin at 0.47 µmol/kg. *Each value represents 
the mean ± SEM of 6 independent determinations. 
Table 20f -- Time dependance of antithrombotic effects of thrombin inhibitors in the 
rabbit model of jugular vein stasis thrombosis, after S.C. injection and 20 minutes stasis. 
Clot Scores After 20 min Stasis* 
Time D-Me-Phe-Pro-Arg-H Ac-D-Phe-Pro- Hirudin Heparin 
(min) boroArg-OH 
15 0.2±0.2 1.4±0.3 0.8±0.4 1.8±0.3 
45 1.2±0.4 1.2±0.5 1.0±0.6 0.8±0.3 
90 1.7±0.5 1.7±0.6 0.9±0.4 1.2±0.3 
D-MePhe-Pro-Arg-H was injected at 4.86 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 0.50 
µmol/kg, hirudin at 0.14 µmol/kg and heparin at 0.47 µmol/kg. *Each value represents 
the mean ± SEM of 6 independent determinations. 
Table 21a -- Comparative dose-dependent 
antithrombotic effects of thrombin inhibitors 
as studied in the rat model of laser induced 
thrombosis, after I. V. injection, 5 min prior 
to initiation of the laser injuries. 
D-Me-Phe-Pro-Arg-H 
Dose Dose #Laser 
µglkg µmo I/kg Exposures* 
500 0.97 4.3±0.8 
1000 1.94 6.3±1.5 
1750 3.40 6.0± 1.1 
2500 4.85 4.5±1.2 
0 0.00 2.9±0.1 
* Each value represents the mean ± SEM of 
6 independent determinations. 
Table 2lb -- Comparative dose-dependent 
antithrombotic effects of thrombin inhibitors 
as studied in the rat model of laser induced 
thrombosis, after I. V. injection, 5 min prior 
to initiation of the laser injuries. 
Ac-D-Phe-Pro-boroArg-OH 
Dose Dose #Laser 
µglkg µmol/kg Exposures* 
50 0.10 3.5±0.2 
75 0.15 5.7±0.6 
100 0.20 10.2±0.4 
0 0.00 2.9±0.1 
* Each value represents the mean ± SEM of 
6 independent determinations. 
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Table 2 lc -- Comparative dose-dependent 
antithrombotic effects of thrombin inhibitors 
as studied in the rat model of laser induced 
thrombosis, after I.V. injection, 5 min prior 
to initiation of the laser injuries. 
Hirudin 
Dose Dose #Laser 
µglkg µmol/kg Exposures* 
50 0.007 3.8±0.5 
100 0.014 5.3±0.5 
500 0.072 8.2±0.7 
0 0.000 2.9±0.1 
*Each value represents the mean ± SEM of 
6 independent determinations. 
Table 21d -- Comparative dose-dependent 
antithrombotic effects of thrombin inhibitors 
as studied in the rat model of laser induced 
thrombosis, after I. V. injection, 5 min prior 
to initiation of the laser injuries. 
Heparin 
Dose Dose #Laser 
µglkg µmol/kg Exposures* 
500 0.047 4.5±0.5 
1000 0.093 6.5±0.5 
5000 0.467 8.0±1.0 
0 0.000 2.9±0.l 
* Each value represents the mean ± SEM of 
6 independent determinations. 
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Table 22a -- Comparative dose-dependent hemorrhagic 
effects of thrombin inhibitors as studied in the rabbit ear 
bleeding model, after I.V. injection, 5 and 20 min prior to 
initiation of the bleeding procedure. 
D-Me-Phe-Pro-Arg-H 
Dose Dose RBC (109/L) RBC (109/L) 
µglkg µmol!kg After 5 min* After 20 min* 
0 0.00 0.100±0.075 0.100±0.075 
500 0.97 0.155 ±0.055 0.165 ±0.110 
1000 1.94 0.990±0.525 0.445 ±0.300 
2500 4.85 4.445±0.730 1.715±0.475 
* Each value represents the mean ± SEM of 6 independent 
determinations. 
Table 22b -- Comparative dose-dependent hemorrhagic 
effects of thrombin inhibitors as studied in the rabbit ear 
bleeding model, after I.V. injection, 5 and 20 min prior to 
initiation of the bleeding procedure. 
Ac-D-Phe-Pro-boroArg-OH 
Dose Dose RBC (109/L) RBC (109/L) 
µg!kg µmollkg After 5 min* After 20 min* 
0 0.00 0.100±0.075 0.100±0.075 
50 0.10 0.215±0.075 0.065 ±0.035 
125 0.25 2.24±1.065 0. 515 ±0. 220 
250 0.50 1.520±0.54 1.395±0.465 
500 1.00 3.245±1.080 11. 790±7.295 
* Each value represents the mean ± SEM of 6 independent 
determinations. 
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Table 22c -- Comparative dose-dependent hemorrhagic 
effects of thrombin inhibitors as studied in the rabbit ear 
bleeding model, after I.V. injection, 5 and 20 min prior to 
initiation of the bleeding procedure. 
Hirudin 
Dose Dose RBC (109/L) RBC (109/L) 
µglkg µmol/kg After 5 min* After 20 min* 
0 0.000 0.100±0.075 0.100±0.075 
500 0.046 0.470±0.245 0.100±0.060 
1000 0.144 3.880± 1.075 0.140±0.050 
2500 0.359 4.910± 1.485 3.025±1.015 
*Each value represents the mean± SEM of 6 independent 
determinations. 
Table 22d -- Comparative dose-dependent hemorrhagic 
effects of thrombin inhibitors as studied in the rabbit ear 
bleeding model, after I.V. injection, 5 and 20 min prior to 
initiation of the bleeding procedure. 
Heparin 
Dose Dose RBC (109/L) RBC(l09/L) 
µglkg µmol/kg After 5 min* After 20 min* 
0 0.000 0.100±0.075 0.100±0.075 
500 0.046 0.975 ±0.370 0.420±0.275 
1000 0.091 0.870±0.530 0.465 ±0.250 
2500 0.227 0. 745 ±0.270 0.920±0.480 
5000 0.455 1.115 ±0.630 0.370±0.130 
*Each value represents the mean ± SEM of 6 independent 
determinations. 
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Table 22e -- Time dependance of hemorrhagic effects of thrombin inhibitors in the rabbit 
ear bleeding model, after I. V. injection. 
RBC (109/L)* 
Time D-Me-Phe-Pro-Arg-H Ac-D-Phe-Pro- Hirudin Heparin 
(min) boroArg-OH 
5 8.655 ±2.865 9.830±5.830 4.910±2.130 1.115 ±0.630 
20 1.865 ±0.425 4.680±2.380 3.025±1.590 0.370±0.130 
30 1.090±0.580 6.650±4.455 0.590±0.275 1.835±0.540 
45 0.210±0.080 1.245 ±0.425 0.130±0.035 1.180±0.415 
60 0.135 ±0.025 0.440±0.265 0.140±0.050 
90 0.150±0.155 0.065 ±0.045 0.165±0.090 
D-MePhe-Pro-Arg-H was injected at 4.86 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 0.50 
µmollkg, hirudin at 0.36 µmol/kg and heparin at 0.47 µmollkg. *Each value represents 
the mean ± SEM of 6 independent determinations. 
Table 23a -- Comparative dose-dependent hemorrhagic 
effects of thrombin inhibitors as studied in the rabbit ear 
bleeding model, after S.C. injection, 45 and 60 min prior 
to initiation of the bleeding procedure. 
D-Me-Phe-Pro-Arg-H 
Dose Dose RBC (109/L) RBC (109/L) 
µg/ml µmol/kg After 45 min* After 60 min* 
0 0.00 0.100±0.075 0.100±0.075 
1000 1.94 0.125±0.080 0.080±0.055 
2500 4.85 0.855 ±0.280 0.225 ±0.105 
5000 9.71 0.680±0.190 0.375 ±0.280 
* Each value represents the mean ± SEM of 6 independent 
determinations. 
Table 23b -- Comparative dose-dependent hemorrhagic 
effects of thrombin inhibitors as studied in the rabbit ear 
bleeding model, after S.C. injection, 45 and 60 min prior 
to initiation of the bleeding procedure. 
Ac-D-Phe-Pro-boroArg-OH 
Dose Dose RBC (109/L) RBC (109/L) 
µglkg µmo I/kg After 45 min* After 60 min* 
0 0.00 0.100±0.075 0.100±0.075 
100 0.20 0.235 ±0.075 0.030±0.020 
250 0.50 0. 730±0.265 0.465±0.180 
500 1.00 1.405 ±0.945 1.150±0.934 
1000 2.01 7.190±3.151 2.645 ±0.655 
*Each value represents the mean ± SEM of 6 independent 
determinations. 
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Table 23c -- Comparative dose-dependent hemorrhagic 
effects of thrombin inhibitors as studied in the rabbit ear 
bleeding model, after S.C. injection, 45 and 60 min prior 
to initiation of the bleeding procedure. 
Hirudin 
Dose Dose RBC (109/L) RBC (109/L) 
µglkg µmol/kg After 45 min* After 60 min* 
0 0.000 0.100±0.075 0.100±0.075 
500 0.046 0.135 ±0.070 0.040±0.035 
1000 0.144 0.315 ±0.285 0.215 ±0.170 
2500 0.359 0.225 ±0.140 0.140±0.075 
5000 0.718 1.865±0.715 0.350±0.140 
* Each value represents the mean ± SEM of 6 independent 
determinations. 
Table 23d -- Comparative dose-dependent hemorrhagic 
effects of thrombin inhibitors as studied in the rabbit ear 
bleeding model, after S.C. injection, 45 and 60 min prior 
to initiation of the bleeding procedure. 
Heparin 
Dose Dose RBC (109/L) RBC (109/L) 
µglkg µmo I/kg After 45 min* After 60 min* 
0 0.000 0.100±0.075 0.100±0.075 
5000 0.455 0.095 ±0.060 0.100±0.055 
10,000 0.909 0.395±0.215 0.160±0.065 
* Each value represents the mean ± SEM of 6 independent 
determinations. 
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Table 23e -- Time dependance of hemorrhagic effects of thrombin inhibitors in the rabbit 
ear bleeding model after S.C. injection. 
RBC (109/L)* 
Time D-Me-Phe-Pro-Arg-H Ac-D-Phe-Pro- Hirudin Heparin 
(min) boroArg-OH 
15 1.445±0.620 2.445 ±0. 700 0.160±0.150 0.100 
30 0.520±0.325 1.245 ±0.529 0.020±0.010 0.150 
45 0.680±0.190 7.190±3.151 1.865 ±0.715 0.395 ±0.215 
60 0.375 ±0.280 2.646±0. 732 0.350±0.140 0.160±0.065 
90 0.140±0.110 1.438±0.412 0.045 ±0.025 0.035 ±0.025 
120 0. 755 ±0.290 1.663±0.443 0.220±0.125 0.055 ±0.020 
D-MePhe-Pro-Arg-H was injected at 9.72 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 2.01 
µmol/kg, hirudin at 0.72 µmol/kg and heparin at 0.93 µmol/kg. *Each value represents 
the mean ± SEM of 6 independent determinations. 
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